david
hoogstra
roland
chu
kanta
bhambhani
maxim
yankelevich
jeffrey
taub
children
hospit
michigan
detroit
michigan
unit
state
background
use
myelotox
chemotherapi
acceler
neutrophil
recoveri
reduc
risk
febril
neutropenia
current
guidelin
recommend
initi
day
myelotox
chemotherapi
howev
optim
time
administr
elucid
previou
work
murin
model
demonstr
reappear
sensit
myeloid
progenitor
occur
bone
marrow
day
complet
chemotherapi
find
suggest
delay
administr
may
equal
efficaci
significantli
cost
effect
compar
current
practic
object
determin
absolut
neutrophil
count
anc
recoveri
myelotox
chemotherapi
would
equival
delay
administr
schedul
compar
standard
administr
schedul
designmethod
studi
util
prospect
treatment
period
crossov
design
children
solid
tumor
receiv
ident
cycl
myelotox
chemotherapi
random
receiv
standard
delay
schedul
standard
schedul
patient
receiv
hour
complet
chemotherapi
delay
schedul
patient
receiv
begin
day
anc
drop
schedul
administ
dose
anc
greater
patient
analyz
studi
result
signific
differ
time
neutrophil
recoveri
number
day
start
chemotherapi
anc
post
nadir
two
administr
schedul
day
standard
group
compar
day
delay
group
p
total
number
dose
given
howev
significantli
less
delay
group
compar
dose
standard
group
p
conclus
preliminari
data
show
delay
administr
post
chemotherapi
result
signific
reduct
number
inject
without
compromis
effect
neutropen
recoveri
myelotox
chemotherapi
children
solid
tumor
jessica
hochberg
javier
oesterheld
olga
militano
liana
klejmont
lauren
harrison
berkley
nickerson
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
despit
excel
outcom
pediatr
multipli
relaps
patient
respons
rate
os
prognosi
relaps
refractori
aml
clofarabin
mitoxantron
proven
efficaci
children
leukemia
offer
possibl
synergist
activ
object
determin
maxim
toler
dose
overal
respons
rate
clofarabin
combin
mitoxantron
reinduct
therapi
refractoryrelaps
acut
leukemia
designmethod
prospect
open
label
phase
iii
studi
patient
old
aml
nhl
relaps
induct
failur
given
cycl
clofarabin
escal
dose
day
combin
mitoxantron
day
dexrazoxan
given
prior
mitoxantron
dose
escal
everi
patient
cn
prophylaxi
intrathec
liposom
cytarabin
patient
allow
subsequ
cycl
pend
respons
anthracyclin
exposur
result
total
patient
enrol
phase
portion
median
age
aml
nhl
progress
diseas
grade
iiiiv
toxic
dose
level
clofarabin
hepat
toxic
prolong
myelosuppress
henc
addit
patient
enrol
dose
level
clofarabin
median
time
neutrophil
recoveri
day
fourteen
leukemia
patient
achiev
cr
cycl
therapi
achiev
mrd
neg
thirteen
patient
achiev
cr
went
receiv
allohsct
continu
remiss
median
follow
time
day
rang
conclus
combin
clofarabin
mitoxantron
reinduct
therapi
relaps
refractori
acut
leukemia
appear
safe
well
toler
children
adolesc
young
adult
poor
risk
hematolog
malign
phase
mtd
combin
establish
clofarabin
initi
data
phase
portion
encourag
cr
rate
neg
mrd
acut
leukem
patient
extend
multicent
phase
ii
studi
british
journal
hematolog
journal
clinic
oncolog
leukemia
lymphoma
gisel
sholler
william
ferguson
geneviev
bergendahl
jeffrey
bond
william
robert
eslin
bredlau
javier
oesterheld
deanna
mitchel
jessica
foley
nehal
parikh
kathleen
nevil
randal
wada
valeri
brown
peter
zage
franci
eshun
jawhar
rawwa
susan
sencer
debra
pankiewicz
moniqu
quinn
jacquelin
kraveka
helen
devo
children
hospitalnmtrc
grand
rapid
michigan
unit
state
background
high
risk
neuroblastoma
hrnb
remain
challeng
pediatr
oncolog
account
pediatr
cancer
death
patient
abl
attain
remiss
natur
histori
hrnb
well
document
approxim
event
free
surviv
ef
year
ef
year
complet
immunotherapi
object
studi
evalu
effect
odc
inhibitor
difluoromethylornithin
dfmo
mainten
therapi
increas
year
ef
hrnb
patient
achiev
remiss
standard
therapi
designmethod
studi
open
label
singl
agent
multicent
studi
neuroblastoma
medulloblastoma
translat
research
consortium
nmtrc
enrol
began
june
end
februari
subject
receiv
cycl
oral
dfmo
dose
day
day
cycl
ef
os
determin
basi
result
total
elig
patient
receiv
dfmo
dfmo
well
toler
grade
transamin
common
toxic
report
patient
ef
overal
surviv
os
year
group
patient
n
previous
enrol
studi
year
ef
os
one
patient
relaps
die
receiv
half
dose
prior
relaps
due
parent
error
conclus
addit
dfmo
year
complet
upfront
therapi
result
improv
ef
os
children
hrnb
safeti
profil
dfmo
show
minim
advers
event
excel
qualiti
life
children
studi
result
confirm
prospect
confirmatori
clinic
trial
jonathan
marron
steven
duboi
julia
glade
bender
aerang
kim
stephani
meyer
brian
crompton
katherin
janeway
jennif
mack
children
cancer
blood
disord
center
boston
massachusett
unit
state
background
genom
tumor
profil
gtp
forefront
care
medic
oncolog
role
pediatr
oncolog
still
evolv
subset
patient
current
expect
receiv
clinic
signific
result
littl
known
perspect
pediatr
oncolog
patientspar
gtp
object
describ
perspect
pediatr
oncolog
patientspar
regard
gtp
includ
hopesconcern
gtp
understand
purpos
impact
particip
famili
designmethod
survey
individu
previous
underw
gtp
icat
pilot
studi
molecular
profil
children
solid
tumor
children
univers
california
san
francisco
columbia
univers
medic
center
children
nation
medic
center
follow
return
profil
result
survey
novel
valid
measur
offer
patient
enrol
parent
subject
elig
patient
live
patientpar
spoke
english
consent
contact
oncologist
gave
permiss
approach
survey
domain
includ
hopesconcern
gtp
understand
purpos
prefer
return
result
impact
result
result
patient
underw
gtp
part
icat
studi
elig
survey
complet
respons
rate
report
hope
particip
would
help
find
cure
futur
patient
hope
would
increas
theirtheir
child
chanc
cure
concern
gtp
worri
would
learn
theirtheir
child
cancer
less
treatabl
aggress
previous
thought
report
feel
particip
help
other
felt
help
themselvestheir
child
despit
one
subject
receiv
target
therapi
match
gtp
find
respond
demonstr
degre
misunderstand
purpos
gtp
research
wish
receiv
avail
profil
data
conclus
particip
pediatr
gtp
research
perceiv
benefit
gtp
other
expect
person
benefit
gtp
may
exceed
actual
benefit
issu
includ
descript
nuanc
purpos
gtp
warrant
consider
consent
discuss
particip
gtp
research
jonathan
mett
dana
clark
adina
alazraki
karen
bradley
georg
thoma
olson
thoma
cash
aflac
cancer
blood
disord
center
children
healthcar
atlantadepart
pediatr
emori
univers
school
medicin
atlanta
georgia
unit
state
background
pediatr
patient
relapsedrefractori
solid
tumor
poor
outcom
therapi
offer
diseas
control
also
preserv
qualiti
life
need
one
regimen
util
gemcitabinedocetaxel
form
paclitaxel
close
relat
docetaxel
shown
effect
alon
combin
gemcitabin
preclin
model
includ
pediatr
solid
tumor
demonstr
efficaci
adult
pancreat
adenocarcinoma
howev
publish
data
clinic
use
pediatr
object
determin
toxic
efficaci
patient
pediatr
solid
tumor
designmethod
retrospect
review
chart
patient
receiv
institut
gemcitabin
administ
intraven
weekli
week
toxic
grade
use
nation
cancer
institut
nci
common
terminolog
criteria
advers
event
ctcae
version
best
overal
respons
determin
use
nci
respons
evalu
criteria
solid
tumor
recist
criteria
result
fourteen
relapsedrefractori
patient
patient
receiv
median
age
year
diagnos
includ
osteosarcoma
n
rhabdomyosarcoma
n
germ
cell
tumor
n
soft
tissu
sarcoma
nrst
n
ewe
sarcoma
n
cycl
administ
cycl
result
grade
iiiiv
toxic
patient
experienc
grade
iiiiv
toxic
common
grade
iiiiv
toxic
hematolog
n
astalt
elev
n
infect
n
myositi
n
fourteen
patient
evalu
respons
recist
criteria
complet
respons
cr
patient
partial
respons
pr
stabl
diseas
give
object
respons
rate
cr
pr
median
time
progress
day
median
day
patient
remain
aliv
diseas
conclus
toler
regimen
mainli
hematolog
toxic
reason
palli
option
clinic
benefit
subset
patient
studi
prospect
fashion
scott
raskin
shanghao
li
sumedh
shah
guillermo
de
angulo
roger
leblanc
regina
graham
univers
miami
miller
school
medicin
miami
florida
unit
state
background
pediatr
brain
tumor
repres
common
form
solid
tumor
among
children
compris
approxim
childhood
cancer
obstacl
success
treatment
inabl
effect
chemotherapi
cross
blood
brain
barrier
bbb
transferrrin
receptor
tfr
increas
brain
tumor
shown
correl
poor
prognosi
chemotherapi
util
transferrin
receptor
success
cross
bbb
via
transcytosi
target
tumor
cell
carbon
dot
new
class
fluoresc
nanoparticl
develop
applic
includ
drug
deliveri
object
determin
efficaci
chemotherapi
conjug
novel
transferrin
molecul
treatment
pediatr
brain
tumor
designmethod
gener
hydrotherm
heat
bread
subsequ
conjug
transferrin
doxorubicin
viabil
pediatr
brain
tumor
cell
line
daoy
medulloblastoma
glioblastoma
chla
glioblastoma
chla
atyp
teratoidrhabdoid
tumor
treat
dox
determin
use
mt
assay
tfr
level
pbt
evalu
western
blot
analysi
cellular
dox
imag
quantit
use
arrayscan
vti
analyz
use
transmiss
electron
microscopi
tem
result
western
blot
analysi
indic
pediatr
brain
tumor
cell
line
express
dox
induc
dose
depend
cell
death
cell
line
cytotox
greater
equal
dox
alon
indic
neg
affect
dox
efficaci
treatment
induc
decreas
cell
viabil
depend
cell
line
tem
confirm
presenc
within
treat
cell
furthermor
treatment
nuclear
dox
fluoresc
approxim
greater
treat
cell
compar
dox
alon
conclus
result
indic
success
conjug
transferrin
doxorubicin
without
affect
efficaci
highli
fluoresc
enabl
imag
chemotherapi
vitro
vivo
clinic
trial
use
therapi
demonstr
mix
result
abil
imag
follow
treatment
may
provid
inform
critic
improv
outcom
clinic
trial
use
transferrin
conjug
chemotherapi
david
stammer
bairbr
connolli
leonardo
brandao
sue
zupanec
sumit
gupta
hospit
sick
children
toronto
ontario
canada
background
central
venou
line
cvl
dysfunct
partial
complet
lumenvessel
occlus
common
complic
childhood
cancer
treatment
manag
often
involv
intralumin
thrombolyt
agent
tissu
plasminogen
activ
tpa
thrombu
suspect
current
practic
mani
pediatr
institut
assess
cvl
posit
chest
cxr
prior
everi
tpa
administr
object
describ
institut
experi
cvl
occlus
patient
childhood
cancer
determin
whether
cxr
requir
give
tpa
designmethod
retrospect
chart
review
children
year
newli
diagnos
cancer
cvl
treat
hospit
sick
children
perform
episod
line
occlus
identifi
review
patient
cxr
indic
identifi
tpa
dose
dispens
episod
review
assess
whether
find
result
manag
tpa
case
result
chang
manag
review
determin
whether
administr
tpa
could
result
potenti
patient
harm
bleed
system
dose
tpa
line
misplac
breakag
result
total
patient
newli
diagnos
cancer
cvl
identifi
patient
experienc
total
episod
cvl
occlus
episod
cvl
occlus
cxr
led
chang
manag
administ
tpa
occur
commonli
case
obstruct
picc
line
cxr
chang
manag
less
frequent
case
occlus
patient
port
extern
cvl
case
multipl
specialist
deem
administr
tpa
would
unlik
caus
patient
harm
conclus
routin
use
cxr
prior
thrombolyt
therapi
cvl
occlus
children
port
given
pauciti
find
result
manag
tpa
though
higher
rate
manag
chang
patient
picc
routin
cxr
may
also
omit
patient
given
low
harm
tpa
administr
karen
ami
sherrod
sherrod
yousef
bushehri
craig
zimr
steven
lewi
megan
denham
aflac
cancer
blood
disord
center
children
healthcar
atlanta
scottish
rite
campu
atlanta
georgia
unit
state
background
children
receiv
chemotherapi
clinic
go
complex
process
involv
multipl
step
provid
room
complex
creat
ineffici
consum
time
patient
famili
could
spend
want
need
object
global
aim
improv
experi
children
receiv
chemotherapi
util
approach
patient
take
activ
role
describ
evalu
improv
care
receiv
designmethod
iter
process
develop
process
map
chemotherapi
administr
engag
patient
famili
clinician
develop
passport
data
collect
tool
patient
use
passport
tool
collect
data
visit
includ
time
stamp
begin
end
activ
qualit
descript
feel
step
process
discret
event
simul
model
creat
use
passport
arriv
staf
data
result
oncolog
patient
age
year
document
journey
passport
tool
mean
visit
durat
minut
rang
time
spent
wait
idl
time
percentag
total
visit
time
incur
registr
triag
wait
nurs
provid
medic
exam
infus
room
qualit
descript
extend
wait
frequent
note
particularli
exam
room
neg
emot
scare
anxiou
bore
commonli
report
exam
infus
room
patient
spent
time
wait
posit
emot
report
game
room
exam
room
wait
area
infus
area
also
posit
neg
emot
report
area
video
game
activ
patient
conclus
research
demonstr
methodolog
activ
engag
empow
pediatr
oncolog
patient
improv
care
receiv
inform
use
futur
pdsa
cycl
identifi
test
opportun
improv
care
reduc
idl
time
spent
chemotherapi
visit
next
month
improv
qualiti
idl
time
target
care
point
children
unhappi
afraid
lyda
pecker
nichola
whippl
juli
krystal
vera
osafo
barbara
lisa
thaniel
banu
aygun
jane
hankin
ellen
silver
michael
roth
deepa
manwani
children
hospit
montefior
children
nation
medic
center
cohen
children
hospit
st
jude
children
research
hospit
bronx
washington
dc
new
hyde
park
memphi
new
york
washington
dc
new
york
tennesse
unit
state
background
sickl
cell
diseas
scd
heterogen
condit
caus
substanti
morbid
earli
mortal
life
expect
improv
recent
decad
research
show
affect
adolescentsyoung
adult
aya
parent
understand
effect
scd
futur
differ
physician
prognosi
address
clinic
practic
unknown
import
share
inform
object
compar
percept
prognosi
among
aya
parent
pediatr
hematologist
designmethod
conduct
survey
aya
age
scd
parent
pediatr
hematologist
prognosi
scd
aya
parent
recruit
four
center
visit
question
group
theme
answer
compar
use
fisher
exact
test
result
adolesc
parent
pediatr
hematologist
complet
survey
adolesc
femal
black
mean
age
year
hbss
take
hydroxyurea
parent
femal
black
children
hbss
take
hydroxyurea
parent
aya
rate
discuss
life
expect
import
howev
parent
aya
report
doctor
often
discuss
long
patient
scd
live
consist
doctor
report
discuss
life
expect
aya
parent
doctor
report
patient
initi
prognost
discuss
aya
parent
want
doctor
discuss
life
expect
hematologist
thought
aya
parent
somewhat
afraid
scd
parent
report
fear
scd
adolesc
vs
afraid
vs
littl
afraid
vs
afraid
p
aya
parent
believ
scd
would
chang
life
expect
conclus
prognost
discuss
includ
life
expect
infrequ
among
aya
scd
aya
parent
report
want
inform
pediatr
hematologist
perceiv
patient
famili
fear
scd
patient
parent
report
studi
provid
novel
inform
design
intervent
guid
convers
regard
diseas
prognosi
possibl
treatment
decis
patient
scd
famili
priti
tewari
betsi
lewi
kimberli
kresta
angela
shaw
rhonda
robert
brittni
maetzold
raymund
valderrama
nicol
harman
ion
cion
quinn
franklin
elsa
mors
debi
skillman
cindi
schwartz
md
anderson
cancer
center
houston
texa
unit
state
background
exercis
mobil
benefici
oncolog
patient
pediatr
adolesc
young
adult
age
patient
respons
incent
award
reinforc
studi
shown
effect
inpati
mobil
program
pediatr
oncolog
object
creat
implement
mobil
incent
program
motiv
pediatr
young
adult
inpati
remain
activ
possibl
hospit
designmethod
use
multidisciplinari
approach
team
consist
physician
nurs
advanc
practic
provid
physic
therapi
occup
therapi
child
life
psycholog
art
medicin
volunt
servic
creat
team
total
excit
move
mobil
exercis
standard
practic
patient
encourag
care
team
remain
activ
inpati
stay
addit
incent
patient
could
earn
sticker
display
team
door
board
along
ticket
earn
tier
prize
data
includ
minut
walk
test
stafffaculti
survey
evalu
percept
barrier
patient
exercis
conduct
pre
post
program
implement
result
data
collect
period
month
prior
program
implement
month
follow
implement
includ
physic
therapi
encount
prior
implement
total
refus
particip
averag
feet
rang
averag
modifi
borg
score
rang
follow
implement
total
refus
averag
feet
rang
averag
modifi
borg
score
rang
facultystaff
survey
conduct
prior
follow
implement
survey
entail
question
perceiv
patient
activ
level
patient
motiv
physic
organiz
barrier
patient
physic
activ
prior
implement
team
staff
member
report
patient
tend
walk
daili
compar
percept
patient
motiv
also
improv
initi
survey
staff
felt
patient
motiv
stay
activ
inpati
compar
conclus
innov
multidisciplinari
program
support
patient
mobil
feasibl
may
benefici
patient
initi
result
show
improv
averag
borg
score
along
staff
percept
inpati
particip
walk
patient
motiv
futur
direct
includ
develop
prospect
clinic
studi
sonata
jodel
adam
nelson
christoph
dandoy
kasiani
myer
javier
ashley
teusink
brian
weiss
stella
davi
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
thrombot
microangiopathi
increasingli
recogn
complic
hsct
commonli
affect
kidney
result
proteinuria
hypertens
may
progress
failur
sever
case
patient
undergo
autolog
hsct
neuroblastoma
requir
good
organ
function
complet
therapi
significantli
compromis
plan
therapi
hsct
overal
outcom
object
goal
studi
examin
incid
impact
organ
function
patient
neuroblastoma
undergo
hsct
institut
designmethod
retrospect
chart
review
perform
patient
neuroblastoma
undergo
high
dose
chemotherapi
autolog
stem
cell
transplant
identifi
incid
tma
outcom
therapi
use
result
sixti
patient
underw
hsct
studi
period
use
carboplatinetoposidemelphalan
cem
n
busulfanmelphalan
bumel
n
tandem
transplant
cytoxanthiotepa
cem
n
twelv
patient
develop
sever
involv
median
day
hsct
occur
patient
receiv
cem
regimen
cytoxanthiotepa
incid
report
bumel
regimen
patient
normal
renal
function
proteinuria
hypertens
hsct
diagnosi
patient
requir
hemodialysi
other
median
gfr
mlmin
cystatin
c
patient
develop
nephrot
rang
proteinuria
sever
hypertens
five
patient
sever
injuri
treat
eculizumab
patient
receiv
median
eculizumab
dose
rang
use
pharmacokineticpharmacodynam
pkpd
monitor
maintain
therapeut
drug
level
pkpd
data
indic
signific
differ
eculizumab
clearanc
base
activ
side
effect
attribut
eculizumab
treat
patient
recov
injuri
abl
complet
radiat
modifi
mainten
therapi
patient
receiv
eculizumab
die
complic
progress
end
stage
renal
diseas
chronic
heart
failur
conclus
report
high
incid
cem
regimen
conclud
eculizumab
well
toler
effect
treatment
pkpd
base
dose
requir
best
clinic
respons
michael
walsh
shukla
neerav
joseph
v
kentsi
alex
kevin
curran
rachel
kobo
angela
arnold
megan
harlan
kennedi
jennif
kasmintan
schrader
zsofia
stadler
cheung
shakeel
modak
brian
kushner
stephen
robert
michael
laquaglia
ira
dunkel
yasmin
khakoo
kim
kramer
leonard
wexler
paul
meyer
alex
chou
diana
mandelk
liy
zhang
david
solit
scott
armstrong
marc
ladanyi
mark
robson
richard
oreilli
michael
berger
kenneth
offit
memori
sloan
ketter
cancer
center
new
york
citi
new
york
unit
state
background
pediatr
patient
adult
patient
harbor
pathogen
herit
genet
alter
predispos
cancer
genom
sequenc
mean
target
therapi
assess
cancer
predisposit
howev
definit
conclus
requir
proper
sampl
standard
variant
call
expertis
provid
accur
curat
data
object
determin
frequenc
germlin
mutat
cancer
predisposit
gene
cancer
pathway
detect
subset
pediatr
oncolog
patient
emphas
potenti
therapeut
prevent
implic
find
designmethod
observ
case
seri
juli
pediatr
cancer
particip
underw
test
hybrid
sequenc
assay
memori
sloan
ketter
cancer
center
analyz
whole
blood
dna
n
pediatr
cancer
patient
neuroblastoma
brain
tumor
solid
tumor
variant
gene
evalu
ingenu
variant
analysi
softwar
manual
curat
classifi
variant
accord
american
colleg
medic
genet
genom
acmg
standard
guidelin
result
pathogen
like
pathogen
germ
line
variant
detect
pediatr
cancer
particip
studi
includ
alter
gene
n
n
rasmeknf
pathway
gene
n
repair
gene
n
pathway
gene
n
cell
cycl
control
gene
n
cebpa
n
energi
metabol
gene
sdha
n
addit
syndrom
associ
find
may
relev
radiat
risk
elig
trial
parp
inhibitor
immunotherapi
conclus
observ
select
seri
pediatr
patient
carri
germlin
variant
presum
pathogen
signific
known
cancer
predisposit
gene
addit
identifi
etiolog
pathway
cancer
suscept
case
find
potenti
impact
prognosi
target
treatment
select
toxic
surgic
plan
risk
second
cancer
particular
result
suggest
subset
pediatr
cancer
patient
benefit
genet
counsel
better
defin
syndrom
phenotyp
provid
option
reproduct
plan
target
earli
detect
prevent
unaffect
famili
member
harbor
inherit
mutat
jessica
meznarich
diana
bareyan
matt
velind
jare
bearss
sunil
sharma
michael
engel
univers
utah
huntsman
cancer
institut
salt
lake
citi
utah
unit
state
background
growth
factor
independ
transcript
repressor
regul
cell
growth
differenti
surviv
necessari
acut
lymphoblast
leukemia
cell
surviv
vitro
vivo
deplet
lead
apoptosi
tumor
regress
transcript
repress
requir
interact
snag
domain
lysin
specif
demethylas
histon
demethylas
domin
effector
deriv
lack
bind
impair
transcript
repressor
fail
complement
phenotyp
hypothes
inhibit
act
surrog
deplet
caus
cell
death
vitro
vivo
object
defin
activ
seri
novel
inhibitor
designmethod
human
cell
line
primari
patient
isol
treat
suspens
cultur
compound
follow
determin
cell
viabil
induct
apoptosi
coloni
format
methylcellulos
xenograft
establish
nsg
mice
treat
daili
vehicl
target
gene
express
marker
apoptosi
surviv
vitro
vivo
determin
follow
treatment
vitro
drug
combin
studi
standard
chemotherapi
agent
perform
determin
combin
indic
result
seri
inhibitor
display
toward
cell
line
primari
patient
isol
relaps
patient
isol
also
sensit
despit
resist
dexamethason
cell
line
treat
undergo
apoptosi
show
clonal
growth
suppress
methylcellulos
coloni
assay
vivo
treatment
revers
otherwis
lethal
tumor
burden
mous
xenotranspl
model
level
target
gene
declin
respons
inhibit
enforc
express
cell
antagon
inhibit
cell
viabil
assay
seri
inhibitor
display
synergi
standard
chemotherapi
agent
use
conclus
inhibit
promot
cell
death
vitro
vivo
cytotox
effect
may
depend
upon
deplet
target
epigenom
via
inhibit
offer
promis
novel
approach
therapi
warrant
inclus
earli
phase
clinic
trial
thoma
alexand
raul
ribeiro
stanley
pound
norman
lacayo
jeffrey
rubnitz
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
although
overal
surviv
rate
children
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
patient
relaps
refractori
diseas
continu
poor
outcom
selinexor
oral
select
inhibitor
nuclear
export
inhibit
caus
differenti
apoptosi
varieti
leukemia
subtyp
spare
normal
hematopoiesi
object
perform
phase
studi
determin
safeti
selinexor
combin
fludarabin
cytarabin
pediatr
patient
relaps
refractori
leukemia
designmethod
eighteen
patient
relaps
refractori
acut
leukemia
enrol
selhem
clinic
trial
featur
includ
case
megakaryoblast
leukemia
seven
patient
enrol
second
relaps
selinexor
given
oral
day
escal
accord
design
fludarabin
cytarabin
administ
day
pharmacokinet
pharmacodynam
studi
perform
day
respons
evalu
perform
day
complet
cours
one
result
seventeen
patient
evalu
toxic
three
treat
three
six
five
two
case
cerebellar
toxic
observ
therebi
defin
dose
limit
toxic
common
grade
toxic
hyponatremia
easili
correct
case
pharmacokinet
paramet
indic
plasma
exposur
dose
proport
sixteen
patient
demonstr
increas
mrna
express
upregul
respons
protein
inactiv
seven
fourteen
evalu
patient
achiev
complet
respons
complet
respons
incomplet
count
recoveri
conclus
selinexor
given
sequenti
fludarabin
cytarabin
toler
pediatr
patient
relaps
refractori
leukemia
selinexor
pharmacokinet
paramet
proport
dose
given
similar
seen
adult
patient
patient
receiv
selinexor
demonstr
target
inhibit
respons
rate
encourag
current
enrol
expans
cohort
dose
therapeut
inc
provid
studi
drug
pharmacokinet
pharmacodynam
support
waitman
aumann
sei
gyung
kim
catherin
lavau
daniel
wechsler
duke
univers
medic
center
durham
north
carolina
unit
state
background
transloc
seen
childhood
acut
lymphoblast
leukemia
difficult
treat
lab
recent
demonstr
nuclear
export
chaperon
play
critic
role
leukemogenesi
studi
mechan
contribut
leukemia
develop
creat
fusion
vector
show
similar
result
increas
hoxa
gene
express
induc
leukemia
mice
sinc
recent
shown
abl
via
defin
dimer
interfac
sought
determin
whether
dimer
import
leukemogenesi
object
determin
whether
dimer
mechanist
involv
leukemogenesi
designmethod
homodimer
interfac
includ
seven
specif
amino
acid
residu
creat
express
vector
six
seven
residu
mutat
order
impair
dimer
use
luciferas
report
assay
measur
hoxa
gene
transcript
cell
transient
transfect
construct
hematopoiet
cell
transduc
fusion
vector
transplant
mice
evalu
leukemia
vivo
result
found
abil
activ
report
significantli
reduc
compar
cell
cell
mice
transplant
transduc
cell
novemb
monitor
develop
leukemia
sinc
usual
induc
leukemia
mice
latenc
day
report
effect
dimer
leukemogenesi
conclus
result
demonstr
homodimer
motif
within
contribut
abil
fusion
protein
activ
hoxa
transcript
suggest
dimer
may
import
mechan
underli
leukemogenesi
futur
experi
evalu
abil
dimer
use
gst
experi
also
examin
role
dimer
leukemia
studi
could
lead
new
therapeut
option
target
dimer
interfac
sankar
kannan
shelley
herbrich
lizhi
zeng
patrick
ut
md
anderson
cancer
center
houston
texa
unit
state
background
chronic
oxid
stress
co
consequ
prolong
elev
reactiv
oxygen
speci
ro
context
aml
co
lead
sustain
induct
antioxid
pathway
compensatori
mechan
co
sustain
lead
patholog
maladapt
refer
reduct
stress
rs
rs
promot
chemo
resist
counteract
oxid
stress
explor
reduct
stress
found
inhibit
abrog
rs
promot
chemo
sensit
aml
object
explor
role
reduct
stress
aml
chemoresist
designmethod
primari
human
aml
sampl
line
use
character
oxid
reduct
stress
inhibit
pharmacolog
inhibitor
brusatol
exposur
notch
ligand
use
evalu
potenti
inhibit
therapeut
approach
result
high
level
express
aml
compar
normal
pbmc
correl
increas
reduct
metabolit
reduc
potenti
ie
reduct
stress
inhibit
brusatol
sirna
knockdown
lead
decreas
antioxid
level
increas
oxid
stress
increas
sensit
doxorubicin
explor
physiolog
regul
uncov
role
notch
signal
pathway
repress
express
thu
activ
notch
pathway
notch
ligand
lead
downregul
recapitul
effect
pharmacolog
inhibit
inde
notch
signal
induc
higher
ro
level
along
decreas
viabil
synergi
doxorubicin
conclus
aml
antioxid
master
regul
contribut
chemoresist
find
support
novel
therapeut
approach
wherebi
either
via
small
molecul
brusatol
novel
mechan
induc
notch
signal
induc
cell
death
human
aml
via
enhanc
chemo
sensit
ahm
daak
kebreab
ghebremeskel
mustafa
elbashir
london
metropolitan
univers
london
unit
kingdom
background
chronic
inflamm
coagul
activ
oxid
stress
increasingli
recogn
major
determin
factor
acut
chronic
clinic
manifest
sickl
cell
diseas
scd
sever
line
evid
indic
long
chanc
fatti
acid
could
safe
effect
modifi
therapi
scd
object
demonstr
clinic
biochem
effect
fatti
acid
dha
epa
treatment
scd
designmethod
one
hundr
forti
patient
homozyg
scd
age
randomli
assign
receiv
daili
age
age
age
age
capsul
contain
mg
docosahexaeno
dha
mg
eicosapentaeno
epa
placebo
year
rate
clinic
crisi
hemolyt
event
blood
transfus
rate
assess
effect
treatment
marker
inflamm
blood
cell
adhes
oxid
stress
coagul
intravascular
hemolysi
investig
result
treatment
reduc
median
rate
clinic
event
p
sever
anemia
p
blood
transfus
white
blood
cell
count
p
plasma
lactat
dehydrogenas
ldh
nuclear
b
gene
express
buffi
coat
express
monocyt
integrin
p
fatti
acid
group
significantli
higher
vitamin
e
plasma
level
treatment
signific
effect
plasma
plasma
tumor
necrosi
p
conclus
find
suggest
treatment
fatti
acid
effect
therapeut
option
patent
sickl
cell
diseas
lori
heath
matthew
heeney
carolyn
hopp
samuel
adjei
tsiri
agbenyega
moham
badr
nicoletta
masera
chunmei
zhou
patricia
brown
joseph
jakubowski
carlton
dampier
multin
multin
multin
multin
background
patient
sickl
cell
anemia
sca
experi
recurr
pain
crise
affect
qualiti
life
studi
use
patient
diari
shown
sca
pain
preval
sever
previous
report
base
healthcar
facil
util
alon
dove
multin
studi
assess
efficaci
safeti
prasugrel
reduc
rate
event
children
sca
dove
incorpor
electron
patient
report
outcom
epro
diari
assess
daili
sickl
cell
pain
object
determin
feasibl
epro
diari
assess
frequenc
intens
daili
pain
impact
daili
function
larg
global
studi
children
adolesc
sca
designmethod
dove
util
epro
devic
collect
daili
data
relat
sickl
cell
pain
use
analges
pain
studi
drug
adher
month
children
year
age
diari
content
translat
languag
compris
subject
pain
intens
activ
interfer
object
analges
use
school
attend
compon
pain
intens
measur
use
modifi
version
face
pain
data
transfer
daili
via
cellular
network
central
databas
access
studi
personnel
monitor
complianc
rate
patient
complianc
defin
diari
complet
rate
least
calcul
complet
calcul
number
daili
diari
entri
divid
total
number
expect
diari
entri
result
total
patient
receiv
diari
patient
provid
month
diari
entri
rate
diari
complianc
complet
high
throughout
diari
collect
period
subject
compon
patient
compliant
overal
complet
rate
object
compon
patient
compliant
overal
complet
rate
data
diari
analyz
report
heeney
et
al
nejm
conclus
care
design
patient
support
appropri
monitor
epro
diari
success
measur
impact
daili
sickl
cell
pain
larg
global
studi
studi
sponsor
daiichi
sankyo
lilli
matthew
schefft
india
sisler
caitlin
swaffar
cadi
ploessl
jennif
newlin
robin
foster
massey
cancer
center
children
hospit
richmond
virginia
commonwealth
univers
richmond
virginia
unit
state
background
crisi
voc
frequent
event
children
sickl
cell
diseas
creat
signific
burden
emerg
depart
ed
previou
report
show
decreas
admiss
rate
individu
pain
plan
ipp
use
conjunct
day
hospit
sickl
cell
nurs
practition
embed
ed
object
reduc
admiss
rate
children
sickl
cell
diseas
present
pediatr
ed
voc
within
six
month
initi
ipp
designmethod
qualiti
improv
team
assembl
includ
member
hematolog
divis
ed
pharmaci
pdsa
format
employ
ipp
document
creat
uniqu
folder
within
electron
medic
record
ipp
initi
creat
retrospect
chart
review
highest
resourc
user
pediatr
resid
ed
resid
ed
attend
physician
instruct
access
use
ipp
studi
measur
presenc
ipp
adher
ipp
time
second
opiat
dose
administr
primari
outcom
admiss
rate
length
stay
return
ed
assess
balanc
measur
result
ipp
avail
children
sickl
cell
diseas
present
ed
voc
studi
period
resid
attend
physician
ed
follow
ipp
time
averag
time
administr
second
opiat
dose
minut
ci
among
patient
discharg
ed
compar
minut
ci
p
among
patient
admit
hospit
admiss
rate
ipp
initi
compar
prior
implement
p
overal
admiss
rate
decreas
among
patient
ipp
compar
p
averag
lo
decreas
day
day
sinc
initi
ipp
differ
return
rate
ed
conclus
ipp
provid
effect
strategi
reduc
admiss
rate
children
sickl
cell
diseas
present
voc
shorter
time
second
opiat
dose
also
associ
reduc
risk
admiss
kiersten
ricci
adrienn
hammil
cameron
trenor
alexand
vink
manish
patel
gulraiz
chaudri
paula
mari
sue
wentzel
anita
gupta
carol
chute
jennif
eil
arnold
merrow
lin
fei
roshni
dasgupta
belinda
dicki
lindsey
hornung
ilona
frieden
beth
drolet
megha
tollefson
dov
charl
goldenberg
shoshana
greenberg
ami
geddi
michael
jeng
denis
adam
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
capillari
lymphat
venou
malform
clvm
rare
vascular
anomali
character
abnorm
network
capillari
lymphat
vessel
vein
patient
clvm
suffer
numer
complic
soft
tissu
overgrowth
lymphedema
recurr
cellul
thrombosi
bleed
skin
involv
organ
individu
also
experi
substanti
psycholog
stress
due
chronic
pain
disfigur
function
disabl
treatment
larg
typic
result
signific
diseas
improv
recent
studi
demonstr
import
regulatori
function
pathway
vasculogenesi
provid
support
mtor
inhibit
sirolimu
treatment
option
clvm
object
evalu
safeti
efficaci
sirolimu
treatment
patient
clvm
designmethod
studi
analyz
combin
data
multicent
systemat
retrospect
review
medic
record
patient
treat
sirolimu
januari
june
prospect
phase
clinic
trial
assess
efficaci
safeti
sirolimu
treatment
complic
vascular
anomali
diseas
improv
determin
radiolog
imag
qualiti
life
qol
measur
clinic
statu
assess
sirolimu
dose
regimen
toxic
side
effect
causal
evalu
result
evalu
patient
clvm
patient
complet
resolut
symptom
radiolog
diseas
sirolimu
percent
patient
improv
qol
improv
clinic
statu
improv
radiolog
respons
patient
coagulopathi
less
bleed
complic
complet
bleed
cessat
patient
thrombot
event
symptom
improv
complet
symptom
resolut
skin
involv
lymphedema
improv
affect
patient
respect
patient
diseas
progress
sirolimu
nine
patient
experienc
grade
drug
toxic
requir
dose
reduct
grade
side
effect
attribut
sirolimu
occur
common
side
effect
bone
marrow
suppress
mild
elev
triglycerid
cholesterol
transaminas
level
conclus
sirolimu
safe
treatment
option
appear
efficaci
reduc
symptom
improv
qol
patient
clvm
studi
necessari
assess
outcom
monitor
possibl
late
effect
sana
usmani
yelena
tkachenko
leti
nunez
craig
mullen
univers
rochest
rochest
new
york
unit
state
background
bone
marrow
stromal
cell
provid
favor
microenviron
cell
contribut
prevent
apoptosi
cell
mechan
poorli
understood
object
object
delin
therapeut
disrupt
critic
pathway
leukemia
marrow
microenviron
contribut
cell
surviv
hypothes
nonmalign
marrow
stromal
cell
effici
prevent
apoptosi
leukemia
cell
distinct
profil
gene
express
product
interact
nonmalign
stromal
cell
cell
induc
chang
gene
express
relev
pathway
stromal
leukemia
cell
designmethod
develop
vitro
system
nonmalign
human
marrow
stromal
cell
prevent
apoptosi
primari
human
high
risk
cell
prevent
leukemia
cell
apoptosi
requir
stromal
cell
contact
b
live
stromal
cell
ie
fix
stromal
cell
prevent
apoptosi
c
stromal
cell
protein
synthesi
conduct
two
class
experi
first
compar
rnaseq
profil
cell
line
effici
prevent
leukemia
cell
apoptosi
rnaseq
profil
cell
line
second
assess
global
gene
express
nonmalign
stromal
cell
leukemia
cell
hour
cocultur
rnaseq
perform
use
illumina
platform
cufflink
use
perform
differenti
express
analysi
fdr
cutoff
function
annot
cluster
differenti
express
gene
perform
use
databas
annot
visual
integr
discoveri
softwar
niaid
result
identifi
gene
differenti
express
stromal
cell
effici
prevent
apoptosi
leukemia
gene
involv
cell
surfac
interact
cell
matrix
interact
growth
factor
bind
includ
pdgf
vegf
igf
regul
cell
death
pathway
relat
oxidoreductas
purin
nucleotid
follow
interact
stromal
cell
identifi
gene
relat
regul
apoptosi
cytokin
respons
purin
metabol
extracellular
matrix
interact
conclus
identifi
pathway
stromal
leukemia
cell
relat
prevent
leukemia
cell
apoptosi
provid
opportun
identifi
critic
node
network
might
therapeut
target
shelley
herbrich
marisa
hornbak
sankar
kannan
gari
li
patrick
univ
texa
md
anderson
cancer
center
houston
texa
unit
state
background
emerg
data
indic
dysregul
tropomyosin
receptor
kinas
trk
may
also
play
role
aml
object
determin
therapeut
potenti
trk
inhibit
aml
designmethod
exist
dataset
aml
line
human
stromal
cell
use
assess
trka
ngf
express
signal
therapeut
efficaci
trk
inhibit
entrectinib
result
trka
highli
express
normal
human
common
myeloid
progenitor
suggest
physiolog
role
myelopoiesi
analysi
aml
patient
sampl
dataset
control
reveal
express
trka
aml
sampl
sampl
express
level
higher
mean
normal
control
express
significantli
elev
level
trka
ie
sd
analysi
addit
dataset
reveal
highest
express
trka
erythroblast
megakaryoblast
leukemia
particularli
syndrom
amkl
panel
human
aml
line
trka
express
line
mrna
protein
level
importantli
human
bone
marrow
stroma
cell
express
high
level
ngf
ligand
trka
suggest
novel
role
ngftrka
importantli
ngf
stimul
induc
mapk
andor
akt
signal
aml
line
potenti
effect
aml
prolifer
chemoresist
therapeut
approach
trk
inhibitor
entrectinib
led
signific
growth
inhibit
line
interestingli
sensit
cell
line
posit
conclus
trka
receptor
express
high
level
common
myeloid
progenitor
suggest
import
role
trka
signal
earli
myeloid
develop
surprisingli
trka
receptor
express
major
human
aml
sampl
line
human
bone
marrow
stream
cell
express
high
level
trka
ligand
ngf
exposur
aml
cell
trka
ligand
ngf
potent
induc
surviv
signal
pathway
nearli
aml
cell
final
potent
trk
inhibitor
entrectinib
inhibit
surviv
nearli
half
aml
line
test
result
reveal
novel
aml
mechan
target
support
develop
clinic
trial
target
trk
aml
patient
use
entrectinib
catherin
goudi
stephani
mourad
william
foulk
montreal
children
hospit
mcgill
univers
health
center
montreal
canada
background
inherit
genet
syndrom
increasingli
associ
develop
pediatr
tumor
tumor
may
present
sign
genet
disord
often
associ
goe
unrecogn
clue
inherit
cancer
predisposit
syndrom
cp
may
aris
patient
person
famili
histori
tumor
characterist
object
facilit
recognit
cp
patient
cancer
creat
simpl
algorithm
criteria
form
educ
tool
call
mcgill
integr
pediatr
oncogenet
guidelin
mipogg
criteria
base
extens
literatur
review
aim
identifi
children
warrant
cancer
genet
referr
assess
valid
feasibl
criteria
mipogg
chosen
present
children
renal
tumor
designmethod
determin
patient
diagnos
renal
tumor
subsequ
cp
would
identifi
use
mipogg
criteria
perform
retrospect
chart
review
n
pediatr
patient
renal
tumor
montreal
children
hospit
result
children
diagnos
follow
renal
tumor
wilm
tumor
n
rhabdoid
tumor
n
neuroblastoma
n
cystic
nephroma
n
metanephr
adenoma
n
renal
cell
carcinoma
n
four
patient
proven
cp
n
rhabdoid
tumor
predisposit
syndrom
n
n
n
malign
present
sign
cp
patient
accord
criteria
patient
would
warrant
cancer
genet
referr
case
reason
referr
sent
evalu
referr
criteria
interv
renal
tumor
diagnosi
cancer
genet
referr
rang
month
conclus
mipogg
criteria
would
identifi
children
renal
tumor
cp
demonstr
strong
sensit
although
criteria
may
lack
stringenc
children
refer
genet
physician
without
mipogg
guidelin
sever
patient
may
undiagnos
cp
would
benefit
cancer
genet
referr
raya
saab
christian
al
haddad
tarek
el
khouri
matthew
wilson
sima
jeha
hassan
el
solh
american
univers
beirut
medic
center
beirut
lebanon
background
surviv
patient
intraocular
retinoblastoma
approach
develop
countri
salvag
eye
outcom
develop
countri
poorer
primarili
due
delay
present
cost
barrier
lack
special
personnel
equip
object
collabor
program
establish
allow
access
children
newli
diagnos
intraocular
retinoblastoma
central
diagnosi
stage
multidisciplinari
approach
therapi
local
treatment
deliv
pediatr
ophthalmologist
tertiari
care
set
designmethod
diseas
stage
central
treatment
plan
multidisciplinari
set
patient
receiv
chemotherapi
local
hospit
examin
anesthesia
focal
therapi
enucl
radiat
therapi
provid
cost
famili
program
develop
initi
st
jude
children
research
hospit
sjcrh
memphi
tennesse
unit
state
challeng
case
discuss
sjcrh
team
via
teleconfer
result
year
patient
evalu
retinoblastoma
confirm
nation
lebanes
syrian
iraqi
two
patient
refus
treatment
twelv
remain
unilater
diseas
underw
enucl
group
tumor
patient
bilater
diseas
eye
eventu
enucl
present
group
tumor
six
enucl
eye
histolog
featur
treatment
coordin
center
feasibl
seventeen
patient
receiv
chemotherapi
twelv
patient
underw
cryotherapi
thermotherapi
two
patient
bilater
diseas
requir
extern
beam
radiat
one
child
bilater
diseas
die
mening
recurr
use
vision
preserv
remain
patient
conclus
facilit
access
special
multidisciplinari
care
resolut
financi
barrier
close
coordin
among
medic
team
contribut
success
program
vision
salvag
affect
children
high
rate
advanc
intraocular
diseas
present
necessit
frequent
enucl
demonstr
need
rais
awar
among
pediatrician
ophthalmologist
earlier
diagnosi
referr
charl
quinn
santosh
saraf
victor
gordeuk
courtney
fitzhugh
susan
creari
prasad
boda
alex
georg
ashok
raj
alecia
nero
catherin
terel
lisa
mccord
omar
niss
rubina
dosani
michael
taylor
prasad
devarajan
punam
malik
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
sickl
nephropathi
sn
common
progress
manifest
sickl
cell
anemia
sca
albuminuria
indic
glomerular
injuri
portend
renal
failur
murin
model
sca
found
increas
signal
underli
sn
downregul
losartan
angiotensin
receptor
blocker
reduc
albuminuria
sn
progress
effect
losartan
human
sca
unknown
object
determin
effect
losartan
sn
studi
inform
design
random
trial
designmethod
oral
losartan
administ
month
individu
sca
hbss
year
age
main
exclus
criteria
chronic
transfus
gfr
hyperkalemia
contraind
losartan
enrol
group
defin
urinari
ratio
uacr
albuminuria
noa
microalbuminuria
microa
macroalbuminuria
macroa
primari
endpoint
reduct
uacr
baselin
sampl
size
calcul
detect
primari
endpoint
microa
group
power
secondari
endpoint
urin
osmol
gfr
uacr
classif
toxic
result
particip
mean
age
femal
group
noa
microa
macroa
four
mark
andor
earli
termin
primari
endpoint
reduct
uacr
met
overal
macroa
microa
noa
among
macroa
microa
particip
met
primari
endpoint
overal
uacr
classif
improv
worsen
macroa
microa
particip
uacr
classif
improv
worsen
mean
uacr
mgg
sem
median
sem
median
losartan
p
urin
osmol
gfr
chang
significantli
vs
p
vs
p
losartan
discontinu
leg
cramp
n
gfr
declin
n
serum
creatinin
rise
n
conclus
losartan
appear
decreas
albuminuria
particip
baselin
macroalbuminuria
appear
greatest
benefit
nearli
show
respons
random
trial
design
determin
efficaci
losartan
usua
oyarbid
mj
kell
jacek
topczewski
seth
corey
divis
pediatr
hematolog
oncolog
stem
cell
transplant
massey
cancer
center
children
hospit
richmond
virginia
commonwealth
univers
development
biolog
stanley
mann
children
research
institut
northwestern
univers
feinberg
school
medicin
chicago
illinoi
richmond
virginia
unit
state
background
syndrom
sd
multisystem
disord
character
neutropenia
exocrin
pancreat
insuffici
skelet
abnorm
individu
sd
also
increas
risk
develop
myelodysplast
syndrom
andor
acut
myeloid
leukemia
sd
result
mutat
sbd
gene
genet
ablat
sbd
result
earli
embryon
lethal
ed
mice
zebrafish
provid
attract
altern
model
organ
demonstr
relev
mammalian
hematopoiesi
genom
analysi
zebrafish
danio
rerio
reveal
presenc
singl
sbd
gene
encod
protein
ident
human
orthologu
object
analysi
zebrafish
sbd
mutant
reveal
new
insight
function
gene
vertebr
develop
pathophysiolog
syndrom
designmethod
use
genom
edit
techniqu
gener
indel
mutat
sbd
determin
whether
loss
sbd
affect
number
neutrophil
macrophag
use
transgen
line
tg
mpx
dendra
tg
mpeg
dendra
stain
use
erythrocyt
stain
result
creat
zebrafish
line
null
sbd
western
blot
show
decreas
sbd
level
dpf
protein
absent
result
suggest
presenc
sbd
earli
stage
develop
due
matern
deposit
sbd
knockout
show
reduc
viabil
unlik
mice
homozyg
mutant
live
week
display
mark
growth
retard
phenotyp
interestingli
growth
retard
observ
day
post
fertil
dpf
observ
significantli
low
number
neutrophil
dpf
dpf
howev
statist
signific
differ
macrophag
number
found
also
differ
hemoglobin
erythrocyt
found
dpf
structur
pancrea
liver
eye
defect
homozyg
mutant
dpf
conclus
gener
zebrafish
model
sd
make
highli
relev
model
understand
pathophysiolog
brian
branchford
juli
jaffray
arash
mahajerin
children
hospit
colorado
children
hospit
lo
angel
children
hospit
orang
counti
aurora
colorado
lo
angel
orang
california
unit
state
background
pediatr
venou
thromboembol
incid
rise
larg
sampl
size
need
prospect
epidemiolog
risk
factor
studi
object
form
children
thrombosi
chat
redcap
registri
identifi
independ
risk
factor
clinic
risk
score
develop
designmethod
retrospect
chart
review
reveal
risk
factor
children
develop
vte
admiss
pediatr
hospit
januari
decemb
use
descript
statist
summar
demograph
medic
comorbid
central
venou
cathet
cvc
characterist
initi
patient
enter
databas
well
characterist
vte
result
vte
diagnos
median
iqr
day
patient
median
age
iqr
year
slight
male
predomin
percent
subject
signific
past
medic
histori
immobil
baselin
major
subject
intub
point
admiss
least
one
infect
surgeri
hospit
major
vte
associ
cvc
symptomat
diagnosi
diagnos
outsid
critic
care
unit
distribut
includ
armsleg
csvt
pe
abdomen
intracardiac
conclus
initi
result
phase
demonstr
slight
male
predisposit
multipl
associ
chronic
medic
ill
acquir
hospit
cours
primarili
cvc
ongo
work
includ
incorpor
subject
multipl
addit
institut
integr
data
control
subject
identifi
independ
factor
develop
risk
score
model
goal
includ
phase
prospect
valid
risk
score
second
cohort
children
hospit
ultim
plan
use
score
system
stratifi
children
phase
futur
random
clinic
trial
efficaci
safeti
variou
prevent
strategi
reduc
pediatr
incid
without
unnecessari
thromboprophylaxi
exposur
carolyn
bennett
cindi
neunert
paul
imbach
rachael
grace
sara
vese
thoma
kuhn
emori
univers
school
medicin
atlanta
georgia
unit
state
background
pediatr
immun
thrombocytopenia
itp
rare
acquir
autoimmun
bleed
disord
spontan
remit
children
approxim
children
develop
chronic
thrombocytopenia
beyond
month
may
increas
bleed
risk
predictor
remiss
well
defin
object
identifi
factor
may
predict
diseas
remiss
pediatr
itp
designmethod
data
ici
group
registri
ii
larg
prospect
cohort
pediatr
patient
itp
analyz
investig
factor
associ
diseas
remiss
result
registri
ii
patient
data
month
patient
data
month
univari
analysi
younger
age
pharmacolog
treatment
diagnosi
associ
remiss
month
p
variabl
time
bleed
diagnosi
also
associ
remiss
p
month
p
multivari
analysi
remiss
month
associ
younger
age
year
ci
year
ci
year
ci
higher
bleed
grade
diagnosi
ci
combin
treatment
intraven
immunoglobulin
ivig
corticosteroid
diagnosi
ci
younger
age
year
ci
year
ci
year
ci
combin
treatment
ivig
steroid
diagnosi
ci
associ
remiss
month
patient
year
like
achiev
remiss
month
gender
platelet
count
diagnosi
associ
remiss
conclus
younger
age
higher
bleed
sever
diagnosi
pharmacolog
treatment
combin
corticosteroid
ivig
diagnosi
associ
remiss
month
ici
registri
ii
patient
year
age
highest
likelihood
remiss
month
relationship
bleed
treatment
diagnosi
pediatr
itp
requir
studi
better
understand
whether
independ
predictor
remiss
kathleen
overholt
hemalatha
rangarajan
sarita
joshi
melissa
rose
rajind
bajwa
rolla
jefferi
auletta
edwin
horwitz
nationwid
children
hospit
columbu
ohio
unit
state
background
osteopetrosi
op
rare
genet
diseas
character
dysfunct
defici
osteoclast
lead
increas
bone
miner
densiti
bmd
secondari
absent
bone
reabsorpt
children
malign
infantil
osteopetrosi
miop
lethal
form
op
exhibit
array
symptom
includ
pancytopenia
neurolog
abnorm
hepatosplenomegali
growth
defici
hypocalcemia
respiratori
compromis
approxim
children
identifi
genet
mutat
current
known
mutat
respons
op
phenotyp
common
mutat
includ
encod
protein
involv
acidif
osteoclast
lacuna
hematopoiet
cell
transplant
hct
potenti
cur
therapi
howev
subset
patient
depend
mutat
respond
hct
object
children
mutat
consid
earli
hct
mutat
children
present
neurolog
symptom
regard
contraind
hct
sinc
abrog
associ
neuropatholog
progress
death
howev
whether
hct
arrest
neuropatholog
progress
child
undergo
transplant
prior
onset
signific
neurolog
symptom
report
designmethod
report
describ
week
old
male
present
tachypnea
increas
bmd
chest
thrombocytopenia
macrocyt
anemia
found
two
heterozyg
mutat
gene
exon
ivsi
neurolog
test
includ
brain
mri
evalu
electroretinogram
normal
given
absenc
signific
neurolog
sign
symptom
care
discuss
famili
decis
made
move
forward
hct
sibl
patient
underw
myeloabl
condit
busulfan
fludarabin
month
age
result
transplant
cours
unev
howev
two
month
transplant
patient
develop
infantil
spasm
brain
mri
show
diffus
cerebr
atrophi
despit
neurolog
progress
month
age
reduc
bmd
healthi
reconstitut
hematopoiesi
conclus
patient
suggest
earli
hct
patient
mutat
prevent
neurolog
deterior
understand
complet
outcom
requir
longer
yamilet
huerta
anant
vatsayan
yousif
matloub
jignesh
dalal
uh
rainbow
babi
children
hospit
cleveland
ohio
unit
state
background
mutat
cytoskeleton
regul
dedic
cytokinesi
syndrom
protein
wasp
often
associ
immunodefici
autosom
recess
mutat
result
immunodefici
syndrom
did
largest
intern
retrospect
survey
patient
did
underw
hematopoiet
stem
cell
transplant
hsct
suggest
potenti
cur
measur
recent
literatur
review
patient
did
undergo
hsct
support
find
howev
consensu
guidelin
therapi
optim
manag
remain
unknown
object
describ
outcom
hsct
patient
did
designmethod
case
report
result
saudi
arabian
male
product
consanguin
marriag
histori
did
refer
center
hsct
medic
histori
reveal
multipl
food
allergi
eczema
asthma
sinc
age
infecti
complic
includ
recurr
bacteri
fungal
viral
skin
infect
besid
sinopulmonari
infect
five
famili
member
die
did
lab
workup
reveal
eosinophilia
lymphopenia
high
ige
mgdl
low
igm
level
gene
sequenc
confirm
defici
homozyg
mutat
patient
receiv
hsct
elder
brother
heterozyg
mutat
patient
condit
regimen
includ
fludarabin
busulfan
short
cours
methotrex
tacrolimu
use
diseas
gvhd
prophylaxi
engraft
peripher
blood
chimer
show
recipi
dna
follow
hsct
patient
good
immun
reconstitut
post
transplant
complic
includ
verruca
plana
mild
reactiv
hsv
blephar
treat
appropri
present
patient
tacrolimu
without
sign
acut
gvhd
conclus
summari
case
repres
typic
natur
cours
patient
did
time
referr
hsct
prove
life
save
patient
treatment
patient
rel
prove
fatal
henc
emphas
import
earli
recognit
screen
famili
member
risk
develop
fatal
complic
case
highlight
need
larg
scale
prospect
clinic
trial
evalu
efficaci
hsct
did
scientif
insight
base
remark
resembl
clinicopatholog
phenotyp
wasp
mutat
suggest
cur
potenti
hsct
did
kristin
marr
helen
nadel
caron
strahlendorf
jeffrey
davi
rebecca
deyel
univers
british
columbiabritish
columbia
children
hospit
vancouv
british
columbia
canada
background
current
upfront
therapi
greater
children
hodgkin
lymphoma
hl
achiev
remiss
howev
remain
challeng
subset
patient
relaps
refractori
diseas
fail
first
line
therapi
requir
salvag
therapi
prior
consolid
autolog
stem
cell
transplant
asct
combin
ifosfamid
gemcitabin
vinorelbin
igev
use
salvag
regimen
adult
relaps
refractori
hl
high
rate
diseas
respons
success
stem
cell
mobil
util
regimen
pediatr
hl
previous
report
object
report
efficaci
toxic
igev
salvag
chemotherapi
regimen
pediatr
patient
refractori
relaps
hl
designmethod
eight
pediatr
patient
age
year
primari
refractori
n
first
relaps
n
hl
includ
patient
treat
singl
institut
cycl
igev
chemotherapi
follow
asct
radiat
therapi
receiv
upfront
therapi
n
result
overal
respons
rate
patient
obtain
complet
respons
partial
respons
base
fdg
petct
diseas
evalu
igev
therapi
median
follow
month
seven
eight
patient
aliv
second
remiss
one
patient
progress
diseas
asct
die
patient
success
stem
cell
mobil
singl
apheresi
procedur
median
cell
count
primari
toxic
hematolog
two
patient
grade
infect
grade
toxic
mortal
conclus
igev
effect
salvag
regimen
children
relaps
refractori
hodgkin
lymphoma
due
high
rate
diseas
respons
success
facilit
autolog
stem
cell
collect
accept
toxic
profil
hannah
g
kay
jennif
andrew
karen
effing
stanford
univers
stanford
california
unit
state
background
hematopoiet
stem
cell
transplant
hsct
techniqu
support
care
improv
children
surviv
transplant
patient
requir
multipl
transfus
may
result
iron
overload
though
preval
popul
unknown
object
determin
preval
differ
preval
iron
overload
year
hsct
predictor
iron
overload
pediatr
hsct
survivor
designmethod
evalu
children
median
age
hsct
year
rang
male
diagnos
underw
hsct
allogen
iron
overload
defin
ferritin
level
ngml
use
sa
softwar
perform
mcnemar
test
sign
test
logist
regress
evalu
differ
preval
iron
overload
chang
ferritin
level
factor
associ
iron
overload
year
hsct
result
patient
ferritin
record
year
year
patient
record
ferritin
like
male
vs
p
allogen
transplant
recipi
vs
p
underli
diagnosi
leukemiamd
vs
p
year
signific
decreas
mean
ferritin
level
ngml
vs
ngml
p
howev
chang
preval
iron
overload
time
point
p
patient
receiv
pack
red
blood
cell
prbc
approxim
transfus
like
iron
overload
ci
factor
includ
age
race
ethnic
gender
underli
diagnosi
stem
cell
sourc
abo
incompat
associ
risk
iron
overload
conclus
quarter
patient
evid
iron
overload
year
hsct
lack
improv
iron
overload
year
highlight
need
regular
iron
overload
screen
treatment
order
reduc
sever
morbid
especi
survivor
receiv
least
prbc
larger
studi
need
assess
risk
factor
iron
overload
popul
ashley
koegel
traci
blonquist
lewi
silverman
lynda
vrooman
boston
children
hospitaldana
farber
cancer
institut
boston
massachusett
unit
state
background
children
undergo
induct
therapi
acut
lymphoblast
leukemia
risk
toxic
lead
morbid
mortal
delay
plan
therapi
object
aim
character
toxic
induct
assess
associ
induct
toxic
delay
start
plan
therapi
explor
whether
delay
start
plan
therapi
ultim
associ
reduc
surviv
df
designmethod
patient
age
year
newli
diagnos
consortium
site
enrol
protocol
patient
receiv
ident
induct
therapi
includ
anthracyclin
regardless
risk
group
induct
toxic
prospect
collect
grade
accord
common
terminolog
criteria
advers
event
ctcae
treatment
delay
assess
follow
day
day
day
date
complet
remiss
cr
start
next
treatment
phase
day
consid
delay
df
compar
group
test
estim
method
result
elig
patient
enrol
achiev
cr
induct
patient
experienc
grade
higher
toxic
common
toxic
infect
patient
gastrointestin
metabol
cardiovascular
hepat
neurolog
sixteen
patient
die
induct
commonli
due
grade
infect
n
evalu
patient
patient
experienc
delay
start
plan
therapi
day
day
day
follow
induct
toxic
associ
delay
infect
p
gastrointestin
neurolog
p
cardiovascular
p
metabol
p
within
gastrointestin
categori
typhliti
p
mucos
p
pancreat
p
associ
delay
hyperglycemia
induct
associ
reduc
df
p
induct
toxic
delay
group
associ
reduc
df
conclus
grade
higher
toxic
frequent
childhood
induct
associ
treatment
delay
howev
induct
toxic
delay
plan
therapi
appear
impact
df
investig
reduc
toxic
antimicrobi
prophylaxi
warrant
dana
lounder
sonata
jodel
pooja
khandelw
christoph
dandoy
gregori
wallac
adam
lane
cynthia
taggart
ashley
teusink
kelli
lake
stella
davi
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
vitamin
metabolit
retino
acid
directli
influenc
develop
function
immun
system
enhanc
differenti
regulatori
mous
model
vitamin
defici
increas
inflammatori
cytokin
lymphoid
tissu
drain
lymph
node
contrast
mous
model
shown
exogen
vitamin
exacerb
gi
gvhd
increas
traffick
gut
genet
ablat
retino
acid
receptor
signal
donor
also
reduc
sever
gvhd
liver
suggest
vitamin
pro
depend
context
object
hypothes
lower
level
vitamin
lead
increas
incid
gvhd
designmethod
conduct
cohort
studi
children
receiv
allogen
hsct
enrol
bmt
repositori
blood
sampl
clinic
data
collect
prospect
weekli
admiss
day
vitamin
level
measur
patient
plasma
baselin
day
use
human
vitamin
elisa
kit
mybiosourc
univari
multivari
analys
perform
primari
endpoint
develop
gvhd
result
cumul
incid
grade
gi
gvhd
increas
children
vitamin
level
median
day
compar
median
vs
day
p
vs
day
p
multivari
analysi
vitamin
level
remain
independ
risk
factor
gvhd
conclus
data
show
vitamin
defici
associ
increas
risk
acut
gvhd
includ
gi
gvhd
possibl
due
direct
effect
vitamin
defici
immun
system
gvhd
lead
reduc
vitamin
level
attempt
address
look
chang
vitamin
level
baselin
day
associ
seen
p
also
level
measur
day
patient
plasma
associ
develop
gvhd
seen
p
futur
studi
seek
replic
current
data
independ
dataset
explor
mechan
find
terzah
horton
xiaomin
lu
maureen
obrien
michael
borowitz
meenakshi
devida
elizabeth
raetz
patrick
brown
hui
zeng
jame
whitlock
stephen
hunger
baylor
colleg
medicin
houston
texa
unit
state
background
cog
conduct
phase
reinduct
studi
first
relaps
lymphoblast
lymphoma
relaps
studi
combin
bortezomib
bortez
proteasom
inhibitor
standard
cog
reinduct
backbon
object
object
primari
object
studi
compar
reinduct
rate
histor
control
rate
object
success
complet
previous
examin
effect
chemotherapi
mrd
therapi
block
correl
mrd
statu
clinic
outcom
designmethod
elig
patient
stratifi
age
diseas
immunotyp
time
relaps
pt
yr
old
stratifi
either
earli
n
intermedi
n
risk
medullari
combin
medullarycn
relaps
trial
also
enrol
evalu
pt
pt
yr
pt
mrd
mrd
assess
follow
therapi
block
event
free
surviv
ef
overal
surviv
os
determin
use
curv
result
total
evalu
patient
stratum
success
mrd
determin
end
block
respect
use
mrd
sensit
cutoff
correspond
rate
percentag
similar
use
mrd
cutoff
mrd
strongli
predict
outcom
high
intermedi
risk
patient
ef
vs
p
similar
result
seen
relaps
diagnosi
ef
vs
p
conclus
mrd
excel
predictor
clinic
outcom
chemotherapi
effect
reduc
mrd
follow
therapi
block
patient
posit
mrd
induct
block
howev
exceedingli
poor
prognosi
siop
samantha
hale
jennif
webb
allistair
abraham
children
nation
medic
center
washington
district
columbia
unit
state
background
hematopoiet
stem
cell
transplant
hsct
potenti
cur
therapi
sickl
cell
diseas
scd
current
signific
research
perform
clinic
impact
hsct
patient
scd
preliminari
studi
analyz
outcom
hsct
red
blood
cell
rbc
antigen
discord
object
investig
frequenc
clinic
signific
minor
rbc
antigen
discord
hsct
outcom
patient
scd
designmethod
studi
retrospect
analysi
cohort
patient
scd
receiv
hsct
singl
institut
result
patient
scd
receiv
hsct
avail
data
minor
rbc
antigen
donor
recipi
patient
receiv
transplant
hla
relat
donor
male
african
american
mean
age
transplant
year
old
major
condit
regimen
myeloabl
primari
indic
transplant
histori
stroke
vasoocclus
crisi
acut
chest
syndrom
prior
transplant
alloantibodi
present
subject
major
two
patient
follow
minimum
year
major
patient
least
minor
rbc
antigen
discord
donor
fourteen
patient
discord
common
discord
blood
group
system
rh
mn
dombrock
none
subject
develop
novel
antibodi
follow
hsct
despit
discord
overal
littl
correl
number
minor
rbc
antigen
discord
hsct
outcom
overal
surviv
graft
failur
transfus
requir
time
engraft
time
transfus
independ
complic
howev
patient
two
minor
rbc
discord
chronic
diseas
gvhd
patient
one
discord
like
develop
acut
gvhd
conclus
appear
trend
toward
increas
chronic
gvhd
patient
greater
number
discord
minor
rbc
antigen
associ
clinic
hsct
outcom
howev
given
limit
size
cohort
studi
requir
matthew
barth
stanton
goldman
javier
oesterheld
kenneth
heym
lauren
harrison
berkley
nickerson
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
highli
curabl
chemotherapi
associ
high
rate
acut
toxic
children
oncolog
group
studi
demonstr
safeti
feasibl
ad
six
dose
rituximab
fab
group
b
stage
iiiiv
fab
group
c
base
chemotherapi
goldman
et
al
leukemia
bjh
intern
trial
random
children
adolesc
higher
risk
diseas
rituximab
recent
stop
prematur
follow
observ
improv
year
ef
addit
rituximab
gross
person
commun
object
safe
reduc
therapi
burden
reduct
anthracyclin
exposur
andor
reduct
standard
intrathec
therapi
use
intrathec
liposom
cytarabin
addit
rituximab
designmethod
intermedi
group
b
high
risk
group
c
matur
lymphoma
leukemia
patient
age
exclud
immunodefici
primari
mediastin
patient
enrol
multicent
studi
patient
receiv
six
rituximab
dose
two
induct
two
dosescours
two
consolid
one
dosecours
cours
doxorubicin
dose
reduct
intermedi
risk
patient
year
year
given
concurr
dexamethason
follow
methotrex
clearanc
induct
cycl
cn
neg
patient
cn
posit
patient
receiv
two
addit
dose
consolid
mainten
result
januari
patient
median
age
year
rang
male
dlbl
group
b
stage
ii
stage
iii
group
c
cn
enrol
one
report
rituximab
relat
grade
anaphylaxi
manag
steroid
subsequ
dose
rate
grade
iiiiv
mucos
febril
neutropenia
induct
intermedi
risk
patient
receiv
reduc
anthracyclin
dose
notabl
neurolog
toxic
associ
median
time
studi
entri
week
rang
week
ef
os
current
conclus
result
date
suggest
safe
reduc
anthracyclin
exposur
subsequ
acut
chemotherapi
relat
toxic
intermedi
risk
limit
side
effect
observ
given
methotrex
clearanc
one
year
ef
remain
high
fund
part
sigma
tau
pharmaceut
brinda
mehta
liana
klejmont
michael
milon
lesli
shaw
erin
morri
lauren
harrison
debra
abram
harshini
mahanti
tamar
horowitz
sandra
fabricator
carmella
van
de
ven
taylor
lamarr
theodor
moor
shalini
shenoy
lisa
murray
john
tse
maggi
londono
barbara
ehrenreich
cori
abikoff
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
busulfan
bu
commonli
use
allohsct
condit
regimen
howev
requir
plasma
level
monitor
due
narrow
therapeut
window
previous
report
bu
dose
iv
compar
pharmacokinet
pk
profil
dose
therapeut
bu
steadi
state
concentr
css
success
pediatr
allohsct
object
determin
pk
bu
iv
clinic
outcom
relat
bu
exposur
cohort
patient
scd
undergo
fhi
tcd
allohsct
enrich
addback
designmethod
patient
scd
featur
elig
myeloabl
condit
regimen
includ
fludarabin
thiotepa
cyclophosphamid
bu
result
fourteen
patient
evalu
median
age
mf
dose
weight
kg
day
pk
analysi
reveal
volum
distribut
vd
life
min
clearanc
cl
mlminkg
therapeut
bu
css
achiev
recipi
ngml
median
neutrophil
platelet
engraft
occur
day
respect
primari
secondari
graft
failur
seen
sever
so
lead
death
occur
one
recipi
bu
css
ngmlauc
mmol
minl
one
grade
seizur
median
whole
blood
rbc
donor
chimer
conclus
pk
paramet
bu
scd
cohort
consist
previous
report
pk
data
popul
also
establish
pk
data
favor
clinic
outcom
low
incid
toxic
suggest
bu
popul
safe
low
incid
so
engraft
gall
jbcairo
et
al
bone
marrow
transplant
glen
lew
xiaomin
lu
rochel
yanofski
susan
rheingold
jame
whitlock
cindi
wang
meenakshi
devida
carolin
hast
naomi
winick
william
carrol
michael
borowitz
michael
pulsiph
stephen
hunger
emori
universitychildren
healthcar
atlanta
atlanta
georgia
unit
state
background
relaps
childhood
poor
prognosi
time
site
relaps
best
predictor
subsequ
outcom
race
ethnic
previous
shown
impact
surviv
children
newli
diagnos
effect
prognosi
relaps
unknown
object
report
updat
outcom
data
assess
prognost
impact
end
induct
minim
residu
diseas
mrd
race
ethnic
patient
relaps
enrol
cog
designmethod
studi
patient
relaps
childhood
defin
earli
cnstesticular
relaps
month
diagnosi
late
bmcombin
relaps
month
raceethn
data
collect
enrol
therapi
base
upon
cog
relaps
protocol
includ
random
vincristin
dose
versu
due
excess
neurotox
result
earli
closur
aspho
subject
exclud
analysi
mrd
measur
flow
cytometri
central
refer
laboratori
result
elig
patient
enrol
overal
distribut
patient
raceethn
black
hispan
similar
cog
trial
efso
bm
relaps
cohort
respect
despit
small
patient
number
race
appear
predict
outcom
ef
black
versu
white
patient
p
ethnic
also
predict
ef
hispan
versu
patient
p
mrd
highli
predict
efso
mrd
versu
mrd
p
conclus
outcom
patient
late
marrow
relaps
childhood
compar
recent
intern
trial
mrd
robust
predictor
outcom
contrast
race
ethnic
appear
impact
subsequ
relapsesurviv
rate
recurr
leukemia
differ
therapeut
intens
diseas
biolog
relaps
could
play
role
explain
lessen
impact
race
ethnic
outcom
juliu
weng
theodor
moor
david
geffen
school
medicin
ucla
lo
angel
california
unit
state
background
cord
blood
use
altern
stem
cell
sourc
hematopoiet
stem
cell
transplant
hsct
object
report
year
experi
singl
institut
impact
center
experi
improv
support
care
increas
number
bank
cord
unit
outcom
time
designmethod
retrospect
chart
review
pediatr
hematopoiet
stem
cell
transplant
year
period
result
hsct
perform
year
period
perform
use
cord
blood
stem
cell
sourc
four
relat
donor
rd
unrel
donor
urd
transplant
diseas
nmd
urd
rd
malign
diseas
md
urd
rd
patient
transplant
relat
donor
malign
condit
year
surviv
ef
overal
surviv
os
respect
incid
acut
gvhd
grade
grade
chronic
gvhd
patient
transplant
unrel
donor
use
total
bodi
irradi
tbi
contain
regimen
depend
diseas
immunosuppress
major
consist
cyclosporin
csa
prednison
patient
match
loci
high
resolut
ef
os
measur
day
year
greater
year
incid
acut
gvhd
grade
grade
chronic
gvhd
absent
evalu
patient
limit
extens
conclus
cord
blood
offer
viabl
altern
bone
marrow
sourc
hematopoiet
stem
cell
transplant
year
cord
blood
use
institut
signific
improv
surviv
appreci
time
like
number
factor
includ
center
experi
improv
support
care
cord
unit
avail
select
better
appreci
factor
import
choos
optim
graft
result
compar
favor
match
bone
marrow
transplant
control
catheren
bernard
rashmika
rajendran
febe
renjitha
suman
juliu
xavier
scott
aruna
rajendran
sri
ramachandra
medic
colleg
research
institut
chennai
tamil
nadu
india
background
pediatr
chronic
myeloid
leukemia
cml
rare
long
term
medic
toxic
famili
support
educ
parent
psychosocioeconom
status
area
studi
especi
develop
countri
object
studi
clinicohematolog
profil
diagnost
therapeut
method
impact
diseas
educ
psychosocioeconom
compromis
parent
designmethod
demographi
clinic
hematolog
featur
present
treatment
complianc
toxic
follow
detail
patient
cml
done
parent
answer
valid
questionnair
assess
psychosocioeconom
impact
result
seven
pediatr
patient
diagnos
cml
incid
pediatr
leukemia
cml
patient
opt
undergo
treatment
male
femal
symptom
abdomin
pain
fever
weight
loss
splenomegali
patient
present
chronic
phase
one
patient
hyperleukocytosi
fish
karyotyp
detect
done
patient
given
standard
dose
timatinib
toxic
symptom
like
gastrointestin
intoler
skin
rash
hyperpigment
bone
pain
myalgia
cramp
toler
patient
five
patient
compliant
complet
molecular
respons
cmr
obtain
month
maintain
cmr
year
follow
one
patient
show
treatment
failur
due
loss
complianc
four
patient
lost
year
school
five
middl
socioeconom
class
patient
travel
bu
met
medic
expens
insur
support
friend
one
upper
class
patient
met
expens
parent
evalu
respond
feel
guilti
includ
interperson
relationship
depress
felt
gloomi
worri
futur
show
difficulti
cope
burden
nobodi
chose
drug
alcohol
econom
constraint
sell
asset
conclus
pediatr
patient
cml
respond
well
minimum
toxic
imatinib
school
affect
parent
depress
difficulti
cope
govern
organ
initi
strategi
provid
psychosocioeconom
support
famili
member
patient
cml
mauricio
chaparro
marcela
hospit
de
la
misericordia
dc
colombia
background
total
bodi
irradi
tbi
associ
mani
acut
chronic
complic
standard
therapi
condit
allogen
stem
cell
transplant
allosct
children
acut
lymphoblast
leukemia
thiotepa
alkyl
compound
myeloabl
activ
mimic
effect
radiat
use
thiotepa
busulfan
fludarabin
acut
leukemia
frequent
europ
adult
children
report
experi
term
secur
altern
probabl
less
toxic
condit
children
object
evalu
rate
acut
complic
graft
failur
acut
ghvd
transplant
relat
mortal
allosct
children
condit
designmethod
perform
retrospect
analysi
consecut
patient
transplant
condit
singl
pediatr
stem
cell
transplant
center
median
follow
month
result
septemb
decemb
patient
receiv
allogen
stem
cell
transplant
condit
median
age
sct
year
percentag
patient
respect
patient
receiv
unrel
cord
blood
match
sibl
bone
marrow
primari
engraft
donor
cell
present
patient
acut
gvhd
grade
observ
patient
patient
develop
sever
mucos
hemorrhag
cystiti
vod
patient
die
bacteri
sepsi
trm
short
follow
period
patient
relaps
conclus
myeloabl
condit
safe
excel
rate
engraft
low
acut
toxic
graft
versu
host
diseas
similar
expect
tbi
longer
follow
conclud
effect
tbi
less
late
effect
children
anand
prakash
sarita
bosco
jyothi
munireddi
st
john
medic
colleg
hospit
bangalor
karnataka
india
background
hemophagocyt
lymphohistiocytosi
hlh
rare
often
life
threaten
syndrom
character
reactiv
system
prolifer
benign
histiocyt
throughout
reticuloendotheli
system
tropic
develop
countri
diagnosi
may
miss
common
caus
triad
high
fever
splenomegali
cytopenia
object
describ
profil
outcom
children
primari
hlh
pediatr
unit
develop
countri
designmethod
retrospect
review
case
primari
hlh
diagnos
year
period
pediatr
hematolog
oncolog
unit
result
fifteen
case
primari
hlh
diagnos
per
hlh
diagnost
criteria
case
refer
case
pyrexia
unknown
origin
puo
syndrom
diagnosi
made
patient
griscelli
syndrom
chediak
higashi
treat
per
hlh
protocol
two
children
neurolog
involv
hlh
twelv
children
respond
induct
therapi
one
expir
treatment
could
initi
three
expir
due
refractori
hlh
induct
chemotherapi
stem
cell
transplant
advis
patient
hlh
control
child
underw
sct
anoth
centr
succumb
sepsi
seven
case
continu
therapi
follow
four
lost
follow
continu
therapi
conclus
hlh
consid
diagnost
possibl
child
present
puo
especi
dysmorph
featur
suggest
griscelli
chediak
higashi
syndrom
therapi
hlh
protocol
success
major
case
access
stem
cell
transplant
still
challeng
develop
world
catalina
ruiz
mesa
melissa
diamond
fernando
leonardo
tamariz
sethuraman
swaminathan
edward
ziga
jackson
memori
hospitalunivers
miami
miami
florida
unit
state
background
stem
cell
transplant
sct
establish
therapi
numer
malign
condit
pediatr
popul
associ
signific
morbid
mortal
acut
cardiac
complic
rare
condit
pericardi
effus
pe
frequent
complic
may
relat
cardiac
toxic
per
se
may
signific
impact
overal
surviv
patient
object
assess
risk
factor
pericardi
effus
pediatr
patient
hematopoiet
stem
cell
transplant
impact
mortal
designmethod
conduct
retrospect
chart
review
cohort
pediatr
patient
less
year
age
admit
academ
tertiari
hospit
miami
florida
underw
sct
either
due
malign
hematolog
disord
result
patient
echocardiogram
prior
transplant
exclud
total
incid
pe
ci
studi
show
differ
outcom
condit
regimen
infect
patient
develop
pe
patient
receiv
total
bodi
irradi
develop
pe
p
also
signific
p
among
infect
adenoviru
p
infect
p
signific
risk
pe
statist
signific
incid
pe
donor
sourc
howev
incid
among
marrow
peripher
cord
blood
stem
cell
recipi
respect
show
import
trend
length
stay
sct
patient
effus
day
compar
day
develop
pe
p
overal
mortal
rate
initi
admiss
condit
stem
cell
infus
pe
mortal
rate
p
conclus
cohort
found
statist
signific
risk
develop
pe
gvhd
alreadi
report
addit
infect
opinion
yet
describ
overal
patient
develop
pe
higher
morbid
mortal
hemant
menghani
cori
morrison
louisiana
state
univers
health
scienc
center
new
orlean
louisiana
unit
state
background
langerhan
cell
histiocytosi
lch
inflammatori
diseas
character
prolifer
accumul
dendrit
cell
background
reactiv
macrophag
lymphocyt
eosinophil
current
classif
lch
broad
spectrum
base
extent
organ
involv
diagnosi
patient
multifoc
diseas
risk
organ
involv
present
usual
carri
wors
prognosi
anoth
import
prognost
factor
initi
respons
therapi
object
determin
incid
treatment
outcom
data
lch
patient
diagnos
children
hospit
new
orlean
time
period
designmethod
retrospect
chart
review
result
total
patient
diagnos
twenti
patient
present
singl
system
ss
present
multisystem
ms
diseas
ms
diseas
present
risk
organ
involv
rove
patient
risk
organ
involv
patient
ms
diseas
reactivationprogress
mean
follow
year
patient
diseas
reactivationprogress
mean
follow
year
discuss
previous
one
signific
prognost
factor
ms
rove
lch
respons
therapi
patient
rove
diseas
activ
diseas
note
one
patient
week
patient
month
patient
month
patient
rove
diseas
either
reactiv
progress
mean
follow
year
analyz
durat
therapi
patient
receiv
month
therapi
reactivationprogress
contrast
patient
receiv
therapi
month
reactivationprogress
group
histiocyt
societi
studi
lch
iii
report
reactiv
rate
conclus
data
repres
rel
small
sampl
size
singl
institut
mortal
note
patient
ss
diseas
patient
event
free
mean
follow
year
patient
ms
diseas
overal
event
free
surviv
mean
follow
year
one
mortal
group
major
prognost
factor
involv
cn
risk
lesion
durat
therapi
daniel
ortiz
catalina
ruiz
mesa
joici
estevez
martin
andreanski
edward
ziga
univers
children
hospit
miami
florida
unit
state
background
children
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
potenti
fatal
viral
infect
includ
adenoviru
major
caus
morbid
mortal
popul
cidofovir
nucleotid
phosphat
analogu
competit
inhibit
incorpor
deoxycytidin
triphosph
dna
viral
dna
polymeras
therebi
disrupt
chain
elong
demonstr
activ
number
dna
virus
includ
adenoviru
herpesviru
poxviru
papillomaviru
polyomaviru
given
intraven
iv
recent
case
repot
describ
safe
success
administr
inhal
treatment
respiratori
viral
infect
object
report
case
pediatr
hematopoiet
stem
cell
transplant
recipi
treat
inhal
cidofovir
adenoviru
pneumon
designmethod
case
report
literatur
review
result
year
old
hispan
femal
past
medic
histori
fanconi
anemia
develop
failur
requir
dialysi
respiratori
support
adenoviru
pneumon
day
umbil
cord
stem
cell
transplant
tracheal
aspir
time
intub
posit
adenoviru
pcr
despit
maxim
dose
iv
cidofovir
adjust
renal
failur
viral
load
continu
trend
clinic
deterior
obtain
parent
consent
treat
inhal
cidofovir
dilut
normal
salin
administ
daili
via
et
tube
total
dose
base
previous
publish
case
report
progress
improv
clinic
eventu
requir
minim
ventil
support
adenoviru
viral
load
tracheal
aspir
drop
progress
dna
copiesml
immedi
complic
observ
conclus
though
adenoviru
pneumon
major
caus
morbid
mortal
among
pediatr
hsct
recipi
treatment
challeng
inhal
cidofovir
offer
altern
iv
cidofovir
patient
renal
failur
iv
cidofovir
might
contraind
due
nephrotox
well
design
studi
need
assess
safeti
efficaci
inhal
cidofovir
eric
thoma
walsh
temp
chen
etan
orgel
miller
children
women
hospit
long
beach
long
beach
california
unit
state
background
invas
fungal
infect
ifi
complic
neutropen
children
treat
acut
myeloid
leukemia
aml
earli
diagnosi
crucial
clinic
sign
isol
prolong
fever
often
make
correct
identif
ifi
challeng
bdg
major
cell
wall
compon
invas
fungi
detect
serum
facilit
diagnosi
ifi
bdg
posit
valid
diagnosi
ifi
adult
popul
correl
bdg
ifi
remain
unproven
pediatr
cancer
object
assess
correl
detect
serum
bdg
via
assay
ifi
pediatr
popul
aml
designmethod
retrospect
cohort
studi
pediatr
subject
aml
year
diagnosi
treat
miller
children
women
hospit
long
beach
least
one
report
bdg
assay
antifung
prophylaxi
quantiti
detect
bdg
associ
ifi
evalu
cultur
radiograph
imag
aspergillu
galactomannan
antigen
patholog
collect
independ
review
studi
posit
ifi
defin
probableproven
accord
consensu
eortcmsg
guidelin
exclud
bdg
multipl
receiv
oper
characterist
roc
curv
gener
vari
bdg
threshold
rang
pgml
use
best
fit
curv
analyz
specif
sensit
true
posit
likelihood
ratio
lr
across
threshold
determin
optim
boundari
limit
serum
bdg
associ
ifi
pediatr
oncolog
popul
result
total
report
bdg
assay
ifi
evalu
review
chemotherapi
cycl
administ
elig
subject
routin
antifung
prophylaxi
administ
subject
fluconazol
echinocandin
posit
ifi
diagnos
subject
inspect
best
fit
roc
curv
auc
identifi
bdg
threshold
pgml
associ
highest
correct
classif
lr
balanc
specif
sensit
increas
threshold
pgml
decreas
correct
classif
markedli
affect
sensit
minor
improv
specif
conclus
detect
bdg
threshold
pgml
suffici
specif
aid
diagnosi
ifi
pediatr
popul
aml
rudayna
tova
chein
eleni
staten
island
univers
hospit
staten
island
new
york
unit
state
background
chronic
administr
opioid
associ
lymphocyt
abnorm
affect
immun
system
function
littl
known
effect
matern
drug
use
neonat
immun
system
lymphocyt
count
hypothes
matern
drug
use
pregnanc
lead
neonat
lymphopenia
recogn
possibl
increas
risk
infect
popul
allow
appropri
counsel
precaut
object
identifi
newborn
expos
intrauterin
drug
experienc
hematolog
abnorm
specif
lymphopenia
designmethod
retrospect
chart
review
neonat
born
document
drug
withdraw
syndrom
conduct
medic
record
obtain
electron
search
infant
follow
code
drug
reaction
intox
specif
newborn
drug
withdraw
syndrom
newborn
nondepend
abus
opioid
gestat
age
infant
birth
birth
weight
type
matern
drug
use
durat
hospit
treatment
neonat
abstin
syndrom
na
infant
absolut
lymphocyt
count
document
durat
drug
exposur
record
result
neonat
document
diagnosi
na
time
period
review
complet
blood
count
drawn
mean
time
hour
life
avail
review
manual
differenti
util
avail
use
alc
percentil
neonat
diagnosi
drug
withdraw
syndrom
lymphopen
lymphopen
infant
note
longer
na
treatment
durat
day
vs
day
well
longer
length
hospit
day
vs
day
lymphopen
infant
preterm
week
gestat
infant
expos
opioid
exposur
confirm
posit
matern
drug
screen
posit
neonat
meconium
drug
screen
conclus
infant
diagnosi
drug
withdraw
syndrom
lymphopen
infant
requir
longer
durat
treatment
na
investig
possibl
relationship
sever
na
neonat
lymphopenia
analysi
need
determin
correl
note
larger
studi
popul
effect
transient
child
clinic
statu
neonat
period
throughout
childhood
may
affect
nickhil
bhakta
qi
liu
matthew
ehrhardt
malek
baassiri
hesham
eissa
monika
metzger
kirsten
ness
melissa
hudson
yutaka
yasui
lesli
robison
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
morbid
associ
individu
cardiac
chronic
health
condit
sever
among
pediatr
hl
survivor
estim
total
cardiac
diseas
burden
howev
remain
incomplet
object
describ
cumul
burden
cardiac
diseas
among
pediatr
hl
survivor
use
medic
ascertain
sjlife
cohort
data
method
hl
survivor
met
sjlife
elig
treat
st
jude
children
research
hospit
surviv
year
year
old
june
particip
mean
age
rang
underw
longitudin
clinic
evalu
differ
cardiac
chronic
health
condit
longitudin
assess
combin
retrospect
clinic
assess
classifi
use
modifi
common
terminolog
criteria
advers
event
ctcae
grade
schema
grade
mild
moder
severedis
ctcae
grade
sjlife
imput
multipl
imput
sampl
sjlife
particip
match
gender
race
age
diagnosi
treatment
era
anthracyclin
dose
chest
radiat
exposur
mean
cumul
count
treat
death
compet
risk
use
estim
cumul
burden
result
year
cohort
experienc
averag
confid
interv
grade
grade
condit
per
survivor
year
grade
cumul
burden
increas
respect
myocardi
infarct
cardiovascular
dysfunct
compris
cardiomyopathi
pulmonari
hypertens
dyslipidemiaessenti
hypertens
contribut
grade
cumul
burden
respect
year
averag
annual
increas
grade
cumul
burden
among
survivor
expos
chest
radiat
rose
grade
increas
equival
increas
among
survivor
grade
grade
among
survivor
averag
annual
increas
chang
grade
grade
conclus
cumul
burden
cardiac
morbid
among
pediatr
hl
survivor
climb
rapidli
time
multipl
cardiac
chronic
health
condit
contribut
total
cardiac
diseas
burden
cumul
burden
metric
provid
comprehens
approach
evalu
overal
morbid
better
assist
design
futur
trial
refin
screen
guidelin
david
mccall
prasannalaxmi
palabindela
lee
hilliard
thoma
howard
jeffrey
lebensburg
univers
alabama
birmingham
birmingham
alabama
unit
state
background
patient
absolut
neutrophil
count
anc
frequent
refer
pediatr
hematolog
oncolog
yet
scant
literatur
exist
outcom
treatment
mild
moder
isol
neutropenia
object
better
understand
outcom
referr
isol
mild
moder
neutropenia
designmethod
four
year
retrospect
chart
review
patient
refer
pediatr
clinic
neutropenia
neutropenia
categor
mild
anc
moder
sever
sever
descript
statist
univari
analysi
perform
use
jmp
result
among
refer
patient
neutropenia
isol
neutropenia
mean
anc
twenti
three
patient
mild
neutropenia
patient
moder
neutropenia
patient
sever
neutropenia
patient
sever
neutropenia
patient
isol
mild
mean
age
year
moder
year
neutropenia
significantli
older
patient
refer
sever
year
sever
neutropenia
year
p
signific
differ
anc
found
among
gender
male
four
patient
posit
antibodi
posit
antibodi
two
ela
mutat
hax
mutat
among
refer
patient
initi
mild
isol
neutropenia
three
progress
cours
anc
moder
rang
current
patient
normal
anc
three
patient
remain
mildli
neutropen
mean
anc
patient
current
moder
sever
sever
neutropenia
among
patient
moder
neutropenia
referr
seven
progress
sever
neutropenia
cours
includ
three
autoimmun
neutropenia
two
viral
ill
two
idiopath
neutropenia
current
three
patient
remain
sever
neutropen
five
patient
receiv
gcsf
four
patient
severeveri
sever
neutropenia
two
month
old
moder
neutropenia
receiv
gcsf
hospit
infect
final
among
patient
refer
outpati
clinic
diagnos
cancer
none
present
isol
neutropenia
conclus
patient
refer
mild
isol
neutropenia
resolv
normal
requir
subspecialti
intervent
patient
refer
moder
isol
neutropenia
identifi
autoimmun
neutropenia
viral
ill
jennif
agrusa
viral
kothari
austin
brown
tim
vece
maria
monica
gramatg
baylor
colleg
medicin
houston
texa
unit
state
background
pulmonari
fibrosi
pf
progress
disord
without
cur
option
adult
survivor
hodgkin
lymphoma
hl
increas
risk
pf
due
therapeut
exposur
includ
bleomycin
pulmonari
radiat
howev
studi
investig
subclin
pulmonari
dysfunct
pediatr
survivor
hl
examin
effect
known
clinic
risk
factor
pf
upon
therapi
pulmonari
function
test
pft
uniformli
treat
pediatr
hl
cohort
hypothes
abnorm
therapi
pft
evid
subclin
pulmonari
dysfunct
may
predict
develop
pf
survivor
hl
expos
pulmonari
toxic
therapi
object
character
relationship
patient
demograph
therapeut
exposur
pft
abnorm
pediatr
survivor
hl
designmethod
obtain
demograph
exposur
outcom
data
local
survivor
hl
year
treatment
retrospect
chart
review
associ
survivor
variabl
dlcoc
diffus
capac
lung
carbon
monoxid
correct
hemoglobin
evalu
use
multivari
linear
regress
model
control
relev
treatment
patient
characterist
result
identifi
subject
mean
age
diagnosi
year
rang
dlcoc
result
avail
month
treatment
complet
mean
month
rang
subject
receiv
combin
bleomycin
chemotherapi
mean
cumul
dose
rang
andor
pulmonari
radiat
mean
dlcoc
rang
adjust
regress
model
dlcoc
posit
associ
age
diagnosi
per
year
increas
age
confid
interv
ci
invers
associ
femal
gender
ci
pulmonari
radiat
ci
conclus
uniformli
treat
hl
cohort
risk
factor
associ
therapi
subclin
pulmonari
dysfunct
includ
younger
age
diagnosi
femal
gender
exposur
pulmonari
radiat
expand
cohort
may
reveal
addit
clinic
factor
influenc
pulmonari
outcom
furthermor
investig
potenti
biomark
pf
telomer
length
serum
inflammatori
marker
may
identifi
individu
risk
progress
sever
pulmonari
dysfunct
creat
opportun
therapeut
intervent
rachael
grace
jenni
despotov
carolyn
bennett
jennif
rothman
michel
lambert
vicki
breakey
jame
bussel
georg
buchanan
melissa
rose
ami
geddi
kristin
shimano
kerri
hege
kristina
haley
adoni
lorenzana
cindi
neunert
alexi
thompson
yve
pastor
michael
jeng
kimo
stine
michel
neier
elli
neufeld
travi
brown
peter
forb
robert
klaassen
boston
children
hospit
boston
massachusett
unit
state
background
adult
patient
itp
report
signific
fatigu
fatigu
assess
larg
pediatr
studi
object
describ
fatigu
correl
clinic
characterist
pediatr
patient
itp
initi
second
line
treatment
designmethod
longitudin
observ
cohort
children
itp
start
second
line
treatment
enrol
icon
center
enrol
requir
includ
age
start
second
line
treatment
ivig
steroid
monotherapi
bleed
assess
use
itp
bleed
score
ibl
fatigu
age
adolesc
age
fatigu
scale
parent
age
administ
use
scale
children
adolesc
cancer
report
high
fatigu
j
pain
symptom
manag
fatigu
score
fatigu
highest
fatigu
result
median
age
sd
chronic
itp
median
number
prior
itp
treatment
enrol
median
score
n
rang
median
score
n
median
n
score
prior
week
half
time
children
report
tire
adolesc
report
bodi
felt
tire
high
fatigu
report
children
adolesc
significantli
differ
report
pediatr
cancer
p
respect
parent
report
child
fatigu
significantli
higher
patient
report
pair
analysi
p
fatigu
score
significantli
associ
current
worst
ever
ibl
oral
site
p
p
respect
correl
fatigu
platelet
count
fatigu
correl
age
number
prior
therapi
race
ethnic
conclus
fatigu
common
children
itp
start
second
line
therapi
similar
sever
report
pediatr
cancer
longitudin
follow
studi
assess
chang
fatigu
second
line
therapi
shawn
lee
thuan
chong
quah
nation
univers
hospit
singapor
background
hodgkin
lymphoma
known
associ
eosinophilia
approxim
patient
signific
blood
count
chang
associ
form
lymphoma
characterist
complet
blood
count
pediatr
lymphoma
patient
well
studi
especi
regard
relaps
monitor
notic
children
type
lymphoma
may
also
inflammatori
chang
reflect
blood
count
object
determin
inde
anecdot
impress
correct
whether
chang
may
aid
prognost
monitor
relaps
designmethod
retrospect
case
note
review
pediatr
patient
diagnos
lymphoma
seen
nuh
aspect
full
blood
count
fbc
diagnosi
relaps
obtain
analyz
along
type
lymphoma
stage
relaps
outcom
patient
laboratori
featur
inflamm
fbc
includ
leukocytosi
neutrophilia
eosinophilia
thrombocytosi
result
examin
pediatr
patient
year
age
lymphoma
n
present
least
one
biochem
featur
inflamm
n
none
greater
associ
relaps
patient
absenc
initi
inflamm
fbc
compar
presenc
inflamm
relaps
patient
show
initi
fbc
inflamm
diagnosi
n
continu
show
fbc
inflamm
relaps
relaps
patient
show
initi
fbc
inflamm
n
continu
absenc
inflamm
relaps
conclus
inflammatori
pictur
diagnosi
may
correl
less
relaps
patient
present
initi
fbc
inflamm
presenc
inflammatori
pictur
subsequ
may
indic
relaps
henc
regular
routin
fbc
would
use
monitor
diseas
statu
patient
absenc
initi
fbc
inflamm
would
use
use
subsequ
fbc
monitor
progress
relaps
use
fbc
monitor
relaps
appropri
case
would
especi
attract
pediatr
oncologist
low
incom
countri
plan
extend
studi
includ
patient
includ
adult
patient
sylwia
jasinski
chana
glasser
mark
weinblatt
winthrop
univers
hospit
mineola
new
york
unit
state
background
autoimmun
cytopenia
character
destruct
hematopoiet
cell
line
idiopath
thrombocytopen
purpura
itp
disord
caus
thrombocytopenia
evan
syndrom
es
caus
anemia
thrombocytopenia
patient
adequ
respond
steroid
intraven
immunoglobulin
andor
whinrho
patient
refractori
diseas
limit
option
effect
therapi
exist
object
purpos
studi
describ
institut
experi
sirolimu
therapi
pediatr
patient
refractori
itp
es
designmethod
identifi
patient
last
decad
treat
institut
refractori
itp
es
sirolimu
collect
demograph
data
assess
respons
therapi
respons
categor
complet
cr
partial
pr
modest
mr
cr
defin
resolut
cytopenia
platelet
count
kul
hemoglobin
gdl
least
month
abil
taper
steroid
pr
improv
cytopenia
least
one
grade
least
month
taper
dose
steroid
stabl
cell
count
taper
steroid
least
mr
increas
platelet
count
kul
kul
asymptomat
result
patient
meet
inclus
criteria
itp
es
median
age
diagnosi
year
rang
itp
year
rang
es
percent
n
patient
itp
achiev
cr
month
n
initi
achiev
pr
follow
cr
month
therapi
durabl
respons
identifi
n
eighti
percent
n
es
patient
achiev
cr
month
one
patient
es
achiev
mr
discontinu
therapi
due
hematuria
identifi
advers
event
patient
cr
remain
cr
therapi
median
year
rang
remain
remain
cr
therapi
rang
month
conclus
institut
experi
sirolimu
safe
effect
agent
treatment
children
refractori
itp
es
naresh
reddivalla
erin
guest
shannon
carpent
children
merci
hospit
kansa
citi
missouri
unit
state
background
famili
platelet
disord
propens
acut
myelogen
leukemia
fpdaml
autosom
domin
disord
character
thrombocytopenia
abnorm
platelet
function
propens
develop
myelodysplasia
md
andor
acut
myeloid
leukemia
aml
caus
heterozyg
mutat
also
known
chromosom
key
regul
hematopoiesi
megakaryopoiesi
myeloid
differenti
patient
inherit
mutat
lifetim
risk
myeloid
malign
childhood
acut
lymphoblast
leukemia
describ
fpdaml
lymphoblast
lymphoma
report
associ
fpdaml
object
first
report
pediatr
patient
develop
lymphoblast
lymphoma
due
inherit
mutat
designmethod
case
report
result
boy
refer
pediatr
hematolog
evalu
thrombocytopenia
sinc
birth
platelet
count
initi
evalu
report
bruis
bleed
symptom
patient
father
diagnos
chronic
idiopath
thrombocytopenia
patern
grandmoth
die
aml
year
patern
great
uncl
die
lymphoma
year
famili
mutat
suspect
due
signific
famili
histori
malign
chronic
thrombocytopenia
molecular
test
reveal
previous
unreport
variant
unknown
signific
c
patient
father
predict
softwar
label
mutat
probabl
damag
toler
patient
monitor
yearli
present
emerg
depart
age
year
larg
anterior
mediastin
mass
pleural
fluid
test
diagnost
cell
lymphoblast
lymphoma
bone
marrow
neg
malign
myelodysplasia
current
mainten
chemotherapi
complet
remiss
conclus
first
report
cell
lymphoblast
lymphoma
associ
fpdaml
due
inherit
mutat
jingyao
hematolog
oncolog
center
beij
children
hospit
capit
medic
univers
beij
china
background
studi
shown
patient
suffer
itp
polar
respons
cytokin
deregul
balanc
well
known
regul
immun
system
normal
condit
impair
autoimmun
diseas
like
itp
order
studi
mechan
lymphocyt
abnorm
children
itp
ensur
homogen
object
due
children
itp
often
abrupt
sever
onset
thrombocytopenia
prescrib
intraven
immunoglobulin
ivig
first
day
hospit
prevent
hemorrhag
well
methypredisolon
mp
often
use
exclus
malign
reason
lymphocyt
function
evalu
involv
detect
cytokin
secret
etc
might
interrupt
treatment
mention
object
studi
design
explor
influenc
intraven
immunoglobulin
ivig
methylprednisolon
mp
cytokin
secret
lymphocyt
children
itp
designmethod
enrol
patient
first
diagnos
itp
ultim
durat
less
month
without
recurr
boy
girl
age
rang
month
median
month
enrol
children
itp
onset
diseas
depart
decemb
march
follow
whole
durat
choos
patient
whose
ultim
durat
less
month
recurr
cytokin
measur
cytometr
bead
array
includ
tnf
ifn
divid
patient
group
accord
treatment
receiv
test
cytokin
level
compar
cell
cytokin
level
among
group
result
enrol
patient
first
diagnos
itp
ultim
durat
less
month
without
recurr
boy
girl
age
rang
month
median
month
found
level
decreas
group
treat
mp
day
n
p
group
patient
treat
ivig
day
n
p
compar
group
without
treatment
n
cytokin
level
differ
among
group
conclus
children
itp
although
pathway
mp
ivig
treat
thrombocytopenia
differ
could
decreas
children
itp
ultim
repres
cytokin
cell
demonstr
import
lymphocyt
activ
mobil
consid
mp
ivig
reduc
cell
activ
product
decreas
amanda
jacobson
bhuvana
setti
nilay
shah
nationwid
children
hospit
columbu
ohio
unit
state
background
thrombocytopenia
trt
common
treatment
pediatr
malign
due
chemotherapi
radiat
therapi
instanc
thrombocytopenia
caus
signific
therapi
delay
lead
suboptim
treatment
underli
malign
romiplostim
thrombopoietin
receptor
agonist
treatment
thrombocytopenia
children
shown
romiplostim
also
success
use
thrombocytopenia
adult
data
use
indic
children
object
report
seri
pediatr
patient
treat
romiplostim
trt
designmethod
retrospect
chart
review
pediatr
patient
receiv
romiplostim
trt
nationwid
children
hospit
result
two
patient
prolong
trt
undergo
treatment
solid
tumor
patient
follow
pelvic
radiat
local
pelvic
ewe
sarcoma
patient
follow
mibg
therapi
neuroblastoma
romiplostim
initi
dose
mcgkg
patient
mcgkg
patient
dose
increas
mcgkg
weekli
platelet
goal
continu
chemotherapi
achiev
continu
steadi
dose
maximum
dose
mcgkg
patient
durat
therapi
week
patient
week
patient
due
religi
object
blood
product
patient
receiv
three
weekli
mcgkg
dose
month
period
maintain
platelet
count
receiv
salvag
therapi
relaps
paramening
rhabdomyosarcoma
patient
maintain
platelet
count
goal
follow
discontinu
romiplostim
advers
effect
romiplostim
inject
observ
conclus
romiplostim
success
treat
trt
without
advers
effect
case
seri
possibl
risk
leukem
clone
prolifer
may
limit
use
romiplostim
trt
children
hematolog
malign
romiplostim
could
benefici
treatment
trt
children
solid
tumor
may
limit
treatment
delay
dose
reduct
ultim
lead
improv
overal
surviv
prospect
studi
use
romiplostim
warrant
pillai
pallavi
madhusoodhan
nikki
evensen
julia
meyer
ashfiyah
chowdhuri
david
araten
jacob
nerst
kjeld
schmeigelow
william
carrol
nyu
langon
medic
center
new
york
new
york
unit
state
background
outcom
patient
relaps
leukemia
remain
suboptim
understand
biolog
mechan
underli
drug
resist
essenti
previous
note
delet
approxim
relaps
patient
form
crucial
part
dna
mismatch
repair
mmr
pathway
recogn
base
pair
mismatch
object
aim
distinguish
two
hypothes
delet
result
hypermut
phenotyp
associ
gener
secondari
mutat
involv
drug
resist
defici
lead
failur
initi
apoptosi
directli
respons
chemotherapeut
agent
designmethod
stabl
cell
gener
mismatch
profici
raji
defici
reh
cell
line
use
short
hairpin
rna
shrna
construct
target
nt
control
cell
expos
chemotherapeut
agent
day
thioguanin
nucleotid
primari
cytotox
thiopourin
metabolit
incorpor
assess
use
liquid
chromatographi
tandem
mass
spectrometri
hypermut
phenotyp
assess
microsatellit
instabl
msi
mutat
rate
gene
determin
loss
flaer
stain
result
upon
knockdown
mmr
profici
cell
line
show
manifold
increas
thiopurin
ratio
kdnt
reflect
resist
seen
mmr
defici
control
cell
line
reh
ratio
kdnt
caus
resist
chemotherapeut
drug
cell
line
cell
increas
incorpor
hour
nt
vs
kd
fmolug
dna
observ
reh
msi
observ
cell
line
delet
patient
sampl
expect
kd
effect
mutat
rate
reh
cell
curious
reduct
mutat
rate
seen
cell
conclus
loss
function
contribut
develop
select
resist
thiopurin
agent
probabl
reflect
compromis
apoptosi
thu
focal
delet
ad
grow
list
genet
alter
associ
resist
purin
analogu
highlight
critic
role
mainten
therapi
kiersten
ricci
erika
huber
ashok
raj
lili
huang
mohammad
azam
theodosia
kalfa
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
essenti
thrombocythemia
et
myeloprolif
neoplasm
character
thrombocytosi
increas
risk
thromboembol
event
progress
myelofibrosi
leukem
transform
mutat
janu
kinas
gene
commonli
known
drive
factor
et
pathogenesi
et
rare
children
famili
case
report
due
germlin
mutat
autosom
domin
inherit
two
sibl
present
clinic
platelet
count
one
histori
stroke
month
age
found
compound
heterozyg
two
novel
germlin
variant
father
two
unaffect
sibl
carri
mother
carri
normal
platelet
red
blood
cell
count
object
explor
causal
signal
mechan
two
novel
variant
et
designmethod
wt
mutat
form
transduc
cell
stabli
express
thrombopoietin
receptor
signal
pathway
prolif
capabl
respons
inhibitor
ruxolitinib
studi
signal
also
evalu
patient
platelet
megakaryocyt
produc
vitro
patient
cell
result
transduc
mutant
demonstr
increas
phosphoryl
compar
contrast
higher
phosphoryl
find
parallel
phosphoryl
chang
patient
platelet
increas
phosphoryl
note
compar
normal
control
platelet
pediatr
patient
increas
megakaryocyt
produc
vitro
patient
cell
show
increas
activ
compar
normal
volunt
prolifer
studi
cytokin
starv
condit
indic
cell
higher
prolifer
rate
decreas
sensit
ruxolitinib
compar
cell
line
conclus
mutat
appear
function
cooper
produc
et
phenotyp
via
mechan
appear
distinctli
differ
vitro
vivo
studi
warrant
gain
insight
activ
regul
waitman
aumann
catherin
lavau
daniel
wechsler
duke
univers
medic
center
durham
north
carolina
unit
state
background
transloc
seen
childhood
acut
lymphoblast
leukemia
difficult
treat
leukemia
share
mani
characterist
leukemia
involv
leukemia
mll
gene
transloc
mll
fusion
leukemia
exhibit
similar
gene
express
profil
character
elev
level
proleukem
hoxa
gene
improv
outcom
patient
leukemia
depend
develop
target
therapi
increas
efficaci
hoxa
gene
known
driver
leukemogenesi
also
import
normal
hematopoiesi
make
less
suitabl
drug
target
previous
determin
nuclear
export
protein
tether
target
gene
exposur
leptomycin
b
lmb
compound
disrupt
interact
abrog
abil
activ
transcript
target
object
discov
novel
target
gene
involv
pathogenesi
leukemia
designmethod
use
identifi
gene
increas
express
hematopoiet
progenitor
transduc
express
vector
identifi
gene
whose
express
depend
perform
affymetrix
microarray
use
murin
leukemia
cell
briefli
treat
lmb
nm
gene
interest
valid
use
result
determin
intersect
among
gene
select
express
transduc
bone
marrow
progenitor
gene
gene
decreas
leukemia
cell
follow
exposur
lmb
gene
identifi
gene
like
direct
target
reassuringli
nine
gene
hoxa
famili
valid
previou
observ
three
novel
gene
hell
role
develop
malign
select
studi
increas
express
valid
use
conclus
use
gene
express
profil
identifi
sever
novel
candid
transcript
target
oncoprotein
three
gene
hell
previous
implic
develop
malign
might
play
role
leukemogenesi
current
examin
effect
overexpress
knockdown
gene
leukemia
cell
line
vitro
vivo
kiersten
ricci
adrienn
hammil
cameron
trenor
paula
carol
chute
mari
sue
wentzel
alexand
vink
manish
patel
gulraiz
chaudri
anita
gupta
jennif
eil
arnold
merrow
roshni
dasgupta
belinda
dicki
lin
fei
lindsey
hornung
ilona
frieden
stephen
nelson
juli
blatt
julia
glade
bender
catherin
mccuaig
anna
synakiewicz
denis
adam
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
gener
lymphat
anomali
gla
diseas
gsd
rare
lymphat
anomali
character
abnorm
develop
lymphat
vessel
multipl
bodi
site
may
caus
effus
organ
dysfunct
patholog
fractur
pain
disfigur
affect
individu
frequent
experi
progress
clinic
symptom
worsen
qualiti
life
qol
unfortun
treatment
option
limit
often
ineffect
surgeri
gener
reserv
local
diseas
convent
medic
treatment
like
steroid
chemotherapeut
agent
produc
substanti
side
effect
variabl
result
current
evid
demonstr
import
regulatori
function
mtor
pathway
vasculogenesi
support
mtor
inhibit
sirolimu
therapeut
target
object
evalu
safeti
efficaci
sirolimu
treatment
patient
gla
gsd
designmethod
studi
analyz
combin
data
multicent
systemat
retrospect
review
medic
record
patient
treat
sirolimu
januari
june
prospect
phase
clinic
trial
assess
efficaci
safeti
sirolimu
treatment
complic
vascular
anomali
diseas
improv
determin
radiolog
imag
qol
measur
clinic
statu
assess
sirolimu
dose
regimen
toxic
side
effect
causal
evalu
result
evalu
patient
nineteen
gla
gsd
gla
gsd
expect
patient
complet
resolut
clinic
symptom
radiolog
diseas
sirolimu
overal
partial
diseas
respons
gla
gsd
patient
improv
qol
improv
clinic
statu
improv
radiolog
respons
improv
occur
patient
pleural
effus
pericardi
effus
patient
pleural
pericardi
effus
worsen
therapi
diseas
progress
occur
gsd
patient
due
report
decreas
qol
five
patient
experienc
grade
drug
toxic
without
requir
dose
reduct
common
side
effect
bone
marrow
suppress
mucositisstomat
hypertriglyceridemia
conclus
sirolimu
safe
treatment
appear
reduc
symptom
andor
stabil
diseas
patient
gla
gsd
given
signific
morbid
mortal
patient
complic
lymphat
malform
futur
treatment
studi
need
address
specif
phenotyp
cornelia
stoian
shania
michael
reed
hannah
choi
muhammad
kamal
shadi
sinisa
dovat
kimberli
payn
loma
linda
univers
loma
linda
california
unit
state
background
genet
alter
caus
overexpress
cytokin
receptor
associ
form
acut
lymphoblast
leukemia
activ
receptor
cytokin
tslp
result
activ
jakstat
pathway
associ
chemoresist
upregul
famili
gene
object
determin
effect
mediat
signal
express
famili
protein
efficaci
target
famili
protein
designmethod
flow
cytometri
western
blot
use
evalu
famili
protein
express
crlf
cell
cultur
without
tslp
flow
cytometri
use
annexin
caspas
assay
apoptosi
follow
treatment
cell
inhibitor
presenc
absenc
tslp
result
tslp
increas
express
famili
protein
cell
line
activ
jak
mutat
treatment
inhibitor
reduc
cell
count
reduct
maintain
presenc
tslp
reduct
cell
number
due
increas
apoptosi
reach
cell
death
day
concentr
um
even
tslp
present
saw
increas
express
dose
inhibitor
um
higher
littl
chang
lower
dose
suggest
observ
increas
like
select
surviv
cell
express
high
level
altern
famili
molecul
rather
compensatori
upregul
express
conclus
data
suggest
tslp
contribut
chemoresist
via
upregul
famili
protein
even
case
activ
jak
mutat
result
provid
evid
therapi
target
could
effect
treatment
overexpress
leonardo
brandao
ellen
hopper
lesli
raffini
margaret
lee
survey
aspho
sig
va
member
questionnair
distribut
new
york
citi
columbia
univers
medic
center
unit
state
background
vascular
anomali
va
includ
patient
vascular
malform
vm
emerg
field
pediatr
grow
recognit
complic
specif
popul
date
specif
guidelin
exist
object
describ
clinic
practic
relat
pediatr
vm
patient
coagul
disturb
north
america
order
facilit
futur
develop
standard
practic
identif
research
gap
designmethod
aspho
conduct
institut
review
board
approv
onlin
survey
member
includ
gener
practic
question
clinic
vignett
describ
issu
item
survey
deriv
expert
experi
literatur
review
suggest
survey
committe
result
date
member
respond
highest
rank
center
us
largest
canada
practic
year
around
respond
work
multidisciplinari
clinic
see
simpl
vmyr
combin
vmyr
use
anticoagul
ie
low
molecular
weight
heparin
lmwh
aspirin
asa
coagulopathi
last
month
pt
pt
none
three
basic
scenario
includ
periprocedur
manag
combin
vm
hypofibrogenemia
elev
would
prescrib
anticoagul
vs
indecis
enoxaparin
agent
choic
dose
mgkddose
wk
b
simpl
vm
isol
elev
symptom
would
prescrib
anticoagul
vs
indecis
enoxaparin
agent
choic
similar
regimen
c
simpl
vm
isol
elev
local
pain
would
prescrib
anticoagul
vs
indecis
agent
choic
asansaid
compress
garment
common
reason
avoid
lmwh
pauciti
literatur
perceiv
increas
bleed
risk
needl
phobia
conclus
despit
preval
vm
children
survey
highlight
expect
practic
variabl
manag
coagulopathi
lack
evid
recogn
main
obstacl
use
anticoagul
character
coagul
complic
well
risk
stratif
bleedingthrombosi
pave
way
toward
futur
guidelin
chandrika
gowda
zheng
ge
chunhua
song
jonathon
payn
malika
kapadia
yali
ding
kimberli
payn
sinisa
dovat
penn
state
hershey
medic
center
penn
state
univers
colleg
medicin
hershey
pennsylvania
unit
state
background
ikaro
protein
encod
gene
act
tumor
suppressor
acut
lymphoblast
leukemia
regul
express
target
gene
use
chromatin
immunoprecipit
coupl
sequenc
show
ikaro
bind
promot
gene
human
gene
encod
small
gtpase
act
oncogen
solid
tumor
associ
leukemia
hypothes
ikaro
regul
express
involv
pathogenesi
object
determin
role
ikaro
regul
express
defin
signific
express
test
therapeut
efficaci
target
inhibit
designmethod
ikaro
overexpress
transduct
retrovir
vector
contain
ikaro
ikaro
shrna
respect
luciferas
report
assay
use
evalu
ikaro
effect
promot
gene
express
assess
use
quantit
pcr
western
blot
dna
bind
measur
quantit
chromatin
immunoprecipit
qchip
cell
prolifer
assay
wst
synergist
cytotox
effect
compound
analyz
use
calcusyn
result
experi
show
ikaro
repress
transcript
overexpress
compar
normal
bone
marrow
overexpress
correl
high
white
blood
cell
count
treatment
specif
inhibitor
produc
cytotox
effect
leukemia
ikaro
bind
promot
abil
repress
impair
due
phosphoryl
casein
kinas
ii
inhibit
inhibitor
restor
ikaro
bind
promot
transcript
repress
use
combin
inhibitor
produc
synergist
cytotox
effect
conclus
result
demonstr
overexpress
potenti
therapeut
target
leukemia
express
regul
ikaro
target
combin
inhibitor
potenti
novel
treatment
juli
strychowski
meghan
ohar
reza
rahbar
horacio
padua
cameron
trenor
boston
children
hospit
boston
massachusett
unit
state
background
lymphat
malform
lm
challeng
manag
particularli
involv
cervicofaci
region
airway
primari
therapi
sclerotherapi
andor
resect
role
sirolimu
evolv
treatment
cervicofaci
lm
object
review
experi
sirolimu
medic
therapi
cervicofaci
lymphat
malform
efficaci
safetytoler
designmethod
retrospect
review
patient
treat
sirolimu
cervicofaci
lm
novemb
octob
result
five
patient
complet
therapi
durat
month
remain
sirolimu
rang
month
age
initi
rang
month
year
nine
patient
microcyst
lm
ten
mix
lm
patient
serial
photograph
patient
serial
imag
gaug
respons
patient
demonstr
reduct
lm
bulk
rang
dramat
visual
modest
younger
patient
mix
diseas
less
prior
therapi
demonstr
signific
respons
patient
report
subject
improv
sirolimu
includ
decreas
lm
bulk
soften
tissu
decreas
bleedingleak
relat
mucos
vesicl
decreas
rate
cellul
patient
n
mucos
vesicl
present
initi
sirolimu
resolv
improv
median
time
initi
respons
month
rang
day
month
six
patient
tracheostomi
one
decannul
maxillofaci
surgeri
two
toler
cap
sirolimu
six
patient
develop
cellul
within
lm
treatment
none
progress
sepsi
episod
cellul
sirolimu
opportunist
infect
occur
two
patient
undergon
surgic
debulk
follow
sirolimu
treatment
decreas
residu
remain
tissu
wound
heal
issu
conclus
use
sirolimu
manag
cervicofaci
lm
appear
efficaci
especi
younger
patient
mucos
diseas
limit
advers
event
durabl
respons
coordin
sirolimu
around
procedur
therapi
need
evalu
aditya
sharma
sunpreet
tandon
christin
mella
jami
burk
steven
kuerbitz
children
hospit
medic
center
akron
akron
ohio
unit
state
background
shown
previous
neuronatin
gene
nnat
undergo
aberr
dna
hypermethyl
associ
transcript
silenc
major
childhood
acut
leukemia
case
clinic
signific
loss
nnat
express
childhood
leukemia
howev
unknown
object
goal
studi
correl
clinic
characterist
outcom
nnat
express
precursor
b
acut
lymphoblast
leukemia
designmethod
sixti
seven
consecut
case
precursor
present
analyz
retrospect
util
bone
marrow
sampl
obtain
diagnosi
data
medic
record
sampl
nnat
methyl
quantit
combin
restrictionbisulfit
analysi
cobra
nnat
mrna
express
qualit
determin
end
point
clinic
characterist
includ
age
present
white
blood
cell
count
wbc
present
immunophenotyp
induct
respons
surviv
compar
nnat
hypermethyl
normal
methyl
group
nnat
expressor
nonexpressor
group
result
nnat
methyl
express
statu
determin
case
hypermethyl
defin
methyl
identifi
sampl
nnat
silenc
loss
express
identifi
sampl
found
case
exhibit
loss
nnat
express
like
expressor
associ
wbc
diagnosi
p
also
ef
group
approach
statist
signific
differ
expressor
group
conclus
loss
nnat
express
associ
elev
wbc
count
present
ef
os
differ
significantli
expressor
group
overal
analysi
restrict
analysi
patient
exhibit
characterist
elev
wbc
age
year
ef
advantag
expressor
approach
statist
signific
given
rel
stabil
tail
ef
curv
analysi
addit
patient
may
yield
statist
signific
differ
nnat
shown
regul
endoplasm
reticulum
calcium
homeostasi
cell
type
biolog
basi
clinic
featur
associ
loss
nnat
express
childhood
remain
determin
alicia
chang
david
steffin
judith
margolin
ionela
iacoba
texa
children
hospit
houston
texa
unit
state
background
hepat
hemangioma
common
benign
liver
tumor
infanc
typic
present
usual
involv
palpabl
abdomin
mass
without
sign
anemia
heart
failur
despit
rel
common
occurr
confus
nomenclatur
still
affect
medic
literatur
classif
schema
base
growth
pattern
immunostain
clinic
behavior
emerg
attempt
better
standard
manag
object
present
case
infant
atyp
clinic
cours
hepat
hemangioma
contrast
patient
present
similar
diagnosi
aim
contribut
grow
data
surround
common
vascular
lesion
hope
standard
diagnost
criteria
outcom
well
better
guid
therapeut
option
designmethod
retrospect
chart
review
perform
babi
boy
texa
children
hospit
compar
previou
case
publish
report
diagnosi
result
patient
boy
born
gestat
present
respiratori
failur
secondari
acut
abdomin
distens
month
age
ultrasound
prior
deliveri
shown
left
hepat
lobe
mass
mri
confirm
cm
left
hepat
lobe
hemangioma
present
repeat
ultrasound
show
hepat
mass
stabl
size
without
signific
shunt
compress
hepat
vessel
larg
amount
ascit
present
afp
level
within
rang
age
workup
fail
reveal
primari
etiolog
ascit
due
critic
statu
decis
made
excis
mass
patholog
reveal
neg
vascular
lesion
consist
hepat
congenit
hemangioma
babi
recov
well
ascit
conclus
wide
rang
clinic
present
focal
hepat
hemangioma
asymptomat
critic
ill
lesion
requir
close
follow
birth
identifi
develop
complic
initi
prompt
treatment
sei
gyung
kim
waitman
aumann
catherin
lavau
daniel
wechsler
duke
univers
medic
center
durham
north
carolina
unit
state
background
transloc
occur
patient
aml
associ
poor
prognosi
leukemia
character
upregul
hoxa
gene
express
known
driver
leukemogenesi
interact
oncoprotein
nuclear
export
factor
essenti
upregul
hoxa
express
previous
demonstr
interact
directli
hoxa
chromatin
suggest
recruit
target
gene
howev
mediat
may
also
involv
particular
compon
nuclear
pore
complex
interact
nucleocytoplasm
transport
macromolecul
transloc
fuse
multipl
differ
partner
describ
leukemia
fusion
oncoprotein
bind
activ
transcript
hoxa
gene
object
determin
whether
cooper
transactiv
hoxa
gene
designmethod
previous
creat
retrovir
fusion
vector
demonstr
abil
activ
transcript
report
design
induc
shrna
retrovir
vector
target
perform
transient
report
shrna
vector
togeth
empti
vector
cell
also
stabli
express
induc
shrna
vector
cell
result
luciferas
assay
show
knockdown
increas
baselin
level
transcript
limit
effect
transcript
activ
induc
knockdown
also
caus
increas
endogen
hoxa
level
cell
conclus
surprisingli
silenc
increas
transcript
activ
endogen
hoxa
transcript
sinc
import
nuclear
export
imped
function
like
result
nuclear
retent
critic
protein
may
indirectli
deregul
hoxa
transcript
experi
underway
determin
role
hoxa
level
cell
express
note
recent
report
demonstr
direct
bind
hox
gene
oka
et
al
elif
highlight
import
interact
among
hox
loci
molecular
basi
leukemogen
hox
gene
dysregul
kelley
hutchin
robert
ross
daisuk
kobayashi
alissa
martin
madhvi
rajpurkar
children
hospit
michigan
detroit
michigan
unit
state
background
infantil
hemangioma
ih
typic
benign
vascular
neoplasm
spontan
involut
time
commonli
found
head
neck
trunk
also
involv
intern
organ
liver
lung
central
nervou
system
oftentim
lesion
treat
conserv
medic
manag
need
consist
laser
treatment
surgic
excis
medic
includ
propranolol
steroid
object
describ
pediatr
patient
diffus
hepat
cutan
ih
failur
thrive
progress
pulmonari
hypertens
ph
due
pulmonari
hemangioma
treat
sirolimu
designmethod
patient
three
year
old
african
american
femal
present
shortli
birth
diffus
cutan
hemangioma
hepatomegali
splenomegali
anemia
abdomin
mrimra
note
replac
entir
liver
parenchyma
numer
nodular
lesion
consist
ih
well
sign
earli
heart
failur
skin
biopsi
confirm
ih
start
propranolol
prednisolon
hemangioma
well
medic
manag
heart
failur
hepat
cutan
hemangioma
improv
time
month
age
howev
develop
sever
idiopath
ph
diagnos
right
cardiac
catheter
system
pulmonari
arteri
pa
pressur
rest
respons
oxygen
nitric
oxid
comput
tomographi
scan
thorax
note
multipl
enhanc
pulmonari
nodul
scatter
throughout
lung
suspici
pulmonari
arterioven
malform
result
patient
start
sildenafil
given
sever
ph
like
pulmonari
hemangioma
persist
liver
cutan
hemangioma
despit
previou
therapi
subsequ
start
sirolimu
repeat
cardiac
catheter
two
month
initi
sirolimu
note
improv
ph
well
liver
hemangioma
unfortun
patient
develop
signific
hypoglycemia
result
demis
conclus
pulmonari
hemangioma
rare
pediatr
popul
sirolimu
act
inhibit
mtor
pathway
thu
decreas
vascular
endotheli
prolifer
steroid
propranolol
first
line
medic
manag
ih
howev
sirolimu
may
effect
treatment
option
hemangioma
refractori
convent
therapeut
option
deanna
maida
craig
mullen
olena
tkachenko
univers
rochest
strong
memori
hospit
rochest
new
york
unit
state
background
cure
rate
acut
lymphoblast
leukemia
relaps
occur
quarter
case
particularli
high
risk
diseas
cell
immunomodul
may
valuabl
adjunct
standard
therapi
howev
studi
date
demonstr
direct
effect
immunomodul
tumor
cell
surviv
work
explor
method
manipul
microenviron
treat
poli
c
dsrna
analog
demonstr
direct
effect
tumor
growth
via
ifn
pathway
give
effect
howev
sirna
studi
primari
stroma
popul
thu
complet
understand
genet
microenvironment
effect
offer
object
determin
whether
poli
c
sirna
upregul
gene
express
measur
activ
interferon
pathway
indirectli
induc
acut
lymphoblast
leukemia
cell
tumor
cell
death
way
alter
primari
stromal
gene
express
designmethod
revers
transfect
differ
stromal
cell
line
rna
extract
cdna
synthesi
follow
quantit
pcr
determin
poli
c
sirna
mediat
upregul
gene
express
transfect
three
primari
stromal
cell
line
poli
c
follow
cell
wash
subsequ
cell
plate
cell
surviv
measur
flow
cytometri
result
poli
c
induc
gene
express
stromal
cell
cell
underw
apoptosi
presenc
poli
c
treat
stromal
cell
conclus
poli
c
dramat
reduc
capac
nonmalign
stromal
cell
support
viabil
primari
cell
find
suggest
drug
target
marrow
stromal
cell
may
provid
new
approach
control
current
studi
lab
explor
key
chang
gene
express
pathway
induc
poli
c
nonmalign
stromal
cell
lead
cell
death
shabnam
arsiwala
wei
ding
wang
pennsylvania
state
hershey
medic
center
depart
pediatr
hershey
pennsylvania
unit
state
background
bone
marrow
bm
nich
cell
specif
perivascular
stromal
cell
lepr
reticular
cell
car
endotheli
cell
play
essenti
role
mainten
function
hematopoiet
stem
cell
hsc
number
molecul
like
stem
cell
factor
scf
angiopoietin
mediat
mainten
function
addit
function
autophagi
within
hsc
known
play
critic
role
maintain
hsc
homeostasi
loss
hsc
lead
loss
normal
hsc
function
sever
myeloprolifer
howev
remain
unclear
hematopoiesi
affect
autophagi
select
block
bone
marrow
nich
cell
object
investig
effect
autophagi
defici
within
bone
marrow
nich
cell
hematopoiesi
designmethod
knockout
mous
model
gener
allow
select
ablat
protein
lepr
perivascular
stromal
cell
delet
inde
restrict
lepr
cell
loss
suffici
block
autophag
function
evid
accumul
protein
result
white
blood
cell
count
wbc
significantli
reduc
old
male
ko
mice
compar
wild
type
wt
control
mice
p
myeloid
popul
bone
marrow
peripher
blood
significantli
decreas
ko
mice
p
valu
atg
ko
vs
wt
control
wbc
count
continu
declin
week
old
ko
male
mice
lsk
long
term
hsc
popul
decreas
old
male
mice
howev
trend
reach
statist
signific
although
absolut
cell
count
lymphocyt
includ
b
cell
respect
peripher
blood
significantli
drop
ko
mice
compar
wt
control
signific
chang
matur
b
cell
bone
marrow
conclus
preliminari
result
suggest
delet
key
autophagi
regul
lepr
bone
marrow
nich
cell
caus
leukopenia
underli
mechan
current
investig
help
us
better
understand
role
autophagi
hematopoiesi
within
bm
microenviron
cathi
lori
gardner
jennif
rabe
susan
zelasko
courtney
jone
christoph
porter
univers
colorado
school
medicin
aurora
colorado
unit
state
background
immunolog
evas
one
hallmark
cancer
mechan
leukemia
evad
immun
system
incomplet
understood
lab
found
calcineurin
leukemia
cell
act
potent
mediat
immun
evas
leukemogenesi
essenti
subunit
calcineurin
knock
immun
compet
host
abl
suppress
leukemia
outgrowth
immunodefici
host
succumb
diseas
hypothes
activ
calcineurin
nfat
nuclear
factor
activ
cell
object
determin
role
activ
calcineurin
measur
nfat
activ
designmethod
cell
transduc
either
empti
vector
mig
cell
kept
cultur
expos
vari
dose
pma
ionomycin
order
stimul
calcineurin
activ
measur
via
analysi
nfat
known
downstream
effector
calcineurin
experi
measur
nfat
express
includ
western
blot
assess
protein
phosphoryl
real
time
pcr
assess
nfat
depend
transcript
nfat
report
assay
assess
transcript
activ
result
nfat
activ
increas
cell
compar
control
mig
cell
evidenc
increas
total
protein
well
activ
protein
increas
dose
pma
ionomycin
also
lead
higher
level
nfat
mig
cell
pronounc
popul
conclus
total
nfat
activ
nfat
protein
present
leukemia
cell
vs
control
suggest
activ
calcineurin
studi
ongo
determin
higher
level
protein
lead
increas
nfat
transcript
activ
mrna
leukemia
cell
compar
mig
increas
activ
may
play
role
abil
leukemia
cell
evad
immun
system
heidi
cho
maria
bortot
leila
noetzli
jess
hinckley
bifeng
gao
katherin
gowan
kenneth
jone
jorg
di
paola
univers
colorado
denver
colorado
unit
state
background
von
willebrand
diseas
vwd
common
inherit
bleed
disord
character
incomplet
penetr
variabl
express
phenotyp
genet
character
amish
pedigre
autosom
domin
vwd
type
sequenc
analysi
vwf
reveal
heterozygos
missens
mutat
posit
c
individu
even
ident
genet
mutat
vwf
individu
show
great
variabl
bleed
tendenc
measur
quantifi
score
provid
bleed
assess
tool
bat
object
identifi
biolog
genet
variant
outsid
vwf
influenc
bleed
vwd
designmethod
whole
exom
sequenc
perform
member
famili
age
sex
match
carri
mutat
least
sever
bleed
sever
bleed
annovar
softwar
tool
use
function
annot
genet
variant
util
analyz
variant
predict
effect
protein
express
concurr
analyz
plasma
individu
use
somalog
proteom
technolog
quantifi
protein
potenti
associ
process
involv
bleed
ingenu
pathway
analysi
ipa
use
interpret
result
result
ipa
analysi
reveal
differenti
protein
express
within
sever
pathway
signific
includ
cellular
movement
immun
cell
traffick
hematolog
system
develop
function
within
pathway
protein
involv
cell
adhes
ie
coagul
ie
plg
inflamm
ie
differenti
express
high
low
bleeder
analysi
whole
exom
sequenc
reveal
genet
variant
enrich
one
group
compar
interestingli
sever
variant
correl
pathway
identifi
proteom
data
includ
selplg
fgb
conclus
preliminari
analys
show
high
preval
gene
involv
inflamm
cell
adhes
hematolog
system
may
associ
bleed
variabl
within
amish
famili
work
focu
replic
variant
rest
member
famili
affect
unaffect
well
hundr
avail
unrel
case
vwd
madelin
huey
amanda
hill
katherin
minson
xiaodong
wang
stephen
frye
shelton
earp
deborah
derycker
dougla
graham
emori
univers
atlanta
georgia
unit
state
background
inhibit
mertk
small
molecul
inhibitor
decreas
tumor
burden
prolong
surviv
acut
leukemia
cell
line
xenograft
model
howev
treatment
reduc
leukemia
peripher
blood
spleen
less
effect
clear
bone
marrow
leukem
blast
mertk
axl
ligand
poor
prognost
factor
aml
mediat
increas
resist
cytotox
chemotherapi
leukemia
cell
present
bone
marrow
stroma
object
determin
bone
marrow
stromal
cell
induc
resist
designmethod
acut
leukemia
cell
line
cultur
presenc
cell
line
bone
marrow
deriv
stromal
cell
bmdsc
wild
type
knockout
mice
ad
bind
deplet
induct
apoptosi
cell
death
determin
flow
cytometri
treatment
vehicl
express
mertk
relat
kinas
axl
determin
immunoblot
result
cell
line
significantli
reduc
leukemia
cell
death
respons
treatment
nm
compar
leukemia
cell
alon
versu
p
protect
effect
reduc
titrat
versu
p
similarli
bmdsc
mice
protect
leukemia
cell
induc
cell
death
effect
bmdsc
knockout
mice
versu
immunoblot
analysi
demonstr
increas
express
leukemia
cell
respons
conclus
mertk
ligand
produc
cell
line
bmdsc
mediat
protect
leukemia
cell
cell
death
induc
mertk
inhibit
deplet
use
genet
mice
biolog
strategi
decreas
resist
leukemia
cell
presenc
stroma
data
consist
mechan
increas
express
activ
andor
axl
promot
cell
surviv
resist
select
mertk
inhibit
combin
treatment
bone
marrow
mobil
agent
may
effect
therapeut
strategi
dian
nugent
alicia
romano
shreya
sabharw
john
germak
david
cooper
novo
nordisk
inc
plainsboro
new
jersey
unit
state
background
noonan
syndrom
ns
genet
condit
individu
involv
characterist
facial
featur
short
statur
congenit
heart
defect
skelet
anomali
development
delay
bleed
problem
hematologist
may
call
upon
evalu
children
ns
bleed
abnorm
particularli
sinc
mani
patient
may
undergo
multipl
surgeri
begin
earli
childhood
object
aim
systemat
review
identifi
specif
laboratori
find
bleed
disord
ns
inform
appropri
scope
diagnost
workup
designmethod
public
review
includ
trial
case
reportsseri
review
identifi
via
medlin
embas
scopu
ns
patient
includ
analysi
studi
presum
bleed
disord
bleed
phenotyp
describ
avail
patient
data
abstract
includ
demograph
bleed
symptom
lab
abnorm
bleed
score
specif
disord
report
result
studi
identifi
relev
data
ns
patient
nearli
half
male
report
bleed
report
bleed
data
bleed
report
bleed
laboratori
test
abnorm
specif
diagnosi
report
abnorm
laboratori
includ
prolong
pt
aptt
ptaptt
singl
factor
defici
vwd
platelet
disord
multipl
defici
overal
factor
xi
defici
common
follow
platelet
abnorm
factor
xii
factor
viii
factor
xixii
xiviii
common
combin
disord
conclus
result
support
import
identifi
bleed
disord
patient
ns
earli
childhood
particularli
wide
span
disord
frequent
presenc
multipl
disord
factor
defici
platelet
function
disord
vwd
suggest
screen
need
go
beyond
ptaptt
platelet
count
includ
assess
platelet
function
result
highlight
import
earli
consult
pediatr
hematologist
special
coagul
disord
need
rigor
document
extent
accur
describ
type
disord
jerusha
samuela
jacob
sai
shalini
febe
renjitha
suman
juliu
xavier
scott
sri
ramachandra
medic
colleg
research
institut
chennai
tamil
nadu
india
background
receptor
hyaluron
acid
mediat
motil
rhamm
identifi
one
leukemia
associ
antigen
studi
rhamm
alon
associ
protein
promot
invas
inhibit
apoptosi
paediatr
acut
lymphoblast
leukemia
good
prognosi
wherea
acut
myeloid
leukemia
aml
lacuna
studi
rhamm
express
prognost
signific
pediatr
acut
leukemia
object
studi
express
rhamm
paediatr
acut
leukemia
prognost
signific
designmethod
paraffin
block
bone
marrow
trephin
biopsi
paediatr
acut
leukemia
process
immunohistochemistri
standard
autom
techniqu
primari
antibodi
use
abcam
usa
rel
proport
percentag
posit
stain
tumor
cell
quantifi
three
observ
blast
percentag
done
bone
marrow
aspir
taken
day
induct
assess
immedi
respons
percentag
rhamm
posit
cell
respons
induct
therapi
correl
clinic
follow
case
plot
initi
rhamm
express
also
correl
result
aml
ratio
male
femal
ratio
mean
age
year
year
aml
express
rhamm
aml
express
blast
percentag
induct
therapi
relaps
prognosi
correl
show
statist
signific
neg
correl
type
leukemia
presenc
rhamm
posit
cell
initi
biopsi
correl
residu
diseas
relaps
bad
outcom
conclus
signific
neg
prognost
effect
rhamm
express
evid
acut
pediatr
leukemia
express
aml
henc
marker
mayb
includ
diagnost
panel
parent
patient
counsel
treatment
intensifi
better
prognosi
evolut
inhibitor
marker
promis
target
therapi
patient
warrant
research
kai
jacobson
clifford
takemoto
brandyn
lau
ruchika
goel
ricardo
velazquez
ramind
chadha
john
hopkin
hospit
baltimor
maryland
unit
state
background
vte
associ
increas
morbid
pauciti
prospect
valid
risk
stratif
tool
venou
thromboembol
vte
hospit
children
object
evalu
perform
electron
vte
risk
assess
pediatr
patient
designmethod
august
vte
screen
tool
incorpor
computer
admiss
order
set
patient
year
hospit
john
hopkin
children
center
nicu
patient
exclud
assess
mobil
vte
risk
factor
bleed
risk
requir
patient
year
age
prior
vte
histori
provid
concern
vte
patient
stratifi
risk
group
base
score
incorpor
age
immobl
risk
factor
pharmacolog
prophylaxi
recommend
patient
high
vte
risk
mechan
prophylaxi
moder
vte
risk
high
vte
risk
bleed
risk
prophylaxi
low
vte
risk
defin
vte
diagnos
hour
hospit
admiss
vte
diagnos
within
day
hospit
discharg
patient
identifi
code
chart
review
result
month
august
januari
total
patient
underw
electron
vte
risk
assess
provid
complianc
complet
screen
within
hour
admiss
identifi
case
rate
per
admiss
ci
similar
rate
ci
observ
prior
implement
screen
tool
rate
per
admiss
increas
vte
risk
low
risk
rate
ci
moder
risk
ci
high
risk
ci
bleed
assess
month
period
rel
risk
patient
receiv
pharmacolog
prophylaxi
ci
bleed
ci
major
bleed
conclus
electron
vte
risk
assess
tool
identifi
patient
increas
risk
howev
vte
rate
significantli
decreas
implement
screen
increas
bleed
associ
pharmacolog
prophylaxi
addit
studi
need
improv
risk
assess
prevent
strategi
seethal
jacob
peter
shaw
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
group
previous
publish
result
juli
june
show
significantli
lower
portion
adolesc
young
adult
aya
patient
age
treat
clinic
trial
compar
younger
patient
common
caus
lack
open
clinic
trial
object
determin
enrol
aya
oncolog
patient
therapeut
studi
institut
improv
recent
year
greater
focu
popul
local
nation
designmethod
retrospect
analyz
cancer
registri
data
children
hospit
pittsburgh
chp
new
oncolog
diagnos
januari
decemb
data
includ
age
gender
diagnosi
race
whether
patient
enrol
open
treatment
studi
univari
analys
done
compar
demograph
data
aya
patient
enrol
studi
fisher
exact
test
use
analyz
differ
aya
patient
enrol
studi
result
new
oncolog
patient
seen
chp
time
year
year
older
patient
treat
clinic
trial
includ
younger
patient
older
patient
statist
signific
p
differ
rate
prior
year
age
group
respect
statist
signific
p
current
data
common
reason
low
enrol
rate
lack
open
therapeut
trial
statist
differ
group
factor
analyz
conclus
despit
initi
chp
nation
level
enrol
aya
patient
clinic
trial
recent
data
show
improv
caus
multifactori
primari
reason
found
institut
lack
open
clinic
trial
potenti
remedi
factor
need
priorit
nation
pediatr
medic
oncolog
commun
iman
sahnoun
rachel
beati
donald
mahoney
donald
yee
baylor
colleg
medicin
texa
children
hospit
houston
texa
unit
state
background
enoxaparin
commonli
use
agent
treat
thrombosi
pediatr
although
use
purpos
standard
practic
pediatr
referr
center
pauciti
data
recommend
literatur
regard
administr
primari
thromboprophylaxi
object
studi
design
character
clinic
care
cours
patient
receiv
enoxaparin
primari
thromboprophylaxi
texa
children
hospit
designmethod
retrospect
chart
review
patient
receiv
least
one
dose
enoxaparin
primari
thromboprophylaxi
studi
period
januari
june
data
collect
includ
demograph
inform
cours
durat
detail
clinic
radiograph
outcom
data
report
use
percentag
mean
standard
error
mean
patient
categor
two
group
immedi
administr
other
eg
immobl
risk
factor
result
forti
patient
receiv
enoxaparin
thromboprophylaxi
immedi
group
age
year
averag
treatment
durat
day
fourteen
patient
group
age
year
receiv
enoxaparin
thromboprophylaxi
reason
averag
day
group
patient
start
adult
dose
enoxaparin
either
mg
daili
mg
bid
compar
group
group
patient
averag
dose
chang
median
rang
group
median
rang
level
monitor
time
group
median
rang
time
group
median
rang
patient
enoxaparin
initi
surgic
servic
bleed
thrombot
complic
identifi
although
patient
report
bruis
inject
conclus
although
limit
scope
find
support
use
enoxaparin
safe
possibl
effect
measur
prevent
clot
children
adolesc
use
fix
dose
regimen
minim
laboratori
monitor
explor
especi
select
popul
patient
hrishikesh
mehta
shawn
damadhoran
chonghui
cheng
seth
corey
virginia
commonwealth
univers
richmond
illinoi
unit
state
background
myelodydsplast
syndrom
md
constitut
heterogen
group
bone
marrow
disord
frequent
termin
acut
myeloid
leukemia
aml
mutual
exclus
mutat
recent
identifi
splice
factor
md
case
granulocyt
coloni
stimul
factor
receptor
indispens
normal
product
neutrophil
two
seven
isoform
clinic
relev
class
form
class
iv
altern
splice
form
compar
class
class
iv
isoform
mediat
enhanc
prolifer
increas
express
class
iv
isoform
found
mdsaml
patient
hypothesi
aberr
splice
promot
mutat
splice
factor
drive
abnorm
granulopoiesi
md
due
increas
express
differenti
defect
class
iv
object
understand
role
cellular
phosphoryl
statu
influenc
mutat
splice
factor
splice
specif
relat
class
vs
class
iv
designmethod
studi
effect
splice
factor
mutat
splice
construct
minigen
consist
exon
cat
gene
atg
site
partial
intron
fuse
intron
region
upstream
exon
retain
intron
present
exon
transduc
cell
minigen
mutant
cell
treat
sodium
orthovanad
phorbol
myrist
acet
pma
inhibit
tyrosin
phosphatas
wherea
pma
promot
activ
protein
kinas
c
pathway
qpcr
use
determin
express
class
class
iv
express
result
site
identifi
nucleotid
sequenc
splice
intron
found
inhibit
tyrosin
phosphatas
activ
result
increas
intron
excis
pma
data
suggest
tyrosin
phosphoryl
import
intron
excis
exogen
express
show
decreas
intron
excis
suggest
mutat
inhibit
class
iv
transcript
format
conclus
splice
regul
modif
meghan
drayton
jackson
joseph
stanek
terah
koch
sarah
obrien
bryce
kerlin
nationwid
children
hospit
columbu
ohio
unit
state
background
prophylact
factor
replac
therapi
increasingli
util
prevent
bleed
complic
sever
hemophilia
increas
prophylaxi
util
may
lead
decreas
admiss
bleed
complic
may
alter
inhibitor
epidemiolog
public
joint
outcom
studi
jo
phase
random
control
trial
primari
prophylaxi
demonstr
prophylaxi
significantli
improv
joint
outcom
children
moder
sever
hemophilia
natur
jo
offer
opportun
studi
epidemiolog
consequ
increas
prophylaxi
use
object
determin
differ
admiss
bleed
episod
inhibitor
bypass
therapi
surrog
marker
inhibitor
well
length
stay
lo
intens
care
icu
util
timefram
public
jo
designmethod
hospit
identifi
pediatr
health
inform
system
phi
databas
children
age
year
old
hemophilia
b
hospit
compar
data
phi
institut
particip
jo
includ
avoid
bia
relat
random
prophylaxi
activ
studi
period
data
remain
hospit
evalu
discharg
diagnos
defin
intern
classif
diseas
revis
clinic
modif
along
medic
charg
util
defin
bleed
episod
bypass
therapi
result
signific
trend
bleed
episod
bleed
diagnosi
use
factor
replac
bypass
therapi
overal
lo
shorten
day
day
p
icu
stay
decreas
admiss
p
era
conclus
studi
demonstr
decreas
overal
hospit
lo
icu
util
era
increas
bypass
therapi
util
suggest
incid
inhibitor
format
remain
stabl
find
directli
attribut
chang
practic
result
public
jo
sinc
hemophilia
sever
util
prophylaxi
directli
determin
phi
howev
suggest
increas
util
primari
prophylaxi
may
decreas
inpati
util
without
alter
inhibitor
epidemiolog
arpan
sinha
adriana
de
la
garza
teresa
bowman
albert
einstein
colleg
medicin
children
hospit
montefior
bronx
new
york
unit
state
background
myelodysplast
syndrom
md
heterogen
spectrum
malign
hematolog
disord
character
dysplast
ineffect
hematopoiesi
propens
transform
acut
myeloid
leukemia
aml
though
uncommon
children
risk
md
increas
children
inherit
bone
marrow
failur
syndrom
surviv
cancer
treatment
human
genom
studi
reveal
genet
mutat
spliceosom
compon
epigenet
regul
present
major
md
patient
relev
connect
spliceosom
epigenet
factor
diseas
poorli
understood
object
describ
use
cripsr
cluster
regularli
interspac
short
palindrom
repeat
technolog
creat
mutant
epigenet
regul
chromodomain
helicas
protein
zebrafish
known
interact
spliceosom
studi
determin
vivo
import
interplay
hematopoiesi
designmethod
creat
break
gene
zebrafish
vitro
transcrib
guid
rna
specif
protein
microinject
fertil
zebrafish
embryo
inject
founder
fish
mate
gener
carrier
progeni
screen
presenc
mutat
perform
polymeras
chain
reaction
pcr
amplifi
target
region
follow
endonucleas
assay
detect
indel
exact
mutat
identifi
clone
sanger
sequenc
follow
bioinformat
analysi
result
screen
fish
found
carri
mutat
mutat
mutat
predict
disrupt
protein
function
introduct
prematur
stop
codon
mutant
fish
incross
defect
overal
morpholog
surviv
note
line
previou
observ
use
oligonucleotid
knockdown
homozyg
mutant
grow
character
hematopoiet
defect
interact
spliceosom
factor
conclus
use
technolog
zebrafish
effect
way
creat
mutat
mdsaml
factor
determin
vivo
contribut
diseas
understand
pathophysiolog
interact
spliceosom
mutat
epigenet
factor
help
identifi
prognost
factor
potenti
guid
treatment
md
aml
fadi
nossair
arash
mahajerin
joann
starr
lilibeth
torno
ivan
kirov
children
hospit
orang
counti
orang
california
unit
state
background
superior
vena
cava
syndrom
svc
obstruct
venou
return
headneck
may
lead
rapid
develop
vascular
obstruct
respiratori
compromis
andor
neurolog
manifest
signific
morbid
mortal
pediatr
svc
typic
occur
due
extern
mass
compress
thrombosi
relat
congenit
heart
diseas
cardiac
transplant
current
knowledg
limit
singl
center
experi
limit
evalu
outcom
prognost
factor
object
determin
associ
clinic
radiolog
therapeut
factor
morbid
mortal
pediatr
svc
particularli
thrombosi
svc
designmethod
systemat
comprehens
search
literatur
pertain
pediatr
svc
perform
conduct
extens
data
extract
detail
case
reportsseri
data
includ
analysi
mention
articl
descript
statist
perform
relat
variabl
evalu
use
fisher
exact
test
test
consid
signific
result
total
patient
age
year
articl
includ
analysi
slight
male
predomin
bimod
age
distribut
infanc
mid
adolesc
morbid
mortal
acut
complic
assess
outcom
svc
case
correl
wors
outcom
svc
case
correl
better
outcom
increas
recurr
rate
thrombosi
present
show
improv
outcom
age
year
signssymptom
present
lack
collater
imag
presenc
acut
complic
present
correl
poorer
outcom
use
gener
anesthesia
case
implic
except
one
mortal
conclus
conduct
comprehens
analysi
pediatr
svc
identifi
factor
infant
age
multipl
signssymptom
present
lack
collater
presenc
acut
complic
may
prognost
util
influenc
clinic
advic
surveil
practic
futur
studi
may
benefit
subgroup
analysi
focu
elucid
guidelin
treatment
pediatr
svc
natalia
colorado
yan
yan
jason
farrar
shelli
lens
michel
luci
liu
peter
emanuel
univers
arkansa
medic
scienc
littl
rock
arkansa
unit
state
background
aml
hematolog
malign
despit
recent
advanc
manag
therapi
treatment
diseas
relaps
relat
death
rate
approxim
children
aberr
chromatin
state
hallmark
aml
make
possibl
therapeut
target
aml
myeloid
blast
also
show
constitut
signal
transduc
activ
transcript
patient
aml
bromodomain
extra
termin
domain
protein
bet
regul
gene
express
via
bind
acetyl
chromatin
activ
transcript
activ
bet
inhibitor
prevent
bind
bromodomain
acetyl
histon
result
inhibit
gene
transcript
also
report
decreas
activ
lymphoblast
leukemia
cell
object
hypothes
suppress
myeloid
leukemia
cell
growth
inhibit
abber
bet
protein
function
activ
designmethod
myeloid
leukemia
cell
treat
concentr
cell
prolifer
rate
evalu
use
hour
coloni
form
assay
establish
agar
mccoy
medium
cell
vari
concentr
flow
cytometri
fac
use
detect
level
activ
form
also
test
mononuclear
cell
cord
blood
cb
order
determin
toxic
normal
cell
result
assay
indic
cell
prolifer
significantli
decreas
dose
p
higher
p
dose
greater
p
cb
suggest
leukemia
cell
sensit
cb
cell
cfu
assay
suggest
significantli
inhibit
coloni
format
dose
depend
fashion
p
fac
analysi
indic
significantli
decreas
cell
p
conclus
preliminari
data
suggest
significantli
decreas
activ
myeloid
leukemia
cell
significantli
inhibit
leukem
cell
prolifer
level
toxic
cb
cell
confirm
studi
may
altern
therapi
treatment
myeloid
leukemia
wood
pediatr
blood
cancer
leukemia
oncotarget
blood
allison
close
lynn
malec
jame
cooper
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
incid
knowledg
deep
venou
thrombosi
children
increas
awar
complic
dvt
syndrom
one
potenti
outcom
dvt
debilit
consequ
dvt
caus
pain
swell
limb
discolor
incomplet
resolv
dvt
often
lead
pt
though
percentag
dvt
resolv
anticoagul
understudi
object
evalu
characterist
patient
develop
dvt
assess
rate
resolut
rate
pt
predictor
designmethod
studi
retrospect
chart
review
children
diagnos
dvt
period
singl
larg
academ
center
inform
regard
patient
age
sex
radiograph
imag
presenc
central
line
dvt
locat
extens
thrombophilia
test
outcom
extract
logist
regress
analys
perform
evalu
predictor
result
case
met
elig
criteria
median
age
present
year
age
rang
year
primari
clot
locat
follow
abdomin
upper
extrem
lower
extrem
percent
clot
associ
central
venou
cathet
thrombophilia
test
perform
patient
posit
patient
screen
percent
dvt
resolv
anticoagul
howev
statist
signific
predictor
thrombosi
resolut
pt
assess
clinic
case
report
symptom
signific
differ
develop
pt
age
sex
primari
site
presenc
inherit
acquir
thrombophilia
conclus
studi
one
larger
studi
look
thrombosi
resolut
pt
develop
children
though
dvt
resolv
subject
report
symptom
pt
clinic
statist
signific
predictor
either
outcom
suggest
factor
commonli
assess
may
play
role
advers
outcom
treatment
dvt
larg
prospect
cohort
studi
need
perform
better
delin
find
nirav
thacker
shripad
banavali
brijesh
arora
gaurav
narula
maya
prasad
nikhil
patkar
prashant
tembhar
pg
subramanian
tata
memori
hospit
mumbai
maharashtra
india
background
mutat
present
nearli
aml
patient
associ
poor
prognosi
treat
convent
chemotherapi
vitro
vivo
studi
demonstr
benefici
effect
sorafenib
pediatr
aml
object
assess
outcom
sorafenib
combin
variou
chemotherapi
regimen
aml
children
designmethod
retrospect
analyz
initi
outcom
aml
patient
receiv
variou
chemotherapeut
regimen
sorafenib
may
decemb
patient
treat
either
daunorubicin
cytarabin
orand
high
dose
hdac
orandor
metronom
therapi
mct
etoposid
prednisolon
orand
cladribin
sorafenib
given
oral
dose
twice
day
result
children
newli
diagnos
one
relaps
aml
male
femal
median
age
present
year
rang
median
wbc
count
rang
mrd
neg
flow
achiev
patient
post
sorafenib
patient
post
mct
sorafenib
patient
post
sorafenib
patient
receiv
hdac
sorafenib
achiev
mrd
neg
patient
achiev
deep
remiss
post
treatment
chemo
sorafenib
remain
patient
yet
receiv
sorafenib
relaps
till
date
receiv
cycl
part
therapi
remiss
death
due
sepsi
post
home
villag
due
unknown
caus
median
month
rang
month
patient
aliv
sorafenib
well
toler
patient
grade
iii
skin
toxic
conclus
preliminari
data
suggest
patient
aml
may
benefit
sorafenib
induct
consolid
regimen
follow
oral
mct
sorafenib
mainten
michel
loi
christoph
silliman
brian
branchford
children
hospit
colorado
denver
colorado
unit
state
background
venou
thromboembol
vte
cite
occur
per
children
annual
base
databas
collect
mainli
popul
sea
level
denver
co
elev
consid
intermedi
altitud
higher
incid
adult
vte
altitud
report
studi
incid
pediatr
vte
higher
altitud
hypothes
children
altitud
also
increas
incid
vte
compar
children
sea
level
object
investig
incid
pediatr
vte
intermedi
altitud
designmethod
obtain
comirb
approv
retrospect
case
control
studi
perform
investig
pediatr
vte
incid
intermedi
altitud
incid
determin
identifi
patient
distinct
diagnos
vte
seen
children
hospit
colorado
diagnost
valid
perform
chart
review
patient
present
outsid
denver
area
exclud
result
uniqu
patient
identifi
code
vte
male
femal
median
age
year
rang
day
year
patient
present
primari
diagnosi
vte
compris
patient
popul
patient
diagnos
secondari
vte
within
hour
admiss
made
patient
patient
vte
diagnos
hour
admiss
made
anoth
patient
gender
distribut
primari
vte
patient
favor
femal
male
patient
present
year
consider
risk
factor
posit
famili
histori
thrombophilia
blood
clot
evid
inflamm
viral
ill
previou
week
diagnosi
significantli
reduc
mobil
patient
took
oral
contracept
obes
conclus
epidemiolog
studi
pediatr
vte
diagnos
singl
institut
intermedi
altitud
suggest
increas
rate
vte
moder
altitud
incid
per
children
doubl
upper
limit
incid
child
per
cite
studi
sea
level
comparison
data
institut
altitud
addit
screen
confound
factor
need
sunil
raikar
daniel
tylawski
robert
moot
lauren
fleischer
david
mccarti
christoph
doer
h
trent
spencer
emori
univers
atlanta
georgia
unit
state
background
relaps
leukemia
overal
poor
prognosi
chimer
antigen
receptor
car
therapi
could
potenti
use
howev
target
diseas
without
specif
antigen
difficult
use
natur
killer
nk
cell
effector
cell
target
antigen
allow
us
overcom
problem
creat
novel
car
substitut
singl
chain
variabl
fragment
scfv
tradit
car
variabl
lymphocyt
receptor
vlr
antigen
recognit
sequenc
vlr
repres
function
unit
adapt
immun
system
jawless
vertebr
lamprey
hagfish
analog
immunoglobulin
vlr
exist
natur
singl
chain
structur
demonstr
high
specif
via
repeat
sequenc
term
leucin
rich
repeat
object
object
develop
cell
leukemia
use
sequenc
designmethod
construct
second
gener
car
use
vlr
sequenc
target
antigen
recognit
sequenc
high
titer
vlr
car
lentiviru
produc
test
car
construct
express
jurkat
cell
transduc
variou
dose
lentiviru
activ
measur
cytotox
studi
cell
use
effector
cell
target
cell
cytotox
measur
differ
effector
target
ratio
use
flow
cytometri
base
assay
result
activ
directli
correl
lentivir
copi
number
car
express
jurkat
cell
cell
express
vlr
car
show
fold
increas
cytotox
toward
cell
compar
cell
howev
low
transduct
effici
copi
number
problemat
improv
creat
bicistrion
vector
express
gfp
vlr
car
jurkat
cell
new
construct
show
direct
correl
gfp
express
activ
thu
confirm
dual
express
function
protein
transduc
cell
new
construct
sort
expand
cell
expand
robustli
demonstr
car
express
function
characterist
target
diseas
conclus
studi
show
use
car
provid
foundat
move
studi
preclin
test
treatment
relaps
childhood
arifa
khalid
children
hospit
institut
child
health
lahor
pakistan
background
hemophilia
rare
recess
clot
factor
defici
disord
overal
incid
per
male
live
birth
patient
present
bleed
tendenc
sever
correl
level
factor
defici
late
diagnosi
improp
manag
lead
lifelong
complic
object
analyz
clinic
data
diseas
develop
countri
limit
resourc
predict
prevent
morbid
improv
qualiti
life
set
designmethod
total
patient
hemophilia
b
review
retrospect
present
children
hospit
institut
child
health
lahor
last
one
year
data
analyz
basi
clinic
featur
age
first
present
age
diagnosi
sever
diseas
factor
replac
life
threaten
bleedptaptt
mix
studi
factor
assay
also
note
result
among
patient
male
around
diagnos
hemophilia
hemophilia
b
mostli
diagnos
year
age
although
symptomat
year
age
moder
diseas
mild
rest
sever
diseas
famili
histori
posit
patient
present
month
age
sever
hemophilia
aptt
prolong
patient
mean
valu
minut
sever
diseas
famili
histori
signific
relat
p
relat
sever
diseas
age
diagnosi
signific
compromis
p
ie
critic
line
post
circumcis
bleed
observ
promin
primari
symptom
follow
bruis
epistaxi
respect
life
threaten
bleed
report
develop
hemarthrosi
patient
aptt
done
circumcis
patient
demand
factor
replac
therapi
primari
prophylaxi
conclus
basi
earli
present
famili
histori
predict
sever
diseas
perform
ptaptt
circumcis
children
cost
effect
screen
investig
earli
diagnosi
adequ
time
prophylaxi
prevent
earli
late
complic
zach
leblanc
larisa
pereboeva
chang
tim
town
fred
golman
univers
alabama
birmingham
birmingham
alabama
unit
state
background
continu
emerg
cellular
therapi
treat
cell
evolv
includ
cell
genet
modifi
express
chimer
antigen
receptor
car
bind
lymphoid
leukem
blast
report
use
express
cell
line
chromium
releas
fac
assay
howev
use
patient
deriv
blast
experi
elus
object
identifi
rapid
assay
assess
cytotox
develop
futur
cell
designmethod
cytotox
assay
set
popul
effector
target
cell
effector
cell
popul
cell
collect
pediatr
patient
healthi
donor
cell
manufactur
use
cell
healthi
donor
transduc
retrovir
vector
contain
target
cell
popul
cell
line
bone
marrow
patient
cell
healthi
donor
effector
target
cell
hour
increas
effector
target
e
ratio
stain
identifi
dead
cell
analyz
fac
percentag
live
target
cell
lc
assay
averag
percent
differ
kill
calcul
use
averag
result
cell
untransduc
effector
popul
percent
differ
kill
popul
cell
percent
differ
kill
cell
target
cell
healthi
donor
show
differ
percent
kill
cultur
untransduc
effector
cell
popul
cell
leukem
blast
bone
marrow
percent
differ
kill
cultur
untransduc
effector
cell
e
compar
percent
differ
kill
cell
conclus
amplifi
kill
patient
leukem
blast
cell
compar
untransduc
cell
plan
continu
use
novel
assay
specif
measur
cytotox
ip
deriv
cell
blast
collect
pediatr
patient
anna
serebrin
sheri
vangunst
poon
macgregor
steel
univers
calgari
calgari
alberta
canada
background
ddavp
use
treatment
prevent
bleed
von
willebrand
diseas
vwd
hemophilia
ha
ddavp
administ
intraven
subcutan
intranas
major
data
effect
ddavp
adult
receiv
intraven
infus
pauciti
data
regard
subcutan
administr
children
object
determin
respons
rate
side
effect
profil
children
vwd
ha
receiv
subcutan
ddavp
designmethod
conduct
retrospect
studi
patient
receiv
subcutan
ddavp
januari
decemb
respons
patient
ha
defin
factor
viii
fviii
iuml
increas
twofold
baselin
one
hour
respons
patient
vwd
defin
vwf
rco
fviii
iuml
increas
twofold
baselin
one
hour
result
studi
patient
mild
ha
median
age
year
rang
year
vwd
median
age
year
rang
year
male
type
type
among
patient
ha
respond
ddavp
median
age
year
respond
year
patient
vwd
respond
respond
type
diseas
patient
ha
baselin
fviii
level
iuml
patient
vwd
vwf
rco
iuml
side
effect
includ
facial
flush
headach
asymptomat
hypotens
tachycardia
seriou
advers
event
report
conclus
respons
rate
patient
mild
ha
cohort
higher
report
compar
cohort
receiv
intraven
ddavp
use
respons
criteria
vs
howev
patient
type
vwd
observ
lower
respons
rate
report
intraven
ddavp
similar
cohort
vs
older
patient
higher
baselin
factor
level
like
respond
subcutan
ddavp
safe
well
toler
mild
side
effect
make
valuabl
therapeut
option
pediatr
patient
demonstr
respons
especi
given
eas
administr
potenti
use
home
elizabeth
martinez
kelli
michelson
melani
arenson
laura
campbel
ann
robert
h
luri
children
hospit
chicago
chicago
illinoi
seattl
children
seattl
washington
unit
state
background
parent
children
cancer
face
challeng
decis
pediatr
intens
care
unit
picu
studi
identifi
decis
parent
perceiv
support
satisfact
decis
make
picu
object
identifi
decis
face
picu
parent
children
cancer
parent
percept
involv
satisfact
decis
make
process
designmethod
parent
complet
written
questionnair
upon
child
admiss
discharg
picu
admiss
questionnair
request
basic
demograph
inform
discharg
questionnair
ask
parent
identifi
import
decis
made
child
picu
indic
someon
help
commun
doctor
decis
complet
decis
regret
scale
tool
score
least
regret
regret
complet
decis
make
compon
pediatr
famili
satisfact
intens
care
unit
scale
tool
score
scale
least
satisfi
satisfi
result
receiv
admiss
discharg
questionnair
parent
patient
patient
rang
age
mean
year
patient
enrol
patient
n
hematolog
cancer
n
solid
tumor
parent
identifi
import
decis
made
child
involv
medic
use
radiat
use
medic
devic
surgic
procedur
gener
care
plan
n
parent
report
receiv
help
commun
doctor
decis
parent
identifi
bedsid
nurs
n
resid
n
fellow
n
social
worker
n
chaplain
n
doctor
subspecialti
n
help
decis
make
process
averag
decis
regret
score
rang
averag
dm
score
rang
conclus
parent
face
complic
decis
critic
ill
children
cancer
half
parent
identifi
member
healthcar
team
help
commun
decis
commonli
bedsid
nurs
data
highlight
potenti
import
role
besid
nurs
support
commun
decis
make
parent
picu
decis
regret
score
low
dm
score
high
room
improv
exist
abdulla
baothman
hassan
khayat
ra
alsulami
abdulaziz
alkahtani
enaam
alsobhi
yousef
marzouk
king
abdulaziz
medic
citi
jeddah
makkah
saudi
arabia
background
homozyg
protein
c
defici
hpcd
rare
hereditari
thrombophilia
caus
genet
mutat
involv
proc
gene
estim
incid
per
million
birth
classic
present
hpcd
purpura
fulminan
pf
develop
shortli
birth
diagnosi
usual
made
base
genet
analysi
protein
c
level
object
aim
discuss
clinic
present
associ
molecular
defect
outcom
five
pediatr
patient
hpcd
well
review
relat
data
literatur
designmethod
data
collect
medic
record
five
pediatr
patient
hpcd
treat
institut
literatur
review
includ
patient
hpcd
includ
paper
written
english
provid
least
clinic
present
andor
outcom
case
studi
result
sampl
includ
two
male
three
femal
median
age
two
year
three
case
posit
c
mutat
two
g
case
pf
atyp
delay
beyond
first
year
life
one
case
found
literatur
pf
beyond
one
year
posit
g
mutat
protein
c
activ
report
less
case
blind
seen
four
case
comparison
case
literatur
review
four
case
develop
blind
two
found
rare
congenit
ophthalm
find
peter
anomali
one
case
intraocular
bleed
shortli
birth
preced
pf
occur
month
later
contrast
case
review
literatur
found
ocular
bleed
simultan
pf
patient
surviv
conclus
defin
two
genet
defect
caus
hpcd
atyp
present
pf
isol
intraocular
bleed
previou
report
provid
clinic
data
particular
mutat
weather
molecular
defect
contribut
atyp
express
yet
answer
associ
peter
anomali
hpcd
never
report
observ
merit
studi
larg
center
andrea
watson
colleen
renier
ami
vanheck
essentia
health
duluth
clinic
duluth
minnesota
unit
state
background
childhood
cancer
treatment
us
typic
offer
tertiari
center
locat
larg
urban
set
children
resid
outstat
area
travel
increas
famili
burden
care
greater
distanc
treat
hospit
associ
greater
econom
hardship
emot
stress
famili
burden
object
purpos
studi
examin
impact
pediatr
cancer
center
burden
care
measur
travel
distanc
cost
time
designmethod
pediatr
cancer
patient
diagnos
roundtrip
distanc
travel
time
treat
pediatr
cancer
center
cbpcc
nearest
tertiari
care
treatment
center
tctc
identifi
gasolin
cost
comput
use
mile
per
gallon
new
car
diagnosi
month
mean
price
per
gallon
three
children
oncolog
group
treatment
scenario
appli
patient
diagnosi
protocol
end
death
leukemia
visit
lymphoma
visit
sarcoma
visit
pair
compar
cbpcc
tctc
singl
visit
three
treatment
scenario
result
total
patient
age
year
median
includ
rural
resid
comparison
signific
p
singl
round
trip
visit
differ
travel
distanc
mile
travel
time
hour
gasolin
cost
leukemia
treatment
scenario
differ
travel
distanc
mile
travel
time
hour
gasolin
cost
similar
result
seen
lymphoma
sarcoma
proport
number
schedul
visit
treatment
scenario
conclus
pediatr
cancer
center
reduc
burden
care
famili
minim
travel
time
associ
hardship
analysi
includ
travel
unschedul
visit
visit
consid
addit
expens
gener
travel
hous
food
child
care
miss
work
cours
child
cancer
treatment
care
closer
home
magnifi
save
time
cost
reduc
overal
burden
care
famili
kaylli
wang
peter
shaw
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
von
willebrand
diseas
vwd
platelet
function
disord
pfd
common
mild
bleed
disord
seen
children
young
adult
patient
usual
good
respons
iv
ddavp
often
prophylact
treat
prior
surgeri
studi
analyz
prophylact
use
iv
ddavp
prevent
postop
bleed
patient
object
goal
evalu
patient
vwd
pfd
prophylact
treat
iv
ddavp
lower
rate
postop
bleed
histor
control
receiv
ddavp
designmethod
perform
retrospect
chart
review
pediatr
patient
seen
coagul
clinic
ddavp
challeng
children
hospit
pittsburgh
januari
decemb
inclus
criteria
patient
year
old
vwd
low
von
willebrand
factor
lvwf
pfd
respond
well
ddavp
surgeri
prophylact
iv
ddavp
without
aminocapro
acid
use
periop
primari
outcom
incid
postop
bleed
first
hour
earli
bleed
hour
day
late
bleed
result
patient
underw
ddavp
challeng
surgeri
mean
age
year
femal
patient
type
vwd
lvwf
pfd
evid
type
vwd
pfd
patient
underw
procedur
postop
aminocapro
acid
use
inconsist
earli
postop
bleed
patient
patient
late
bleed
tonsillectomi
without
adenoidectomi
procedur
tonsillectomi
without
adenoidectomi
bleed
rate
none
patient
procedur
develop
postop
bleed
publish
bleed
rate
larg
seri
untreat
patient
known
bleed
disord
high
conclus
patient
vwd
pfd
receiv
prophylact
iv
ddavp
lower
rate
postop
bleed
versu
untreat
patient
diagnos
unclear
aminocapro
acid
provid
addit
benefit
angela
feraco
joshua
gagn
sarah
brand
susan
block
joann
wolf
cancer
institut
boston
massachusett
unit
state
background
first
six
month
childhood
cancer
treatment
may
lead
chang
ill
understand
alter
commun
need
among
famili
compar
diagnosi
current
framework
guid
commun
earli
treatment
period
object
elicit
live
ill
experi
first
month
accept
engag
novel
convers
primari
pediatr
oncologist
day
talk
period
prefer
topic
goal
designmethod
conduct
interview
children
age
year
parent
children
cancer
undergo
treatment
week
month
sampl
interview
constant
compar
qualit
analysi
inform
ground
theori
result
five
adolesc
parent
particip
interview
five
particip
children
particip
solid
tumor
brain
tumor
hematolog
malign
mean
treatment
durat
week
emerg
theme
reflect
combin
rel
normalci
earli
treatment
week
still
fight
new
normal
compos
cancer
care
new
relationship
alter
daili
live
particip
speak
emerg
wood
get
sea
leg
earli
treatment
period
abl
engag
care
differ
diagnosi
frequent
one
parent
take
charg
ill
child
care
maintain
work
home
life
role
divis
lead
differ
inform
need
member
famili
overal
parent
endors
adolesc
though
adolesc
endors
desir
discuss
futur
particip
suggest
could
serv
reflect
progress
consolid
ill
understand
creat
share
understand
famili
member
differ
role
ensur
current
treatment
path
still
right
manag
transit
care
conclus
famili
endors
concept
could
serv
reflect
progress
deepen
famili
ill
understand
revisit
treatment
decis
anticip
futur
transit
futur
work
develop
integr
oncolog
provid
perspect
moham
elshinawi
abdulhakim
yasser
wali
sultan
qaboo
univers
hospit
muscat
oman
background
rare
bleed
disord
rbd
autosom
recess
heterogen
group
inherit
coagul
factor
defici
preval
rang
remark
pauciti
data
rbd
middl
east
despit
educ
social
modern
oman
still
high
preval
consanguin
marriag
reach
regist
marriag
rbd
expect
rel
high
oman
compar
western
countri
object
aim
current
work
studi
demograph
characterist
clinic
present
manag
rbd
omani
pediatr
patient
designmethod
retrospect
data
analysi
children
diagnos
inherit
coagul
factor
defici
pediatr
hematolog
unit
sultan
qaboo
univers
hospit
muscat
oman
januari
till
decemb
result
defici
fibrinogen
fv
fvii
fx
fxiii
diagnos
pediatr
patient
male
femal
account
children
inherit
coagul
factor
defici
hypofibrinogenemia
fv
defici
commonest
disord
diagnos
patient
respect
age
rang
day
year
consanguin
marriag
found
case
clinic
spectrum
vari
mild
mucocutan
bleed
seriou
intraocular
hemorrhag
neonat
afibrinogenemia
initi
present
intracrani
hemorrhag
occur
case
two
patient
one
fv
defici
anoth
fxiii
defici
suffer
global
development
delay
due
sever
intracrani
hemorrhag
earli
infanc
regard
manag
patient
sever
fv
defici
one
sever
fxiii
fresh
frozen
plasma
ffp
prophylaxi
patient
receiv
therapi
conclus
conclus
children
rbd
constitut
almost
one
tenth
case
hereditari
coagul
factor
defici
centr
uniqu
featur
term
sever
clinic
profil
need
prophylaxi
earli
life
recommend
establish
nationalregion
registri
rbd
collabor
centr
serv
identifi
epidemiolog
clinic
present
correl
therapeut
option
rare
yet
signific
disord
part
world
anil
georg
partha
sinha
gari
conrad
emili
dressler
lar
wagner
univers
kentucki
lexington
kentucki
unit
state
background
positron
emiss
tomographi
pet
scan
use
fdg
increasingli
use
cancer
stage
treatment
respons
assess
physiolog
uptak
fdg
brown
adipos
tissu
bat
neck
chest
common
pediatr
patient
confound
interpret
pet
scan
creat
fals
posit
mimick
tumor
fals
neg
obscur
malign
node
fdg
uptak
bat
mediat
adrenerg
signal
block
propranolol
shown
previou
studi
adult
oncolog
patient
object
prospect
assess
safeti
singl
low
dose
propranolol
fast
adolesc
young
adult
oncolog
patient
undergo
imag
also
retrospect
review
data
pediatr
oncolog
patient
undergon
pet
scan
institut
identifi
featur
like
associ
bat
uptak
designmethod
propranolol
mg
mgkg
given
one
hour
prior
fdg
inject
vital
sign
blood
glucos
measur
symptom
assess
perform
scan
imag
review
blind
radiologist
chart
retrospect
review
addit
patient
assess
whether
gender
age
bodi
mass
index
bmi
season
year
predict
fdg
uptak
bat
result
nine
patient
receiv
propranolol
median
age
year
rang
clinic
signific
chang
observ
blood
pressur
heart
rate
serum
glucos
follow
propranolol
administr
patient
observ
subject
report
advers
event
four
patient
previou
uptak
bat
none
follow
propranolol
retrospect
review
total
patient
median
age
year
rang
bat
uptak
identifi
patient
multivari
analysi
lower
bmi
factor
associ
bat
uptak
p
conclus
propranolol
conveni
safe
fast
pediatr
oncolog
patient
undergo
pet
scan
effect
elimin
bat
uptak
patient
find
previou
scan
lower
bmi
import
factor
predict
bat
uptak
futur
studi
could
target
patient
low
bmi
compar
efficaci
propranolol
drug
like
fentanyl
use
reduc
bat
uptak
sanja
joskimov
glisov
maja
krajinov
carolin
leclerc
daniel
sinnett
yve
pastor
cancer
center
chu
research
center
montreal
quebec
canada
background
neutropenia
infect
major
side
effect
chemotherapi
risk
initi
infect
subsequ
complic
directli
relat
depth
durat
neutropenia
recent
public
provid
evid
genet
variant
darc
gene
locu
chromosom
gene
influenc
total
white
blood
cell
wbc
neutrophil
count
irrespect
treatment
object
evalu
associ
polymorph
captur
variabl
loci
chemotherapi
complic
children
treat
acut
lymphoblast
leukemia
designmethod
retrospect
studi
children
treat
use
dfci
protocol
tagsnp
darc
gene
snp
locu
snp
gene
analyz
chart
review
perform
evalu
episod
neutropenia
infecti
complic
result
caucasian
children
origin
diagnos
chu
montreal
januari
juli
correct
multipl
test
darc
snp
associ
low
absolut
phagocyt
count
apc
p
p
respect
hospit
due
neutropenia
p
also
observ
associ
among
upstream
darc
variant
chemotherapi
cessat
due
neutropenia
p
apc
p
snp
locu
associ
hospit
due
infect
p
hospit
due
infect
neutropenia
p
p
p
conclus
studi
identifi
first
time
loci
modul
wbc
neutrophil
count
may
play
role
onset
chemotherapi
complic
may
thu
serv
marker
adjust
treatment
childhood
melissa
markel
sydney
ross
jenni
jami
renbarg
riley
hospit
children
indianapoli
indiana
unit
state
background
cisplatin
chemotherapeut
agent
use
treatment
medulloblastoma
potenti
caus
nephrotox
monitor
renal
injuri
reli
chang
serum
creatinin
delay
may
observ
signific
renal
injuri
occur
urinari
protein
biomark
may
serv
sensit
method
detect
renal
injuri
current
studi
numer
clinic
set
object
evalu
chang
urinari
biomark
respons
cisplatin
contain
chemotherapi
children
medulloblastoma
designmethod
urinari
creatinin
biomark
analysi
sampl
collect
pediatr
patient
medulloblastoma
treat
cisplatin
n
sampl
collect
pre
post
treatment
cisplatin
lab
valu
obtain
serum
creatinin
magnesium
phosphoru
potassium
gfr
urinari
creatinin
level
obtain
use
cayman
chemic
urin
creatinin
assay
millipor
human
kidney
toxic
panel
human
kidney
injuri
panel
biorad
human
kidney
toxic
panel
run
flexmap
suspens
array
system
protein
examin
includ
osteopontin
albumin
ngal
cystatin
c
clusterin
assay
run
per
manufactur
recommend
protocolsdata
analysi
data
analyz
use
graphpad
prism
consid
signific
biomark
valu
normal
urinari
creatinin
level
express
ng
urinari
biomarkermg
creatinin
biomark
lab
valu
analyz
unpair
compar
pre
post
treatment
determin
differ
biomark
concentr
treatment
result
trefoil
factor
express
higher
concentr
post
cisplatin
treatment
compar
pretreat
p
signific
found
biomark
addit
serum
phosphoru
level
decreas
post
cisplatin
treatment
p
conclus
member
trefoil
factor
peptid
famili
secret
epitheliod
cell
urinari
tract
proxim
distal
collect
duct
studi
children
receiv
cisplatin
signific
chang
concentr
post
cisplatin
treatment
serum
creatinin
chang
post
cisplatin
treatment
suggest
may
sensit
biomark
acut
kidney
injuri
secondari
cisplatin
shirley
qiong
yan
brian
seyboth
rachel
kobo
nina
cohen
susan
seo
memori
sloan
ketter
cancer
center
new
york
new
york
unit
state
background
voriconazol
dose
pharmacokinet
pk
pharmacodynam
pd
data
limit
children
especi
year
variou
factor
impact
pk
pd
infant
young
children
due
chang
drug
absorpt
distribut
metabol
elimin
object
primari
object
evalu
proport
patient
achiev
plasma
trough
concentr
initi
dose
voriconazol
fungal
prophylaxi
treatment
pediatr
oncolog
hematopoiet
stem
cell
transplant
hsct
secondari
object
evalu
efficaci
side
effect
voriconazol
designmethod
review
data
pediatr
patient
year
old
receiv
consecut
day
voriconazol
either
prophylaxi
treatment
invas
fungal
infect
ifi
least
measur
voriconazol
trough
concentr
result
median
age
patient
year
rang
year
median
weight
kg
rang
kg
includ
patient
actual
bodi
weight
abw
kg
eleven
patient
voriconazol
trough
concentr
median
rang
first
measur
median
voriconazol
dosag
referenc
abw
patient
mgkgday
rang
mgkgday
patient
concentr
younger
age
median
year
rang
year
p
lower
abw
median
kg
rang
kg
p
patient
experienc
breakthrough
ifi
perman
side
effect
voriconazol
conclus
use
dose
recommend
patient
age
year
old
result
plasma
trough
concentr
patient
year
concentr
frequent
seen
patient
kg
year
work
may
need
develop
dose
recommend
voriconazol
achiev
target
therapeut
level
first
dose
voriconazol
patient
year
nichola
richardson
bruce
behring
michael
warren
vanderbilt
univers
school
medicin
nashvil
tennesse
unit
state
background
tobacco
use
increas
risk
lung
mani
tobacco
relat
cancer
higher
risk
confer
longer
durat
intens
tobacco
use
tobacco
use
associ
advers
health
outcom
cardiovascular
diseas
stroke
chronic
obstruct
pulmonari
diseas
decreas
physic
fit
may
result
shorten
life
span
smoker
initi
tobacco
use
prior
age
year
million
adult
current
smoke
us
rate
cigarett
smoke
remain
higher
nation
averag
tennesse
start
use
tobacco
master
settlement
fund
tennesse
depart
health
initi
goal
integr
tobacco
cessat
intervent
commun
primari
care
clinic
howev
sever
barrier
aros
success
promot
integr
commun
tobacco
cessat
object
object
studi
identifi
common
barrier
integr
success
commun
tobacco
prevent
cessat
intervent
develop
action
plan
facilit
success
program
establish
designmethod
key
inform
interview
conduct
seven
tennesse
counti
depart
health
director
assess
facilit
barrier
implement
tobacco
cessat
intervent
within
commun
primari
care
practic
facilit
barrier
organ
theme
includ
factor
institut
factor
commun
factor
defin
model
result
barrier
elucid
includ
time
constraint
document
challeng
organiz
cultur
resourc
avail
alloc
leadership
approv
lack
partnership
barrier
identifi
studi
highlight
need
organ
action
plan
facilit
integr
tobacco
cessat
intervent
action
plan
develop
includ
effect
program
champion
util
local
data
adequ
staff
resourc
commun
educ
strateg
plan
key
stakehold
conclus
leverag
strategi
offset
common
barrier
integr
tobacco
cessat
intervent
essenti
establish
practic
tobacco
cessat
prevent
program
clinic
practic
joel
thompson
jefferi
auletta
jennif
muszynski
mark
hall
nationwid
children
hospit
columbu
ohio
unit
state
background
minim
residu
diseas
mrd
pediatr
prognost
relaps
surviv
littl
known
patient
innat
adapt
immun
function
may
relat
mrd
statu
host
defens
import
aspect
effect
greater
understand
relationship
may
identifi
novel
target
strategi
leukemia
treatment
object
test
hypothesi
patient
posit
mrd
mrd
induct
significantli
wors
innat
adapt
immun
function
patient
neg
mrd
designmethod
prospect
longitudin
observ
studi
patient
newli
diagnos
pediatr
age
test
function
immun
recoveri
day
induct
day
consolid
immun
function
test
peripher
blood
includ
mch
class
ii
express
neutrophil
express
monocyt
neutrophil
phagocytosi
flow
cytometri
product
respons
lipopolysaccharid
stimul
immunosuppress
regulatori
treg
percentag
cell
nk
cell
flow
cytometri
result
fifteen
patient
studi
date
n
nci
standard
risk
cell
n
nci
high
risk
cell
n
five
fifteen
patient
mrd
end
induct
mrd
patient
higher
percentag
treg
day
induct
versu
patient
median
vs
interquartil
rang
vs
p
day
consolid
differ
seen
nk
cell
count
similar
group
time
point
differ
innat
immun
function
day
induct
day
consolid
patient
posit
mrd
lower
neutrophil
count
flow
cytometri
vs
p
conclus
show
pediatr
patient
mrd
higher
percentag
circul
treg
compar
patient
impair
neutrophil
recoveri
evid
day
consolid
studi
ongo
quantifi
lymphocyt
function
patient
data
may
inform
futur
immunotherapeut
approach
popul
ana
luiza
fabro
alin
bessen
nelson
miyagu
flora
watanab
edna
carboni
ana
paula
pedro
bom
gabriela
fernand
luiz
camil
vicentini
cilmara
kuwahara
samantha
nichel
euripid
ferreira
hospit
pequeno
curitiba
parana
brazil
background
anthracyclin
doxorubicin
idarubicin
remain
import
class
chemotherapeut
agent
unfortun
efficaci
treat
cancer
limit
cumul
cardiotox
caus
irrevers
heart
failur
object
observ
echocardiograph
chang
patient
use
anthracyclin
designmethod
perform
retrospect
cohort
studi
analyz
echocardiogram
patient
start
chemotherapi
year
follow
children
receiv
chemotherapi
protocol
anthracyclin
januari
decemb
pediatr
oncolog
unit
hospit
pequeno
result
profil
patient
male
mean
age
month
diagnosi
mean
cumul
dose
found
incid
heart
dysfunct
whole
period
signific
differ
found
sex
type
dose
anthracyclin
group
without
cardiac
dysfunct
averag
age
higher
patient
cardiac
dysfunct
analysi
echocardiograph
paramet
group
receiv
dose
show
significantli
lower
extent
left
ventricular
diastol
diamet
period
month
month
group
also
show
lower
systol
diamet
left
ventricl
paramet
statist
differ
conclus
frequenc
cardiac
dysfunct
similar
literatur
close
relat
age
diagnosi
chang
ventricular
volum
occur
frequent
year
patient
higher
dose
mg
apurvi
patel
justin
montoya
daniel
wai
robert
arceci
david
azorsa
institut
molecular
medicin
phoenix
children
hospitalunivers
arizona
phoenix
arizona
unit
state
background
despit
major
advanc
pediatr
leukemia
therapi
toxic
still
concern
morbid
chemotherapi
regimen
detriment
advanc
genom
research
well
precis
medicin
help
identifi
specif
mutat
may
suscept
target
therapi
patient
leukemia
overal
use
target
drug
therapi
rise
pediatr
oncolog
field
object
complement
genom
analysi
leukemia
patient
laboratori
develop
drug
sensit
resist
screen
assay
would
provid
clinic
relev
drug
respons
data
patient
leukemia
cell
designmethod
part
lab
develop
assay
first
prepar
librari
plate
clinic
activ
drug
cell
ad
plate
treat
hour
time
cell
viabil
determin
preliminari
work
laboratori
use
librari
target
agent
test
aml
cell
line
cell
line
biolog
replic
perform
cell
line
drug
respons
data
form
area
curv
auc
calcul
hierarch
cluster
perform
determin
similar
respons
cell
line
drug
result
result
identifi
sever
cell
line
show
hypersensit
specif
drug
among
aml
cell
line
show
sensit
three
fgfr
inhibitor
includ
ponatinib
previous
report
valid
screen
result
done
use
drug
dose
respons
assay
conclus
test
includ
expans
drug
librari
applic
ex
vivo
patient
sampl
result
studi
lead
establish
drug
sensit
resist
assay
could
provid
specif
engin
therapi
patient
form
precis
therapi
would
lead
diminish
toxic
system
therapi
well
allow
increas
cure
rate
joseph
bernard
jeff
gregori
lucien
notr
dame
dhaiti
haiti
background
pediatr
cancer
repres
diagnos
cancer
around
world
epidemiolog
studi
childhood
cancer
haiti
date
absent
object
princip
object
studi
determin
predictor
mortal
pediatr
cancer
manag
haitian
pediatr
hospit
designmethod
studi
case
pediatr
cancer
admit
oncolog
depart
st
damien
hospit
haiti
chart
children
diagnos
type
cancer
review
collect
data
key
variabl
could
predictor
mortal
number
case
diagnos
mortal
due
cancer
evalu
year
studi
period
odd
ratio
chi
squar
test
evalu
whether
gender
age
group
region
origin
depart
cancer
type
type
treatment
occurr
relaps
complic
signific
predictor
mortal
popul
result
one
hundr
case
pediatr
cancer
male
femal
among
live
admit
studi
period
nineteen
differ
type
cancer
diagnos
common
one
wilm
tumor
leukemia
retinoblastoma
children
cancer
less
year
age
overal
cure
rate
relaps
rate
overal
mortal
rate
mortal
rate
significantli
higher
children
blood
cancer
odd
ratio
p
relaps
p
complic
p
conclus
blood
cancer
relaps
complic
main
predictor
mortal
among
children
cancer
manag
st
damien
hospit
studi
period
pediatr
cancer
care
need
significantli
improv
order
reduc
unfavor
outcom
especi
blood
cancer
e
ward
et
al
childhood
adolesc
cancer
statist
saroj
panda
nirmalya
pradhan
maya
prasad
gaurav
narula
tushar
vora
girish
chinnaswami
brijesh
arora
shripad
banavali
tata
memori
hospit
mumbai
maharastra
india
background
synerg
cytarabin
cladribin
acut
myeloid
leukemia
aml
well
demonstr
object
current
retrospect
analysi
aim
evalu
efficaci
toxic
cladribin
cytarabin
high
risk
aml
patient
primari
refractori
diseas
earli
relaps
designmethod
children
aml
year
age
receiv
least
one
cycl
cladribin
base
chemotherapi
januari
decemb
retrospect
analyz
cycl
consist
cytarabin
infus
cladribin
half
hour
infus
patient
achiev
partial
remiss
receiv
second
similar
cours
patient
complet
remiss
receiv
consolid
combin
cytarabin
cladribin
regimen
result
eighti
six
patient
includ
median
age
year
molecular
studi
avail
case
cytogenet
twelv
patient
receiv
cladribin
post
oral
chemotherapi
patient
primari
resist
diseas
post
standard
induct
chemotherapi
receiv
consolid
view
high
risk
diseas
salvag
follow
relaps
cr
achiev
patient
singl
cours
induct
among
mrd
neg
seven
patient
die
induct
eight
refractori
diseas
febril
neutropenia
fungal
pneumonia
common
complic
patient
experienc
grade
neutropenia
thrombocytopenia
one
forth
requir
icu
admiss
median
period
month
overal
surviv
os
patient
receiv
cladribin
cytarabin
induct
post
oral
chemotherapi
consolid
view
high
risk
diseas
os
year
yr
patient
receiv
cladribin
cytarabin
salvag
relaps
resist
diseas
os
yr
yr
conclus
preliminari
result
suggest
cladribin
cytarabin
effect
salvag
regimen
high
risk
refractori
relaps
aml
show
high
rate
complet
remiss
manag
toxic
erika
lopez
bertieri
sandi
pruitt
lei
xuan
ut
southwestern
medic
center
dalla
texa
unit
state
background
new
case
cancer
occur
among
children
adolesc
unit
state
approxim
children
hispan
prior
research
hispan
children
cancer
shown
increas
risk
death
compar
white
peer
howev
data
impact
hispan
ethnic
pediatr
cancer
outcom
rel
scarc
strongest
evid
date
field
pediatr
leukemia
acut
lymphoblast
acut
myeloid
leukemia
hispan
patient
compar
white
lower
surviv
object
evalu
associ
hispan
ethnic
mortal
among
children
cancer
type
texa
designmethod
conduct
retrospect
analysi
use
texa
cancer
registri
data
includ
patient
year
age
diagnos
first
primari
malign
examin
differ
hispan
white
patient
mortal
differ
surviv
surviv
rate
estim
use
unadjust
curv
fit
separ
cancer
type
leukemia
lymphoma
solid
tumor
patient
cancer
type
multivari
cox
proport
hazard
model
control
patient
age
sex
year
diagnosi
cancer
type
stage
result
total
patient
identifi
hispan
white
leukemia
lymphoma
solid
tumor
unadjust
analysi
hispan
leukemia
p
solid
tumor
p
higher
risk
death
compar
white
hispan
vs
white
respect
surviv
follow
leukemia
vs
lymphoma
vs
solid
tumor
vs
patient
cancer
type
combin
hispan
vs
white
higher
mortal
adjust
covari
adjust
hazard
ratio
ahr
ci
conclus
hispan
children
leukemia
solid
tumor
texa
higher
risk
death
compar
white
futur
research
seek
understand
reason
underli
dispar
develop
intervent
design
improv
surviv
among
hispan
children
cancer
addit
research
also
explor
reason
behind
observ
low
surviv
rate
molli
brickler
nathan
schloemer
yumei
cao
raymond
hoffmann
vanessa
mcfadden
joseph
block
richard
tower
ii
michael
burk
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
acut
myeloid
leukemia
aml
compris
pediatr
cancer
report
event
free
surviv
ef
approxim
overal
surviv
os
follow
intens
chemotherapi
anthracyclin
cornerston
treatment
aml
howev
associ
acut
late
cardiac
toxic
nearli
pediatr
patient
receiv
anthracyclin
may
develop
congest
heart
failur
chf
higher
incid
cumul
dose
exceed
importantli
current
aml
treatment
children
commonli
includ
anthracyclin
dose
excess
known
caus
chf
object
children
hospit
wisconsin
chw
previous
adopt
standard
clinic
practic
administ
dexrazoxan
prior
anthracyclin
begin
report
differ
cardiac
treatment
outcom
children
young
adult
aml
treat
without
dexrazoxan
chw
designmethod
retrospect
chart
review
children
age
year
receiv
chemotherapi
aml
chw
januari
decemb
perform
data
collect
electron
medic
record
includ
variabl
anthracyclin
administr
echocardiogram
measur
relaps
statu
statist
analys
conduct
use
sa
statist
softwar
version
two
side
p
valu
consid
statist
signific
data
express
frequenc
count
percentag
categor
variabl
result
total
patient
median
age
includ
receiv
dexrazoxan
statist
differ
ef
os
significantli
higher
eject
fraction
lower
shorten
fraction
higher
left
ventricular
systol
volum
patient
receiv
dexrazoxan
conclus
summari
util
dexrazoxan
prior
anthracyclin
chemotherapi
pediatr
patient
aml
demonstr
signific
differ
either
ef
os
rel
institut
histor
control
appear
improv
cardiac
function
promis
studi
patient
popul
need
confirm
find
jessica
zerillo
erin
santacroc
mari
ann
zimmerman
melissa
freeman
teresa
lau
greenberg
phuong
nguyen
susan
chi
pratiti
bandopadhayay
sharon
lane
audrea
szabatura
kathleen
houlahan
ami
billett
cancer
institut
children
cancer
blood
disord
center
boston
massachusett
unit
state
background
safeti
check
ensur
safe
prescrib
parenter
chemotherapi
oral
chemotherapi
usual
prescrib
singl
clinician
grow
use
oral
chemotherapi
process
includ
patient
famili
educ
need
protect
patient
prescript
error
object
describ
process
oral
chemotherapi
prescript
verif
present
process
measur
includ
nurs
time
need
illustr
benefit
oral
chemotherapi
prescript
verif
process
designmethod
nurs
prescrib
pharmacist
administr
develop
new
process
checklist
nurs
verif
oral
chemotherapi
prescript
children
cancer
blood
disord
center
oncolog
clinic
prescript
verifi
independ
treatment
plan
two
pediatr
oncolog
nurs
verif
checklist
includ
drug
dosag
modif
final
dose
height
weight
laboratori
valu
patient
instruct
avail
prescript
bottl
also
verifi
process
implement
patient
one
diseas
center
data
collect
pilot
period
result
prescript
verif
occur
verif
rate
retail
pharmaci
fill
prescript
prescript
decemb
mean
time
verif
minut
sd
per
nurs
nurs
identifi
problem
outsid
prescript
verif
includ
miss
prior
author
unclear
treatment
plan
medic
bottl
routin
avail
verif
one
identifi
near
miss
would
result
everolimu
conclus
prescript
verif
nurs
pediatr
oncolog
clinic
feasibl
success
identif
one
medic
error
reach
patient
prescript
verifi
sinc
prescript
bottl
usual
obtain
visit
verif
actual
bottl
requir
new
workflow
addit
clinic
visit
upload
pictur
via
patient
portal
involv
nurs
review
oral
chemotherapi
identifi
prescript
error
also
highlight
issu
within
aspect
patient
care
includ
need
patientfamili
educ
inconsist
document
treatment
plan
inclus
nurs
review
manag
oral
chemotherapi
potenti
improv
safeti
outcom
patient
rachel
kobo
grace
egan
cheryl
fischer
ira
dunkel
yasmin
khakoo
stephen
gilheeney
neerav
shukla
tanya
trippett
peter
steinherz
nanci
kernan
memori
sloan
ketter
cancer
center
new
york
citi
new
york
unit
state
background
guidelin
exist
childhood
cancer
survivor
follow
chemotherapi
object
prospect
determin
respons
rate
follow
immun
cohort
patient
designmethod
conduct
phase
ii
singl
center
studi
patient
remiss
follow
chemotherapi
exclud
receiv
autolog
allogen
hsct
immun
recoveri
defin
absolut
cell
prolif
respons
pha
lower
limit
normal
igg
without
supplement
ivig
respons
vaccin
defin
seroconvers
posit
titer
result
patient
year
median
year
male
enrol
median
month
rang
month
patient
sr
hr
aml
n
hodgkin
lymphoma
n
lymphoma
n
cn
tumor
n
retinoblastoma
n
germ
cell
tumor
n
embryon
rhabdomyosarcoma
n
wilm
tumor
n
patient
complet
plan
vaccin
serolog
test
complet
least
complet
less
reason
incomplet
particip
includ
relaps
poor
complianc
death
time
start
vaccin
rang
month
median
month
protect
titer
absent
patient
polio
tetanu
diphtheria
mmr
varicella
hepat
b
haemophilu
influenza
b
meningococc
c
w
pneumococc
pertussi
seroposit
tetanu
diphtheria
polio
haemophilu
influenza
b
hepat
b
pneumococc
complet
trial
rate
seroposit
remain
pathogen
pertussi
meningococc
c
w
measl
mump
rubella
varicella
primari
diseas
type
predict
respons
conclus
studi
confirm
poor
residu
immun
mani
vaccin
prevent
diseas
childhood
survivor
cancer
vaccin
schedul
may
provid
protect
level
mani
pathogen
howev
patient
continu
risk
pertussi
meningococc
c
w
mmr
varicella
stephen
nelson
jennif
lee
michel
allard
bruce
bostrom
children
hospit
clinic
minnesota
minneapoli
minnesota
unit
state
background
children
oncolog
group
cog
play
major
role
improv
surviv
children
cancer
diagnos
patient
treat
pediatr
oncolog
center
much
better
outcom
children
treat
standard
protocol
better
project
everi
child
protocol
recent
launch
cog
registri
elig
screen
biolog
outcom
studi
requir
enrol
order
particip
cog
treatment
studi
requir
may
lead
even
fewer
children
color
abl
benefit
cog
treatment
protocol
object
goal
studi
quantifi
number
refus
enrol
cog
registri
race
ethnic
designmethod
review
databas
oncolog
patient
children
hospit
clinic
minnesota
find
patient
offer
particip
cog
studi
april
decemb
data
collect
race
ethnic
well
refus
enrol
racial
differ
evalu
use
fisher
exact
probabl
test
result
total
patient
offer
enrol
inform
raceethn
avail
children
famili
refus
enrol
white
patient
refus
enrol
refus
rate
much
higher
patient
color
p
asian
patient
highest
refus
rate
p
follow
black
patient
p
nativ
american
hispan
refus
rate
also
higher
refus
rate
patient
reach
statist
signific
p
conclus
refus
rate
enrol
significantli
higher
patient
color
fact
alon
would
great
concern
immedi
impact
access
care
outcom
requir
enrol
like
lead
even
fewer
children
color
benefit
cog
treatment
protocol
would
encourag
cog
revisit
requir
enrol
project
everi
child
protocol
like
exacerb
alreadi
inferior
outcom
patient
color
parul
rai
jame
feusner
anurag
agraw
children
hospit
research
center
oakland
oakland
california
unit
state
background
pediatr
patient
acut
lymphoblast
leukemia
develop
neurotox
secondari
intrathec
methotrex
mtx
remain
unclear
switch
mtx
cytarabinehydrocortison
increas
risk
isol
central
nervou
system
relaps
icnsr
patient
also
unknown
neurotox
risk
factor
develop
icnsr
object
determin
whether
substitut
mtx
neurotox
event
increas
risk
icnsr
addit
sought
determin
neurotox
event
lead
increas
icnsr
designmethod
perform
retrospect
chart
review
patient
complet
treatment
januari
decemb
children
hospit
research
center
oakland
patient
cn
leukemia
diagnosi
exclud
quantifi
patient
neurotox
event
compar
result
cohort
without
neurotox
event
subsequ
compar
risk
icnsr
neurotox
continu
mtx
switch
result
patient
treat
time
period
definit
neurotox
relat
mtx
patient
classifi
hr
either
present
risk
stratif
significantli
higher
risk
mtx
neurotox
compar
sr
patient
vs
p
fisher
exact
test
total
patient
icnsr
differ
risk
icnsr
hr
sr
patient
patient
mtx
neurotox
trend
toward
increas
risk
icnsr
vs
without
neurotox
p
fisher
exact
test
patient
neurotox
switch
three
icnsr
remain
methotrex
one
subsequ
icnsr
differ
icnsr
rate
conclus
pediatr
patient
mtx
neurotox
increas
rate
icnsr
switch
hr
patient
increas
risk
mtx
neurotox
neurotox
may
risk
factor
subsequ
icnsr
marina
reppucci
jonathan
fish
charl
schleien
cohen
children
medic
center
new
hyde
park
new
york
unit
state
background
childhood
cancer
survivor
cc
bear
high
burden
chronic
diseas
cc
us
like
care
larg
impact
health
care
spend
littl
publish
cost
care
object
quantifi
actual
cost
reimburs
screen
amongst
cc
singl
institut
screen
recommend
follow
children
oncolog
group
guidelin
designmethod
retrospect
review
medic
record
patient
seen
survivor
face
forward
program
cohen
children
medic
center
perform
demograph
data
origin
cancer
diagnosi
chemotherapi
radiat
surgeri
exposur
collect
screen
test
recommend
survivorship
program
subsequ
complet
tabul
actual
cost
defin
estim
cost
incur
hospit
perform
procedur
reimburs
defin
amount
refund
hospit
cost
incur
calcul
per
patient
per
visit
use
hospit
cpt
dollar
amount
provid
hospit
financ
depart
linear
mix
model
use
examin
outcom
patient
demograph
clinic
characterist
mix
model
approach
use
account
hierarch
structur
data
result
patient
male
seen
time
period
rang
visit
averag
actual
cost
per
patient
per
visit
averag
reimburs
per
patient
per
visit
frequenc
visit
alkyl
use
cancer
diagnosi
radiat
therapi
significantli
associ
reimburs
frequenc
visit
alkyl
use
radiat
therapi
significantli
associ
cost
conclus
overal
patient
greater
exposur
greater
cost
associ
screen
particular
patient
prior
alkyl
chemotherapi
radiat
therapi
treatment
highest
cost
screen
note
reimburs
exceed
cost
wide
margin
research
requir
assess
whether
direct
provis
survivorship
care
cost
effect
institut
well
societ
perspect
joy
bartholomew
hongi
dai
keith
august
robin
ryan
kristin
stegenga
alan
gami
children
merci
hospit
kansa
citi
kansa
citi
missouri
unit
state
background
hdmtx
given
four
hospit
interim
mainten
high
risk
pediatr
significantli
improv
surviv
increas
resourc
util
children
remain
hospit
iv
hydrat
bloodurin
monitor
mtx
clearanc
paramet
reach
improv
support
care
extend
infus
center
hour
pediatr
home
health
expertis
afford
altern
prolong
hospit
admiss
potenti
offer
qualiti
approach
posit
impact
deliveri
care
object
compar
feasibl
safeti
cost
effect
continu
hdmtx
infus
outpati
vs
inpati
pediatr
patient
designmethod
conveni
sampl
patient
de
novo
age
randomli
assign
receiv
first
hdmtx
infus
outpati
inpati
second
infus
altern
set
pediatr
home
health
compani
provid
hdmtx
infus
oversight
support
need
skill
nurs
care
data
includ
bill
charg
pocket
expens
mtx
level
time
clearanc
chang
creatinin
antiemet
usag
emet
episod
patient
serv
control
analysi
comparison
outpati
subject
track
emesi
urin
ph
antiemet
usag
standard
form
result
six
outpati
inpati
infus
success
complet
compar
outpati
inpati
hdmtx
infus
patient
signific
reduct
pocket
patient
expens
median
rang
singl
infus
vs
p
billabl
care
charg
vs
p
safeti
measur
similar
outpati
inpati
infus
includ
time
mtx
clearanc
vs
p
chang
serum
creatinin
start
hdmtx
infus
clearanc
vs
p
number
emet
episod
vs
p
wherea
number
emet
episod
similar
signific
decreas
number
dose
antiemet
outpati
set
vs
p
conclus
feasibl
studi
outpati
hdmtx
administr
safe
cost
effect
pediatr
patient
toler
evidenc
signific
decreas
antiemet
use
lorin
hall
vivian
paintsil
papa
yaw
jeff
robison
eduardo
zamora
mark
fluchel
komfo
anoky
teach
hospit
kumasi
ghana
africa
background
children
cancer
live
low
countri
lmic
cure
rate
significantli
lower
compar
countri
hic
mani
african
countri
mispercept
cancer
among
patient
caregiv
may
contribut
poorer
surviv
due
delay
cancer
diagnos
abandon
care
object
studi
aim
identifi
attitud
percept
childhood
cancer
care
among
caregiv
pediatr
cancer
patient
kumasi
ghana
designmethod
administ
survey
caregiv
pediatr
oncolog
patient
komfo
anoky
teach
hospit
kumasi
ghana
measur
includ
time
first
symptom
diagnosi
util
tradit
healer
question
percept
childhood
cancer
result
averag
patient
age
year
lymphoma
wilm
tumor
leukemia
common
diagnos
among
children
particip
averag
time
symptom
onset
cancer
diagnosi
week
particip
report
use
tradit
healer
treat
child
initi
symptom
util
healer
averag
week
seek
medic
provid
half
particip
report
use
herbal
remedi
treat
child
cancer
prior
child
diagnosi
particip
awar
children
could
get
cancer
believ
cancer
contagi
believ
curs
bewitch
conclus
misconcept
exist
among
caregiv
childhood
cancer
patient
kumasi
ghana
may
impact
treatment
decis
mani
caregiv
use
tradit
healer
present
medic
provid
could
caus
diagnost
delay
laura
gilchrist
lynn
tanner
kirsten
ness
children
hospit
clinic
minnesota
minneapoli
minnesota
unit
state
background
peripher
neuropathi
cipn
develop
children
cancer
therapi
littl
known
resolut
impact
object
object
describ
cipn
balanc
deficit
longitudin
children
follow
treatment
cancer
impact
diagnosi
chemotherapi
type
cipn
also
investig
designmethod
children
n
mean
age
year
male
treat
cancer
assess
pediatr
modifi
total
neuropathi
score
balanc
test
month
treatment
base
diagnosi
month
complet
chemotherapi
treatment
categor
neurotox
drug
use
vincristin
v
v
intrathec
methotrex
vm
v
etoposid
result
score
decreas
time
entir
group
initi
mo
mo
f
p
effect
size
adjust
age
sex
compar
n
children
solid
tumor
ost
n
lymphoma
n
higher
score
treatment
lymphoma
ost
f
p
lymphoma
ost
higher
score
lymphoma
ost
f
p
children
treat
n
compar
v
n
vm
n
highest
score
treatment
v
vm
month
time
period
balanc
score
improv
initi
month
month
f
p
effect
size
never
popul
norm
neither
diagnosi
treatment
associ
balanc
recoveri
month
conclus
mani
children
experi
cipn
cancer
treatment
recov
month
treat
vincristin
etoposid
may
nerv
dysfunct
group
improv
balanc
time
yet
none
achiev
balanc
control
compar
popul
norm
nathan
hall
terri
flatt
alan
gami
gerald
wood
shannon
carpent
gari
doolittl
children
merci
hospit
kansa
citi
missouri
unit
state
background
use
telemedicin
pediatr
hematolog
oncolog
popul
greatli
underutil
despit
technolog
advanc
made
telemedicin
visit
effect
visit
telemedicin
resourc
abil
lower
health
care
cost
bridg
geograph
dispar
mani
patient
famili
face
child
requir
subspecialti
care
howev
willing
util
telemedicin
come
physician
famili
object
evalu
cost
satisfact
patient
famili
could
use
telemedicin
deliv
qualiti
care
patient
hematolog
oncolog
diagnos
live
underserv
area
designmethod
studi
two
subject
group
age
year
old
hematolog
oncolog
diagnosi
live
mile
children
merci
hospit
kansa
citi
missouri
evalu
studi
experiment
group
consist
subject
follow
outreach
clinic
telemedicin
capabl
control
group
subject
outreach
clinic
option
must
travel
kansa
citi
total
patient
per
group
evalu
experiment
group
answer
cost
analysi
telemedicin
satisfact
questionnair
follow
telemedicin
visit
wherea
control
group
answer
cost
analysi
util
telemedicin
survey
result
studi
result
preliminari
anticip
closur
februari
point
studi
experiment
group
note
save
hundr
dollar
expens
famili
abl
miss
less
school
work
major
thought
telemedicin
visit
good
visit
major
would
will
util
telemedicin
subsequ
visit
comparison
control
group
addit
major
control
group
would
will
util
telemedicin
believ
would
allow
famili
save
money
miss
less
school
work
conclus
knowledg
first
satisfact
survey
evalu
use
telemedicin
pediatr
hematolog
oncolog
popul
preliminari
result
favor
futur
research
invest
telemedicin
care
subspeci
patient
popul
underserv
commun
nathan
gossai
lara
boman
michael
richard
sara
gernbach
yoav
messing
joanna
perkin
bruce
bostrom
children
hospit
clinic
minnesota
minneapoli
minnesota
unit
state
background
asparaginas
pillar
pediatr
leukemia
therapi
multipl
sourc
toxic
profil
recent
year
increas
amount
asparaginas
deriv
bacterium
erwinia
chrysanthemi
use
encount
seri
symptomat
hyperammonemia
pediatr
patient
follow
erwinia
administr
object
sought
character
incid
symptomat
hyperammonemia
pediatr
leukemia
patient
receiv
asparaginas
deriv
erwinia
portion
therapi
addit
sought
identifi
clinic
relev
associ
ammonia
asparaginas
level
designmethod
retrospect
review
reveal
consecut
patient
receiv
erwinia
children
hospit
clinic
minnesota
juli
august
laboratori
evalu
analyz
spss
softwar
version
x
hyperammonemia
defin
ammonia
greater
symptomat
hyperammonemia
defin
refractori
nausea
vomit
fatigu
malais
coma
tempor
correl
elev
ammonia
level
without
identifi
etiolog
result
patient
found
symptomat
hyperammonemia
ammonia
level
drawn
trough
prior
erwinia
dose
rang
n
median
std
dev
normal
l
asparaginas
level
drawn
time
rang
iuml
n
median
iuml
std
dev
therapeut
level
iuml
ammonia
asparaginas
level
drawn
simultan
correl
statist
signific
p
measur
asparaginas
level
therapeut
ie
iuml
patient
trough
ammonia
greater
correspond
therapeut
asparaginas
activ
conclus
ammonia
expect
product
erwinia
metabol
symptomat
hyperammonemia
previous
report
rare
occurr
yet
find
indic
increas
incid
addit
data
demonstr
correl
ammonia
asparaginas
activ
level
follow
erwinia
dose
furthermor
nearli
asparaginas
activ
level
therapeut
despit
dose
reduct
case
thu
seri
provid
suffici
evid
investig
determin
patient
requir
intervent
prevent
symptomat
hyperammonemia
patient
may
ammonia
level
use
asparaginas
activ
surrog
patient
may
achiev
equival
efficaci
abridg
dose
lindi
zhang
scott
moerdler
nanci
goodman
elena
gerasimov
michael
roth
daniel
weiser
albert
einstein
colleg
medicin
bronx
new
york
unit
state
background
expand
access
also
known
compassion
use
program
provid
opportun
select
patient
access
investig
drug
biolog
medic
devic
outsid
clinic
trial
success
expand
access
applic
requir
treat
physician
obtain
agreement
pharmaceut
compani
develop
investig
agent
author
food
drug
administr
fda
author
hospit
institut
review
board
poorli
understood
difficult
execut
step
especi
pediatr
cancer
case
present
barrier
obtain
access
investig
drug
via
expand
access
program
object
creat
intervent
help
pediatr
provid
make
inform
decis
regard
expand
access
base
analysi
avail
resourc
assess
pediatr
oncologist
experi
challeng
expand
access
applic
designmethod
analysi
current
regulatori
framework
review
literatur
focus
pediatr
oncolog
expand
access
process
physician
experi
survey
develop
assess
pediatr
oncologist
experi
knowledg
expand
access
applic
process
result
fda
process
simplifi
approv
applic
form
expand
access
current
bill
consider
us
congress
reform
expand
access
program
howev
remain
lack
data
physician
experi
barrier
affect
use
expand
access
program
addit
pauciti
support
physician
guid
process
final
data
number
outcom
expand
access
applic
pediatr
oncolog
patient
distribut
survey
pediatr
oncologist
identifi
experi
challeng
uncov
gap
knowledg
expand
access
approv
data
present
aspho
annual
meet
conclus
limit
resourc
guid
pediatr
oncologist
seek
expand
access
investig
agent
educ
resourc
provid
patient
help
navig
process
need
katherin
harri
raul
ribeiro
stanley
pound
dario
campana
lei
shi
john
choi
sheila
shurtleff
susana
raimondi
pui
jeffrey
rubnitz
hiroto
inaba
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
mutat
advers
prognost
featur
acut
myeloid
leukemia
aml
therapi
intensifi
aml
allel
ratio
ar
minim
residu
diseas
mrd
remiss
induct
two
cours
ade
howev
establish
whether
ar
mrd
interrel
risk
factor
object
primari
aim
determin
whether
ar
independ
prognost
factor
designmethod
compar
data
patient
aml
accord
ar
valu
patient
enrol
st
jude
children
research
hospit
protocol
remiss
induct
regimen
compris
two
cycl
cytarabin
plu
etoposid
daunomycin
ade
consolid
therapi
consist
chemotherapi
without
sorafenib
andor
transplant
result
comparison
patient
ar
n
versu
ar
n
show
signific
differ
median
age
year
vs
year
p
white
blood
cell
count
vs
p
normal
karyotyp
vs
p
mrd
two
cours
ade
vs
p
surviv
ef
estim
case
mrd
two
cours
ade
ci
compar
ci
case
mrd
p
convers
ef
estim
case
ar
significantli
differ
ar
vs
p
data
ar
integr
mrd
two
cours
ade
ef
estim
case
mrd
ar
significantli
differ
mrd
ar
vs
p
conclus
ar
may
contribut
prognost
inform
patient
neg
mrd
two
cours
ade
chemotherapi
observ
must
confirm
larger
cohort
patient
aml
meghan
courban
maria
rina
meyer
suni
stoni
brook
school
medicin
stoni
brook
new
york
unit
state
background
mucos
signific
caus
morbid
treatment
delay
pediatr
patient
receiv
chemotherapi
evid
suggest
role
cryotherapi
adult
patient
mucos
prevent
fulli
studi
prevent
treatment
children
object
studi
feasibl
cryotherapi
pediatr
cancer
patient
designmethod
particip
patient
activ
chemotherapi
year
old
sampl
ice
chip
ice
water
three
ice
pop
flavor
form
ice
pellet
full
ice
pop
offer
particip
prefer
determin
survey
standard
tast
test
protocol
particip
use
prefer
prepar
sixti
minut
minut
face
scale
use
measur
oral
pain
complet
particip
parent
patient
year
older
complet
survey
regard
challeng
cryotherapi
estim
total
time
cryotherapi
use
result
patient
invit
particip
nine
consent
common
reason
includ
feel
ill
day
invit
reluct
spend
addit
time
clinic
particip
patient
n
male
n
femal
age
rang
year
mean
percent
n
particip
prefer
flavor
ice
prepar
patient
util
cryotherapi
rang
minut
median
time
minut
trend
toward
longer
use
older
patient
mean
pain
score
minut
minut
common
challeng
includ
patient
distract
discomfort
due
temperatur
conclus
among
pediatr
cancer
patient
cryotherapi
appear
short
period
time
show
greatest
feasibl
older
children
adolesc
like
show
benefit
mitig
mucos
caus
agent
rel
short
predict
peak
concentr
addit
children
caregiv
may
amen
cryotherapi
attempt
possibl
therapeut
purpos
rather
feasibl
studi
data
collect
ongo
order
elucid
specif
subgroup
feasibl
chen
journal
oncolog
pharmaci
practic
ross
mangum
caitlin
agraw
joseph
stanek
molli
sturm
sarah
obrien
nationwid
children
hospit
columbu
ohio
unit
state
background
past
sever
decad
signific
advanc
manag
pediatr
malign
result
increas
surviv
rate
averag
life
expect
heighten
awar
previous
outcom
late
effect
endocrin
system
particularli
growth
hormon
axi
particularli
vulner
deleteri
effect
current
treatment
modal
presenc
absenc
growth
hormon
defici
attain
final
adult
height
becom
princip
measur
interest
current
medic
literatur
focus
late
effect
well
document
cranial
craniospin
irradi
neg
impact
height
concurr
chemotherapi
may
intensifi
growth
deter
effect
radiat
howev
effect
chemotherapi
alon
growth
hormon
axi
final
adult
height
absenc
confound
variabl
radiat
exposur
andor
presenc
cn
tumor
less
well
understood
object
investig
effect
chemotherapi
growth
veloc
pediatr
cancer
survivor
variou
stage
therapi
designmethod
studi
retrospect
chart
review
patient
oncolog
clinic
registri
nationwid
children
hospit
receiv
chemotherapi
without
radiat
primari
brain
tumor
diagnosi
result
first
year
therapi
percentag
patient
growth
veloc
third
percentil
specif
age
gender
respect
associ
specif
cancer
type
chemotherapeut
agent
delay
growth
veloc
discuss
conclus
chemotherapi
alon
lead
delay
growth
veloc
pediatr
cancer
survivor
pediatr
oncologist
gener
practition
low
threshold
includ
bone
age
radiograph
growth
hormon
level
placement
endocrinolog
referr
growth
delay
note
patient
popul
kati
bergstrom
judith
margolin
heather
soni
ionela
iacoba
texa
children
hospit
vascular
anomali
clinic
houston
texa
unit
state
background
phenotyp
associ
pten
hamartoma
syndrom
pht
pediatr
patient
variabl
may
includ
macrocephali
one
featur
pht
mucocutan
find
pathognomon
pht
includ
oral
papillomatosi
gingiva
though
may
appear
adolesc
earli
adulthood
often
dentist
first
refer
patient
evalu
base
oral
papillomatosi
case
report
show
adult
refer
dentist
pten
evalu
individu
pten
gene
mutat
risk
sever
health
problem
includ
vascular
anomali
malign
breast
thyroid
endometrium
follow
appropri
specialist
recommend
surveil
protocol
earli
identif
individu
utmost
import
prevent
treat
symptom
object
determin
gingiv
hyperplasia
gingiv
phenotyp
cohort
five
pediatr
patient
pht
follow
vascular
anomali
clinic
texa
children
cancer
center
designmethod
five
pediatr
patient
confirm
pten
molecular
diagnos
follow
vascular
anomali
clinic
texa
children
cancer
center
note
gingiv
hyperplasia
phenotyp
patient
either
refer
dental
divis
texa
children
hospit
evalu
record
primari
dentist
request
review
result
five
five
pediatr
patient
cohort
patient
confirm
pten
molecular
diagnosi
gingiv
hyperplasia
dental
record
confirm
moder
sever
gingiv
three
patient
two
dental
record
review
pend
conclus
gingiv
hyperplasia
gingiv
may
earli
indic
oral
find
associ
pht
pediatr
clinic
provid
includ
dentist
see
patient
macrocephali
gingiv
hyperplasia
gingiv
consid
referr
pht
evalu
may
also
indic
aid
identifi
rel
may
young
yet
develop
papillomatosi
pediatr
patient
confirm
pht
refer
follow
dentist
gingiv
hyperplasia
gingiv
surveil
treatment
erin
lampson
matt
clem
alic
ann
holland
univers
texa
southwestern
medic
center
children
medic
center
dalla
texa
unit
state
background
mani
survivor
childhood
acut
lymphoblast
leukemia
exhibit
deficit
neurocognit
function
follow
treatment
despit
gener
uniform
treatment
protocol
individu
neurocognit
outcom
predict
one
potenti
genet
risk
factor
neurocognit
late
effect
apolipoprotein
apo
allel
allel
strongli
associ
increas
risk
dementia
also
implic
risk
factor
cognit
deficit
follow
variou
neurolog
stressor
central
nervou
system
cn
chemotherapi
util
childhood
treatment
may
consid
similar
insult
brain
object
evalu
associ
apo
genotyp
neuropsycholog
function
follow
treatment
childhood
designmethod
particip
survivor
childhood
treat
chemotherapi
current
year
age
routin
clinic
visit
blood
obtain
apo
genotyp
particip
complet
brief
neuropsycholog
assess
batteri
evalu
attent
process
speed
memori
execut
function
analysi
covari
ancova
multipl
analysi
covari
mancova
use
detect
signific
differ
neurocognit
perform
variabl
group
defin
apo
statu
control
age
gender
educ
socioeconom
statu
result
patient
enrol
male
caucasian
mean
age
year
averag
age
time
diagnosi
year
averag
time
complet
treatment
year
fifteen
particip
found
carri
apo
allel
preliminari
result
indic
pediatr
survivor
carri
apo
allel
signific
differ
attent
process
speed
memori
execut
function
compar
allel
p
conclus
previou
studi
effect
apo
genotyp
neurocognit
outcom
children
mix
pilot
sampl
found
signific
differ
neurocognit
function
carrier
apo
allel
larger
sampl
size
need
evalu
subtl
neurocognit
differ
two
group
thu
enrol
ongo
longitudin
requir
investig
whether
carrier
statu
influenc
neurocognit
outcom
survivor
pediatr
blackman
dev
med
child
neurol
alex
georg
jennif
tran
texa
children
hospit
houston
texa
unit
state
background
babi
hug
clinic
trial
hydroxyurea
infant
young
children
sickl
cell
diseas
scd
establish
safeti
clinic
benefit
hydroxyurea
therapi
age
group
studi
establish
howev
escal
maximum
toler
dose
mtd
could
safe
effect
accomplish
age
group
object
sought
determin
safeti
effect
hydroxyurea
therapi
children
scd
age
two
year
designmethod
conduct
retrospect
chart
review
children
hbss
hb
thalassemia
age
two
year
start
hydroxyurea
therapi
texa
children
hematolog
center
determin
laboratori
respons
therapi
well
clinic
laboratori
advers
event
associ
hydroxyurea
therapi
result
identifi
patient
rang
month
age
mean
median
month
initi
hydroxyurea
therapi
studi
period
mtd
reach
patient
studi
period
remaind
dose
escal
reach
mtd
mean
median
mtd
mgkg
mgkg
respect
mtd
dose
correl
strongli
baselin
absolut
reticulocyt
count
arc
absolut
neutrophil
count
anc
less
baselin
creatinin
bodi
mass
index
patient
signific
increas
hemoglobin
concentr
hbf
declin
arc
anc
magnitud
increas
hb
hbf
greater
seen
babi
hug
cohort
hydroxyurea
clinic
signific
advers
event
attribut
exclus
hydroxyurea
therapi
six
episod
neutropenia
nine
reticulocytopenia
four
thrombocytopenia
associ
intercurr
ill
conclus
hydroxyurea
therapi
dose
escal
mtd
appear
safe
infant
young
children
standard
clinic
set
result
signific
increas
hemoglobin
concentr
hbf
seen
fix
dose
babi
hug
studi
chelsea
meenan
john
kelli
kim
ritchey
scott
maurer
univers
pittsburgh
school
medicin
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
comorbid
obes
correl
advers
event
ae
children
acut
myelogen
leukemia
patient
acut
lymphoblast
leukemia
mainten
therapi
less
known
ae
obes
patient
intens
chemotherapi
object
evalu
relationship
obes
bmi
ae
chemotherapi
pediatr
patient
designmethod
chart
children
age
year
complet
chemotherapi
institut
evalu
infect
hypertens
necessit
medic
hyperglycemia
necessit
insulin
pancreat
picu
admiss
sepsi
febril
neutropenia
admiss
fn
thrombosi
hepatotox
nephrotox
patient
bmi
medic
condit
trisomi
relaps
diseas
exclud
univari
analysi
fisher
exact
test
compar
proport
obes
versu
patient
experienc
ae
univari
analysi
examin
effect
age
nci
risk
statu
ae
follow
multivari
analysi
evalu
independ
predictor
result
patient
elig
obes
group
similar
type
age
demograph
nci
risk
statu
earli
respons
treatment
ae
occur
significantli
frequent
obes
patient
includ
hypertens
vs
rr
confid
interv
ci
p
hyperglycemia
vs
rr
ci
p
infect
vs
rr
ci
p
fn
admiss
vs
rr
ci
p
account
age
year
nci
risk
statu
obes
independ
risk
factor
hypertens
ci
p
hyperglycemia
ci
p
infect
ci
p
obes
effect
fn
admiss
confound
age
risk
statu
age
nci
risk
statu
independ
risk
factor
hypertens
hyperglycemia
infect
conclus
chemotherapi
obes
independ
risk
factor
develop
hypertens
hyperglycemia
infect
fn
admiss
research
provid
implic
develop
prevent
support
care
guidelin
popul
patient
omar
niss
charl
quinn
catherin
terel
lisa
mccord
santosh
saraf
victor
gordeuk
courtney
fitzhugh
susan
creari
prasad
boda
alex
georg
ashok
raj
alecia
nero
prasad
devarajan
michael
taylor
punam
malik
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
america
background
cardiopulmonari
renal
complic
major
caus
morbid
mortal
sickl
cell
anemia
sca
recent
observ
sca
character
uniqu
cardiomyopathi
featur
restrict
physiolog
diastol
dysfunct
disproportion
left
atrial
la
enlarg
normal
systol
function
hyperdynam
state
ventricular
enlarg
restrict
physiolog
could
lead
secondari
elev
tricuspid
regurgit
jet
veloc
trv
exercis
intoler
independ
pulmonari
arteri
hypertens
albuminuria
earli
manifest
sickl
nephropathi
albuminuria
correl
pulmonari
hypertens
use
trv
surrog
measur
whether
sickl
cardiomyopathi
correl
nephropathi
unknown
object
assess
relationship
sickl
cardiomyopathi
albuminuria
sca
designmethod
echocardiogram
perform
individu
sca
ss
particip
clinic
trial
losartan
sickl
nephropathi
analyz
baselin
result
correl
cardiac
phenotyp
urin
ratio
uacr
walk
distanc
hematolog
marker
albuminuria
defin
uacr
mgg
result
sca
patient
includ
mean
age
femal
fifteen
normal
uacr
mgg
patient
albuminuria
uacr
mgg
patient
albuminuria
wors
diastol
function
indic
ratio
mitral
inflow
veloc
ea
vs
p
septal
annular
veloc
e
vs
p
significantli
larger
la
volum
vs
ml
p
systol
function
normal
similar
group
shorten
fraction
vs
p
patient
albuminuria
significantli
lower
hemoglobin
vs
gdl
p
howev
differ
trv
lv
mass
lv
diamet
reticulocyt
count
group
correl
significantli
diastol
measur
ea
septal
e
p
p
respect
patient
albuminuria
significantli
shorter
vs
ft
p
conclus
restrict
physiolog
sickl
cardiomyopathi
irrespect
elev
trv
associ
albuminuria
marker
sickl
nephropathi
common
mechan
may
underli
complic
albuminuria
studi
predictor
cardiomyopathi
sca
elysia
alvarez
keri
zabokrtski
leonard
sender
children
hospit
orang
counti
orang
california
unit
state
background
vitamin
signific
topic
interest
patient
acut
lymphoblast
leukemia
particularli
survivor
shown
decreas
bone
densiti
howev
lack
investig
vitamin
level
diagnosi
treatment
leukemia
object
primari
aim
singl
institut
prospect
pilot
studi
evalu
vitamin
level
time
diagnosi
patient
closest
age
sibl
secondari
aim
determin
efficaci
vitamin
supplement
increas
serum
level
vitamin
patient
designmethod
vitamin
level
measur
oh
obtain
patient
match
sibl
control
diagnosi
addit
blood
drawn
patient
month
interv
total
blood
draw
patient
level
less
given
vitamin
supplement
per
institut
medicin
recommend
result
studi
includ
patient
newli
diagnos
sibl
control
averag
age
respect
signific
differ
vitamin
level
patient
sibl
diagnosi
p
diagnosi
patient
suffici
insuffici
defici
serum
vitamin
level
decreas
vitamin
level
diagnosi
second
blood
draw
p
continu
differ
diagnosi
vitamin
level
p
mainten
latter
higher
patient
get
supplement
second
vitamin
serum
level
lower
patient
compar
patient
without
supplement
conclus
exploratori
pilot
studi
suggest
treatment
associ
signific
decreas
vitamin
level
even
face
supplement
diagnosi
leukemia
appear
effect
vitamin
level
given
find
import
perform
larger
studi
evalu
level
vitamin
treatment
effect
increas
supplement
serum
level
bone
health
nichola
mcgregor
daniel
paulin
colin
wendt
amelia
black
emmelin
lerebour
prasad
boda
st
damien
hospit
tabarr
haiti
background
sickl
cell
diseas
scd
global
distribut
preval
greatest
popul
african
descent
popul
haiti
deriv
mainli
west
africa
estim
greater
haitian
live
birth
affect
scd
despit
high
preval
univers
screen
program
exist
haiti
studi
describ
present
clinic
characterist
children
diseas
object
describ
present
find
clinic
characterist
haitian
children
scd
designmethod
studi
retrospect
chart
review
patient
care
st
damien
hospit
tabarr
haiti
child
record
age
diagnosi
method
diagnosi
present
symptom
number
hospit
admiss
transfus
acut
chest
ac
voc
episod
laboratori
data
recent
encount
result
review
patient
chart
contain
inpati
outpati
encount
electrophoresi
data
avail
patient
among
genotyp
distribut
hgb
ss
hgb
sc
median
age
diagnosi
common
present
symptom
fever
anemia
pain
count
total
hospit
admiss
cohort
mean
per
patient
percent
children
requir
least
one
transfus
lifetim
mean
per
patient
mean
number
episod
voc
ac
respect
hepatomegali
splenomegali
document
patient
mean
hemoglobin
concentr
mean
wbc
count
mean
platelet
count
conclus
clinic
featur
haitian
children
sickl
cell
diseas
similar
african
countri
patient
present
morbid
encount
studi
provid
valuabl
data
describ
present
clinic
characterist
children
scd
haiti
may
use
consid
initi
newborn
screen
comprehens
care
model
set
nitya
narayan
juli
janecek
daniel
choi
mari
lou
schmidt
keith
thulborn
univers
chicago
illinoi
unit
state
background
mani
adult
survivor
pediatr
acut
lymphoblast
leukemia
suffer
unexplain
neurocognit
nc
deficit
magnet
reson
mr
imag
measur
brain
volum
bv
tissu
sodium
concentr
tsc
elev
tsc
reflect
decreas
cell
volum
fraction
cvf
measur
brain
cell
densiti
biolog
mechan
nc
chang
never
studi
object
bv
region
tsc
nc
perform
measur
investig
nc
perform
relat
chang
neuroimag
treatment
intrathec
system
chemotherapi
radiat
hypothes
lower
nc
perform
decreas
bv
possibl
cvf
designmethod
adult
patient
diagnosi
childhood
therapi
least
two
year
recruit
sign
inform
consent
imag
nc
test
quantit
mr
imag
provid
tsc
map
region
tsc
bv
valu
measur
mean
bv
valu
linear
correl
region
tsc
valu
bv
valu
perform
group
valid
nc
assess
perform
group
relationship
nc
score
region
tsc
bv
examin
pearson
correl
result
ten
femal
mean
age
year
enrol
bv
decreas
p
control
signific
invers
linear
correl
exist
bv
region
tsc
frontal
p
pariet
p
lobe
basal
ganglia
p
thalami
p
tempor
p
occipit
p
lobe
ol
nc
perform
relat
bv
suggest
increas
nc
perform
increas
ol
tsc
promin
process
speed
p
conclus
result
exploratori
studi
show
treatment
childhood
result
smaller
cerebr
volum
decreas
correl
region
increas
tsc
reflect
decreas
cvf
deep
gray
matter
region
preliminari
result
also
suggest
possibl
relationship
ol
tsc
process
speed
etiolog
relationship
unclear
small
sampl
size
lack
consist
region
correl
like
reflect
wide
variat
nc
perform
found
futur
larger
studi
warrant
nichola
mcgregor
nichola
hall
beth
robert
prasad
boda
akron
children
hospit
akron
ohio
unit
state
background
nation
heart
lung
blood
institut
strongli
recommend
infant
greater
month
age
children
adolesc
sickl
cell
anemia
begin
hydroxyurea
hu
regardless
clinic
sever
proven
benefit
includ
fewer
episod
pain
acut
chest
syndrom
blood
transfus
hospit
nonetheless
identifi
barrier
prevent
elig
sickl
cell
patient
treat
hu
fewer
elig
patient
unit
state
current
therapi
object
map
process
hu
elig
util
effect
dose
develop
implement
process
map
base
tool
increas
hu
util
pediatr
sickl
cell
diseas
clinic
designmethod
identifi
children
practic
elig
hu
map
process
patient
identif
hu
util
hu
util
pathway
creat
address
access
hu
confirm
patient
elig
identifi
barrier
guid
clinic
laboratori
follow
intent
move
patient
along
pathway
toward
goal
maximum
hu
dose
report
period
last
month
implement
tool
result
patient
month
age
hemoglobin
ss
chronic
transfus
identifi
practic
male
femal
mean
age
util
barrier
includ
lack
hu
discuss
provid
patient
poor
clinic
appoint
fear
side
effect
parent
refus
persist
use
pathway
hu
util
increas
patient
alreadi
hu
studi
outset
maximum
dose
patient
increas
toward
maximum
increas
patient
maximum
dose
conclus
use
process
map
priorit
patientphysician
interact
identif
address
specif
barrier
effici
increas
hu
util
jovana
pavis
jacinta
r
leyden
hannah
g
kay
nicol
dalal
paul
fisher
karen
effing
stanford
univers
palo
alto
california
unit
state
background
childhood
cancer
survivor
experi
increas
risk
obes
physic
inact
relat
chronic
diseas
littl
known
parent
knowledg
provid
educ
topic
object
evalu
knowledg
commun
weight
statu
physic
activ
chronic
diseas
risk
among
parent
childhood
cancer
survivor
oncolog
provid
designmethod
date
parent
children
conclud
therapi
cancer
median
age
year
rang
median
time
month
rang
male
complet
survey
likert
statement
weight
exercis
chronic
diseas
risk
commun
regard
topic
oncolog
provid
parent
report
whether
child
appropri
weight
accuraci
assess
base
child
bmi
percentil
parent
document
exercis
goal
actual
practic
child
result
parent
report
oncolog
provid
discuss
least
half
time
child
anthropometr
exercis
chronic
diseas
risk
howev
parent
misidentifi
weight
statu
children
obes
children
overweight
children
normal
weight
children
underweight
identif
much
child
exercis
median
hrswk
rang
much
child
exercis
median
hrswk
rang
significantli
less
cdc
recommend
hour
per
week
p
particip
particip
overweightobes
meet
cdc
goal
mani
parent
report
provid
rare
never
offer
specif
exercis
recommend
help
establish
exercis
goal
exercis
progress
percent
parent
disagre
child
increas
risk
chronic
diseas
conclus
parent
childhood
cancer
survivor
report
frequent
commun
weight
physic
activ
chronic
diseas
risk
oncolog
provid
parent
knowledg
topic
inadequ
approach
improv
knowledg
elicit
behavior
chang
need
sherif
badawi
alexi
thompson
robert
liem
ann
robert
h
luri
children
hospit
chicago
feinberg
school
medicin
northwestern
univers
chicago
il
unit
state
background
complic
result
signific
declin
qualiti
life
outcom
pro
howev
pro
routin
monitor
set
hydroxyurea
reduc
complic
decreas
hospit
improv
pro
scd
patient
yet
hydroxyurea
adher
remain
suboptim
especi
among
adolesc
young
adult
aya
scd
previou
studi
address
relationship
hydroxyurea
adher
pro
object
assess
feasibl
evalu
pro
hydroxyurea
adher
aya
scd
outpati
set
explor
relationship
pro
hydroxyurea
adher
designmethod
survey
administ
electron
tablet
aya
year
old
genotyp
steadi
state
hydroxyurea
scd
clinic
januari
decemb
pro
assess
patient
report
outcom
measur
inform
system
promi
computer
adapt
test
cat
hydroxyurea
adher
assess
use
modifi
moriski
adher
result
survey
time
particip
male
black
hb
ss
mean
year
taken
hydroxyurea
mean
dose
mgkgday
averag
month
commonli
recurr
pain
patient
approach
agre
particip
success
complet
assess
clinic
visit
meet
feasibl
criterion
complet
rate
averag
time
complet
secondsinstru
particip
low
hydroxyurea
adher
compar
moderatehigh
adher
significantli
wors
mean
fatigu
vs
p
depress
vs
p
score
particip
fetal
hemoglobin
hb
f
compar
significantli
wors
mean
fatigu
vs
p
peer
relationship
vs
p
score
mean
pro
score
correl
mean
hb
hb
f
hydroxyurea
dose
durat
conclus
pro
assess
clinic
set
feasibl
incorpor
part
routin
care
patient
low
hydroxyurea
adher
lower
hb
f
level
significantli
wors
fatigu
depress
peer
relationship
track
pro
time
relationship
pain
complic
may
repres
use
strategi
improv
hydroxyurea
adher
aya
scd
schlosser
daniel
burd
alexandra
ahmet
sarah
lawrenc
mylen
bassal
children
hospit
eastern
ontario
ottawa
ontario
canada
background
adren
suppress
found
follow
use
corticosteroid
treatment
acut
lymphoblast
leukemia
research
shown
present
earli
phase
treatment
preval
durat
fulli
understood
especi
later
phase
treatment
mainten
patient
may
symptom
challeng
stress
infect
surgeri
patient
risk
adren
crisi
time
stress
mean
hypoglycemia
hypotens
critic
ill
associ
signific
morbid
mortal
treatment
improv
need
reduc
risk
treatment
adren
crisi
standard
protocol
monitor
despit
potenti
seriou
effect
proven
presenc
least
earli
phase
treatment
object
identifi
present
patient
mainten
treatment
designmethod
case
treat
children
hospit
eastern
ontario
cheo
retrospect
review
patient
characterist
clinic
featur
laboratori
data
treatment
advers
event
outcom
examin
result
patient
diagnos
cheo
prompt
clinic
suspicion
test
done
investig
fourteen
patient
cortisol
level
symptom
requir
manag
four
identifi
first
time
mainten
mani
patient
document
symptom
could
attribut
never
adren
test
done
conclus
identifi
children
treat
includ
mainten
phase
therapi
may
present
greater
number
children
routin
test
protocol
exist
identifi
patient
studi
support
need
conduct
research
determin
preval
durat
goal
develop
standard
screen
protocol
effect
screen
could
lead
earli
identif
improv
manag
reduc
morbid
mortal
nihal
bakeer
jeann
jame
swarnava
roy
janaka
wansapura
shiva
kumar
shanmukhappa
hanna
osinska
kurt
backer
hubi
archana
shrestha
omar
niss
robert
fleck
charl
quinn
michael
taylor
enkhsaikhan
purevjav
bruce
aronow
jeffrey
towbin
punam
malik
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
sickl
cell
anemia
sca
common
monogen
disord
associ
signific
morbid
mortal
high
incid
unexplain
sudden
death
young
adult
current
cardiopulmonari
complic
lead
caus
mortal
sca
elev
tricuspid
veloc
pulmonari
hypertens
diastol
autonom
dysfunct
describ
unifi
pathophysiolog
mechan
explain
poor
prognosi
propens
sudden
death
elus
object
defin
progress
cardiac
patholog
sca
determin
pathophysiolog
underli
divers
report
cardiopulmonari
phenotyp
includ
sudden
death
designmethod
mous
model
sca
anemia
mice
underw
longitudin
comprehens
cardiac
analysi
combin
cardiac
imag
cardiac
mri
echocardiographi
electrocardiographi
histopatholog
molecular
analysi
determin
basi
cardiac
dysfunct
result
sca
mice
show
hyperdynam
physiolog
gradual
addit
develop
restrict
physiolog
progress
increas
left
atrial
diamet
diastol
dysfunct
despit
normal
systol
function
restrict
physiolog
notic
absent
chronic
anemia
mice
sca
mice
associ
increas
extracellular
volum
result
microscop
myocardi
fibrosi
mitochondri
ultrastructur
chang
consist
sever
hypoxiaischemiaoxid
stress
significantli
shorten
sarcomer
diastol
length
note
transcript
gene
involv
angiogenesi
lipid
metabol
oxid
stresshypoxia
upregul
transport
metabol
gene
downregul
function
interact
network
analysi
suggest
lower
express
gene
essenti
normal
cardiac
conduct
inde
prolong
qtc
remark
increas
prolong
occur
arrhythmia
ischem
chang
observ
prior
sudden
death
conclus
collect
sca
mice
develop
distinct
sickl
cardiomyopathi
restrict
physiolog
cumul
cardiomyocyt
fibrosi
result
arrhythmogen
myocardium
sudden
cardiac
death
common
restrict
cardiomyopathi
prolong
qt
syndrom
comprehens
longitudin
analysi
find
cardiomyopathi
preclin
sca
mous
model
may
unifi
cardiac
pathophysiolog
previous
report
divers
cardiac
phenotyp
also
explain
sudden
death
seen
diseas
furthermor
also
open
new
avenu
earli
diagnost
target
therapi
human
cardiac
diseas
melissa
acquazzino
sarah
dobrozsi
mahua
dasgupta
raymond
hoffmann
amanda
brandow
medic
colleg
wisconsinchildren
hospit
wisconsin
milwauke
wisconsin
unit
state
background
neuropath
pain
known
complic
cancer
therapi
worsen
qualiti
life
poor
understand
patient
risk
factor
neuropath
pain
limit
develop
target
screen
prevent
strategi
decreas
morbid
therapi
object
pediatr
oncolog
patient
determin
preval
neuropath
pain
investig
risk
factor
neuropath
pain
designmethod
conduct
retrospect
cohort
studi
newli
diagnos
relaps
pediatr
oncolog
patient
neuropath
pain
defin
priori
document
one
follow
medic
record
neuropath
pain
pain
nerv
distribut
pain
qualit
neuropath
pain
descriptor
ie
numb
burn
pain
initi
neuropath
pain
medic
demograph
variabl
compar
use
test
continu
variabl
test
categor
variabl
multivari
logist
regress
forward
stepwis
select
method
perform
find
best
set
predict
factor
diagnosi
neuropath
pain
result
chart
review
patient
median
iqr
age
cancer
diagnosi
year
femal
diagnos
includ
leukemialymphoma
solid
tumor
central
nervou
system
tumor
percent
ci
patient
met
definit
neuropath
pain
age
significantli
differ
without
neuropath
pain
p
significantli
lower
treat
vincristin
median
age
vs
year
p
older
age
ci
vincristin
therapi
ci
associ
increas
odd
neuropath
pain
diagnosi
radiat
therapi
ci
associ
decreas
odd
neuropath
pain
diagnosi
gender
ethnic
intrathec
chemotherapi
surgeri
signific
impact
neuropath
pain
diagnosi
conclus
neuropath
pain
diagnos
quarter
children
cancer
older
age
vincristin
therapi
associ
increas
risk
diagnosi
neuropath
pain
improv
prevent
diagnost
treatment
modif
strategi
need
reduc
burden
neuropath
pain
cancer
treatment
catherin
taylor
alexandra
coria
tubman
boston
children
hospit
boston
massachusett
unit
state
background
mortal
children
sickl
cell
diseas
scd
low
countri
lmic
high
major
death
like
relat
infecti
complic
unit
state
dramat
decreas
childhood
mortal
scd
past
year
aid
intervent
reduc
mortal
associ
infect
lmic
intervent
ie
penicillin
prophylaxi
rapid
investig
treatment
febril
ill
vaccin
may
consist
avail
object
determin
provid
practic
lmic
regard
prevent
infecti
complic
patient
scd
designmethod
survey
english
provid
scd
program
lmic
survey
avail
onlin
offlin
distribut
via
email
distribut
list
applic
meet
referr
result
provid
lmic
return
interpret
survey
includ
area
newborn
screen
associ
n
program
pneumococc
conjug
vaccin
avail
n
program
penicillin
prophylaxi
prescrib
patient
n
respond
malaria
prophylaxi
prescrib
n
area
percent
program
n
written
fever
manag
protocol
patient
scd
present
fever
n
respond
alway
give
antibiot
although
n
give
antibiot
almost
alway
first
line
antibiot
given
oral
n
n
would
consid
oral
antibiot
circumst
prefer
first
line
antibiot
ceftriaxon
give
ivim
antibiot
give
oral
antibiot
program
area
n
alway
almost
alway
give
antimalari
febril
patient
percent
n
respond
report
major
febril
patient
receiv
antibiot
prior
present
area
n
report
major
receiv
antimalari
prior
present
conclus
consider
practic
variat
around
manag
infect
prophylaxi
fever
patient
scd
lmic
major
respond
program
oral
antibiot
accept
use
febril
patient
scd
result
survey
inform
protocol
fever
manag
scd
lmic
vibhuti
agarw
eric
sandler
harri
abram
manisha
bansal
wolfson
children
hospit
jacksonvil
florida
unit
state
background
intracrani
hypertens
ih
character
elev
cerebrospin
fluid
csf
pressur
defin
open
pressur
greater
mmhg
context
normal
csf
composit
normal
neuroimag
studi
ih
uncommon
condit
particularli
childhood
present
per
children
annual
untreat
ih
caus
signific
debilit
particularli
chronic
headach
lead
papilledema
visual
failur
object
aim
studi
determin
incid
ih
pediatr
patient
mainten
therapi
acut
lymphoblast
leukemia
designmethod
studi
conduct
wolfson
children
hospit
jacksonvil
florida
unit
state
open
pressur
measur
routin
schedul
lumbar
punctur
gener
anesthesia
intrathec
chemotherapi
administr
mainten
therapi
ih
defin
open
pressur
greater
mmhg
patient
ih
measur
repeat
addit
time
routin
lumbar
punctur
result
twenti
seven
patient
age
enrol
open
pressur
measur
time
intracrani
hypertens
found
time
patient
overal
incid
ih
particip
except
one
asymptomat
time
diagnosi
ih
patient
symptomat
ih
treat
success
acetazolamid
incid
ih
statist
signific
base
gender
age
group
leukemia
risk
type
addit
number
prior
lumbar
puncturesintrathec
chemotherapi
administr
associ
develop
ih
conclus
result
indic
significantli
higher
incid
ih
patient
undergo
mainten
therapi
suggest
treatment
may
associ
develop
ih
given
high
incid
ih
strongli
consid
child
treat
persist
headach
visual
disturb
studi
need
determin
ih
develop
patient
treat
physician
consid
measur
open
pressur
routin
intrathec
chemotherapi
administr
identifi
patient
ih
becom
symptomat
may
prevent
signific
symptom
irrevers
damag
optic
atrophi
lead
blind
vartz
ped
blood
cancer
sarah
tehseen
mariann
yee
clinton
joiner
emori
universitychildren
healthcar
atlanta
atlanta
georgia
unit
state
background
nephropathi
chronic
complic
sickl
cell
diseas
scd
begin
childhood
lead
esrd
adult
hbss
thu
earli
identif
treatment
critic
prevent
irrevers
renal
damag
earli
sickl
nephropathi
character
hyperfiltr
microalbuminuria
therefor
urin
albumincreatinin
ratio
acr
effect
screen
tool
detect
earli
nephropathi
object
investig
effect
hydroxyurea
hu
therapi
urin
acr
level
among
children
sickl
cell
anemia
sca
hbss
thalassemia
designmethod
retrospect
review
sca
patient
age
year
start
hu
therapi
children
healthcar
atlanta
conduct
patient
includ
urin
acr
measur
prior
month
start
hu
patient
exclud
chronic
transfus
arb
medic
diseas
caus
renal
damag
result
patient
sca
met
elig
criteria
mean
age
yr
hemoglobin
gdl
follow
acr
data
avail
patient
year
patient
year
post
hu
albuminuria
acr
mgg
prior
initi
hu
patient
albuminuria
lower
baselin
hemoglobin
compar
patient
albuminuria
vs
frequenc
patient
albuminuria
decreas
year
n
n
year
hu
therapi
median
urin
acr
level
declin
year
mgg
year
mgg
hu
therapi
among
patient
abnorm
urin
acr
pre
hu
n
frequenc
patient
albuminuria
decreas
n
year
n
year
hu
therapi
patient
albuminuria
pre
hu
signific
declin
median
urin
acr
level
vs
year
hu
conclus
hu
therapi
lead
reduct
urin
acr
level
time
especi
among
sca
patient
abnorm
urin
acr
level
seth
karol
wenjian
yang
colton
smith
cheng
clinton
stewart
sharyn
baker
john
sandlund
jeffrey
rubnitz
michael
bishop
alberto
pappo
sima
jeha
pui
mari
rell
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
chemotherapi
induc
acral
erythema
ciae
uncommon
side
effect
cytotox
chemotherapi
children
prior
case
report
ciae
pediatr
limit
predispos
factor
ciae
remain
unknown
object
identifi
characterist
genet
risk
factor
ciae
children
designmethod
advers
event
databas
treatment
protocol
review
identifi
case
ciae
follow
either
methotrex
cytarabin
confirm
chart
review
control
compris
patient
treat
protocol
receiv
either
methotrex
cytarabin
germlin
dna
genotyp
two
stage
associ
studi
gwa
treat
ciae
categor
outcom
measur
perform
stage
perform
gwa
lymphoblast
leukemia
case
compar
control
stage
includ
diagnos
adjust
ancestri
chemotherapi
result
patient
experienc
total
episod
ciae
symptom
last
mean
day
hand
feet
involv
initi
episod
ciae
occur
follow
administr
cytarabin
event
patient
matur
lymphoma
patient
acut
myeloid
leukemia
patient
methotrex
event
patient
patient
osteosarcoma
patient
matur
lymphoma
patient
also
ciae
follow
cytarabin
administr
agent
togeth
occur
prior
event
patient
matur
lymphoma
parenter
opioid
requir
symptom
control
patient
genet
variant
reach
associ
threshold
p
top
identifi
variant
intron
msra
p
risk
allel
frequenc
case
control
addit
intron
variant
also
associ
increas
risk
ciae
p
patient
develop
ciae
follow
methotrex
carri
risk
allel
conclus
ciae
rare
toxic
children
receiv
methotrex
cytarabin
genet
variant
folat
metabol
oxid
stress
respons
gene
may
predispos
develop
ciae
rida
abid
bruce
bernstein
jennif
eng
deepti
raybagkar
natali
apollonski
st
christoph
hospit
children
philadelphia
pennsylvania
unit
state
background
patient
sickl
cell
anemia
sca
risk
overt
stroke
risk
silent
infarct
lifetim
routin
screen
transcrani
doppler
ultrasound
tcd
allow
select
patient
highest
risk
provid
chronic
transfus
decreas
risk
stroke
abnorm
veloc
tcd
associ
increas
risk
stroke
also
poor
cognit
perform
irrevers
chang
magnet
reson
imag
mri
subset
patient
even
absenc
mri
abnorm
patient
sca
experi
neurocognit
problem
declin
perform
time
earli
laboratori
predictor
tcd
veloc
would
allow
identif
patient
risk
first
year
life
introduc
appropri
treatment
modal
educ
support
object
studi
linear
correl
earli
biomark
tcd
veloc
differ
age
interv
designmethod
perform
retrospect
chart
review
patient
sca
follow
marian
anderson
center
st
christoph
hospit
children
philadelphia
identifi
consecut
patient
meet
inclus
criteria
pearson
correl
calcul
explor
linear
associ
steadi
state
biomark
anemia
hemolysi
inflamm
patient
maximum
left
middl
cerebr
arteri
mca
veloc
differ
age
interv
year
year
older
year
result
year
age
group
posit
linear
correl
tcd
veloc
left
mca
lactat
dehydrogenas
n
r
p
reticulocyt
count
n
r
p
bilirubin
n
p
p
white
blood
cell
count
n
r
p
neg
linear
correl
hemoglobin
n
r
p
year
age
group
signific
correl
lactat
dehydrogenas
n
r
p
correl
laboratori
biomark
older
age
group
conclus
decreas
hemoglobin
increas
white
blood
cell
count
increas
bilirubin
increas
lactat
dehydrogenas
first
year
life
correl
increas
mca
veloc
year
age
group
may
help
identifi
high
risk
patient
melinda
pauli
brian
lee
curti
traver
glen
lew
himale
sabni
sharon
castellino
aflac
center
cancer
blood
disord
children
healthcar
atlanta
depart
pediatr
emori
univers
school
medicin
atlanta
georgia
unit
state
background
antimetabolit
dose
intens
complianc
mainten
therapi
associ
improv
event
free
surviv
focu
racial
dispar
poor
complianc
indic
high
anc
surrog
marker
less
known
influenc
benign
ethnic
neutropenia
ben
prescrib
mtx
dose
object
evalu
whether
prescrib
dose
andor
mtx
vari
patient
race
mainten
therapi
designmethod
singl
institut
retrospect
studi
prescrib
mtx
dose
monthli
visit
first
cycl
mainten
therapi
done
children
treat
children
oncolog
group
studi
initi
averag
anc
weight
averag
dose
mtx
prescrib
per
visit
number
visit
prescrib
dose
less
goal
abstract
descript
statist
dichotom
race
univari
analysi
result
among
patient
elig
black
differ
key
demograph
risk
characterist
tpmt
statu
race
median
anc
studi
entri
thouul
differ
race
vs
p
averag
anc
cours
therapi
greater
vs
p
median
weight
dose
mtx
prescrib
cours
respect
p
p
differ
race
interestingli
number
visit
prescrib
mtx
dose
less
expect
black
p
differ
present
respect
conclus
despit
incid
ben
black
children
anc
patient
entri
mainten
differ
race
popul
lack
signific
differ
prescrib
may
reflect
small
number
black
patient
studi
black
children
significantli
visit
less
expect
mtx
prescrib
prompt
need
analysi
factor
influenc
prescrib
antimetabolit
dose
intens
elizabeth
perri
patricia
carter
heather
becker
alexandra
garcia
michael
mackert
karen
johnson
georg
buchanan
baylor
univers
dalla
texa
unit
state
background
health
literaci
defin
degre
individu
capac
obtain
process
understand
basic
health
inform
servic
need
make
appropri
health
decis
pauciti
literatur
regard
health
literaci
adolesc
specif
publish
data
describ
state
health
literaci
adolesc
sickl
cell
diseas
scd
object
purpos
studi
evalu
health
literaci
cohort
adolesc
scd
designmethod
descript
correl
studi
includ
assess
demograph
measur
evalu
data
result
complet
newest
vital
sign
nv
instrument
black
adolesc
scd
follow
children
medic
center
cmc
dalla
texa
conveni
sampl
util
inclus
criteria
diagnosi
one
four
primari
genotyp
scd
age
year
ut
austin
ut
southwestern
institut
review
board
approv
studi
result
male
femal
recruit
studi
mean
age
year
sd
rang
grade
level
rang
mean
sd
follow
scd
genotyp
repres
ss
sc
score
rang
mean
sd
score
nv
rang
mean
sd
health
literaci
score
lower
use
nv
instrument
compar
score
healthi
adolesc
adult
control
howev
mean
score
sampl
slightli
higher
black
control
valid
studi
current
grade
level
health
literaci
score
show
moder
high
posit
correl
r
p
health
literaci
score
also
significantli
posit
correl
age
r
p
incom
r
p
conclus
health
literaci
adolesc
scd
appear
suboptim
futur
research
includ
identifi
facilit
barrier
health
literaci
level
larger
cohort
adolesc
scd
ratzan
c
parker
r
nation
librari
medicin
current
bibliographi
medicin
health
literaci
sy
nasir
abba
bukhari
shaukat
khanam
cancer
memori
hospit
research
center
pakistan
lahor
punjab
pakistan
background
common
malign
children
treatment
protocol
includ
multipl
bone
marrow
examin
check
treatment
respons
includ
minim
residu
diseas
mrd
countri
follow
protocol
even
absenc
mrd
facil
object
acut
lymphoblast
leukemia
common
hematolog
malign
among
pediatr
popul
differ
protocol
like
ukal
cog
use
manag
protocol
suggest
bone
marrow
biopsi
day
day
induct
phase
day
minimum
residu
diseas
mdr
statu
usual
advis
develop
countri
facil
mdr
avail
patient
treat
accord
protocol
bone
marrow
biopsi
advis
day
day
hypothesi
day
bone
marrow
remiss
signific
day
bone
marrow
absenc
mrd
facil
designmethod
patient
admit
jan
dec
surviv
induct
includ
induct
therapi
accord
standard
arm
ukal
given
bone
marrow
biopsi
done
day
depend
upon
regimen
day
patient
mdr
avail
result
total
patient
includ
male
femal
ratio
age
rang
month
year
seventeen
patient
yr
patient
cell
pre
b
seventeen
patient
bone
marrow
bone
marrow
day
none
residu
leukemia
day
patient
bone
marrow
remiss
day
none
evid
residu
leukemia
day
bone
marrow
conclus
absenc
mrd
facil
signific
day
bone
marrow
day
bone
marrow
remiss
vivien
sheehan
anthoni
wood
sachin
allahabadi
sara
curti
allexa
hammond
chien
jaden
schupp
matthew
ree
peter
yeh
kate
travi
john
shumway
baylor
colleg
medicin
houston
texa
unit
state
background
estim
sickl
cell
diseas
scd
patient
reach
adulthood
high
resourc
countri
studi
show
grow
cohort
young
adult
scd
patient
age
year
old
experi
mark
rise
medic
complic
earli
mortal
coincid
decreas
use
therapi
increas
use
emerg
care
object
survey
scd
patient
previous
transit
adult
care
determin
current
adult
scd
provid
continu
therapi
percept
transit
process
designmethod
scd
patient
transit
pediatr
care
texa
children
hematolog
center
tchc
contact
patient
last
known
address
phone
number
request
complet
question
survey
assess
patient
demograph
medic
outcom
person
experi
result
survey
complet
patient
lack
provid
top
reason
lack
insurancefund
ca
nt
find
physician
patient
without
adult
physician
within
month
transit
less
like
physician
current
p
patient
hydroxyurea
pediatr
patient
continu
hydroxyurea
therapi
transit
subject
report
difficulti
find
knowledg
adult
provid
medic
insur
inadequ
transit
prepar
exampl
qualit
result
includ
comment
follow
adult
doctor
awar
call
pediatrician
anoth
said
hard
find
physician
two
year
tchc
insur
loss
health
worsen
nt
get
medic
need
ask
patient
want
dedic
scd
transit
clinic
patient
identifi
deceas
caus
conclus
survey
show
first
month
transit
critic
period
identifi
sickl
cell
healthcar
provid
support
need
dedic
transit
clinic
facilit
transit
scd
patient
also
quantit
qualit
demonstr
lack
sickl
cell
focus
healthcar
provid
adult
barrier
success
transit
ami
wu
david
leonard
naomi
winick
univers
texa
southwestern
medic
center
dalla
texa
unit
state
background
adolesc
young
adult
ayao
may
experi
greater
toxic
younger
patient
treat
greater
vulner
steroid
asparaginas
commonli
includ
induct
phase
therapi
rel
role
age
ethnic
bodi
mass
index
bmi
taken
account
address
object
sought
determin
impact
age
number
andor
maximum
grade
toxic
induct
control
bmi
ethnic
gender
designmethod
consecut
syndrom
patient
hr
age
year
diagnosi
treat
per
children
oncolog
group
protocol
past
year
identifi
pediatr
oncolog
registri
children
health
retrospect
chart
review
conduct
toxic
grade
use
system
patient
characterist
summar
quartil
age
diagnosi
unadjust
trend
toxic
outcom
age
test
use
nonparametr
method
trend
toxic
outcom
age
adjust
bmi
ethnic
gender
test
use
poisson
regress
model
result
patient
experienc
distinct
toxic
common
toxic
includ
febril
neutropenia
fn
sepsi
hypertens
hyperglycemia
death
induct
age
diagnosi
omit
fn
analys
sinc
patient
infect
unadjust
trend
age
diagnosi
maximum
grade
toxic
number
grade
toxic
signific
p
respect
howev
multipl
regress
analysi
indic
relationship
age
diagnosi
toxic
adjust
bmi
ethnic
gender
relationship
longer
signific
conclus
age
signific
risk
factor
higher
number
greater
sever
toxic
adjust
bmi
ethnic
gender
research
allow
better
support
care
measur
counsel
patient
parent
respect
risk
associ
therapi
daniel
michalik
bradley
taylor
glenn
bushe
juli
panepinto
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
util
electron
medic
record
emr
offer
uniqu
opportun
studi
larg
cohort
patient
time
howev
abil
identifi
follow
cohort
reli
use
valid
comput
phenotyp
consist
defin
set
data
element
form
comput
queri
emr
data
warehous
although
comput
phenotyp
previous
identifi
patient
popul
variou
condit
comput
phenotyp
yet
develop
identifi
patient
sickl
cell
diseas
scd
object
develop
comput
phenotyp
identifi
patient
popul
scd
use
algorithm
approach
valid
refin
comput
phenotyp
mean
improv
accuraci
designmethod
retrospect
studi
util
comput
phenotyp
search
emr
data
warehous
elig
patient
includ
age
year
diagnos
qualifi
scd
code
follow
scd
clinic
children
hospit
wisconsin
comput
phenotyp
develop
seri
queri
data
warehous
aim
identifi
patient
popul
scd
queri
includ
patient
qualifi
diagnosi
scd
also
two
outpati
visit
least
day
apart
one
hospit
emr
valid
studi
use
medic
record
number
clinic
program
databas
run
result
queri
result
comput
phenotyp
identifi
patient
patient
confirm
meet
inclus
criteria
two
patient
identifi
comput
phenotyp
incorrectli
identifi
scd
comput
phenotyp
fail
identifi
patient
meet
inclus
criteria
overal
comput
phenotyp
accur
identifi
patient
known
fit
inclus
criteria
conclus
advent
emr
provid
uniqu
opportun
track
follow
known
cohort
patient
given
diseas
rich
resourc
futur
clinic
trial
comput
phenotyp
develop
studi
allow
rapid
accur
identif
pediatr
patient
scd
provid
distinct
advantag
administr
claim
method
suleimman
rafat
jafri
khawar
siddiqui
ali
alahmari
ibrahim
ghemla
amal
alseraihi
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
background
hyperleukocytosi
defin
peripher
leukocyt
count
problem
seen
newli
diagnos
case
caus
hyperviscos
culmin
earli
morbid
mortal
patient
object
review
factor
predict
clinic
outcom
hyperleukocytosi
designmethod
perform
retrospect
review
patient
diagnos
treat
institut
data
patient
hyperleukocytosi
compar
non
hyperleukocyt
patient
refer
clinic
characterist
outcom
result
median
age
diagnosi
hyperleukocyt
patient
year
min
compar
year
min
max
group
male
group
respect
median
wbc
hyperleukocyt
min
vs
min
other
amongst
hyperleukocyt
day
bm
compar
group
p
hyperleukocyt
patient
vs
other
p
hyperleukocyt
group
biphenotyp
vs
biphenotypt
other
p
patient
hyperleukocyt
group
abnorm
cytogenet
compar
other
amongst
hyperleukocyt
posit
mll
other
wherea
trisomi
posit
hyperleukocyt
vs
patient
non
hyperleukocyt
p
patient
die
hyperleukocyt
group
five
year
overal
surviv
compar
death
non
hyperleukocyt
five
year
overal
surviv
p
wherea
relaps
hyperleukocyt
patient
non
hyperleukocyt
five
year
event
free
surviv
respect
p
conclus
result
show
hyperleukocytosi
associ
less
frequent
favor
cytogenet
slow
earli
respond
poor
outcom
frequent
death
relaps
compar
publish
data
april
naeg
lori
heath
chunmei
zhou
neehar
gupta
carlton
dampier
multin
background
modifi
face
pain
scale
revis
modifi
outcom
measur
establish
content
valid
use
assess
pain
intens
children
adolesc
year
age
sickl
cell
diseas
scd
daili
evalu
pain
provid
import
insight
clinic
consequ
scd
obtain
occasion
inpati
outpati
healthcar
visit
object
evalu
psychometr
properti
valid
reliabl
respons
modifi
pediatr
patient
scd
designmethod
evalu
conduct
context
random
multin
clinic
studi
pediatr
patient
scd
year
age
symptom
intens
report
daili
diari
week
screen
periodprior
random
start
visit
month
modifi
ask
patient
consid
pain
relat
scd
report
worst
pain
cours
day
mean
monthli
score
calcul
base
number
chosen
face
select
patient
pain
worst
pain
possibl
correl
coeffici
icc
use
reliabl
month
month
pearson
correl
monthli
mean
intens
pain
analges
use
narcot
use
conduct
assess
converg
valid
respons
assess
correl
calcul
chang
baselin
correspond
chang
analges
use
chang
activ
score
month
month
result
icc
n
indic
agreement
among
stabl
patient
moder
associ
shown
modifi
analges
use
r
narcot
use
r
associ
observ
modifi
chang
analges
use
p
activ
score
p
conclus
result
quantit
analys
support
use
modifi
children
adolesc
age
year
scd
instrument
suffici
reliabl
valid
respons
measur
pain
clinic
studi
provid
valuabl
insight
measur
daili
basi
studi
sponsor
daiichi
sankyo
ltd
eli
lilli
compani
suleimman
khawar
siddiqui
jafri
sy
amal
alseraihi
ibrahim
ghemla
ali
alahmari
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
background
treatment
often
mar
relaps
patient
main
caus
treatment
failur
case
high
risk
patient
object
review
factor
predict
relaps
designmethod
retrospect
review
patient
relaps
vs
diagnos
treat
institut
result
median
age
diagnosi
group
year
rang
min
min
max
relaps
relaps
year
relaps
wherea
group
male
relaps
male
other
median
wbc
relaps
group
min
vs
min
patient
relaps
dna
amongst
relaps
patient
day
bm
compar
group
relaps
patient
vs
other
relaps
group
biphenotyp
vs
biphenotypt
other
patient
relaps
group
abnorm
cytogenet
compar
other
amongst
relaps
posit
mll
other
wherea
trisomi
posit
relaps
vs
patient
patient
die
relaps
group
five
year
overal
surviv
compar
five
year
overal
surviv
p
five
year
event
free
surviv
respect
p
conclus
result
show
relaps
associ
poor
outcom
compar
publish
data
trend
increas
relaps
rate
biphenotyp
leukemia
male
gender
abnorm
cytogenet
dna
index
less
kunal
sanghavi
margaret
holtz
kathleen
dempsey
beth
vogel
michel
caggana
joann
bodurtha
debra
cohen
children
hospit
pittsburgh
univers
pittsburgh
medic
center
pittsburgh
pennsylvania
unit
state
background
patient
sickl
cell
diseas
scd
live
long
distanc
specialti
care
center
difficulti
clinic
visit
complianc
children
hospit
pittsburgh
chp
new
york
consortium
genet
newborn
screen
servic
nymac
feder
fund
region
collabor
recogn
need
famili
provid
improv
access
clinic
servic
patient
object
continu
provid
servic
util
telemedicin
pediatr
patient
scd
host
onsit
telemedicin
train
illustr
telehealth
improv
access
care
increas
workforc
capac
identifi
barrier
implement
chp
pediatr
hematologist
nymac
region
dc
de
md
nj
ny
pa
va
wv
designmethod
telemedicin
infrastructur
establish
satellit
clinic
eri
johnstown
western
pennsylvania
monthli
telemedicin
session
chp
staff
chp
scd
provid
complet
telemedicin
train
patient
satisfact
survey
administ
follow
telemedicin
visit
pediatr
hematologist
nymac
region
invit
particip
onsit
train
program
chp
result
nine
pediatr
patient
seen
eri
clinic
yield
complet
telemedicin
visit
two
pediatr
patient
seen
johnstown
clinic
yield
complet
telemedicin
visit
improv
clinic
access
hydroxyurea
adher
patient
satisfact
note
posit
result
telemedicin
pilot
chp
result
increas
proport
patient
receiv
four
annual
clinic
visit
well
access
genet
counsel
scd
famili
proport
patient
receiv
hydroxyurea
increas
scd
telemedicin
servic
save
patientsfamili
crucial
time
resourc
conclus
telemedicin
potenti
cost
effect
model
deliv
improv
scd
servic
onsit
telemedicin
train
program
establish
pediatr
hematologist
alli
health
profession
chp
nymac
continu
promot
awar
educ
scd
telemedicin
servic
well
identifi
barrier
strategi
implement
telemedicin
servic
region
shakilu
jumann
patricia
scanlan
khamza
maunda
karim
manji
muhimbili
nation
hospit
dar
es
salaam
tanzania
east
africa
dar
es
salaam
tanzania
background
treatment
respons
consid
import
prognost
indic
pediatr
acut
lymphoblast
leukemia
also
induct
phase
therapi
carri
highest
mortal
risk
children
acut
lymphoblast
leukemia
due
diseas
complic
treatment
relat
toxic
audit
review
treatment
respons
day
mortal
characterist
children
treat
acut
lymphoblast
leukemia
complet
induct
therapi
object
evalu
end
induct
morpholog
remiss
statu
mortal
among
children
treat
acut
lymphoblast
leukemia
muhimbili
nation
hospit
mnh
dar
es
salaam
tanzania
designmethod
retrospect
chart
review
conduct
evalu
remiss
statu
mortal
characterist
end
induct
therapi
among
pediatr
leukem
patient
treat
januari
decemb
chart
review
look
clinic
characterist
diseas
bone
marrow
morpholog
remiss
statu
mortal
characterist
day
mnh
protocol
local
revis
induct
phase
therapi
result
acut
leukemia
account
children
treat
patient
acut
lymphoblast
leukemia
file
review
end
induct
therapi
patient
aliv
got
treat
regimen
low
risk
regimen
end
induct
therapi
patient
intermedi
risk
regimen
low
risk
regimen
confirm
morpholog
remiss
respect
remaind
patient
bone
marrow
sampl
taken
day
result
report
inconclus
day
patient
die
end
induct
therapi
caus
death
includ
anemia
bleed
febril
neutropenia
tumor
lysi
syndrom
conclus
result
audit
highlight
need
improv
document
attent
protocol
requir
induct
phase
mortal
unaccept
high
underscor
need
effort
improv
earli
access
treatment
improv
support
care
patient
present
high
diseas
burden
experienc
high
treatment
relat
toxic
rate
hafsat
mashegu
frederick
barr
rommel
tirona
marshal
summar
kim
adcock
richard
ogletre
gari
cunningham
melissa
rhode
suvankar
majumdar
univers
mississippi
medic
center
jackson
mississippi
unit
state
background
perturb
arginin
pathway
hemolysi
associ
nitric
oxid
deplet
play
central
role
pathogenesi
sickl
cell
diseas
scd
multipl
studi
shown
citrullin
effect
booster
even
condit
inflamm
acut
arginin
defici
characterist
scd
object
assess
safeti
pharmacokinet
profil
intraven
iv
scd
clinicaltri
designmethod
cohort
particip
receiv
iv
bolu
five
minut
dose
increment
mgkg
target
citrullin
level
level
known
elev
base
previou
studi
plasma
sampl
collect
certain
time
point
pharmacokinet
studi
advers
event
follow
accord
nci
common
terminolog
criteria
advers
event
ctcae
result
first
cohort
four
particip
intraven
bolu
infus
yield
mean
peak
level
trough
level
rang
hour
infus
averag
rate
citrullin
appear
rapp
sd
averag
constant
citrullin
remov
krem
sd
mean
clearanc
volum
distribut
subject
signific
rise
arginin
level
within
one
hour
receiv
bolu
iv
citrullin
mean
increment
one
subject
transient
drop
diastol
blood
pressur
within
minut
studi
drug
intervent
need
report
side
effect
analysi
use
simul
dose
scheme
show
mgkg
bolu
dose
iv
citrullin
follow
continu
infus
mgkghour
need
maintain
target
citrullin
concentr
conclus
bolu
intraven
safe
well
toler
patient
scd
rapid
clearanc
studi
need
evalu
pharmacokinet
safeti
profil
continu
dose
iv
citrullin
scd
includ
effect
product
potenti
novel
therapeut
option
sickl
cell
pain
crisi
heba
say
amani
ali
mahmoud
moham
south
egypt
cancer
center
assiut
univers
assiut
egypt
background
pediatr
cancer
rare
diseas
one
lead
caus
children
death
intensif
treatment
lead
signific
improv
cancer
outcom
also
signific
complic
admiss
pediatr
oncolog
intens
care
unit
poicu
costli
event
pediatr
risk
mortal
score
prism
iii
physiolog
base
predictor
outcom
critic
ill
patient
object
assess
efficaci
prism
iii
predict
risk
mortal
patient
cancer
admit
poicu
follow
poicu
stay
assess
relationship
prism
iii
length
stay
poicu
assess
effect
factor
type
malign
septic
shock
number
organ
failur
type
intervent
use
mortal
risk
poicu
designmethod
prospect
studi
conduct
poicu
pediatr
oncolog
depart
south
egypt
cancer
institut
seci
assiut
univers
studi
popul
consist
pediatr
cancer
patient
admit
poicu
pediatr
oncolog
depart
result
one
hundr
twenti
three
pediatr
cancer
patient
admit
poicu
median
age
year
male
femal
ratio
rate
patient
hematolog
malign
lymphoma
repres
sepsi
respiratori
failur
main
indic
admiss
median
length
stay
day
first
prism
iii
within
hour
admiss
mean
first
prism
iii
correl
significantli
outcom
p
indic
admiss
p
first
prism
iii
correl
weakli
posit
length
stay
r
p
prism
iii
done
serial
everi
day
poicu
admiss
discharg
mean
prism
iii
survivor
p
mean
prism
iii
non
survivor
p
outcom
also
correl
number
organ
failur
p
indic
admiss
p
stage
treatment
p
intervent
use
inotrop
p
ventil
p
oxygen
therapi
p
conclus
prism
iii
use
predict
risk
mortal
follow
patient
cancer
admit
poicu
cancer
relat
risk
factor
indic
admiss
stage
treatment
number
organ
failur
consid
taumoha
ghosh
lorrain
canham
ashley
munchel
regina
macatangay
univers
maryland
medic
center
baltimor
maryland
unit
state
background
asthma
common
comorbid
condit
patient
sickl
cell
diseas
well
report
patient
sickl
cell
asthma
increas
risk
morbid
mortal
especi
regard
acut
chest
syndrom
limit
research
howev
done
establish
role
asthma
crisi
object
studi
design
clinic
assess
hypothesi
patient
sickl
cell
diseas
asthma
increas
sever
frequenc
crisi
secondari
increas
impair
oxygen
exchang
associ
sickl
designmethod
follow
develop
comprehens
institut
databas
patient
identifi
sickl
cell
diseas
comorbid
asthma
age
year
age
addit
patient
identifi
phenotyp
control
rate
emerg
depart
visit
hospit
frequenc
crise
associ
respiratori
symptom
use
asthma
control
medic
retrospect
analyz
year
period
data
collect
interpret
accompani
review
exist
literatur
result
studi
period
patient
sickl
cell
asthma
increas
frequenc
acut
chest
present
respiratori
symptom
previous
establish
note
similar
increas
seen
pain
present
compar
hospit
encount
per
patient
result
definit
show
causat
respiratori
symptom
onset
crise
data
suggest
direct
correl
addit
statist
signific
associ
use
asthma
control
medic
patient
present
pain
identifi
p
conclus
asthma
manag
may
role
treatment
sickl
cell
crisi
evidenc
frequent
pain
present
patient
asthma
well
correl
patient
control
therapi
studi
use
asthma
manag
progress
intent
improv
pain
manag
decreas
hospit
encount
hospit
length
stay
karen
fernandez
ann
bostwick
veronica
giron
claudia
garrido
mauricio
castellano
huap
wang
patricia
valverd
federico
pedro
de
alarcon
univers
illinoi
colleg
medicin
peoria
peoria
illinoi
unit
state
background
event
free
surviv
ef
children
acut
lymphoblast
leukemia
treat
countri
hic
cure
rate
much
lower
countri
lic
lack
technolog
perform
accur
contribut
dispar
assess
absolut
lymphocyt
count
alc
recoveri
end
induct
report
signific
independ
predictor
surviv
hic
object
determin
earli
recoveri
absolut
lymphocyt
count
alc
independ
prognost
factor
patient
acut
lymphoblast
leukemia
receiv
standard
therapi
guatemala
low
incom
countri
lic
designmethod
retrospect
review
patient
age
year
treat
unidad
nacion
de
oncologia
pediatrica
unop
guatemala
may
may
result
elig
patient
includ
evalu
year
age
wbc
time
diagnosi
neg
cn
posit
cn
data
avail
major
patient
b
abil
cytogenet
analysi
alc
recoveri
day
assess
signific
discrimin
prognosi
patient
n
ef
p
vs
p
ef
patient
vs
patient
p
conclus
alc
induct
predict
poor
prognosi
guatemalan
children
differenti
surviv
group
differ
respect
find
impli
patient
higher
probabl
recurr
compar
patient
lic
alc
recoveri
end
induct
may
use
surrog
mrd
allow
risk
stratif
find
need
confirm
prospect
current
therapi
guatemala
melissa
wendi
bere
sandra
nanc
geralyn
meni
univers
texa
health
scienc
center
san
antonio
texa
unit
state
background
blood
transfus
essenti
treatment
prevent
sickl
cell
diseas
scd
morbid
mortal
standard
aborh
cross
match
attempt
prevent
acut
hemolyt
transfus
reaction
address
alloantibodi
format
risk
develop
alloantibodi
singl
transfus
may
high
patient
receiv
multipl
chronic
transfus
object
evalu
use
flow
cytometri
fc
detect
red
cell
bound
immunoglobulin
patient
scd
designmethod
prospect
cohort
studi
perform
patient
scd
genotyp
year
elig
exclus
criteria
baselin
test
includ
serolog
test
direct
antiglobulin
test
dat
fc
tube
gel
techniqu
repeat
everi
six
month
acut
admiss
two
week
discharg
fc
gel
test
perform
use
blind
sampl
clinic
data
includ
scd
genotyp
number
transfus
alloantibodi
histori
medic
collect
result
patient
enrol
male
averag
age
year
rang
transfus
histori
includ
chronic
transfus
least
one
transfus
previou
transfus
standard
serolog
test
posit
one
patient
concord
gel
fc
result
eight
patient
neg
serolog
tube
gel
fc
result
thirteen
patient
neg
serolog
tube
gel
test
posit
fc
result
four
patient
neg
serolog
test
posit
tube
gel
test
concord
fc
result
one
patient
insuffici
sampl
seven
patient
multipl
sampl
four
progress
igm
igg
fc
neg
serolog
test
one
patient
becam
igm
igg
posit
subsequ
develop
clinic
evid
delay
hemolyt
transfus
reaction
although
serolog
test
remain
neg
maintain
posit
red
cell
bound
igg
subsequ
fc
test
patient
whose
sampl
neg
test
sign
clinic
transfus
reaction
conclus
present
novel
method
use
evalu
red
cell
destruct
patient
scd
investig
correl
fc
result
alloantibodi
format
need
catherin
taylor
shakilu
jumann
sean
rooney
luke
harrington
patricia
scanlan
muhimbili
nation
hospit
dar
es
salaam
tanzania
background
intern
proport
acut
lymphoblast
leukemia
diagnos
around
studi
suggest
may
common
popul
publish
seri
immunophenotyp
africa
muhimbili
nation
hospit
mnh
comprehens
pediatr
oncolog
servic
center
tanzania
flow
cytometri
recent
establish
clinic
use
object
determin
rel
frequenc
overal
surviv
differ
immunophenotyp
amongst
new
diagnos
mnh
designmethod
retrospect
cohort
studi
children
age
year
diagnos
mnh
june
major
flow
cytometri
done
mnh
use
becton
dickinson
facscalibur
remot
review
medic
scientist
hematologist
ladi
children
hospit
crumlin
ireland
facscalibur
unavail
result
equivoc
sampl
ship
ireland
flow
cytometri
transfix
solut
tm
histopatholog
patient
treat
modifi
ukal
protocol
surviv
analyz
use
kaplan
meier
method
compar
use
test
median
compar
use
test
result
identifi
patient
suspect
chart
avail
known
immunophenotyp
n
cell
n
n
immunophenotyp
includ
mix
lineag
burkitt
nk
cell
unknown
immunophenotyp
die
work
diagnosi
acut
leukemia
definit
diagnosi
made
patient
wors
overal
surviv
compar
cell
log
rank
p
older
median
vs
year
p
higher
white
cell
count
diagnosi
median
vs
p
conclus
cohort
east
african
pediatr
patient
found
contrast
publish
seri
proport
doubl
seen
larg
consortium
trial
us
europ
may
reflect
biolog
differ
popul
expect
patient
wors
surviv
higher
risk
featur
hugo
paquin
evelyn
trottier
yve
pastor
nanci
robitail
bergeron
benoit
bailey
chu
quebec
canada
background
sickl
cell
crisi
voc
one
frequent
caus
emerg
visit
admiss
children
condit
object
evalu
whether
implement
oral
morphin
protocol
led
improv
care
sickl
cell
diseas
scd
translat
reduc
hospit
rate
increas
oral
administr
rate
faster
opiat
administr
time
compar
cohort
patient
present
emerg
depart
ed
hematolog
outpati
clinic
hoc
voc
pre
post
implement
designmethod
retrospect
chart
review
patient
scd
follow
chu
patient
voc
diagnosi
studi
period
select
depart
databas
primari
outcom
evalu
hospit
rate
rate
oral
administr
opiat
administr
time
also
calcul
estim
patient
per
arm
would
suffici
power
detect
least
rate
reduct
admiss
power
signific
result
two
period
total
patient
includ
ed
patient
hoc
depart
show
reduct
hospit
rate
differ
ci
ed
ci
hoc
show
increas
rate
oral
administr
differ
ci
ed
ci
hoc
differ
min
ci
opiat
administr
time
ed
oppos
hoc
signific
differ
min
ci
found
present
median
time
recommend
minut
post
implement
set
show
increas
percentag
patient
without
iv
differ
ci
ed
ci
hoc
conclus
studi
valid
use
oral
morphin
protocol
treatment
voc
show
signific
reduct
hospit
rate
although
delay
remain
opiat
administr
time
protocol
decreas
number
iv
procedur
ana
luiza
fabro
juliana
nardelli
ana
paula
azambuja
flora
watanab
edna
carboni
ana
paula
pedro
bom
gabriela
fernand
luiz
camil
vicentini
cilmara
kuwahara
samantha
nichel
euripid
ferreira
hospit
pequeno
curitiba
parana
brazil
background
aid
immunophenotyp
cytogenet
becam
essenti
complement
studi
aml
prognosi
directli
relat
patient
risk
stratif
well
establish
treatment
object
identifi
phenotyp
relat
greater
lesser
surviv
patient
evalu
respons
induct
treatment
correl
cytogenet
phenotyp
profil
designmethod
conduct
review
medic
record
children
aml
diagnos
treat
pequeno
princip
hospit
januari
decemb
result
evalu
children
includ
children
treat
accord
protocol
st
jude
aml
protocol
bfm
boy
age
rang
three
day
year
median
year
initi
less
leukocyt
peripher
blood
commai
cell
common
subtyp
aml
aml
repres
accord
cytogenet
analysi
aml
recurr
abnorm
promyelocyt
aml
leukemia
transloc
leukemia
group
sampl
better
prognosi
one
syndrom
amount
patient
search
drm
posit
induct
surviv
rate
sampl
period
month
relaps
rate
posit
drm
children
neg
drm
recurr
main
reason
death
diseas
progress
overal
surviv
month
conclus
patient
cytogenet
alter
good
prognosi
neg
drm
presenc
induct
higher
surviv
sandeepkumar
kuril
mari
johnson
juli
kanter
medic
univers
south
carolina
charleston
south
carolina
unit
state
background
cerebrovascular
diseas
sever
complic
sickl
cell
diseas
scd
affect
common
cerebrovascular
event
scd
patient
ischem
howev
increas
hemorrhag
decad
life
attribut
moyamoya
ruptur
intracrani
aneurysm
ia
thought
respons
intracrani
hemorrhag
scd
incid
preval
ia
remain
unknown
scd
object
assess
preval
ia
cohort
scd
patient
suffer
stroke
identifi
abnorm
transcrani
doppler
tcd
designmethod
retrospect
review
scd
databas
identifi
patient
meet
object
underw
brain
magnet
reson
imag
mri
angiographi
mra
screen
headach
indic
time
period
includ
patient
scan
demograph
inform
collect
includ
age
scan
gender
genotyp
ia
indic
imag
manag
includ
patient
nt
report
histori
stroke
abnorm
tcd
result
patient
averag
age
year
sd
includ
five
patient
imag
mrimra
found
incident
unruptur
ia
four
patient
hbss
one
patient
hbsbeta
patient
asymptomat
multipl
aneurysm
seen
patient
ia
locat
anterior
posterior
cerebr
circul
territori
patient
manag
conserv
follow
scan
patient
taken
aneurysm
coil
resect
malform
conclus
preval
unruptur
ia
cohort
much
higher
report
preval
ia
gener
scd
patient
ia
like
increas
risk
hemorrhag
stroke
subarachnoid
hemorrhag
age
none
patient
includ
cohort
histori
abnorm
tcd
larger
prospect
studi
need
accur
identifi
preval
outcom
optim
manag
unruptur
ia
scd
addit
maintain
high
index
suspicion
ia
scd
patient
neurolog
symptom
necessari
studi
limit
due
small
sampl
size
select
popul
marina
sandra
yacob
donna
johnston
children
hospit
eastern
ontario
divis
hematolog
oncolog
ottawa
ontario
canada
background
complementari
altern
medicin
cam
includ
therapi
practic
remedi
part
convent
medicin
use
cam
increas
among
canadian
pediatr
popul
incid
within
pediatr
oncolog
known
object
determin
incid
cam
use
within
canadian
pediatr
oncolog
popul
designmethod
questionnair
develop
complet
parentsguardian
pediatr
oncolog
patient
age
year
old
children
hospit
eastern
ontario
januari
juli
questionnair
cam
includ
reason
use
type
practic
frequenc
use
unwant
side
effect
satisfact
therapi
amount
spent
supervis
demograph
characterist
includ
ethnic
marit
statu
level
educ
profess
also
collect
result
respond
parent
report
use
cam
child
cancer
treatment
use
cam
therapi
common
reason
use
cam
cam
may
interfer
medicin
therapi
child
cam
scientif
base
n
use
cam
therapi
commonli
use
modal
prayersfaith
n
femal
male
equal
like
use
cam
ethnic
play
role
cam
use
identifi
european
aborigin
use
cam
wherea
approxim
half
identifi
canadian
french
asian
african
use
cam
parent
identifi
marri
least
like
use
cam
widow
like
use
cam
parent
complet
univers
degre
least
like
use
cam
attain
colleg
degre
like
use
cam
patient
discuss
cam
use
physician
conclus
percent
pediatr
oncolog
patient
use
cam
therapi
inform
physician
cam
use
emphas
import
physician
nurs
consult
patient
cam
use
monitor
side
effect
interact
cancer
therapi
anjulika
chawla
philippa
sprinz
patricia
kavanagh
hasbro
children
hospit
provid
rhode
island
unit
state
background
hydroxyurea
hu
shown
efficaci
individu
sickl
cell
diseas
scd
drug
label
give
prescrib
guidanc
use
adult
use
children
base
expert
consensu
random
trial
lead
variat
hu
initi
counsel
monitor
discontinu
object
describ
prescrib
practic
hu
children
scd
identifi
area
improv
designmethod
conduct
onlin
survey
hu
prescrib
practic
among
provid
new
england
pediatr
sickl
cell
consortium
care
approxim
children
scd
result
respons
provid
new
england
institut
six
provid
estim
elig
patient
hu
hu
initi
indic
use
respond
includ
patient
hemoglobin
ss
condit
tcd
veloc
pain
episodesyear
multipl
hospit
parent
request
provid
felt
hu
safe
children
year
old
offer
children
year
respond
report
patient
famili
declin
common
reason
initi
hu
reason
given
includ
increas
frequenc
offic
visit
difficulti
daili
medic
fear
side
effect
concern
depend
loss
fertil
reason
inelig
includ
hepat
renal
dysfunct
splenic
sequestr
neutropenia
high
baselin
hemoglobin
histori
poor
adher
prescrib
either
provid
refer
patient
counsel
birth
control
perform
urin
pregnanc
test
routin
provid
requir
document
birth
control
femal
respond
typic
start
hu
mgkgd
mainten
dose
vari
wide
lab
monitor
done
everi
week
escal
everi
month
stabl
dose
adher
commonli
monitor
infer
lab
valu
top
three
indic
discontinu
hu
includ
miss
visit
poor
adher
neutropenia
conclus
signific
variat
hu
prescrib
practic
even
within
region
consortium
protocol
guidelin
studi
pediatr
use
hydroxyurea
need
optim
prescrib
practic
impact
sickl
cell
diseas
allison
close
gerald
montano
lauren
alessi
jame
cooper
noel
zuckerbraun
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
abnorm
uterin
bleed
aub
frequent
gynecolog
complaint
adolesc
despit
research
manag
strategi
aub
limit
often
variat
acut
care
object
object
improv
pediatr
resid
knowledg
confid
manag
aub
emerg
set
implement
local
consensu
algorithm
electron
health
record
ehr
order
set
concomit
educ
designmethod
use
multidisciplinari
approach
involv
depart
emerg
medicin
adolesc
medicin
hematologyoncolog
creat
implement
algorithm
emerg
manag
aub
along
accompani
ehr
order
set
facilit
test
treatment
educ
aub
manag
algorithm
ehr
order
set
provid
pediatr
resid
via
didact
electron
mail
resid
knowledg
scenario
question
confid
aub
manag
assess
pre
algorithmehr
order
set
implement
didact
electron
survey
statist
use
compar
group
result
intervent
survey
complet
resid
respect
knowledg
aub
manag
improv
p
resid
report
lack
confid
aub
manag
less
often
versu
p
conclus
implement
algorithm
ehr
order
set
may
effect
method
improv
resid
knowledg
manag
aub
emerg
set
futur
hope
assess
associ
implement
clinic
outcom
alexi
leonard
nihal
godiwala
robert
mccarter
matthew
sharron
emili
meier
children
nation
medic
center
washington
district
columbia
unit
state
background
acut
chest
syndrom
ac
lead
caus
mortal
patient
sickl
cell
diseas
scd
treatment
multimod
includ
like
corticosteroid
system
corticosteroid
may
decreas
length
hospit
stay
ac
risk
readmiss
crise
voc
limit
use
inhal
corticosteroid
ic
may
safe
altern
efficaci
current
unknown
object
investig
effect
initi
ic
time
hospit
admiss
reduc
ac
morbid
designmethod
case
control
studi
compar
scd
patient
discharg
diagnosi
ac
receiv
ic
case
admiss
control
histori
asthma
sever
ac
unilater
infiltr
vs
bilater
collect
outcom
measur
includ
transfus
oxygen
requir
rate
picu
transfer
intub
bipap
initi
need
readmiss
statist
analys
includ
pearson
student
result
one
hundr
twenti
scd
patient
control
case
includ
studi
significantli
higher
proport
control
bilater
infiltr
vs
case
p
fewer
asthma
vs
case
p
twelv
case
control
transfer
picu
p
lower
proport
case
requir
intub
vs
control
p
case
requir
bipap
vs
p
transfus
rate
p
oxygen
requir
p
readmiss
rate
p
differ
group
conclus
control
bilater
infiltr
studi
suggest
sever
ac
yet
initi
ic
case
significantli
decreas
morbid
despit
less
sever
diseas
case
diagnos
asthma
may
treat
ic
admiss
despit
less
sever
ac
overal
initi
ic
decreas
ac
morbid
measur
need
transfus
oxygen
supplement
picu
intervent
system
steroid
increas
risk
readmiss
voc
case
like
readmit
use
ic
despit
plausibl
pathogen
mechan
reduc
airway
hyperreact
studi
demonstr
signific
benefit
ic
treatment
ac
jennif
snaman
erica
kay
carlo
torr
deborah
gibson
justin
baker
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
bereav
parent
experi
signific
psychosoci
health
sequela
suggest
popul
may
benefit
ongo
extens
support
resourc
throughout
grief
journey
interact
healthcar
provid
hcp
hospit
staff
patient
famili
end
child
life
death
profoundli
affect
parent
grief
experi
offer
uniqu
opportun
medic
commun
posit
impact
bereav
experi
object
explor
role
health
care
team
institut
grief
journey
parent
lost
child
cancer
designmethod
eleven
bereav
parent
particip
focu
group
respons
main
prompt
code
analyz
independ
use
semant
content
analysi
techniqu
result
four
main
concept
identifi
within
parent
narr
includ
import
strong
ongo
relationship
hcp
bereav
famili
import
high
qualiti
commun
hcp
famili
effect
neg
experi
hcp
famili
parent
grief
import
institut
role
grief
journey
bereav
parent
conclus
bereav
parent
consist
identifi
critic
role
play
hcp
medic
institut
throughout
grief
journey
key
compon
bereav
support
identifi
parent
serv
guid
action
hcp
well
provid
templat
develop
comprehens
bereav
program
within
institut
eiymo
mpollo
quarmyn
caryn
gonsalv
johnson
hayn
christian
uwe
karen
kalinyak
alexand
vink
clinton
joiner
punam
malik
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
sickl
cell
diseas
scd
associ
airway
ahr
augment
inflamm
leukotrien
product
known
mediat
ahr
zileuton
specif
inhibitor
key
enzym
leukotrien
synthet
pathway
licens
asthma
howev
safetypharmacokinet
investig
patient
scd
liver
renal
function
often
compromis
hypothes
zileuton
safe
patient
scd
pharmacokinet
similar
asthma
object
primari
object
determin
safeti
toler
pharmacokinet
twice
daili
administr
zl
zyflo
cr
patient
scd
designmethod
employ
dose
design
twice
daili
zileuton
week
nine
patient
year
age
scd
steadi
state
hydroxyurea
chronic
transfus
enrol
pharmacokinet
perform
first
dose
use
bayesian
model
total
zileuton
exposur
defin
area
curv
zero
normal
dose
result
zileuton
well
toler
dose
signific
chang
clinic
laboratori
safeti
paramet
occur
advers
event
limit
common
pain
hypertens
pharmacokinet
paramet
zileuton
mean
cv
plasma
clearanc
clf
lhkg
volum
distribut
vf
lkg
absorpt
rate
constant
ka
elimin
phase
h
per
mg
popul
clf
estim
lhkg
nonmem
analysi
consist
mwpharm
result
lhkg
variabl
smaller
clf
vf
normal
bodi
mass
suggest
differ
bodi
weight
help
explain
variabl
coeffici
determin
bodi
weight
clf
p
bodi
weight
vf
p
conclus
trial
demonstr
zileuton
safe
well
toler
patient
scd
although
signific
pharmacokinet
variabl
warrant
futur
phase
trial
studi
efficaci
reduc
ahr
associ
pulmonari
morbid
scd
juliu
jame
martin
latha
magatha
sneha
lalitha
subramanian
manipriya
ravindran
sri
ramachandra
univers
chennai
tamilnadu
india
background
parent
report
end
life
decis
difficult
treatment
relat
decis
face
child
cancer
experi
research
parent
perspect
qualiti
end
life
care
cancer
children
scarc
particularli
develop
countri
like
india
object
studi
aim
identifi
symptom
medicalsocialemot
concern
parent
last
day
child
life
identifi
strategi
parent
found
help
period
designmethod
parent
lost
child
cancer
treat
institut
interview
valid
prepar
questionnair
result
abl
understand
concept
palliat
vs
cur
option
could
understand
abl
come
term
palli
mode
treatment
could
opt
altern
medicin
accept
worsen
symptom
want
child
hospit
period
death
opt
home
place
death
question
made
opt
aggress
therapi
toward
end
life
report
hope
miracl
want
everyth
possibl
reduc
suffer
retrospect
felt
right
want
help
child
possibl
way
toward
death
dull
irrit
withdrawn
surround
common
symptom
encount
children
fear
alon
children
fear
death
pain
fatigu
loss
appetit
main
distress
symptom
child
suffer
parent
perspect
conclus
develop
countri
scarc
financi
resourc
increas
magnitud
compet
problem
littl
resourc
left
hospic
palli
care
servic
howev
human
factor
underestim
end
life
care
far
medic
treatment
pain
killer
greater
attent
paid
symptom
control
overal
child
end
life
care
gabriel
vanspeybroeck
tokunbo
adeniyi
lewi
hsu
univers
illinoi
chicago
colleg
medicin
chicago
illinoi
unit
state
background
sickl
cell
diseas
scd
chronic
disord
lifelong
effect
complic
includ
pain
crise
chronic
fatigu
organ
damag
infect
acut
chest
syndrom
stroke
research
show
health
relat
qualiti
life
suffer
along
daili
activ
stem
cell
transplant
option
elig
patient
cure
transplant
markedli
improv
qualiti
life
patient
perceiv
benefit
clear
object
goal
studi
explor
effect
scd
work
school
along
common
theme
regard
particip
perspect
life
without
scd
hypothes
patient
perceiv
greater
disabl
scd
age
recogn
transplant
could
reliev
disabl
designmethod
mix
method
survey
administ
person
patient
seen
ui
health
comprehens
sickl
cell
center
hospit
pediatr
clinic
adolesc
transit
clinic
particip
age
rang
exclus
criteria
respiratori
contact
isol
extrem
pain
qualit
respons
examin
use
themat
analysi
result
theme
identifi
age
effect
scd
work
school
includ
disabl
school
absenc
motiv
disprov
odd
themat
analysi
identifi
patient
would
live
live
differ
cure
energi
improv
new
educ
goal
career
aspir
potenti
stem
cell
transplant
would
reliev
disabl
recogn
nearli
subject
older
age
correl
significantli
p
respons
reliev
disabl
almost
univers
patient
would
pursu
career
educ
cure
conclus
advanc
transplant
scd
achiev
cure
adult
often
reduc
disabl
pain
heighten
percept
benefit
adult
support
import
role
adult
scd
transplant
program
survey
first
examin
percept
disabl
among
factor
patient
consid
decis
stem
cell
transplant
sickl
cell
studi
includ
adolesc
adult
sickl
cell
patient
singl
survey
open
door
differ
percept
stem
cell
transplant
peter
anderson
kristen
powaski
lynel
houser
nicol
englert
kathi
bielek
elizabeth
darti
erin
feldman
alana
lopez
cleveland
clinic
children
cleveland
ohio
unit
state
background
famili
caregiv
pediatr
oncolog
patient
get
overwhelm
cope
multitud
task
requir
maintain
health
much
less
improv
health
although
children
hospit
love
care
environ
place
like
home
object
goal
transform
care
deliveri
larg
inpati
focus
solid
tumor
chemotherapi
team
one
could
provid
outpati
forward
observ
involv
facilit
outpati
chemotherapi
b
anticip
prevent
side
effect
c
improv
nutrit
provid
resourc
enabl
famili
caregiv
take
activ
role
encourag
forward
observ
mind
set
designmethod
tool
use
facilit
foster
forward
observ
activ
particip
improv
health
includ
improv
emr
note
use
snip
tool
emb
calendar
imag
photo
emr
note
better
team
commun
web
resourc
lotsahelpinghandsorg
chemocareorg
aspho
chemo
diseas
orient
group
acor
osteosarcoma
ewe
sarcoma
provis
calendar
famili
pharmaci
infus
nurs
summari
care
includ
contact
inform
previou
treatment
provid
relev
clinic
detail
facilit
meaning
discuss
clinic
visit
improv
anticip
plan
task
flash
drive
contain
articl
nutrit
info
imag
calendar
roadmap
summari
caregiv
advanc
direct
inform
thing
look
forward
colleg
scholarship
result
provid
chemotherapi
regimen
safe
outpati
clinic
includ
vac
vdc
ie
hdmtx
fewer
readmiss
forward
observ
mindset
improv
health
patient
metastat
medullari
thyroid
carcinoma
clear
cell
sarcoma
neuroectoderm
tumor
rhabdomyosarcoma
ewe
sarcoma
osteosarcoma
desmoplast
round
cell
tumor
result
provid
success
outpati
care
snip
tool
use
epic
made
note
inform
mani
children
aya
seem
improv
perform
statu
excel
qol
superl
cope
skill
posit
affect
famili
dynam
outcom
conclus
instead
expect
worst
adopt
forward
observ
mind
set
activ
creat
environ
hope
prepar
best
routin
exceed
expect
yasser
wali
shahina
daar
maha
alwaidi
taimoora
al
subhi
aisha
elkhayat
shoaib
alzadjali
aisha
alhosni
heba
omar
halima
albalushi
abdulhakim
moham
elshinawi
sultan
qaboo
univers
hospit
muscat
muscat
oman
background
hemoglobin
soman
result
doubl
mutat
globin
chain
classic
mutat
second
mutat
chain
ident
hboarab
literatur
carrier
describ
carrier
sever
clinic
present
match
sickl
cell
diseas
frequent
crise
acut
chest
syndrom
even
cerebrovascular
accid
object
studi
clinic
phenotyp
genotyp
cell
biolog
carrier
hbsoman
compound
heterozygot
designmethod
cross
section
studi
includ
identifi
carrier
hbsoman
compound
heterozygot
demograph
clinic
phenotyp
data
collect
includ
famili
pedigre
track
grandmoth
indic
founder
effect
hematolog
paramet
hplc
perform
chain
haplotyp
done
use
rflp
next
gener
exom
sequenc
gene
mutat
mutat
genet
modifi
includ
ahsp
perform
delet
mutat
identifi
use
scan
sampl
process
hemolysi
test
k
efflux
use
radioact
tracer
studi
result
identifi
carrier
male
femal
patient
male
femal
age
rang
year
hemoglobin
rang
gdl
soman
carrier
hb
rang
gdl
soman
compound
heterozygot
clinic
sever
index
correl
soman
percent
carrier
valu
decreas
product
due
delet
mutat
howev
correl
compound
heterozygot
present
earli
infanc
sever
genet
modifi
seem
effect
activ
kflux
ie
permeabl
lack
gardo
channel
activ
minim
activ
potassium
chlorid
found
soman
carrier
conclus
hbsoman
sever
form
scd
carrier
sever
symptomat
compound
heterozygot
present
thalassemia
major
earli
transfus
depend
alpha
thalassemia
mutat
main
genet
modifi
carrier
soman
cell
increas
sickl
hemolyt
characterist
susumu
inou
crystal
tammi
scherrer
jenni
lachanc
hurley
children
hospit
flint
michigan
unit
state
background
pediatr
symptom
checklist
well
valid
questionnair
complet
caregiv
minut
screen
children
adolesc
psychosoci
difficulti
pediatr
symptom
less
extens
studi
parallel
version
psc
design
youth
age
year
neither
studi
adolesc
chronic
hematolog
disord
object
studi
examin
use
screen
adolesc
sickl
cell
diseas
chronic
idiopath
thrombocytopen
purpura
itp
psychosoci
problem
may
requir
evalu
andor
intervent
designmethod
subject
patient
routin
visit
comprehens
sickl
cell
pediatr
hematolog
clinic
itp
dyad
age
elig
invit
particip
consent
caregiv
complet
cbcl
achenbach
child
behavior
checklist
correspond
adolesc
complet
ysr
achenbach
youth
self
report
total
number
evalu
pair
femal
hemoglobin
hb
sc
diseas
hb
ss
diseas
hb
thalassemia
chronic
itp
agreement
parallel
form
analyz
descript
correl
coeffici
calcul
pair
instrument
cblc
ysr
result
patient
age
rang
year
mean
regard
cbcl
ysr
refer
instrument
four
patient
exceed
cbcl
threshold
score
indic
psychosoci
risk
also
exceed
threshold
point
percent
agreement
cbcl
n
agreement
ysr
n
instrument
detect
risk
detect
parallel
instrument
conclus
result
suggest
may
limit
screen
sickl
cell
diseas
chronic
itp
patient
psychosoci
problem
though
conclus
tent
due
small
sampl
size
contrast
may
reason
altern
cbcl
explor
joli
ramesar
catherin
boston
vandi
black
univers
florida
colleg
medicin
gainesvil
florida
unit
state
background
consensu
guidelin
recommend
chronic
transfus
therapi
ctt
stroke
prevent
patient
sickl
cell
diseas
scd
histori
overt
stroke
abnorm
transcrani
doppler
tcd
veloc
typic
goal
maintain
baselin
hemoglobin
hb
observ
studi
report
consider
variat
hb
children
ctt
outsid
alloimmun
reason
variabl
object
report
possibl
chronic
splenic
sequestr
caus
poor
hb
control
patient
scd
ctt
stroke
prevent
suggest
consider
splenectomi
optim
transfus
paramet
select
children
designmethod
patient
age
year
hb
ss
diseas
manag
chronic
prbc
transfus
everi
week
follow
standard
institut
protocol
poor
hb
control
indic
ctt
prior
stroke
abnorm
tcd
surveil
magnet
reson
angiographi
show
progress
cn
vasculopathi
spleen
measur
cm
evid
alloimmun
care
consider
patient
underw
laparoscop
splenectomi
mean
hematolog
paramet
compar
pair
month
pre
post
splenectomi
result
prior
splenectomi
mean
hb
gmdl
reticulocyt
count
hb
post
splenectomi
hb
gmdl
reticulocyt
count
hb
follow
splenectomi
mean
reduct
hb
ci
p
mean
month
periop
infecti
complic
one
patient
appear
reduc
iron
burden
mean
reduct
baselin
serum
ferritin
ngml
perhap
part
transfus
space
due
improv
hb
control
conclus
data
suggest
splenic
sequestr
may
caus
shorten
red
cell
surviv
result
suboptim
hb
control
increas
risk
incid
recurr
stroke
splenectomi
may
reason
therapeut
option
select
patient
addit
research
warrant
caus
variabl
hb
control
patient
scd
ctt
therapeut
option
refin
reduc
risk
overt
stroke
paulina
daniel
stella
davi
kathleen
demmel
laura
flesch
amanda
geiger
melissa
hayward
sonata
jodel
hirsch
matani
samantha
michael
abigail
pate
ashley
teusink
christoph
dandoy
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
time
antibiot
administr
febril
neutropen
patient
associ
improv
outcom
analysi
inpati
bmt
unit
reveal
patient
new
onset
fever
receiv
antibiot
within
minut
aim
project
increas
percentag
febril
bmt
inpati
receiv
antibiot
within
minut
octob
use
model
improv
object
recogn
import
time
antibiot
administr
immunocompromis
identifi
potenti
barrier
time
antibiot
demonstr
import
establish
standard
process
provid
notif
antibiot
order
entri
administr
designmethod
pareto
analysi
failur
mode
effect
analysi
fmea
identifi
variabl
underli
caus
associ
delay
pareto
analysi
reveal
order
place
provid
delay
pharmaci
process
delay
order
placement
delay
notif
new
onset
fever
associ
failur
fmea
reveal
insuffici
awar
pharmaci
nurs
provid
new
onset
fever
standard
order
process
lack
provid
nurs
account
like
caus
time
antibiot
deliveri
failur
find
creat
key
driver
small
test
chang
develop
standard
process
consist
bedsid
nurs
notifi
order
provid
charg
nurs
safeti
coach
febril
patient
standard
order
set
specif
use
inpati
first
fever
pharmaci
notif
newli
febril
patient
via
stat
sticker
print
antibiot
enter
via
order
set
monitor
complianc
process
via
softwar
monitor
system
call
vigilanz
result
implement
antibiot
order
set
develop
process
bedsid
nurs
notifi
charg
nurs
safeti
coach
febril
patient
saw
increas
percentag
patient
receiv
antibiot
within
sixti
minut
document
fever
median
median
time
antibiot
administr
decreas
minut
minut
conclus
implement
standard
process
provid
notif
order
entri
result
improv
time
antibiot
administr
patient
nanci
robitail
clair
yve
pastor
chu
faculti
medicin
de
quebec
canada
background
romiplostin
thrombopoietin
analog
approv
therapi
immun
thrombocytopenia
itp
safeti
patient
sickl
cell
diseas
secondair
thrombocytopenia
howev
unknown
object
describ
use
romiplostin
patient
sickl
cell
diseas
designmethod
singl
case
report
result
year
old
femal
hb
ss
sickl
cell
diseas
scd
system
lupu
erythematosu
sle
develop
secondari
itp
juli
platelet
count
alreadi
prednison
mgkg
sle
therefor
treat
intraven
immunoglobulin
ivig
gkg
x
dose
partial
respons
month
later
receiv
two
cycl
rituximab
good
respons
januari
platelet
count
went
back
receiv
third
cours
rituximab
sustain
respons
decid
introduc
romiplostin
februari
start
dose
mcgkg
increas
maxim
dose
mcgkg
within
month
normal
platelet
count
romiplostin
titrat
per
standard
recommend
maintain
platelet
count
although
platelet
count
remain
stabl
ofatumumab
given
one
month
later
avoid
relaps
immun
manifest
sle
given
sustain
normal
platelet
count
romiplostin
gradual
wean
ceas
septemb
medic
well
toler
patient
experienc
pain
crisi
conclus
knowledg
first
report
util
romiplostin
patient
scd
medic
efficaci
well
toler
particular
increas
pain
crisi
note
contrast
gcsf
romiplostin
might
safe
use
scd
christoph
dandoy
tammi
kelley
aditya
gaur
rajaram
nagarajan
kathleen
demmel
terri
guinipero
stephani
savelli
hana
hakim
angi
owe
victor
aquino
roland
chu
mari
lynn
rae
katharin
schjodt
traci
kilcreas
michel
scurlock
ann
marshburn
margaret
hill
jessica
castillo
joel
kaplan
ruth
adedeji
laura
metz
rochel
power
mari
langevin
paulin
mitbi
jennif
lee
anthoni
yost
raven
cooksey
mian
amir
shelbi
eckl
brian
turpin
john
lawlor
jeffrey
hord
ami
billett
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
bloodstream
infect
bsi
seriou
complic
children
receiv
chemotherapi
undergo
stem
cell
transplant
sct
outcom
pediatr
hematologyoncologysct
pho
patient
develop
bsi
unknown
object
object
project
determin
outcom
hospit
pho
patient
develop
bsi
designmethod
conjunct
children
hospit
associ
childhood
cancer
blood
disord
network
pho
center
prospect
track
categor
bsi
accord
nhsn
criteria
hospit
pho
patient
central
line
bsi
includ
associ
blood
stream
infect
clab
secondari
bsi
singl
posit
blood
cultur
spbc
chart
review
bsi
novemb
thru
april
perform
identifi
specif
patient
diseas
treatment
outcom
data
result
demograph
outcom
data
individu
bsi
collect
thu
far
includ
clabsi
secondari
bsi
spbc
major
patient
male
median
age
year
iqr
patient
pho
patient
underli
malign
aml
n
n
common
n
underli
immun
defici
syndrom
patient
malign
n
uncontrol
diseas
time
infect
patient
underw
sct
prior
bsi
allogen
transplant
sct
patient
bsi
grade
gvhd
day
patient
prophylactictreat
antibiot
patient
prophylact
antifung
time
infect
patient
die
within
day
develop
bsi
die
within
day
resuscit
direct
place
time
bsi
patient
admit
intens
care
within
hour
bsi
stay
median
day
cvc
remov
within
day
patient
conclus
first
multicent
studi
evalu
demograph
outcom
pho
patient
develop
bsi
data
help
support
high
risk
poor
outcom
follow
bsi
enforc
bsi
prevent
measur
elizabeth
van
dyne
elizabeth
nkosi
rose
bubili
manda
kamanga
janet
iver
beat
ritz
karl
seydel
judith
baker
karin
theodor
moor
univers
california
lo
angel
lo
angel
california
unit
state
background
children
born
annual
sickl
cell
anemia
sca
africa
die
adulthood
due
insuffici
implement
simpl
prevent
intervent
sever
infect
fulmin
sepsi
kill
youth
less
hour
malawi
sca
incid
unknown
newborn
screen
program
devis
sustain
initi
detect
screen
treat
sca
urgent
blantyr
malawi
second
largest
citi
greater
million
resid
address
unmet
sca
public
health
medic
need
object
develop
implement
sca
newborn
screen
neonat
infect
prevent
program
blantyr
malawi
set
foundat
sustain
longitudin
care
designmethod
univers
california
lo
angel
pediatr
depart
blantyr
queen
elizabeth
central
hospit
uk
malawi
base
chariti
friend
sick
children
malawi
initi
collabor
effort
septemb
build
local
sca
screen
capac
blantyr
children
age
month
three
screen
method
rflp
cellulos
acet
gel
electrophoresi
test
determin
accur
feasibl
method
local
research
nurs
conduct
sca
educ
map
resid
conduct
home
visit
built
popul
level
trust
promot
sca
infect
prevent
adher
newborn
test
posit
enrol
sca
clinic
infect
prevent
chiefli
penicillin
prophylaxi
vaccin
result
august
septemb
nearli
blantyr
nurs
doctor
lab
technician
commun
health
worker
educ
sca
diagnosi
detect
screen
prevent
care
sca
registri
creat
enrol
protocol
devis
septemb
decemb
children
age
month
screen
sca
preliminari
result
reveal
least
posit
full
confirmatori
test
still
underway
conclus
institut
earli
detect
sca
larg
malawi
citi
appear
feasibl
use
collabor
build
local
sca
public
health
medic
care
capac
longitudin
data
need
assess
well
screen
infect
prevent
reduc
morbid
mortal
children
age
inform
cost
valu
servic
expans
throughout
malawi
emili
wall
nicol
benzoni
jarrod
dornfeld
rusha
bhandari
bryan
sisk
graham
colditz
washington
univers
st
loui
missouri
unit
state
background
hpv
vaccin
safe
effect
cancer
prevent
method
underus
unit
state
despit
increas
understand
barrier
vaccin
rate
remain
low
global
develop
develop
nation
achiev
high
rate
vaccin
object
identif
effect
strategi
necessari
optim
uptak
hpv
vaccin
studi
systemat
review
literatur
nation
intern
intervent
success
increas
hpv
vaccin
uptak
designmethod
conduct
search
use
standard
protocol
electron
databas
pubm
scopu
embas
identifi
intervent
design
increas
hpv
vaccin
uptak
among
adolesc
year
old
studi
design
accept
manuscript
includ
post
intervent
vaccin
rate
includ
two
author
independ
review
articl
data
extract
qualiti
assess
three
review
independ
classifi
intervent
accord
predefin
criteria
result
manuscript
classifi
accord
commun
guid
result
report
accord
framework
manuscript
met
elig
criteria
inform
intervent
behavior
intervent
environment
intervent
factor
associ
hpv
vaccin
uptak
increas
vaccin
avail
decreas
financi
barrier
intervent
target
provid
patient
conclus
popul
base
vaccin
strategi
increas
vaccin
avail
reach
greatest
number
adolesc
success
achiev
high
rate
vaccin
intervent
target
provid
patient
also
success
nupur
mittal
lewi
hsu
univers
illinoi
chicago
chicago
illinoi
unit
state
background
acut
chest
syndrom
ac
common
caus
death
children
sickl
cell
diseas
scd
hematologist
need
awar
assess
ac
sever
guid
therapi
measur
prevent
ac
ac
sever
assess
tool
util
research
valid
set
exist
guidelin
includ
nhlbi
provid
uniform
grade
ac
sever
contrast
evid
role
incent
spirometri
prevent
decreas
sever
ac
strong
incent
spirometri
recommend
includ
guidelin
object
assess
current
knowledg
resid
physician
nurs
regard
two
aspect
ac
sever
assess
incent
spirometri
designmethod
tertiari
care
hospit
admit
patient
scd
per
month
pediatr
floor
pediatr
resid
nurs
learn
ac
manag
prevent
didact
session
scdyear
bedsid
teach
anonym
survey
administ
pediatr
pediatr
nurs
routin
engag
care
ac
patient
follow
educ
session
ac
result
sever
score
nurs
educ
use
ac
sever
assess
past
overwhelm
felt
score
system
would
use
assess
patient
condit
guid
manag
howev
resid
nurs
use
sever
score
ac
past
clinic
vignett
ac
answer
incorrectli
resid
nurs
incent
spirometri
respond
awar
incent
spirometri
decreas
sever
improv
outcom
ac
nurs
thought
patient
compliant
less
time
incent
spirometri
almost
alway
order
conclus
knowledg
resid
nurs
regard
sever
assess
ac
limit
greater
effort
need
educ
includ
assess
manag
decis
import
incent
spirometri
recogn
howev
patient
complianc
desir
reinforc
need
improv
ac
outcom
pilot
studi
identifi
room
qualiti
improv
sever
step
care
process
scd
michael
winstead
jolen
molli
szuminski
holli
pariuri
jennif
michlitsch
anurag
agraw
ucsf
benioff
children
hospit
oakland
oakland
california
unit
state
background
febril
neutropenia
fn
frequent
complic
cancer
treatment
contribut
burden
hospit
children
cancer
although
children
fn
seriou
infect
best
strategi
reduc
hospit
time
popul
establish
object
develop
ration
strategi
reduc
hospit
time
pediatr
oncolog
patient
fn
describ
institut
experi
explor
clinic
featur
associ
higher
risk
infecti
complic
popul
designmethod
conduct
retrospect
cohort
studi
patient
admit
ucsf
benioff
children
hospit
oakland
oakland
california
unit
state
record
fn
admiss
review
patient
nonmalign
marrow
dysfunct
histiocytosi
fn
symptom
cancer
relaps
previou
hematopoiet
stem
cell
transplant
patient
receiv
induct
chemotherapi
acut
lymphoblast
leukemia
exclud
seriou
infect
defin
bacteremia
viremia
septic
shock
bacterialfung
infect
proven
probabl
infect
requir
intens
care
result
analyz
fn
episod
among
subject
femal
median
age
year
interquartil
rang
iqr
median
length
stay
day
iqr
fever
resolv
median
day
iqr
admiss
patient
spent
median
day
iqr
hospit
fever
resolut
seriou
infect
commonli
bacteremia
complic
admiss
diagnos
prior
fever
resolut
case
prior
histori
seriou
infect
fever
recurr
day
afebril
temperatur
c
first
day
episod
significantli
increas
risk
seriou
infect
conclus
quarter
subject
fn
develop
seriou
infect
infect
diagnos
prior
fever
resolut
patient
lack
featur
hospit
discharg
hour
fever
resolut
may
safe
reduc
burden
hospit
prospect
data
need
assess
safeti
feasibl
approach
emili
meier
paul
levett
indiana
hemophilia
thrombosi
center
indianapoli
indiana
unit
state
background
patient
hbss
sca
share
genet
mutat
clinic
phenotyp
variabl
difficult
predict
earli
life
avail
cure
sca
hematopoeit
stem
cell
transplant
hsct
earli
trial
hsct
sca
patient
reveal
sca
patient
higher
complic
rate
increas
age
patient
undergo
hsct
reliabl
sever
predictor
exist
hsct
could
perform
patient
sca
highest
risk
sca
complic
prior
onset
vasculopathi
organ
damag
object
goal
project
systemat
review
literatur
determin
diseas
sever
predictor
valid
pediatr
patient
sca
designmethod
search
pubm
cochran
clinic
trial
regist
scopu
perform
use
follow
term
sickl
cell
anemia
diseas
complic
mortal
classif
prognosi
sever
ill
predict
valu
test
risk
proport
hazard
model
stroke
risk
hematopoiet
stem
transplant
method
data
extract
use
standard
data
collect
form
result
full
text
refer
identifi
review
base
titleabstract
articl
includ
analysi
articl
exclud
base
exclus
criteria
fetal
hemoglobin
hbf
alpha
globin
gene
number
commonli
studi
sever
predictor
studi
hemoglobin
white
blood
cell
count
absolut
reticulocyt
count
round
top
studi
predictor
systemat
review
nearli
three
quarter
hbf
studi
report
benefici
effect
increas
hbf
level
howev
increas
hbf
level
associ
lower
rate
hospit
stroke
risk
two
articl
increas
arc
posit
associ
increas
risk
complic
report
studi
alpha
thalassemia
trait
protect
stroke
abnorm
tcd
rate
pain
crisi
conclus
abil
predict
sca
complic
mix
studi
variabl
includ
hbf
reliabl
predictor
diseas
complic
urgent
need
guid
therapeut
decis
pediatr
patient
sca
nupur
mittal
paul
kent
rush
univers
medic
center
chicago
illinoi
unit
state
background
survivor
pediatr
cancer
risk
term
consequ
therapi
one
loss
protect
antibodi
predispos
ill
measl
measl
recipi
immunosuppress
chemotherapi
mortal
rate
children
year
lose
humor
immun
measl
result
chemotherapi
induc
alter
immun
system
despit
proven
strategi
improv
measl
vaccin
coverag
diseas
still
continu
circul
lead
outbreak
develop
countri
us
experienc
major
measl
outbreak
relat
amus
park
california
case
year
report
across
state
includ
state
measl
highli
contagi
hour
prior
first
symptom
pediatr
oncolog
practic
share
offic
floor
space
pediatr
practic
place
patient
risk
measl
infect
object
measl
protect
humor
immun
statu
check
patient
new
risk
measl
period
outbreak
time
standard
practic
check
measl
titer
prior
initi
chemotherapi
designmethod
patient
year
receiv
chemotherapi
januari
depart
includ
prospect
review
defin
immun
accord
lab
standard
result
total
femal
patient
includ
three
patient
non
protect
measl
antibodi
level
patient
year
diagnosi
leukemia
one
adolesc
sarcoma
three
came
weekli
clinic
admit
floor
chemotherapi
period
thu
share
common
clinic
floor
space
none
patient
develop
measl
remiss
conclus
measl
outbreak
us
pose
grave
threat
recipi
chemotherapi
danger
increas
nosocomi
set
share
clinic
space
univers
vaccin
stringent
isol
pediatr
clinic
area
standard
practic
check
measl
immun
patient
prior
chemotherapi
initi
may
prevent
devast
diseas
sensit
popul
moham
elshinawi
nada
al
marhoobi
rashid
al
abri
taimoora
alsubhi
heba
omar
yasser
wali
sultan
qaboo
univers
hospit
muscat
muscat
oman
background
adenotonsillar
hypertrophi
patient
sickl
cell
diseas
scd
predispos
sever
complic
includ
obstruct
sleep
apnea
vasocclus
crisi
voc
pulmonari
hypertens
acut
chest
syndrom
ac
tradit
children
sickl
cell
diseas
scd
indic
adenoidectomi
andor
tonsillectomi
expos
exchang
transfus
preoper
aim
reduct
surgic
complic
postop
period
object
address
need
transfus
patient
scd
undergo
adenotonsillectomi
report
risk
benefit
designmethod
patient
scd
admit
sultan
qaboo
univers
hospit
adenoidectomi
tonsillectomi
juli
till
januari
includ
studi
patient
file
review
retrospect
data
recod
studi
prospect
result
cohort
includ
patient
scd
male
femal
age
rang
year
accord
transfus
need
prior
surgeri
patient
categor
group
name
transfus
group
simpl
transfus
group
ii
exchang
transfus
group
iii
group
includ
patient
respect
signific
differ
studi
group
regard
main
complic
scd
vasoocclus
crisi
occur
compar
number
case
three
group
respect
acut
chest
syndrom
develop
patient
group
exchang
transfus
group
patient
simpl
transfus
group
averag
hemoglobin
valu
significantli
lower
simpl
transfus
group
comparison
group
note
patient
simpl
transfus
requir
almost
half
blood
volum
compar
exchang
transfus
mlkg
vs
mlkg
statist
highli
signific
differ
group
p
conclus
conclud
safe
adenotonsillectomi
without
simpl
exchang
transfus
patient
scd
maintain
hemoglobin
level
gdl
transfus
improv
surgic
outcom
sharon
castellino
katherin
pleasant
katherin
poehl
janet
tooz
wake
forest
school
medicin
north
carolina
unit
state
background
quadrival
hpv
vaccin
fda
approv
femal
male
respect
nation
immun
survey
indic
vaccin
initi
rate
plateau
us
femal
mmwr
cancer
survivor
repres
uniqu
popul
benefit
cancer
prevent
vaccin
object
estim
proport
institut
cancer
survivor
initi
complet
hpv
vaccin
cours
evalu
north
carolina
immun
registri
ncir
ascertain
hpv
uptak
designmethod
follow
irb
approv
identifi
cancer
patient
born
institut
cancer
center
registri
patient
attain
first
remiss
less
month
ncir
record
exclud
analysi
identifi
patient
link
ncir
record
via
manual
search
valid
linkag
confirm
name
birth
date
address
match
registri
institut
medic
record
ncir
record
abstract
receipt
number
hpv
vaccin
dose
childhood
vaccin
institut
medic
record
abstract
demograph
characterist
cancer
diagnosi
treatment
report
receipt
hpv
vaccin
date
recurr
last
cancer
treatment
last
visit
institut
oncolog
clinic
use
descript
statist
summar
studi
popul
proport
vaccin
uptak
result
elig
patient
n
mean
year
age
cancer
diagnosi
half
femal
nine
percent
femal
male
receiv
hpv
vaccin
prior
cancer
diagnosi
among
vaccin
prior
diagnosi
ncir
linkag
indic
cancer
patient
initi
hpv
vaccin
complet
seri
three
dose
proport
cancer
survivor
initi
hpv
vaccin
among
femal
among
male
predictor
vaccin
uptak
pend
analysi
conclus
substanti
number
cancer
survivor
receiv
hpv
vaccin
repres
miss
opportun
access
robust
state
immun
registri
allow
oncolog
survivorship
clinic
assess
gap
vaccin
target
vaccin
deliveri
fulfil
healthi
peopl
object
taylor
olmst
david
steffin
alex
georg
texa
children
hospit
houston
texa
unit
state
background
intrahepat
cholestasi
sickl
hepatopathi
rare
complic
seen
patient
hemoglobin
ss
condit
sickl
within
hepat
sinusoid
lead
stasi
hypoxia
swell
liver
parenchyma
therebi
result
pressur
intrahepat
bile
duct
lead
intracanalicular
cholestasi
patient
ultim
present
sever
conjug
hyperbilirubinemia
howev
vari
degre
clinic
compromis
object
littl
data
evolut
sickl
hepatopathi
pediatr
patient
furthermor
consensu
optim
manag
intrahepat
cholestasi
present
two
case
pediatr
patient
intrahepat
cholestasi
secondari
sickl
cell
diseas
hope
better
elucid
cours
diseas
progress
manag
futur
designmethod
retrospect
chart
review
perform
two
teenag
male
patient
hemoglobin
ss
texa
children
hospit
houston
texa
result
first
patient
male
hemoglobin
ss
gilbert
syndrom
present
fever
cough
admit
manag
acut
chest
syndrom
hospit
persist
elev
conjug
bilirubin
level
peak
mgdl
liver
enzym
elev
ptinr
remain
normal
liver
biopsi
done
follow
discharg
show
intrahepat
cholestasi
sinusoid
sickl
cell
aggreg
second
patient
male
hemoglobin
ss
gilbert
syndrom
chronic
transfus
transfus
five
day
prior
present
scleral
icteru
dark
urin
cbc
hemoglobin
profil
concern
hyperhemolysi
total
bilirubin
peak
mgdl
conjug
bilirubin
mgdl
suggest
hyperhemolysi
caus
hyperbilirubinemia
ast
alt
ptinr
mildli
elev
mrcp
neg
obstruct
patient
manag
conserv
discharg
ursodiol
improv
conclus
adult
sickl
cell
patient
intrahepat
cholestasi
often
sever
cours
pediatr
patient
often
requir
liver
transplant
contrast
intrahepat
cholestasi
pediatr
patient
benign
cours
without
sign
hepat
dysfunct
encephalopathi
patient
could
manag
conserv
close
observ
tristan
nichol
miranda
lan
lisa
almaz
dessi
erika
chacona
anurag
agraw
children
hospit
research
center
oakland
oakland
california
unit
state
background
adult
febril
neutropenia
fn
decreas
time
antibiot
administr
tta
appear
associ
improv
outcom
includ
decreas
mortal
length
stay
bacteremia
howev
pediatr
fn
patient
multipl
report
fail
convincingli
show
decreas
tta
improv
length
stay
lo
bacteremia
mortal
pediatr
emerg
care
set
prompt
identif
fn
rapid
administr
antibiot
becom
recommend
practic
gold
standard
mani
qualiti
improv
qi
project
invest
ampl
time
money
meet
recommend
object
studi
sought
identifi
whether
tta
significantli
associ
improv
outcom
pediatr
fn
designmethod
retrospect
electron
chart
review
pediatr
fn
episod
present
novemb
may
children
hospit
research
center
oakland
emerg
depart
complet
extract
patient
demograph
tta
outcom
data
perform
tandem
qi
project
implement
standard
process
order
set
time
result
signific
decreas
tta
clinic
outcom
includ
admiss
lo
fluid
resuscit
pediatr
intens
care
unit
picu
admiss
mortal
administr
addit
antibiot
examin
result
total
occurr
fever
suspect
neutropenia
record
three
subgroup
admit
neutropen
patient
tta
tta
tta
signific
differ
measur
outcom
includ
notabl
need
picu
admiss
mean
fluid
resuscit
mean
lo
mortal
conclus
tta
current
use
surrog
qualiti
care
qoc
measur
emerg
care
patient
fever
suspect
neutropenia
evid
tta
improv
outcom
pediatr
popul
compar
tta
lack
larger
multicent
prospect
studi
requir
determin
valu
presum
qualiti
control
measur
andrea
zivot
natali
apollonski
bruce
bernstein
rida
abid
deepti
raybagkar
st
christoph
hospit
children
philadelphia
pennsylvania
unit
state
background
children
sickl
cell
diseas
scd
significantli
lower
height
weight
bodi
mass
index
bmi
compar
standard
growth
curv
previou
public
reveal
consist
pattern
diminish
growth
among
individu
scd
evid
link
growth
failur
poor
nutrient
intak
hemolysi
chronic
anemia
high
metabol
rate
sever
studi
evalu
associ
bmi
clinic
manifest
sickl
cell
diseas
demonstr
children
sickl
cell
diseas
higher
bmi
associ
higher
abil
academ
achiev
specif
sickl
cell
therapi
hydroxyurea
blood
transfus
could
improv
growth
cognit
abil
predict
growth
develop
first
year
life
would
allow
physician
provid
earli
dietari
nutrit
intervent
institut
earli
hydroxyurea
therapi
object
goal
studi
evalu
correl
earli
biomark
diseas
sever
bmi
children
scd
designmethod
perform
retrospect
chart
review
patient
scd
follow
marian
anderson
center
st
christoph
hospit
children
philadelphia
identifi
consecut
patient
met
inclus
criteria
spearman
correl
calcul
explor
associ
bmi
percentil
differ
age
group
steadi
state
biomark
anemia
hemolysi
inflamm
year
life
addit
steadi
state
hemoglobin
reticulocyt
count
white
blood
cell
count
absolut
neutrophil
count
platelet
count
recod
three
categori
high
medium
low
differ
bmi
percentil
associ
categori
assess
test
result
signific
correl
found
steadi
state
marker
bmi
either
set
analys
conclus
saw
signific
correl
marker
anemia
hemolysi
inflamm
first
year
life
bmi
differ
age
group
import
note
bmi
patient
either
normal
close
normal
compar
standard
possibl
imped
demonstr
statist
signific
correl
prospect
studi
larger
sampl
size
requir
clearli
elucid
associ
michel
schoettler
wen
tao
lauren
kerr
margaret
stack
elain
shu
dionn
graham
elli
neufeld
rachael
grace
children
cancer
blood
disord
center
boston
massachusett
unit
state
background
despit
publish
recommend
wide
practic
variat
treatment
pediatr
itp
scamp
tool
use
evalu
variat
clinic
practic
prospect
evalu
strategi
improv
care
object
compar
initi
rate
manag
strategi
compar
pharmacolog
therapi
newli
diagnos
pediatr
itp
case
develop
scamp
designmethod
retrospect
data
collect
children
itp
develop
scamp
itp
implement
revis
elig
criteria
includ
platelet
diagnosi
prior
treatment
durat
onset
week
age
year
bleed
grade
use
buchanan
adix
score
j
pediatr
first
scamp
guidelin
recommend
observ
unless
bleed
score
ivig
steroid
recommend
second
iter
subdivid
grade
bleed
score
lower
higher
risk
group
observ
recommend
grade
patient
result
prior
scamp
patient
initi
observ
implement
first
scamp
signific
increas
patient
initi
observ
p
patient
enrol
grade
bleed
grade
bleed
second
iter
initi
observ
rate
significantli
increas
p
howev
cohort
exhibit
less
bleed
patient
present
initi
bleed
score
patient
grade
bleed
receiv
pharmacolog
treatment
wherea
patient
treat
conclus
institut
histor
treat
major
newli
diagnos
itp
patient
pharmacolog
therapi
observ
initi
scamp
correspond
differ
practic
increas
fraction
observ
buchanan
adix
grade
bleed
cover
wide
rang
sever
modifi
scamp
took
account
concomit
abil
discrimin
high
low
risk
treat
accordingli
rate
initi
observ
increas
patient
group
also
lower
bleed
score
implement
itp
scamp
encourag
consist
treatment
futur
analysi
determin
extent
chang
clinic
practic
nichola
mcgregor
nichola
hall
beth
robert
prasad
boda
akron
children
hospit
akron
ohio
unit
state
background
children
sickl
cell
diseas
may
experi
complic
cognit
develop
academ
perform
mani
children
live
sickl
cell
diseas
fail
least
one
grade
mani
patient
experi
stroke
silent
cerebr
infarct
andor
impair
complic
result
poor
academ
perform
school
attend
advers
affect
frequent
pain
crise
hospit
pain
last
approxim
day
pain
may
persist
day
accord
nation
center
educ
statist
african
american
student
graduat
rate
academ
year
nationwid
graduat
rate
african
american
student
cleveland
municip
akron
citi
school
district
respect
patient
sickl
cell
diseas
expect
lower
graduat
rate
object
measur
graduat
rate
children
receiv
care
sickl
cell
program
compar
rate
diseas
free
peer
designmethod
clinic
locat
akron
oh
addit
diseas
manag
clinic
offer
educ
assess
nurs
school
visit
plan
assist
review
popul
individu
would
expect
graduat
base
age
review
conduct
decemb
result
patient
identifi
seven
patient
exclud
transit
adult
care
record
graduat
lost
follow
move
geograph
review
patient
record
mean
age
yr
eighteen
patient
graduat
track
graduat
time
spring
conclus
sickl
cell
patient
receiv
comprehens
care
achiev
graduat
rate
compar
diseas
free
peer
diseas
manag
educ
assess
nurs
school
visit
plan
may
contribut
futur
studi
examin
servic
like
improv
achiev
children
sickl
cell
diseas
jennif
green
lin
david
tapp
laurenc
corash
ceru
corpor
concord
california
unit
state
background
photochem
treatment
process
pct
util
amotosalen
uva
light
intercept
blood
develop
inactiv
virus
bacteria
parasit
leukocyt
contamin
blood
compon
intend
transfus
treat
compon
demonstr
retent
therapeut
efficaci
random
control
clinic
trial
european
surveil
studi
process
use
center
countri
decemb
intercept
fda
approv
use
us
object
object
studi
character
safeti
profil
platelet
compon
administ
pediatr
patient
popul
designmethod
open
label
observ
hemovigil
program
transfus
conduct
clinic
center
countri
transfus
monitor
advers
event
ae
occur
within
hour
seriou
advers
event
sae
seven
day
post
transfus
ae
assess
sever
grade
causal
relationship
transfus
inclus
criteria
need
transfus
result
pediatr
patient
n
receiv
transfus
mean
age
year
rang
approxim
half
patient
diseas
requir
convent
chemotherapi
hematopoiet
stem
cell
transplant
primari
diagnosi
remain
patient
gener
medic
cardiovascular
surgeri
solid
organ
transplant
mean
number
transfus
receiv
rang
signsymptom
rel
frequenc
ae
attribut
platelet
transfus
pruritusurticariarash
feverchil
tachycardia
dyspnea
patient
experienc
sae
judg
relat
ae
occur
neonat
patient
day
old
n
case
acut
lung
injuri
infect
death
attribut
transfus
conclus
longitudin
hemovigil
safeti
program
routin
transfus
demonstr
low
rate
ae
safeti
profil
consist
previous
report
convent
platelet
compon
joseph
bernard
gerri
marcel
augustin
jean
hugu
henri
notr
dame
dhaiti
haiti
background
children
born
year
sever
form
hemoglobinopathi
gene
carri
nearli
world
popul
sickl
cell
diseas
scd
genet
hemoglobinopathi
seriou
psychosoci
intellectu
develop
consequ
object
princip
object
studi
determin
predictor
complic
infect
sequestr
crisi
children
scd
sickl
cell
trait
sct
hospit
st
damien
hospit
sdh
haiti
januari
decemb
designmethod
studi
conduct
children
younger
fifteen
year
age
scd
sct
hospit
sdh
studi
period
chart
review
perform
collect
key
variabl
gender
age
genotyp
level
anemia
preval
among
hospit
children
proport
complic
determin
odd
ratio
associ
clinic
demograph
characterist
complic
report
statist
signific
associ
evalu
use
chi
squar
result
preval
scd
sct
among
children
hospit
sdh
among
children
includ
studi
ss
genotyp
frequent
mean
hemoglobin
hb
level
gdl
symptomatolog
domin
fever
mucocutan
pallor
jaundic
cough
children
sever
anemia
hb
level
less
genotyp
ss
children
develop
complic
mortal
rate
deceas
genotyp
ss
odd
develop
complic
significantli
higher
among
children
age
year
old
p
hb
level
less
gdl
found
signific
protect
factor
p
conclus
main
caus
hospit
children
scd
sct
appear
sever
decompens
anemia
complic
occur
mainli
children
year
old
hb
level
less
found
protect
factor
complic
mainli
due
priti
tewari
kati
ahlstrom
branko
cuglievan
patricia
craven
michel
gatliff
camil
shepard
md
anderson
cancer
center
houston
texa
unit
state
background
oncolog
stem
cell
transplant
sct
inpati
requir
frequent
complet
blood
count
cbc
monitor
blood
product
transfus
cumbersom
task
clinic
team
time
result
care
delay
object
creat
pilot
establish
transfus
paramet
order
set
high
acuiti
inpati
oncolog
unit
sct
patient
cohort
enabl
nurs
independ
initi
transfus
expedit
patient
care
allow
clinic
team
focu
complex
patient
care
issu
designmethod
order
set
entail
nurs
transfus
paramet
process
creat
implement
sct
recipi
order
set
includ
paramet
pack
red
blood
cell
prbc
platelet
transfus
base
patient
specif
clinic
need
includ
diuret
option
paramet
order
initi
septemb
gener
oncolog
patient
continu
preexist
process
clinician
follow
daili
result
gener
individu
order
clinic
indic
transfus
data
point
collect
group
patient
sct
gener
oncolog
lab
draw
time
transfus
order
submit
time
blood
product
compon
distribut
time
time
administr
blood
product
data
collect
differ
time
point
prior
implement
pilot
year
post
order
set
establish
result
median
time
lab
draw
baselin
sct
group
minut
rang
decreas
minut
rang
pilot
decreas
min
rang
establish
order
set
signific
decreas
comparison
oncolog
group
signific
decreas
observ
ident
time
lab
draw
time
product
administr
sct
group
follow
establish
decreas
median
minut
conclus
implement
paramet
order
set
blood
product
transfus
facilit
nurs
autonomi
initi
indic
transfus
decreas
transfus
delay
improv
patient
care
deliveri
base
posit
result
success
qualiti
improv
initi
great
potenti
system
increas
nurs
autonomi
futur
direct
includ
wider
implement
order
set
survey
understand
nurs
clinician
patient
percept
paramet
order
set
patient
care
deliveri
maria
boucher
patienc
obasaju
yara
park
rupa
univers
north
carolina
chapel
hill
north
carolina
unit
state
background
male
sickl
cell
diseas
scd
lifetim
probabl
develop
priapism
manag
priapism
controversi
red
cell
exchang
transfus
use
manag
sickl
relat
complic
sever
case
report
describ
acut
neurolog
event
follow
exchang
transfus
priapism
limit
enthusiasm
routin
adopt
therapi
present
littl
data
character
exchang
transfus
util
safeti
treat
priapism
object
determin
compar
incid
advers
event
seen
patient
scd
receiv
red
cell
exchang
transfus
refractori
priapism
secondari
stroke
prophylaxi
designmethod
univers
north
carolina
blood
bank
databas
use
identifi
patient
scd
enrol
chronic
exchang
transfus
program
refractori
priapism
year
cohort
seven
patient
enrol
exchang
protocol
secondari
stroke
prophylaxi
identifi
first
exchang
procedur
group
use
comparison
advers
event
vital
sign
instabl
acut
neurolog
event
collect
data
collect
analyz
determin
differ
advers
event
priapism
group
compar
receiv
exchang
transfus
secondari
stroke
prophylaxi
result
identifi
seven
patient
scd
enrol
red
cell
exchang
protocol
refractori
priapism
evalu
episod
exchang
transfus
per
patient
mean
age
six
patient
hbss
one
patient
hbsc
two
episod
hypotens
record
one
patient
two
separ
procedur
resolv
decreas
inlet
pump
flow
rate
patient
advers
neurolog
event
record
one
patient
experienc
lip
tingl
resolv
calcium
carbon
tablet
comparison
data
patient
transfus
secondari
stroke
prevent
collect
conclus
although
exchang
transfus
infrequ
use
treat
refractori
priapism
patient
scd
incid
advers
event
appear
minim
analysi
ongo
compar
safeti
red
cell
exchang
transfus
priapism
stroke
futur
control
trial
use
blood
exchang
transfus
refractori
priapism
need
refer
br
j
haematol
rackoff
j
pediatr
siegel
j
urol
jacquelyn
power
georg
buchanan
leah
adix
timothi
mccavit
univers
texa
southwestern
medic
center
dalla
texa
unit
state
background
iron
defici
anemia
ida
preval
young
children
whose
diet
includ
prolong
breastfeed
without
iron
supplement
andor
excess
cow
milk
consumpt
yet
data
guid
clinic
regard
optim
manag
bestiron
studi
clinicaltrialsgov
initi
compar
ferrou
sulfat
oral
iron
polysaccharid
hypothes
better
absorb
toler
iron
salt
object
primari
aim
compar
efficaci
ferrou
sulfat
improv
hemoglobin
concentr
week
treatment
period
secondari
aim
includ
comparison
advers
effect
reconstitut
iron
store
adher
group
well
efficaci
daili
regimen
mgkg
element
iron
designmethod
studi
random
control
singl
center
superior
trial
elig
patient
month
age
confirm
nutrit
ida
histori
laboratori
studi
random
receiv
either
ferrou
sulfat
novaferrum
mgml
element
iron
week
result
eighti
patient
target
accrual
enrol
studi
predominantli
male
latino
caucasianwhit
median
age
month
rang
primari
outcom
chang
hemoglobin
concentr
upon
serial
measur
week
given
mean
baselin
hemoglobin
valu
gdl
predict
mean
hemoglobin
valu
gdl
gdl
week
respect
ferrou
sulfat
group
pool
result
date
demonstr
median
baselin
hemoglobin
gdl
improv
week
median
hemoglobin
valu
gdl
complet
result
avail
late
januari
present
aspho
annual
meet
conclus
ida
major
health
problem
young
children
global
limit
scientif
data
support
current
treatment
approach
ida
ferrou
sulfat
mgkgday
divid
dose
consid
standard
care
thu
lower
daili
iron
dose
andor
prove
superior
bestiron
clinic
trial
could
substanti
impact
treatment
young
children
nutrit
ida
acknowledg
gensavi
pharmaceut
llc
support
studi
ellen
fraint
maureen
leffler
corinna
schultz
nemoursalfr
dupont
hospit
children
wilmington
delawar
unit
state
background
sickl
cell
diseas
scd
chronic
diseas
frequent
mark
multisystem
morbid
crisi
voc
common
caus
musculoskelet
pain
scd
howev
import
keep
broad
differenti
consid
etiolog
pain
object
describ
novel
present
juvenil
dermatomyos
jdm
patient
scd
case
illustr
challeng
identifi
jdm
context
multipl
comorbid
designmethod
case
report
result
year
old
femal
scd
eczema
avascular
necrosi
avn
knee
hip
shoulder
present
musculoskelet
msk
pain
limp
diffus
erythemat
macular
skin
lesion
lost
follow
year
due
deterior
social
circumst
diagnos
treat
voc
acut
chest
syndrom
voc
eczema
resolv
continu
sever
diffus
msk
pain
persist
violac
discolor
eyelid
erythemat
maculopapular
lesion
overli
dorsum
mcp
pip
joint
extensor
surfac
elbow
knee
nailfold
capillari
appear
dilat
tortuou
develop
edema
proxim
distal
extrem
dysphagia
dysarthria
muscl
weak
brain
mri
reveal
infarct
laboratori
evalu
reveal
elev
cpk
mri
reveal
diffus
edema
hip
girdl
pelvic
muscl
diagnosi
jdm
confirm
detect
antibodi
cours
complic
gi
vascul
treatment
date
includ
methylprednisolon
prednison
methotrex
cyclophosphamid
conclus
first
known
case
report
concomit
jdm
scd
pediatr
patient
proven
diagnost
therapeut
challeng
jdm
symptom
may
present
prior
earli
describ
hospit
lack
routin
follow
prevent
earlier
identif
symptom
initi
hospit
symptom
readili
mask
sever
eczema
avn
complic
treatment
like
yield
insult
bone
integr
case
remind
us
maintain
high
degre
suspicion
patient
scd
altern
diagnos
overlap
symptomatolog
audra
reiter
henri
rice
jennif
rothman
duke
univers
medic
center
durham
north
carolina
unit
state
background
children
congenit
hemolyt
anemia
cha
often
requir
splenectomi
control
complic
sever
anemia
hypersplen
splenic
sequestr
favor
short
term
outcom
follow
either
total
splenectomi
ts
partial
splenectomi
ps
report
howev
outcom
follow
splenectomi
remain
poorli
describ
object
purpos
pilot
studi
defin
outcom
children
cha
follow
ts
ps
singl
institut
designmethod
collect
data
children
cha
underw
ts
ps
duke
univers
use
research
electron
data
captur
redcap
databas
children
includ
data
year
follow
surgeri
hematolog
outcom
hemoglobin
reticulocyt
bilirubin
clinic
outcom
well
advers
event
ae
infect
stroke
acut
chest
syndrom
ac
summar
result
children
includ
hereditari
spherocytosi
hs
sickl
cell
diseas
scd
type
cha
mean
age
splenectomi
year
rang
mean
year
rang
least
year
ts
perform
children
ps
children
children
hs
increas
hemoglobin
baselin
decreas
reticulocyt
percentag
bilirubin
remain
stabl
year
hematolog
outcom
remain
stabl
scd
year
common
ae
ac
scd
episod
one
patient
scd
recurr
salmonella
osteomyel
seriou
bacteri
infect
episod
sepsi
identifi
patient
ps
requir
second
surgeri
ts
children
receiv
prophylact
antibiot
continu
antibiot
year
conclus
conclus
clinic
hematolog
outcom
children
hs
improv
ts
ps
children
scd
clinic
outcom
improv
hematolog
laboratori
valu
unchang
advers
event
surgeri
infrequ
children
scd
pilot
find
suggest
multicent
studi
may
better
defin
import
outcom
follow
differ
type
splenectomi
children
cha
nicol
kucin
alexand
aledo
katherin
bergstrom
christoph
cunniff
weill
cornel
medicin
new
york
new
york
unit
state
background
cluster
chromosom
includ
five
gene
essenti
product
normal
hemoglobin
hbe
hbd
hbb
epsilon
gamma
delta
beta
thalassemia
result
delet
gene
cluster
usual
associ
prenat
neonat
anemia
improv
time
rare
fewer
case
report
fewer
delet
describ
object
describ
clinic
cours
medic
manag
two
unrel
infant
uniqu
delet
designmethod
case
seri
affect
newborn
one
diagnos
prenat
second
diagnos
postnat
result
babi
e
diagnos
prenat
chromosom
microarray
perform
fetal
ascit
approxim
mb
delet
includ
gene
interv
support
three
red
blood
cell
transfus
born
week
gestat
birth
hemoglobin
mcv
fl
reticulocyt
count
reach
physiolog
nadir
week
gestat
age
hemoglobin
gdl
requir
transfus
test
parent
reveal
de
novo
mutationbabi
j
born
week
gestat
hemoglobin
mcv
reticulocyt
count
requir
four
transfus
red
blood
cell
alpha
beta
thalassemia
rule
bone
marrow
examin
unremark
polymeras
chain
reaction
multiplex
probe
amplif
identifi
contigu
heterozyg
delet
involv
beta
globin
gene
cluster
analysi
snp
microarray
confirm
kb
interstiti
delet
cbc
age
month
show
hemoglobin
gdl
rbc
count
mcv
chromosom
analysi
parent
avail
father
cbc
reveal
microcytosi
elev
red
blood
cell
count
make
like
inherit
conclus
rare
caus
sever
fetal
neonat
anemia
lead
prematur
birth
fetal
demis
pre
postnat
detect
good
outcom
manag
appropri
nichola
whippl
vijay
joshi
ronak
naik
guolian
kang
joseph
moen
sarala
devi
govindaswami
jane
hankin
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
patient
sickl
cell
diseas
scd
increas
risk
cardiopulmonari
diseas
subsequ
higher
morbid
prematur
mortal
decreas
myocardi
deform
earli
sign
myocardi
systol
dysfunct
may
result
preced
restrict
cardiomyopathi
studi
investig
right
left
ventricular
global
longitudin
strain
rvgl
lvgl
among
children
scd
hemolyt
anemia
none
investig
role
therapi
hydroxyurea
chronic
transfus
elev
tricuspid
regurgit
veloc
trv
strain
scd
object
compar
rvgl
lvgl
pediatr
scd
pediatr
hemolyt
anemia
investig
associ
age
therapi
trv
global
longitudin
strain
scd
designmethod
prospect
measur
rvgl
lvgl
trv
echocardiographi
children
n
hemolyt
anemia
hereditari
spherocytosi
pyruv
kinas
defici
n
age
perform
central
read
one
singl
cardiologist
trv
categor
normal
ms
elev
ms
result
univari
analysi
increas
worsen
rvgl
lvgl
associ
age
therapi
children
scd
p
control
age
multivari
model
howev
treatment
longer
associ
strain
year
increas
age
increas
rvgl
p
elev
trv
associ
increas
lvgl
scd
rho
p
hemolyt
anemia
age
associ
increas
lvgl
rho
p
lvgl
rvgl
significantli
decreas
scd
compar
hemolyt
anemia
vs
p
patient
scd
elev
trv
compar
hemolyt
anemia
vs
p
conclus
global
longitudin
cardiac
strain
declin
age
children
hemolyt
anemia
may
repres
earli
marker
patholog
cardiac
chang
elev
trv
common
scd
hemolyt
anemia
may
modul
lvgl
global
longitudin
strain
studi
longitudin
prospect
cohort
patient
hemolyt
anemia
valu
marker
earli
cardiac
damag
jame
bartram
christian
elli
stephen
kirchner
isabel
elssner
daniel
wechsler
michael
armstrong
duke
univers
durham
north
carolina
unit
state
background
neuroblastoma
common
extracrani
malign
childhood
myc
famili
protein
regul
cell
growth
prolifer
implic
etiolog
mani
cancer
mycn
amplifi
neuroblastoma
associ
poor
prognosi
investig
specif
tumor
pathway
understand
neuroblastoma
pathogenesi
lead
futur
therapeut
option
member
mad
famili
inhibit
activ
altern
splice
variant
differ
first
exon
exon
whose
function
determin
object
test
hypothesi
differenti
impact
neuroblastoma
cell
prolifer
designmethod
express
shep
neuroblastoma
cell
shep
cell
stabli
transfect
express
high
level
mycn
shepmycn
also
util
nativ
neuroblastoma
cell
line
induc
express
cell
prolifer
surviv
quantifi
use
brdu
mtt
assay
respect
impact
express
measur
immunoblot
analysi
result
overexpress
inhibit
neuroblastoma
cell
viabil
convers
overexpress
neuroblastoma
cell
line
lead
increas
viabil
suggest
role
examin
reveal
chang
viabil
partial
due
chang
cell
prolifer
decreas
prolifer
augment
addit
observ
level
decreas
respons
express
increas
express
compar
express
result
enhanc
chemoresist
neuroblastoma
cell
doxorubicin
etoposid
conclus
overexpress
neuroblastoma
cell
line
lead
inhibit
cell
prolifer
appear
promot
cell
growth
express
enhanc
chemosensit
neuroblastoma
cell
opposit
effect
effect
may
partial
due
alter
express
better
understand
interact
among
rel
express
level
protein
affect
neuroblastoma
physiolog
may
aid
develop
effect
target
therapi
improv
outcom
pediatr
neuroblastoma
patient
angela
girvin
jame
cooper
ken
smith
children
hospit
pittsburgh
pittsburgh
pennsylvania
unit
state
background
current
standard
nation
guidelin
regard
optim
time
screen
iron
defici
anemia
ida
infant
children
unit
state
prevent
servic
task
forc
cdc
american
academi
pediatr
recommend
screen
differ
age
group
popul
base
ida
risk
potenti
subsequ
poor
outcom
object
aim
studi
compar
screen
ida
vari
age
within
high
risk
group
gener
popul
designmethod
use
markov
decis
analysi
model
estim
screen
ida
within
group
entir
popul
ident
hypothet
cohort
evalu
month
track
anemia
sever
time
possibl
neurodevelopment
outcom
undiagnos
sever
anemia
clinic
outcom
util
cost
obtain
via
literatur
review
vari
paramet
estim
sensit
analys
result
base
case
screen
month
old
gain
life
year
qali
cost
screen
gain
screen
month
old
cost
gain
screen
month
old
cost
gain
strategi
elimin
due
domin
use
accept
standard
dollarsqali
gain
cost
effect
screen
month
old
cost
effect
strategi
vari
uncertain
variabl
model
plausibl
rang
specif
probabl
neurodevelopment
outcom
probabl
anemia
popul
probabl
prefer
strategi
remain
screen
month
old
probabilist
sensit
analysi
vari
paramet
simultan
plausibl
distribut
result
screen
month
old
favor
threshold
conclus
screen
children
month
age
ida
econom
reason
strategi
light
reexamin
variou
current
suggest
guidelin
may
warrant
valeria
smith
sarah
whittl
sarah
woodfield
peter
zage
baylor
colleg
medicin
houston
texa
unit
state
background
neuroblastoma
remain
common
solid
extracrani
solid
tumor
children
approxim
new
diagnos
made
year
despit
advanc
therapi
includ
multimod
approach
high
risk
neuroblastoma
remain
difficult
treat
current
long
term
surviv
rate
high
risk
neuroblastoma
approxim
forti
percent
biolog
target
novel
therapeut
potenti
treatment
neuroblastoma
could
improv
cure
rate
aberr
growth
factor
receptor
gfr
express
receptor
kinas
signal
associ
pathogenesi
mani
malign
kinas
therefor
serv
target
number
novel
therapi
fibroblast
growth
factor
fgf
activ
cognat
receptor
stimul
cell
prolifer
migrat
fgfr
inhibit
effect
varieti
preclin
cancer
model
object
test
novel
inhibitor
ponatinib
efficaci
preclin
model
neuroblastoma
designmethod
treat
panel
establish
neuroblastoma
tumor
cell
line
increas
concentr
ponatinib
viabil
determin
use
mtt
assay
addit
neuroblastoma
cell
migrat
wound
treatment
ponatinib
monitor
hour
time
interv
cell
treat
ponatinib
western
blot
use
antibodi
downstream
target
perform
result
neuroblastoma
cell
line
test
sensit
ponatinib
valu
nanomolar
micromolar
rang
migrat
neuroblastoma
cell
inhibit
treatment
ponatinib
significantli
decreas
treatment
ponatinib
conclus
treatment
neuroblastoma
tumor
cell
ponatinib
caus
cell
death
reduc
cell
migrat
inhibit
fgfr
famili
member
repres
novel
therapeut
strategi
neuroblastoma
preclin
studi
ponatinib
addit
fgfr
inhibitor
warrant
shveta
gupta
jacquelyn
baskin
theodosia
kalfa
mari
rising
kejian
zhang
children
hospit
lo
angel
lo
angel
california
unit
state
background
inherit
stomatocytos
group
hemolyt
anemia
disord
character
alter
red
blood
cell
rbc
membran
permeabl
monoval
cation
cryohydrocytosi
one
subtyp
cation
leak
mild
significantli
increas
temperatur
approach
singl
amino
acid
substitut
transport
domain
band
caus
mutat
demonstr
caus
phenotyp
object
describ
novel
mutat
associ
monoval
cation
leak
particularli
mark
patient
congenit
hemolyt
anemia
designmethod
sequenc
analysi
gene
associ
hemolyt
anemia
perform
old
femal
present
neonat
hemolyt
anemia
jaundic
famili
histori
posit
hemolysi
rbc
phenotyp
analysi
includ
ektacytometri
red
cell
cytogram
measur
intracellular
k
na
content
compar
control
sampl
result
patient
hemoglobin
normal
gdl
elev
reticulocyt
count
indic
persist
hemolysi
elev
mean
corpuscular
hemoglobin
concentr
gdl
red
cell
cytogram
show
major
cell
hyper
chromic
zone
consist
increas
cell
densiti
ektacytometri
patient
rbc
produc
curv
indic
impress
cellular
dehydr
low
omin
hypoton
osmol
cell
hemolyz
osmot
fragil
assay
mosmkg
normal
low
el
elong
index
max
normal
indic
decreas
deform
low
ohyp
mosmkg
normal
indic
increas
intracellular
viscos
rbc
intracellular
k
cation
content
reduc
mmolkg
hb
control
sequenc
analysi
patient
sampl
reveal
novel
heterozyg
variant
gene
g
caus
singl
amino
acid
substitut
transport
domain
band
conclus
report
novel
genet
defect
associ
signific
rbc
cation
leak
cold
temperatur
patient
congenit
hemolyt
anemia
substitut
possibl
novel
cryohydrocytosi
mutat
convert
band
anion
exchang
unregul
cation
channel
natasha
alexand
kati
sullivan
meredith
irwin
hospit
sick
children
toronto
ontario
canada
background
comparison
malign
form
peripher
neuroblast
tumor
pnt
neuroblastoma
nb
ganglioneuroma
gn
demonstr
favour
histolog
clinic
featur
surgeri
often
perform
due
symptom
andor
theoret
concern
gn
may
transform
nb
howev
mani
public
identifi
signific
morbid
object
studi
compar
natur
histori
biolog
clinic
featur
gn
manag
surgeri
observ
inform
recommend
potenti
surveil
approach
gn
designmethod
retrospect
studi
includ
patient
n
histolog
diagnosi
gn
sick
kid
clinic
patholog
featur
tumor
dimens
manag
record
result
median
age
diagnosi
yr
yr
median
maxim
tumor
diamet
cm
cm
volum
ml
ml
patient
line
surgeri
without
biopsi
observ
later
underw
resect
observ
patient
like
older
median
yr
vs
yr
diagnos
recent
median
volum
increas
diagnosi
surgeri
postop
complic
imag
defin
risk
factor
idrf
associ
increas
complic
p
residu
diseas
p
median
growth
cmyear
trend
increas
growth
rate
patholog
growth
recurr
occur
surgic
patient
patient
surveil
median
imag
alter
clinic
manag
median
year
year
patient
aliv
complet
respons
partial
respons
stabl
diseas
progress
diseas
asymptomat
increas
incid
symptom
surgic
patient
n
n
compar
observ
patient
n
patholog
classif
chang
resect
five
case
gn
reclassifi
nb
conclus
gn
gni
slow
growth
rate
resect
may
associ
signific
morbid
watch
wait
approach
may
consid
patient
gn
carolin
nathali
fournier
josett
champagn
josef
prchal
yve
pastor
chu
faculti
medicin
montreal
univers
montreal
quebec
canada
background
polycythemia
extrem
rare
disord
childhood
past
decad
sever
gene
mutat
discov
caus
congenit
polycythemia
cp
includ
gene
mutat
epor
object
describ
clinic
characterist
patient
epor
mutat
designmethod
singl
case
report
yr
epor
sequenc
perform
sanger
sequenc
previous
publish
genom
dna
peripher
blood
mononuclear
cell
nail
proband
confirm
germlin
mutat
result
french
canadian
male
incident
found
polycythem
age
yr
old
hb
hct
abnorm
evid
oxygen
desatur
normal
calcul
bone
marrow
reveal
morpholog
cytogenet
abnorm
epo
level
undetect
vitro
test
reveal
increas
erythroid
sensitivi
rare
erythroid
growth
search
exon
somat
mutat
neg
germlin
heterozyg
epor
mutat
detect
although
mutat
previous
report
among
caus
dominantli
inherit
primari
famili
congenit
polycythemia
pfcp
mutat
found
famili
member
given
develop
moder
sever
headach
phlebotomi
eventu
initi
age
four
maintain
hematocrit
yr
develop
mild
arteri
hypertens
hyperuricemia
never
thrombot
complic
aspirin
prophylaxi
therapi
switch
enalapril
age
yr
old
age
spite
hematocrit
level
agent
zolimitriptan
serotonin
receptor
agonist
initi
due
worsen
headach
phlebotomi
ceas
week
given
stabl
hematocrit
sinc
introduct
medic
bone
marrow
remain
normal
without
evid
marrow
fibrosi
conclus
although
usual
benign
inherit
epor
mutat
may
caus
vascular
complic
hypertens
given
serotonin
known
role
erythropoiesi
propos
zolmitriptan
alon
combin
angiotensin
antagonist
may
benefici
effect
evalu
studi
andrea
gross
srivandana
akshintala
eva
dombi
andrea
baldwin
somto
ukwuani
ann
goodwin
david
liewehr
seth
steinberg
brigitt
widemann
nation
institut
health
bethesda
maryland
unit
state
background
neurofibromatosi
type
autosom
domin
disord
character
mutat
gene
approxim
patient
develop
plexiform
neurofibroma
pn
though
histolog
benign
pn
associ
signific
morbid
ongo
clinic
trial
evalu
effect
target
therapi
pn
volum
howev
previou
studi
assess
associ
increas
pn
volum
develop
morbid
object
util
data
obtain
nation
institut
health
nih
natur
histori
studi
assess
hypothesi
increas
pn
volum
associ
increas
morbid
designmethod
retrospect
chart
review
patient
enrol
natur
histori
studi
year
histor
data
avail
patient
morbid
assess
two
time
baselin
pn
mri
volumetr
analysi
time
mri
maximum
pn
volum
morbid
evalu
includ
presenc
pain
motor
dysfunct
airway
compromis
bowel
bladder
dysfunct
vision
loss
pn
relat
surgeri
result
patient
distinct
pn
includ
median
pn
volum
ml
baselin
ml
maximum
assess
baselin
pn
least
one
associ
morbid
increas
number
pn
requir
schedul
pain
medic
compar
baselin
maximum
volum
base
locat
pn
potenti
motor
relat
morbid
pn
motor
impair
baselin
maximum
volum
larger
volum
compar
motor
morbid
ml
larger
baselin
ci
ml
larger
maximum
ci
conclus
mani
patient
signific
pn
relat
morbid
even
baselin
assess
studi
reinforc
need
evalu
see
chang
pn
associ
morbid
increas
motor
morbid
increas
pn
volum
well
trend
toward
increas
need
pain
medic
increas
pn
volum
futur
analys
larger
patient
popul
ongo
may
help
elucid
associ
neelam
giri
helen
reed
pamela
stratton
sharon
savag
blanch
alter
nation
cancer
institut
rockvil
maryland
unit
state
background
pregnanc
femal
fanconi
anemia
fa
dyskeratosi
congenita
dc
anemia
dba
syndrom
sd
associ
increas
complic
studi
pregnanc
outcom
unaffect
mother
patient
inherit
bone
marrow
failur
syndrom
ibmf
object
determin
outcom
pregnanc
offspr
unaffect
mother
patient
ibmf
designmethod
evalu
pregnanc
data
questionnair
complet
unaffect
ibmf
mother
fa
dc
dba
sd
healthi
femal
rel
unaffect
children
n
serv
control
pregnanc
outcom
compar
across
group
complic
occur
week
gestat
evalu
compar
within
group
mother
affect
unaffect
offspr
result
median
number
pregnanc
similar
mother
fa
dc
dba
sd
control
respect
age
first
last
pregnanc
mother
miscarriag
abort
stillbirth
similar
across
group
fa
pregnanc
affect
fetus
like
iugr
vs
p
low
birthweight
vs
kg
p
unaffect
dc
affect
pregnanc
commonli
fetal
distress
vs
p
iugr
vs
p
low
birthweight
v
p
tend
born
preterm
week
vs
p
dba
affect
fetus
like
fetal
distress
vs
p
due
sever
anemia
low
birthweight
vs
p
preterm
birth
vs
p
iugr
vs
p
sd
affect
pregnanc
commonli
prolong
labor
fetal
distress
vs
p
low
birthweight
vs
p
unaffect
complic
occur
often
affect
unaffect
pregnanc
within
ibmf
p
conclus
pregnanc
offspr
associ
increas
complic
iugr
low
birthweight
common
affect
children
advers
outcom
vari
syndrom
like
contribut
higher
rate
may
reflect
phenotyp
ibmf
brian
lee
karen
fernandez
jane
maksimov
sarah
martin
julian
lin
reuben
antoni
univers
illinoi
colleg
medicin
peoria
illinoi
unit
state
background
neurocutan
syndrom
ns
repres
group
inherit
cancer
predisposit
syndrom
character
tumor
nervou
system
eye
skin
viscera
part
bodi
includ
neurofibromatosi
tuber
sclerosi
complex
ts
ataxia
telangiectasia
syndrom
diseas
object
retrospect
review
patient
ts
follow
cn
tumor
institut
character
cn
tumor
seen
group
data
collect
regard
age
ns
diagnos
diagnosi
ns
made
age
ns
relat
tumor
diagnos
clinic
present
tumor
radiolog
featur
tumor
patholog
tumor
treatment
outcom
designmethod
case
seri
result
patient
n
eight
patient
diagnos
relat
tumor
age
year
patient
optic
tract
glioma
two
patient
hemispher
tumor
corpu
callosum
pilocyt
astrocytoma
pleomorph
xanthoastrocytoma
pxa
patient
brainstem
tumor
midbrain
pon
medulla
patient
tumor
cerebellum
patient
cervic
spinal
cord
lesion
patient
tumor
resect
found
pilocyt
astrocytoma
pxa
plexiform
neurofibroma
patient
recurr
tumor
resect
pxa
pilocyt
astrocytoma
corpu
callosum
patient
receiv
treatment
chemotherapi
vincristin
carboplatin
vinblastin
gleevec
patient
succumb
tumor
ts
patient
n
patient
subependym
giant
cell
astrocytoma
sega
unilater
later
ventricl
foramen
munro
bilater
foramina
munro
thalamu
patient
diagnos
prenat
diagnos
month
three
patient
diagnos
year
age
patient
new
onset
headach
indic
sega
progress
sega
resect
without
recurr
tumor
found
grade
astrocytoma
patient
sega
manag
mtor
inhibit
conclus
patient
cohort
diagnos
malign
cn
tumor
pxa
seen
one
patient
atyp
radiolog
featur
progress
resect
patient
ts
manag
mtor
inhibit
shown
progress
sega
payal
khincha
sharon
savag
blanch
alter
alison
bertuch
neelam
giri
christin
kuo
steven
artandi
farid
boulad
suneet
agarw
sioban
keel
akiko
shimamura
daniel
townsley
tregoni
simoneau
charl
mccaslin
de
cox
sara
chaffe
nation
institut
health
bethesda
maryland
unit
state
background
dyskeratosi
congenita
dc
inherit
bone
marrow
failur
bmf
syndrom
caus
germlin
mutat
telomer
biolog
gene
triad
reticular
skin
pigment
dysplast
nail
oral
leukoplakia
diagnost
mani
patient
may
present
manifest
risk
medic
problem
includ
pulmonari
fibrosi
pf
liver
diseas
pulmonari
malform
pavm
report
limit
number
dc
patient
often
relat
hepatopulmonari
syndrom
hp
pavm
lead
clinic
signific
shunt
result
decreas
oxygen
respiratori
insuffici
object
character
pavm
phenotyp
dc
designmethod
case
seri
evalu
patient
age
race
gender
diagnos
dc
pavm
concurr
separ
time
data
obtain
retrospect
review
medic
record
primari
institut
maintain
nci
result
report
thirteen
unrel
patient
dc
pavm
nine
evid
liver
diseas
portal
hypertens
pavm
diagnosi
median
age
dc
diagnosi
year
rang
year
rang
pavm
genet
caus
dc
vari
one
patient
five
two
tert
one
one
parn
three
unknown
gene
ten
patient
underw
hematopoiet
cell
transplant
hct
bmf
myelodysplasia
two
patient
pavm
diagnos
prior
dc
diagnosi
five
prior
hct
diffus
capac
carbon
monoxid
dlco
decreas
proport
pulmonari
function
test
pft
includ
patient
pf
report
rang
predict
bubbl
echocardiographi
agit
salin
indic
pavm
one
patient
major
pavm
dc
multipl
microscop
conclus
case
seri
establish
pavm
import
pulmonari
phenotyp
dc
occur
independ
hp
clinician
vigil
respiratori
symptom
abnorm
pft
particularli
decreas
dlco
explain
pulmonari
patholog
earli
detect
pavm
key
time
symptomat
manag
howev
research
clinic
trial
need
determin
cur
treatment
patient
vasudev
bhat
maya
prasad
girish
chinnaswami
tata
memori
hospit
mumbai
maharashtra
india
background
use
treatment
relapsedrefractori
nb
past
respons
rate
around
use
regimen
often
conjunct
chemotherapi
myeloabl
therapydata
lmic
lackingw
describ
experi
therapi
treatment
nb
object
evalu
role
mibg
therapi
relapsedrefractori
neuroblastoma
designmethod
retrospect
audit
patient
nb
tata
memori
hospit
receiv
mibg
therapi
frontlin
relapsedrefractori
set
mibg
therapi
administ
radiat
medicin
centr
neighbor
institut
apart
routin
evalu
patient
underw
scan
urinari
vanillyl
mandel
acid
vma
level
prior
treatment
patient
underw
computeris
tomogram
ctscan
andor
fluorodeoxyglucos
positron
emissiontomographi
scan
dose
mibg
bodi
weight
cap
isol
treatment
caregiv
screen
exposur
agent
reassess
done
clinic
evalu
mibg
scan
urinari
vma
level
result
data
receiv
total
mibg
therapi
median
median
age
male
femal
ratio
intent
palli
total
high
risk
nb
receiv
multipl
cours
treatment
includ
autolog
stem
cell
transplant
respons
rate
patient
aliv
last
follow
median
time
progress
ten
patient
receiv
total
mibg
therapi
part
frontlin
therapi
inoper
refractori
residu
respons
rate
aliv
last
followup
common
toxic
document
patient
often
delay
cours
conclus
limit
retrospect
studi
feasibl
relapsedrefractorya
well
frontlin
nb
lmic
accept
toxic
mibg
therapi
offer
reason
salvag
strategi
lmic
set
aggress
salvag
therapi
often
possibl
hope
incorpor
mibg
therapi
frontlin
treatment
regimen
centr
near
futur
help
improv
outcom
high
risk
nb
adrianna
vlacho
philip
rosenberg
jessica
kang
eva
atsidafto
blanch
alter
jeffrey
lipton
feinstein
institut
medic
research
manhasset
new
york
unit
state
background
diamond
blackfan
anemia
dba
inherit
bone
marrow
failur
syndrom
character
red
cell
aplasia
congenit
anomali
dba
known
major
case
caus
haploinsuffici
one
small
larg
ribosom
protein
rp
subunit
addit
cancer
predisposit
dba
inde
somat
germlin
rp
mutat
associ
number
malign
object
quantit
incid
neoplasia
patient
dba
designmethod
dba
registri
north
america
dbar
largest
establish
patient
cohort
prospect
sinc
interrog
ascertain
incid
neoplasia
dba
rel
risk
cancer
dba
exclud
myelodysplast
syndrom
md
compar
gener
popul
approach
use
estim
hazard
function
cumul
incid
curv
dba
done
previous
result
dbar
report
first
quantit
assess
incid
neoplasia
dba
patient
median
age
year
analysi
august
seventeen
patient
receiv
bmt
cancer
patient
md
significantli
elev
oe
observ
expect
ratio
respect
colon
carcinoma
n
osteosarcoma
n
acut
myeloid
leukemia
aml
n
md
n
decemb
n
median
patient
age
year
addit
patient
receiv
bmt
cancer
addit
patient
develop
md
total
cancer
report
patient
includ
patient
gastrointestin
carcinoma
sarcoma
aml
patient
md
statist
analysi
avail
time
present
includ
analysi
patient
develop
colorect
cancer
two
os
one
respect
follow
hematopoiet
stem
cell
transplant
conclus
extend
analys
includ
addit
patient
inform
assess
cancer
type
risk
uniqu
dba
meghna
motiani
huap
wang
kay
save
karen
fernandez
univers
illinoi
colleg
medicin
peoria
peoria
illinoi
unit
state
background
hyponatremia
serum
na
frequent
electrolyt
abnorm
children
previou
research
report
hyponatremia
affect
hospit
pediatr
patient
studi
done
evalu
incid
hyponatremia
pediatr
oncolog
patient
oncolog
etiolog
hyponatremia
depend
mani
factor
ill
type
cancer
type
chemotherapi
type
hydrat
chemotherapi
object
determin
incid
hyponatremia
pediatr
oncolog
patient
compar
admit
chemotherapi
admit
acut
ill
designmethod
retrospect
cohort
studi
involv
chart
review
pediatr
oncolog
admiss
children
hospit
illinoi
month
period
result
studi
period
elig
patient
admit
receiv
chemotherapi
due
acut
ill
signific
differ
two
group
regard
sex
p
age
p
patient
receiv
fluid
normal
salin
serum
na
found
patient
admit
chemotherapi
admit
acut
ill
p
even
account
differ
fluid
type
hyponatremia
time
like
occur
patient
admit
acut
ill
contrast
admit
schedul
chemotherapi
p
patient
hyponatremia
present
time
admiss
first
hour
none
patient
symptomat
hyponatremia
differ
hospit
length
stay
p
two
group
conclus
among
oncolog
patient
present
acut
ill
like
develop
hyponatremia
admiss
hyponatremia
subclin
prolong
length
stay
plan
compar
incid
hyponatremia
patient
receiv
differ
regimen
chemotherapi
patient
leukemia
versu
solid
tumor
nihal
bakeer
charl
nakar
francisca
fasip
william
gun
robert
lorsbach
keijan
zhang
theodosia
kalfa
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
congenit
dyserythropoiet
anemia
cda
heterogen
group
rare
genet
disord
character
ineffect
erythropoiesi
characterist
abnorm
bone
marrow
erythroid
precursor
lead
anemia
suboptim
reticulocytosi
splenomegali
iron
overload
frequent
disproportion
histori
transfus
object
describ
two
novel
variant
associ
sever
cda
phenotyp
designmethod
case
report
gene
sequenc
famili
inform
consent
result
caucasian
male
refer
clinic
evalu
hemolyt
anemia
suboptim
reticulocytosi
skelet
deform
involv
finger
toe
child
present
soon
birth
sever
neonat
jaundic
hepatosplenomegali
blood
smear
red
cell
show
mark
anisopoikilocytosi
dacryocyt
red
cell
fragment
macrocyt
bone
marrow
aspir
erythroid
cell
show
promin
dyserythropoiesi
includ
megaloblastoid
matur
binucl
nuclear
contour
irregular
chromatin
bridg
occasion
multinucl
erythroid
present
sequenc
analysi
gene
associ
hemolyt
dyserythropoiet
anemia
perform
dna
isol
peripher
blood
patient
found
compound
heterozyg
two
mutat
confirm
suspect
diagnosi
cda
first
mutat
previous
unreport
delet
result
frameshift
second
mutat
missens
variant
affect
highli
conserv
amino
acid
residu
use
mutat
predict
softwar
amino
acid
substitut
predict
deleteri
probabl
damag
variant
known
found
exac
databas
low
maf
patient
current
manag
regular
blood
transfus
iron
chelat
effect
monitor
mri
liver
iron
famili
consid
option
tri
therapi
conclus
cda
consid
differenti
diagnosi
hemolyt
anemia
suboptim
reticulocytosi
sequenc
provid
definit
diagnosi
may
unveil
new
mutat
may
allow
consider
therapi
like
found
increas
hemoglobin
level
decreas
iron
overload
patient
cda
stephen
kirchner
jame
bartram
daniel
wechsler
michael
armstrong
duke
univers
durham
north
carolina
unit
state
background
myc
famili
regul
cell
growth
implic
etiolog
mani
cancer
includ
neuroblastoma
member
mad
famili
inhibit
activ
altern
splice
variant
differ
first
exon
exon
whose
function
determin
protein
appear
differenti
function
neuroblastoma
pathogenesi
inhibit
neuroblastoma
cell
prolifer
promot
mostli
homolog
includ
repress
domain
possess
distinct
exon
suggest
critic
role
exon
differenti
function
object
determin
role
subcellular
local
potenti
mechan
differenti
function
designmethod
creat
construct
exon
assess
cellular
local
protein
protein
express
cell
subcellular
local
exon
detect
immunofluoresc
assess
whether
protein
undergo
nuclearcytoplasm
transloc
cell
treat
leptomycin
b
lmb
block
nuclear
export
result
examin
subcellular
locat
reveal
resid
nucleu
found
primarili
cytoplasm
exon
also
display
cytoplasm
local
indic
presenc
exon
contribut
differenti
local
treatment
lmb
result
accumul
nucleu
suggest
cycl
nucleu
respons
appropri
signal
effect
appear
mediat
exon
also
accumul
nucleu
nuclear
export
inhibit
conclus
exhibit
distinct
subcellular
local
pattern
resid
nucleu
found
predominantli
cytoplasm
exon
direct
cytoplasm
local
final
nuclear
export
inhibit
lead
nuclear
accumul
suggest
protein
transloc
respons
appropri
signal
better
understand
impact
neuroblastoma
physiolog
exon
impart
differenti
function
may
aid
develop
effect
target
therapi
improv
outcom
children
neuroblastoma
suzann
forrest
alanna
church
susan
chi
katherin
janeway
children
cancer
blood
disord
center
boston
massachusett
unit
state
background
swisnf
subunit
mutat
identifi
mani
cancer
type
mutat
lead
specif
vulner
may
target
novel
therapi
recent
phase
clinic
trial
inhibitor
adult
advanc
cancer
tumor
respons
seen
patient
loss
subunit
detect
neg
immunohistochemistri
ihc
patient
neg
ihc
data
suggest
loss
function
also
result
suscept
inhibit
phase
studi
inhibitor
current
underway
children
relaps
refractori
neg
tumor
object
identifi
character
pediatr
malign
loss
ihc
inactiv
mutat
swisnf
complex
designmethod
conduct
search
patholog
databas
tumor
loss
year
period
tumor
pediatr
particip
clinic
sequenc
studi
subject
target
sequenc
tumor
mutat
swisnf
subunit
identifi
result
patholog
databas
patient
identifi
tumor
loss
ich
tumor
type
includ
atyp
teratoid
rhabdoid
tumor
n
rhabdoid
tumor
n
epithelioid
sarcoma
n
chordoma
n
one
choroid
plexu
carcinoma
neuroblastoma
papillari
carcinoma
glomu
tumor
synovi
sarcoma
tumor
sequenc
reveal
three
patient
inactiv
mutat
one
swisnf
complex
subunit
diagnos
includ
two
patient
glioblastoma
multiform
one
patient
malign
rhabdoid
tumor
kidney
missens
mutat
unknown
function
signific
least
one
three
gene
present
case
relev
ihc
test
evalu
function
consequ
variant
unknown
signific
vu
underway
conclus
loss
inactiv
swisnf
complex
mutat
identifi
varieti
pediatr
malign
previous
recogn
harbor
swisnf
inactiv
result
may
implic
design
futur
clinic
trial
inhibitor
pediatr
cancer
patient
paulo
maluf
univers
sao
paulo
sao
paulo
sao
paulo
brazil
background
clostridium
difficil
infect
gain
relev
last
decad
particularli
among
pediatr
cancer
patient
metronidazol
pattern
primari
choic
treatment
wherea
vancomycin
even
long
cours
elect
line
relaps
infect
case
multipl
recurr
refractori
infect
drug
choic
scars
proven
efficaci
pediatr
patient
fecal
microbiota
transplant
evolv
safe
success
tool
patient
fail
antimicrobi
therapi
minim
pediatr
data
avail
warrant
use
childhood
name
immunosuppress
treatment
object
end
point
errad
recurr
c
difficil
infect
end
point
demonstr
procedur
safeti
designmethod
year
old
boy
high
risk
neuroblastoma
develop
abdomin
pain
diarrhea
caus
c
difficil
chemotherapi
metronidazol
use
first
place
induc
symptom
relief
bout
ocur
featur
despit
administr
oral
vancomycin
vancomycin
taper
fecal
microbiota
transplant
consid
father
select
donnat
health
overview
includ
screen
std
viral
infect
parasit
infest
take
day
vancomycin
qid
boy
admmit
duoden
probe
place
stool
donnor
colect
stuff
homogen
salin
filter
twice
infus
final
solut
flush
salin
probe
remov
result
day
procedur
stool
test
neg
toxin
dna
agent
side
effect
report
neither
transplant
day
conclus
fecal
microbiota
transplant
expect
overcom
unrespons
c
difficil
infect
fidaxomicin
could
option
aprov
set
although
promis
also
children
fecal
transplant
need
extens
studi
abhishek
bavl
enriqu
ramo
jacquelyn
reuther
frank
lin
oliv
hampton
david
wheeler
andrew
jea
arnold
paulino
murali
chintagumpala
sharon
plon
angshumoy
roy
adekunl
adesina
donald
parson
baylor
colleg
medicin
houston
texa
unit
state
background
malign
epithelioid
glioneuron
tumor
megnt
rare
brain
tumor
exhibit
featur
glial
neuron
differenti
includ
current
classif
limit
case
seri
describ
highli
aggress
tumor
poor
surviv
shed
littl
light
megnt
biolog
improv
understand
genet
alter
underli
megnt
necessari
object
aim
studi
molecularli
character
megnt
provid
insight
biolog
tumor
identifi
potenti
target
treatment
designmethod
whole
exom
sequenc
we
transcriptom
sequenc
perform
tumor
sampl
three
patient
megnt
well
two
addit
sampl
one
patient
blood
avail
germlin
we
one
case
clinic
inform
obtain
retrospect
chart
review
result
three
patient
underw
subtot
patient
gross
total
patient
resect
follow
involv
field
radiat
therapi
patient
diseas
recurr
less
year
treatment
patient
stabl
diseas
six
month
therapi
target
clinic
test
reveal
patient
fusion
braf
mutat
we
identifi
addit
frameshift
mutat
analysi
patient
reveal
fusion
rare
found
pediatr
high
grade
glioma
patient
found
braf
mutat
we
reveal
fusion
previous
report
case
thyroid
cancer
cn
tumor
sampl
patient
reveal
mutat
seen
primari
tumor
conclus
potenti
target
somat
alter
target
mapk
pathway
identifi
three
case
megnt
mutat
indic
activ
mtor
signal
also
found
two
tumor
molecular
studi
larger
seri
megnt
need
confirm
primari
role
pathway
rare
tumor
clinic
trial
evalu
efficaci
agent
braf
mek
ntrk
mtor
inhibitor
target
genet
lesion
identifi
patient
indic
abigail
cruz
hima
bansal
sanjay
bansal
gail
tomlinson
steven
weitman
univers
texa
health
scienc
center
san
antonio
san
antonio
texa
unit
state
background
vorinostat
histon
deacetylas
hdac
inhibitor
interest
adult
pediatr
cancer
howev
concern
effect
hdac
inhibitor
compens
autophagi
hydroxychloroquin
autophagi
inhibitor
treatment
lead
accumul
autophagosom
acceler
tumor
cell
death
hypothes
combin
hdac
inhibitor
hydroxychloroquin
improv
respons
compar
hdac
inhibitor
alon
pediatr
cancer
cell
line
object
determin
improv
efficaci
vorinostat
combin
hydroxychloroquin
pediatr
solid
tumor
cell
line
designmethod
differ
pediatr
cancer
cell
line
treat
vari
concentr
vorinostat
hydroxychloroquin
cell
viabil
measur
curv
plot
determin
inhibitori
concentr
western
blot
analysi
perform
measur
express
prolifer
autophagi
marker
result
vorinostat
hydroxychloroquin
rang
respect
combin
treatment
result
dramat
decreas
cell
viabil
two
drug
cooper
manner
hydroxychloroquin
treatment
result
profound
convers
indic
autophagi
blockad
effect
greater
cell
treat
vorniostat
hydroxychloroquin
alon
final
exposur
combin
vorinostat
hydroxycholroquin
result
decreas
level
compar
treatment
signifi
reduc
cell
prolifer
taken
togeth
data
demonstr
autophagi
inhibit
hydroxychloroquin
presenc
vorinostat
autophagosom
accumul
cell
viabilityprolifer
reduc
conclus
result
show
clear
improv
respons
vorinostat
combin
hydroxychloroquin
compar
vorinostat
alon
also
observ
increas
autophagi
inhibit
well
decreas
cell
prolifer
combin
studi
furthermor
concentr
vorinostat
necessari
effect
well
within
achiev
clinic
rang
combin
drug
yet
explor
pediatr
potenti
enhanc
effect
establish
chemotherapi
agent
easili
access
drug
moham
elsaid
eric
armstrong
dana
baiu
paul
harari
jamey
weichert
mario
otto
univers
wisconsin
school
medicin
public
health
madison
wisconsin
unit
state
background
drug
radiosensit
tumor
cell
spare
normal
tissu
could
signific
impact
efficaci
cancer
radiotherapi
novel
alkyl
phosphocholin
analog
belong
famili
synthet
alkyl
phospholipid
compound
demonstr
radiosensit
capabl
show
uptak
wide
varieti
malign
tissu
therefor
hypothes
could
use
radiosensit
augment
radiat
respons
varieti
solid
tumor
object
examin
capabl
radiosensit
augment
radiat
respons
varieti
solid
tumor
designmethod
examin
radiosensit
effect
sever
pediatr
adult
solid
human
cell
line
vitro
vivo
select
uptak
cancer
cell
versu
normal
cell
evalu
flow
cytometri
use
fluoresc
deriv
vitro
radiosensit
cancer
cell
evalu
clonogen
surviv
assay
use
differ
concentr
without
extern
beam
radiat
xrt
tumor
growth
rate
radiosensit
follow
xrt
examin
vivo
athym
nude
mice
result
demonstr
significantli
higher
uptak
retent
cancer
line
test
neuroblastoma
rhabdomyosarcoma
rd
ewe
sarcoma
prostat
carcinoma
compar
uptak
normal
human
fibroblast
p
significantli
reduc
clonogen
surviv
dose
depend
manner
combin
xrt
p
treatment
human
tumor
xenograft
fraction
extern
beam
radiat
combin
reveal
signific
increas
tumor
growth
delay
compar
radiat
treatment
alon
p
observ
toxic
treatment
conclus
conclud
tumor
target
capac
augment
therapeut
respons
extern
beam
radiat
varieti
solid
tumor
given
import
radiotherapi
pediatr
cancer
treatment
strategi
data
warrant
test
goal
translat
find
futur
clinic
trial
warren
alperstein
j
william
harbour
joseph
panoff
fernando
univers
miami
miller
school
medicin
jackson
memori
hospit
bascom
palmer
sylvest
cancer
center
miami
florida
unit
state
background
retinoblastoma
common
ocular
tumor
pediatr
standard
care
current
includ
local
control
laser
therapi
surgic
approach
enucl
radiat
chemotherapi
potenti
treatment
option
despit
advanc
chemotherapi
administr
allow
pediatr
oncologist
use
intravitr
chemotherapi
attempt
avoid
system
chemotherapi
side
effect
recurr
case
continu
challeng
treat
tri
preserv
sight
avoid
enucl
use
plaqu
brachytherapi
yet
option
recurr
retinoblastoma
object
discuss
role
brachytherapi
relaps
retinoblastoma
patient
designmethod
case
report
result
month
old
male
diagnos
bilater
retinoblastoma
group
c
diseas
right
eye
group
left
eye
present
pediatrician
mild
strabismu
extens
treatment
histori
due
continu
diseas
recurr
follow
close
exam
anesthesia
eua
local
control
differ
laser
therapi
receiv
five
cycl
system
chemotherapi
vincristin
carboplatin
etoposid
follow
chemotherapi
includ
melphalan
carboplatin
topotecan
etoposid
combin
intravitr
chemotherapi
melphalan
includ
left
eye
enucl
due
continu
diseas
recurr
despit
measur
central
macular
tumor
remain
measur
x
depth
choroid
invas
without
seed
right
eye
decid
attempt
plaqu
brachytherapi
salvag
treatment
plaqu
use
eye
physic
notch
gold
ophthalm
plaqu
seed
diamet
contain
sourc
vari
activ
millicuri
millicuri
deliv
gy
depth
treatment
time
hour
toler
brachytherapi
well
signific
immedi
side
effect
continu
excel
respons
evid
activ
tumor
week
initi
plaqu
placement
conclus
excel
diseas
respons
seen
plaqu
brachytherapi
seen
case
use
plaqu
brachytherapi
consid
viabl
treatment
option
retinoblastoma
relaps
case
research
need
determin
maxim
incorpor
brachytherapi
within
standard
care
practic
retinoblastoma
neelum
jest
inna
lobeck
daniel
von
allmen
jame
geller
joseph
pressey
cincinnati
children
hospit
cincinnati
ohio
unit
state
background
patient
small
appendic
carcinoid
tumor
low
risk
recurr
current
nccn
guidelin
recommend
monitor
clinic
indic
practic
variat
provid
institut
regard
extent
durat
object
character
patient
appendic
carcinoid
tumor
designmethod
retrospect
chart
review
perform
institut
patient
patholog
diagnosi
appendic
carcinoid
variabl
analyz
includ
demograph
tumor
locat
size
extent
invas
surgic
intervent
postop
stage
surveil
tumor
recurr
cost
includ
financi
time
famili
anxieti
note
result
thirti
patient
incident
diagnos
carcinoid
tumor
appendix
undergo
appendectomi
clinic
indic
averag
age
year
rang
mean
tumor
size
rang
microscop
occur
appendic
tip
n
node
infiltr
found
though
three
patient
perineur
one
patient
lymphovascular
invas
six
tumor
appendic
perfor
five
tumor
transmur
invas
mesoappendix
nineteen
patient
refer
oncolog
postop
stage
surveil
examin
includ
ultrasonographi
n
mri
n
ct
n
scan
major
n
underw
serial
test
mean
oncolog
month
n
continu
surveil
two
patient
ongo
year
diagnosi
includ
referr
cancer
survivor
clinic
surveil
test
normal
patient
requir
intervent
least
two
patient
travel
hour
clinic
visit
one
patient
comment
stressor
relat
cancer
diagnosi
medic
cost
includ
clinic
visit
laboratori
monitor
imag
rang
per
patient
patient
without
oncolog
surgeri
oncolog
clinic
conclus
appendectomi
adequ
treatment
pediatr
appendic
carcinoid
despit
presenc
histolog
risk
factor
length
intens
vari
within
institut
prolong
surveil
base
find
recommend
minim
oncolog
prolong
surveil
lead
identif
recurr
rather
heighten
famili
inconveni
anxieti
cost
medic
care
michael
deel
katrina
slemmon
rex
bentley
corinn
linard
duke
univers
medic
center
durham
north
carolina
unit
state
background
alveolar
rhabdomyosarcoma
armss
aggress
pediatr
malign
origin
primit
mesenchym
tissu
associ
skelet
muscl
lineag
sarcomagenesi
driven
signatur
fusion
gene
use
genet
defin
model
arm
base
earli
express
human
skelet
muscl
precursor
laboratori
identifi
transcript
chang
silenc
hippo
pathway
recent
describ
tumor
suppressor
network
wide
dysregul
human
cancer
taz
transcript
motif
transcript
ordinarili
kept
check
upstream
hippo
kinas
implic
adult
epitheli
cancer
taz
known
regul
although
convey
mesenchym
phenotyp
role
sarcoma
report
object
investig
oncogen
role
taz
arm
tumorigenesi
designmethod
confirm
taz
upregul
arm
model
determin
use
nih
oncogenom
databas
taz
upregul
human
rm
tissu
sampl
examin
basal
taz
express
human
arm
cell
line
cultur
monolay
sphere
use
two
independ
taz
shrna
interrog
role
taz
support
transform
vitro
last
use
taz
shrna
system
murin
xenograft
interrog
role
taz
support
tumorigenesi
vivo
result
taz
express
human
arm
cell
line
enrich
arm
rhabdospher
suggest
increas
stem
shrna
suppress
taz
mrna
protein
level
caus
profound
growth
arrest
vivo
mous
xenograft
studi
render
strong
phenotyp
tumor
mice
treat
doxycyclin
exhibit
decreas
tumor
growth
prolong
surviv
median
surviv
day
sucros
group
vs
day
dox
group
p
conclus
transcript
taz
support
arm
cell
growth
vitro
vivo
suggest
silenc
hippo
tumor
suppressor
pathway
futur
studi
investig
mechan
occur
determin
taz
alter
transcript
output
physic
interact
current
therapeut
tractabl
hypothes
target
taz
may
attract
approach
treat
patient
arm
priya
mahajan
judith
margolin
ashwin
pimpalwar
ionela
iacoba
baylor
colleg
medicinetexa
children
cancer
hematolog
center
houston
texa
unit
state
background
lymphat
malform
vascular
anomali
typic
occur
head
neck
less
frequent
mesenteri
object
describ
clinic
characterist
treatment
outcom
children
mesenter
lymphat
malform
singl
institut
designmethod
retrospect
analysi
children
diagnos
mesenter
lymphat
malform
perform
result
median
age
diagnosi
patient
year
approxim
patient
male
common
present
symptom
abdomin
pain
less
commonli
patient
present
volvulu
n
small
bowel
obstruct
n
four
patient
febril
present
two
document
bacteri
infect
diagnosi
confirm
histopatholog
assess
immunostain
posit
marker
lymphat
endothelium
patient
underw
gross
total
resect
partial
bowel
resect
two
patient
complic
involv
fever
feed
intoler
andor
perfor
one
patient
underw
biopsi
alon
follow
observ
remain
asymptomat
stabl
growth
malform
proportion
size
imag
year
length
patient
rang
month
record
recurr
conclus
mesenter
lymphat
malform
pediatr
rare
patient
commonli
present
abdomin
pain
differenti
diagnosi
includ
abdomin
solid
tumor
surgic
resect
often
standard
care
institut
howev
altern
manag
strategi
includ
medic
therapi
sclerotherapi
warrant
investig
nayf
edre
mohammad
athar
joseph
pressey
ritesh
srivastava
univers
alabama
birmingham
uab
birmingham
alabama
unit
state
background
rhabdomyosarcoma
common
pediatr
sarcomahedgehog
pathway
effector
andor
major
embryon
rm
cell
aberr
hh
pathway
activ
confer
poor
prognosi
rhabdomyosarcomacanon
hh
signal
pathway
activ
modul
express
gli
transcript
factor
besid
canon
hh
pathway
gli
protein
also
activ
manner
via
phosphoryl
ra
mapkerkcrosstalk
hh
signal
observ
differ
tumor
entiti
mount
evid
show
canon
well
mechan
lead
hh
activ
object
use
alreadi
exist
cancer
therapi
ato
temsirolimu
hedgehog
pathway
novel
approach
synergist
apoptosi
induct
tumor
growth
reduct
alveolar
rm
designmethod
inhibit
hh
signal
combin
inhibit
signal
respect
signal
inhibitor
arsen
trioxid
ato
temsirolimu
establish
cancer
therapi
result
ato
temsirolimu
synergist
reduc
alveolar
rm
viabil
prolifer
also
dampen
prolifer
alveolar
rm
xenograft
tumor
therebi
block
growth
synergist
drug
interact
confirm
calcul
combin
index
ci
xenograft
model
combin
treatment
result
inhibit
tumor
growth
western
blot
result
show
total
akt
protein
express
inhibit
combin
treatment
cell
conclus
combin
hedgehog
inhibit
repres
promis
novel
approach
synergist
apoptosi
induct
tumor
growth
reduct
implic
new
treatment
strategi
alveolar
rm
kri
ann
schultz
ann
harri
karen
hamr
nichola
cost
dougla
stewart
dominik
schneider
loui
dehner
lindsay
frazier
ashley
hill
yoav
messing
children
hospit
clinic
minnesota
minneapoli
minnesota
unit
state
background
ovarian
sex
tumor
occur
children
adolesc
young
adult
includ
juvenil
granulosa
cell
tumor
jgct
cell
tumor
slct
gynandroblastoma
may
associ
germlin
mutat
object
investig
clinic
biolog
aspect
rare
tumor
designmethod
particip
avail
patholog
central
review
germlin
test
perform
comparison
made
among
test
result
group
use
pearson
fisher
exact
test
wilcoxon
test
result
individu
slct
jgct
gynandroblastoma
enrol
otst
registri
sinc
decemb
overal
median
age
diagnosi
year
interquartil
rang
percent
n
stage
percent
slct
gynandroblastoma
n
intermedi
poorli
differenti
percent
n
slct
heterolog
element
includ
sarcomat
n
n
retiform
pattern
nineteen
percent
n
patient
thyroid
nodul
n
thyroid
cancer
four
percent
n
patient
develop
metachron
ovarian
stromal
tumor
n
patient
pleuropulmonari
blastoma
addit
n
report
non
tumor
n
recur
n
die
progress
diseas
forti
percent
n
patient
test
germlin
mutat
patient
slct
test
patient
germlin
mutat
patient
gynandroblastoma
preliminari
analys
show
addit
slct
biallel
somat
mutat
compar
germlin
neg
patient
preval
thyroid
nodul
vs
p
thyroid
cancer
vs
p
significantli
higher
among
germlin
posit
patient
germlin
mutat
appear
impact
outcom
primari
tumor
risk
factor
tumor
impact
biallel
somat
mutat
investig
conclus
enrol
ongo
half
individu
slct
patient
gynandroblastoma
germlin
mutat
biallel
somat
mutat
also
found
slct
find
warrant
investig
germlin
somat
mutat
review
screen
guidelin
bhuvana
setti
joseph
stanek
moham
elgendi
leo
mascarenha
alexandra
miller
rochel
bagatel
lauren
nichol
david
lysecki
abha
gupta
nationwid
children
hospit
columbu
ohio
unit
state
background
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
children
overal
surviv
rang
base
risk
group
anecdot
report
describ
use
vincristin
irinotecan
temozolomid
vit
patient
relaps
rm
object
determin
respons
rate
rr
surviv
pf
patient
relaps
rm
treat
vit
designmethod
retrospect
review
patient
relaps
rm
treat
vit
tertiari
care
hospit
characterist
includ
age
diagnosi
histolog
subtyp
primari
tumor
locat
chemotherapi
local
control
time
relaps
number
relaps
time
recurr
surviv
time
number
prior
salvag
regimen
collect
respons
assess
treat
institut
result
median
age
patient
year
rang
year
diagnosi
male
alveolar
rm
metastat
diseas
diagnosi
chemotherapi
use
upfront
receiv
upfront
chemotherapi
vincristin
actinomycin
cyclophosphamid
median
time
relaps
month
rang
month
vit
use
line
therapi
patient
respect
patient
site
relaps
solitari
distant
relaps
remaind
local
relaps
dose
vincristin
irinotecan
intraven
oral
administ
daili
day
temozolomid
administ
oral
daili
x
day
local
control
includ
radiat
surgeri
patient
best
respons
vit
follow
cr
pr
sd
pd
overal
rr
pf
month
median
follow
month
patient
aliv
without
diseas
aliv
diseas
patient
die
progress
diseas
conclus
retrospect
studi
demonstr
vit
moder
activ
patient
relaps
rhabdomyosarcoma
studi
backbon
combin
newer
agent
warrant
tami
john
daniela
bota
univers
california
irvin
irvin
california
unit
state
background
impair
memori
attent
execut
function
affect
childhood
leukemia
survivor
associ
methotrex
exposur
system
cisplatin
use
treat
varieti
childhood
adult
cancer
yet
risk
extent
cognit
impair
due
chemotherapi
unknown
system
cisplatin
cn
penetr
cytotox
neuron
neuron
stem
cell
hippocamp
dendrit
survivor
cancer
may
risk
signific
memori
impair
relat
cisplatin
driven
neurotox
object
explor
effect
system
cisplatin
hippocamp
memori
function
juvenil
rat
model
designmethod
male
spragu
dawley
rat
obtain
wean
day
cisplatin
consecut
day
intraperiton
administ
infanc
day
adolesc
day
match
control
receiv
normal
salin
intraperiton
valid
memori
test
complet
adulthood
day
includ
novel
object
explor
contextu
object
discrimin
object
explor
record
second
discrimin
ratio
calcul
divid
differ
exploratori
time
object
total
exploratori
time
context
cu
fear
condit
perform
examin
hippocampu
amygdala
function
respect
percent
time
spent
freez
respons
context
stimulu
cu
stimulu
observ
comparison
made
use
unpair
result
novel
object
test
cisplatin
treat
adolesc
show
significantli
poor
retriev
familiar
object
compar
control
p
cisplatin
treat
infant
adolesc
howev
show
poor
discrimin
familiar
object
compar
control
infant
p
adolesc
p
final
cisplatin
treat
infant
show
near
signific
diminish
freez
respons
condit
context
stimulu
p
cisplatin
treat
infant
also
show
signific
diminish
respons
condit
cu
stimulu
p
conclus
memori
function
impair
rat
expos
system
cisplatin
infanc
adolesc
type
degre
hippocamp
dysfunct
differ
depend
age
time
cisplatin
exposur
exposur
infanc
affect
hippocampu
amygdala
function
signifi
global
effect
memori
function
age
pooja
hingorani
sumar
yarapureddi
saravana
kumar
omar
asad
jazmin
abril
paul
dickman
janin
faraj
aparna
sertil
univers
arizona
phoenix
arizona
unit
state
background
optim
treatment
strategi
patient
refractori
andor
metastat
osteosarcoma
os
yet
defin
continu
persist
challeng
high
degre
genet
aberr
tumor
heterogen
imped
identif
test
effect
therapeut
target
therefor
find
character
cellular
mechan
contribut
os
chemoresist
promis
strategi
design
therapi
chang
outlook
patient
diseas
object
endoplasm
reticulum
er
stress
pathway
known
promot
surviv
progress
cancer
cell
object
current
studi
examin
role
pathway
promot
chemoresist
os
designmethod
util
immunohistochemistri
western
blot
qpcr
immunofluoresc
bioinformat
tool
techniqu
examin
role
activ
transcript
downstream
effector
os
cell
patient
sampl
result
use
pathway
analysi
gene
express
dataset
human
os
primari
tumor
protein
process
er
found
significantli
enrich
os
tumor
compar
normal
tissu
confirm
activ
er
stress
pathway
perk
human
os
cell
line
found
three
pathway
differenti
activ
os
cell
line
activ
significantli
enhanc
chemoresist
cisplatin
irinotecan
combinatori
treatment
cisplatin
mtor
inhibitor
rapamycin
occur
via
inhibit
bax
activ
suppress
inhibit
notch
signal
find
highlight
novel
mechan
os
retrospect
analysi
primari
tumor
patient
os
show
tumor
express
high
level
er
stress
induc
transcript
factor
downstream
effector
bip
pdi
express
associ
poor
histolog
respons
poor
surviv
patient
conclus
find
emphas
previous
uncharacter
role
nexu
uniqu
versatil
signal
network
regul
pathway
crucial
pathogenesi
therapi
resist
os
henc
therapeut
target
pathway
hold
promis
innov
effect
treatment
strategi
os
ionela
iacoba
mari
carrol
shapiro
matteo
trucco
prakash
masand
thuy
phung
judith
margolin
sanjeev
vasudevan
john
goss
andra
heczey
texa
children
hospit
houston
texa
unit
state
background
hepat
infantil
hemangioma
hih
benign
vascular
tumor
natur
cours
prolifer
stabil
involut
angiosarcoma
rare
highli
fatal
soft
tissu
sarcoma
endotheli
cell
origin
review
literatur
case
pediatr
hepat
angiosarcoma
hepat
hemangioma
accept
guidelin
monitor
hepat
hemangioma
accept
standard
care
pediatr
treatment
angiosarcoma
object
describ
experi
hepat
hemangioma
associ
hepat
angiosarcoma
integr
result
publish
literatur
designmethod
patient
unrel
present
abdomin
distens
constip
histori
small
untreat
cutan
infantil
hemangioma
result
case
one
girl
admit
multipl
diffus
hepat
hemangioma
requir
liver
transplant
histolog
analysi
resect
liver
reveal
posit
hih
island
highli
prolif
cellular
atypia
malign
transform
one
year
transplant
surveil
imag
detect
pulmonari
nodul
two
nodul
resect
histolog
reveal
patholog
complet
six
cycl
ifosfamidedoxorubicin
remain
complet
remiss
sixteen
month
diagnosiscas
two
boy
admit
larg
hepat
mass
hypothyroid
multipl
pulmonari
nodul
underw
gross
total
resect
tumor
patholog
show
posit
hih
island
angiosarcoma
diseas
progress
rapidli
sorafenib
therapi
therapi
chang
ifosfamidedoxorubicin
initi
partial
respons
diseas
progress
subsequ
switch
bevacizumabgemcitabinedocetaxel
despit
good
qualiti
life
experienc
progress
diseas
newli
form
metastat
hepat
nodul
prove
posit
infantil
hemangioma
die
fourteen
month
diagnosi
due
massiv
intratumor
hemorrhag
conclus
hih
may
risk
factor
develop
angiosarcoma
young
age
recommend
hepat
posit
hemangioma
ad
potenti
cancer
predisposit
condit
patient
monitor
prospect
vascular
anomali
cancer
predisposit
clinic
incidencetru
risk
develop
angiosarcoma
ascertain
hope
earli
detect
atyp
progress
may
lead
medic
intervent
jade
wulff
jason
yustein
gargi
ghosal
ryan
shuck
lyazat
kurenbekova
baylor
colleg
medicin
houston
texa
unit
state
background
despit
advanc
diagnost
therapeut
approach
metastat
ewe
sarcoma
es
continu
extrem
poor
overal
surviv
mechan
drive
metastasi
remain
larg
unknown
necessit
examin
molecular
mechan
pathogenesi
novel
target
investig
therapi
integrin
famili
protein
particip
import
intracellular
signal
pathway
involv
regul
critic
tumor
cell
properti
differenti
prolifer
dissemin
apoptosi
hypothesi
upregul
downstream
signal
event
perform
import
role
metastasi
es
may
potenti
therapeut
target
object
investig
role
downstream
signal
pathway
drive
establish
metastasi
es
designmethod
perform
vivo
studi
design
gain
insight
metastat
transcriptom
proteom
signatur
es
establish
human
es
cell
orthotop
transplant
tibia
mice
week
primari
bone
tumor
well
distal
metastat
lesion
isol
process
complet
proteom
studi
use
protein
array
compar
protein
express
profil
primari
es
tumor
correspond
metastat
lesion
lung
secondari
bone
site
use
western
blot
analysi
valid
result
result
array
show
signific
alter
key
signal
molecul
includ
upregul
metastat
lung
secondari
bone
lesion
compar
primari
bone
lesion
fold
chang
p
valid
upregul
perform
protein
isol
previous
resect
primari
metastat
tumor
individu
assess
express
use
western
blot
analysi
confirm
consist
elev
express
metastat
site
compar
primari
tumor
es
cell
line
model
conclus
result
suggest
downstream
signal
event
may
play
key
role
abil
es
establish
metastat
foci
may
serv
potenti
therapeut
target
continu
investig
pathway
vitro
vivo
use
knockdown
overexpress
approach
assess
prolifer
apoptosi
invasionmigr
well
small
molecul
inhibitor
investig
pathway
potenti
therapeut
target
angela
shaw
keri
schadler
cindi
schwartz
eugeni
kleinerman
md
anderson
cancer
center
houston
texa
unit
state
background
anthracyclin
commonli
use
agent
pediatr
oncolog
howev
use
limit
due
potenti
sever
cardiac
toxic
attempt
mitig
cardiotox
includ
dose
limit
use
iron
chelat
dexrazoxan
recent
preclin
data
shown
low
moder
intens
exercis
attenu
cardiotox
anim
receiv
chronic
doxorubicin
treatment
littl
known
effect
exercis
doxorubicin
diffus
cardiac
tissu
object
determin
whether
exercis
precondit
prior
treatment
reduc
doxorubicin
uptak
heart
mice
designmethod
tc
ewe
sarcoma
cell
inject
subcutan
nude
mice
tumor
allow
grow
day
anim
alloc
exercis
exercis
group
anim
exercis
group
exercis
treadmil
minday
rate
consecut
day
follow
day
rest
period
exercis
repeat
second
week
hour
final
exercis
session
anim
receiv
bolu
dose
doxorubicin
via
tail
vein
inject
remain
anim
serv
tissu
control
organ
excis
minut
post
inject
organ
tissu
weigh
prior
homogen
tissu
sampl
evalu
doxorubicin
uptak
use
acid
isopropanol
extract
spectrophotometri
result
averag
heart
size
exercis
train
anim
larger
train
anim
adjust
cardiac
tissu
size
exercis
precondit
anim
significantli
less
doxorubicin
present
cardiac
tissu
compar
unexercis
control
vs
fluoresc
unit
p
fig
interestingli
may
cardiac
specif
effect
chang
doxorubicin
level
liver
soleu
muscl
exercis
mice
fig
conclus
found
exercis
precondit
decreas
doxorubicin
uptak
cardiac
tissu
current
evalu
cardiac
vasculatur
express
mdr
transport
may
impact
doxorubicin
uptak
identifi
mechan
exercis
precondit
reduc
doxorubicin
cardiac
tissu
mari
carrol
wale
gaber
cristian
coarfa
kimal
rajapaksh
ryan
shuck
lyazat
kurenbekova
tien
tang
jason
yustein
baylor
colleg
medicin
houston
texa
unit
state
background
osteosarcoma
os
ewe
sarcoma
ew
common
pediatr
bone
cancer
patient
os
ew
dismal
five
year
overal
surviv
rate
metastat
diseas
adequ
local
control
imper
patient
surviv
littl
done
elucid
mechan
bone
sarcoma
radioresist
ew
consid
radiosensit
os
rel
radioresist
hypothes
specif
mechan
contribut
form
radiotherapeut
resist
bone
sarcoma
object
elucid
mechan
radiotherapeut
resist
os
ew
designmethod
administ
radiat
vitro
three
os
cell
line
three
ew
cell
line
establish
popul
control
popul
respect
wild
type
cell
receiv
radiat
character
popul
phenotyp
prolifer
invasionmigr
clonogen
assay
well
cell
surviv
repeat
radiat
exposur
also
perform
microarray
gene
express
gex
revers
phase
protein
array
rppa
popul
result
signific
chang
cell
prolifer
clonogen
chang
consist
os
ew
popul
note
differ
cell
surviv
cell
line
radiat
howev
see
upward
trend
invas
variou
cell
line
gex
rppa
data
also
reveal
two
pathway
interest
statist
signific
differ
rna
protein
express
pathway
mtor
pathway
derang
link
multipl
cancer
mtor
pathway
implic
pathogenesi
bone
sarcoma
conclus
data
suggest
increas
invas
well
demonstr
statist
signific
differ
rna
protein
express
pathophysiolog
relev
pathway
bone
sarcoma
cell
conclud
find
warrant
investig
vitro
vivo
model
elucid
mechan
radiotherapeut
resist
current
develop
ewe
sarcoma
mous
model
use
cell
popul
also
plan
appli
relev
radiosensit
model
goal
translat
signific
result
improv
outcom
patient
bone
sarcoma
kathryn
sutton
anindya
dasgupta
david
mccarti
christoph
doer
h
trent
spencer
emori
univers
atlanta
georgia
unit
state
background
immunotherapi
reli
sever
paramet
includ
cell
number
expans
ii
target
immun
cell
tumor
iii
cell
surviv
function
infus
iv
advers
event
novel
approach
expans
gamma
delta
cell
oppos
alpha
beta
cell
pursu
gamma
delta
cell
reason
candid
immunotherapi
possess
inher
ii
requir
prime
iii
direct
tumor
kill
via
recognit
ligand
show
iv
expand
cgmp
serum
free
media
sfm
bioengin
gamma
delta
cell
express
chimer
antigen
receptor
car
augment
effect
neuroblastoma
appropri
choic
gamma
delta
immunotherapi
gamma
delta
cell
cytotox
neuroblastoma
cell
neuroblastoma
cell
express
known
target
antigen
object
optim
expans
transduct
gamma
delta
cell
designmethod
effect
gamma
delta
cell
expans
stimul
bisphosphon
evalu
sever
sfm
expand
gamma
delta
cell
evalu
transduct
effici
use
lentivir
vector
expand
modifi
gamma
delta
cell
assess
cytox
toward
neuroblastoma
cell
result
sfm
cultur
one
show
reliabl
expans
clinic
relev
number
optmiz
media
supplement
led
robust
expans
well
effici
transduct
across
multipl
donor
compar
observ
alpha
beta
cell
similar
multipl
infect
gamma
delta
cell
cytotox
toward
neuroblastoma
cell
line
enhanc
addit
car
conclus
optim
method
gamma
delta
cell
expans
transduct
develop
test
earli
phase
clinic
trial
absenc
afford
opportun
appropri
elimin
alpha
beta
cell
use
allogen
set
limit
risk
graft
versu
host
diseas
use
sfm
provid
clinic
safer
potenti
efficaci
cellular
immunotherapi
gamma
delta
cell
display
cytotox
toward
neuroblastoma
increas
addit
car
jame
mcauley
rachel
bridwel
linda
klei
emili
hess
peter
luca
linda
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
osteosarcoma
common
primari
bone
cancer
children
adolesc
despit
real
improv
patient
outcom
past
decad
diagnosi
metastat
osteosarcoma
portend
except
poor
prognosi
surviv
rate
patient
metastas
less
even
neoadjuv
chemotherapi
treatment
coupl
cell
surfac
receptor
activ
intracellular
signal
cascad
act
upon
thrombin
secret
serin
proteas
import
coagul
cascad
express
associ
increas
osteosarcoma
invas
metastasi
sought
determin
molecular
mechan
increas
occur
endotheli
cell
laboratori
observ
stimul
caus
activ
inflammatori
transcript
factor
famili
activ
close
associ
tissu
invas
extravas
step
metastasi
osteosarcoma
cancer
hypothes
intracellular
signal
complex
signalosom
may
play
role
signal
transduct
object
identifi
mechan
activ
osteosarcoma
determin
whether
pathway
suitabl
pharmacolog
inhibit
designmethod
activ
examin
use
immunoblot
phosphoryl
inhibitor
use
luciferas
report
assay
gene
transcript
evalu
pcr
studi
osteosarcoma
invas
vitro
use
transwel
chamber
boyden
chamber
assay
cell
invad
matrigel
layer
result
found
treatment
human
osteosarcoma
cell
either
thrombin
peptid
agonist
induc
robust
activ
canon
signal
pathway
specif
observ
phosphoryl
transcript
activ
luciferas
report
plasmid
nuclear
transloc
rela
subunit
discov
knockdown
complet
abrog
activ
osteosarcoma
cell
addit
gene
express
profil
array
data
detail
metastat
reprogram
osteosarcoma
cell
present
conclus
stimul
caus
activ
fashion
osteosarcoma
cell
proteolyt
activ
inhibit
may
potenti
therapeut
strategi
combat
osteosarcoma
futur
brenda
weigel
anuradha
banerje
holli
meani
suman
malempati
jason
fangusaro
ying
zhang
ying
ou
tien
hoang
paul
meyer
univers
minnesota
minneapoli
minnesota
unit
state
background
panitumumab
human
growth
factor
receptor
egfr
antibodi
approv
treatment
metastat
colorect
cancer
adult
pediatr
solid
tumor
express
egfr
limit
studi
indic
therapi
may
activ
popul
clinic
trial
report
use
panitumumab
pediatr
patient
object
evalu
safeti
pharmacokinet
efficaci
panitumumab
monotherapi
pediatr
patient
relapsedrefractori
solid
tumor
designmethod
patient
year
old
elig
egfr
express
statu
evalu
ihc
six
dose
cohort
patient
plan
use
roll
dose
escal
design
mgkg
weekli
b
mgkg
everi
week
c
mgkg
everi
week
age
group
group
yr
group
yr
dose
limit
toxic
dlt
assess
use
pharmacokinet
assess
first
week
determin
first
dose
kinet
steadi
state
respons
evalu
everi
week
use
modifi
recist
criteria
result
enrol
patient
total
group
group
cn
tumor
bone
sarcoma
soft
tissu
sarcoma
wilm
tumor
dlt
dlt
evalu
period
report
patient
includ
patient
cohort
apnoea
peripher
motor
neuropathi
respiratori
acidosi
seizur
elev
alanin
aminotransferas
patient
cerebr
haemorrhag
hypoxia
reduc
neutrophil
platelet
skin
gastrointestin
advers
event
report
grade
grade
total
patient
respect
among
patient
baselin
measur
diseas
best
respons
stabl
diseas
patient
cn
tumor
pharmacokinet
paramet
estim
mgkg
cohort
similar
adult
patient
mean
day
first
dose
mean
pharmacokinet
profil
group
similar
trend
lower
exposur
cmax
auc
compar
group
conclus
safeti
pharmacokinet
profil
panitumumab
pediatr
patient
similar
adult
trial
sponsor
amgen
inc
jillian
davenport
kieuhoa
vo
robert
goldsbi
daniel
west
steven
duboi
ucsf
benioff
children
hospit
san
francisco
california
unit
state
background
long
term
survivor
ewe
sarcoma
ew
consider
risk
futur
complic
includ
late
relaps
death
data
prognost
factor
late
death
surviv
beyond
five
year
lack
object
util
data
surveil
epidemiolog
end
result
seer
databas
conduct
retrospect
cohort
studi
follow
aim
first
sought
util
registri
describ
clinic
featur
clinic
outcom
patient
ew
surviv
year
initi
diagnosi
second
aim
identifi
univari
multivari
prognost
factor
death
survivor
ewe
sarcoma
therebi
enabl
care
designmethod
conduct
retrospect
cohort
studi
use
surveil
epidemiolog
end
result
seer
databas
obtain
clinic
featur
outcom
data
patient
ew
surviv
month
greater
data
perform
univari
multivari
analys
overal
surviv
use
test
cox
proport
hazard
model
result
patient
cohort
death
report
due
ew
os
survivor
year
confid
interv
univari
advers
prognost
factor
late
death
survivor
includ
age
year
initi
diagnosi
male
sex
axialpelv
primari
site
initi
stage
prognost
independ
advers
prognost
factor
late
death
includ
black
race
hazard
ratio
hr
p
age
year
diagnosi
hr
p
male
sex
hr
p
axialpelv
primari
site
hr
p
conclus
major
late
death
survivor
due
ew
black
race
age
diagnosi
male
sex
axialpelv
primari
site
stage
diagnosi
independ
associ
increas
risk
late
death
heather
vicker
nichola
moor
alan
l
felsenfeld
noah
federman
univers
california
lo
angel
lo
angel
california
unit
state
background
central
giant
cell
granuloma
cgcg
benign
osteolyt
neoplasm
jaw
character
mass
infiltr
osteoclast
like
giant
cell
typic
slow
grow
painless
caus
loosen
displac
teeth
well
anatom
distort
teeth
manag
cgcg
conserv
though
minor
patient
may
requir
aggress
surgic
manag
affect
area
denosumab
inhibitor
demonstr
induc
regress
giant
cell
tumor
bone
gctb
though
distinct
condit
share
mani
similar
cgcg
object
evalu
label
use
denosumab
manag
cgcg
designmethod
male
present
histori
larg
recurr
progress
mandibular
biopsi
proven
cgcg
although
initi
treat
numer
attempt
curettag
subsequ
progress
also
receiv
intralesion
steroid
calcitonin
recurr
ongo
progress
consider
definit
surgic
manag
consist
partial
mandibulectomi
reconstruct
avoid
potenti
morbid
procedur
label
use
denosumab
initi
base
current
use
patient
gctb
patient
receiv
denosumab
sc
everi
week
three
week
follow
denosumab
sc
everi
month
respons
therapi
base
panoram
dental
radiograph
well
physic
exam
result
initi
exam
prior
start
denosumab
show
opaqu
greyish
lesion
anterior
mandibl
nontend
nonmobil
adjac
teeth
also
loosen
mobil
radiograph
show
radioluc
multilocul
anterior
mandibular
lesion
four
week
treatment
denosumab
lesion
show
regress
later
medial
aspect
lesion
increas
cortic
stabil
radiograph
show
calcif
lesion
month
denosumab
almost
complet
resolut
lesion
toxic
advers
event
denosumab
treatment
conclus
although
underli
pathogenesi
cgcg
unclear
variou
studi
implic
disregul
odontoclast
osteoclast
associ
resorpt
decidu
teeth
hypothes
inhibit
signal
pathway
diseas
may
effect
therapeut
modal
twana
jackson
christoph
bowman
jonathan
killian
kristen
thoma
fang
bu
jonathan
serrano
richard
gorlick
marc
ladanyi
matija
snuderl
matthia
karajanni
nyu
langon
medic
center
new
york
new
york
unit
state
background
pediatr
sarcoma
divers
group
malign
bone
soft
tissu
account
approxim
pediatr
cancer
subset
sarcoma
harbor
known
recurr
genom
alter
oncogen
gene
fusion
pathognomon
tumor
lack
recurr
alter
frequent
repres
diagnost
challeng
epigenet
modif
global
specif
chang
dna
methyl
increasingli
recogn
primari
mechan
oncogenesi
pediatr
cancer
methyl
profil
emerg
power
tool
identifi
biolog
clinic
relev
subgroup
date
studi
limit
sampl
size
examin
dna
methyl
pediatr
sarcoma
object
use
illumina
infinium
human
beadchip
array
array
platform
perform
dna
methyl
analysi
pilotdiscoveri
cohort
pediatr
sarcoma
identifi
associ
gene
promot
cpg
island
methyl
signatur
explor
key
clinic
biolog
associ
designmethod
analyz
dna
pediatr
sarcoma
sampl
includ
osteogen
sarcoma
n
ewe
sarcoma
n
rhabdomyosarcoma
n
synovi
sarcoma
n
unsupervis
hierarch
cluster
analysi
perform
compar
epigenet
signatur
among
diseas
subtyp
result
unsupervis
hierarch
cluster
analysi
reveal
osteogen
sarcoma
ewe
sarcoma
synovi
sarcoma
tumour
distinct
dna
methyl
profil
whose
distribut
associ
known
histolog
subtyp
although
dna
methyl
profil
rhabdomyosarcoma
cluster
distinctli
tend
group
either
osteogen
synovi
sarcoma
conclus
abl
identifi
epigenet
signatur
distinctli
associ
known
histolog
subtyp
pediatr
sarcoma
result
suggest
dna
methyl
profil
diagnost
util
tumour
exploratori
analysi
investig
clinic
prognost
signific
geneticepigenet
chang
current
ongo
sibo
zhao
huiyuan
zhang
laszlo
perlaki
adekunl
adesina
ching
lau
donald
parson
murali
chintagumpala
li
baylor
colleg
medicin
texa
children
hospit
houston
texa
unit
state
background
ependymoma
epn
third
common
malign
pediatr
brain
tumor
current
standard
treatment
maxim
safe
surgic
resect
follow
radiat
therapi
chemotherapi
proven
increas
surviv
outcom
event
free
surviv
prognosi
even
dismal
recurr
epn
occur
nearli
half
patient
known
cur
option
therefor
imper
learn
biolog
recurr
diseas
identifi
cellular
driver
epn
recurr
well
understand
mechan
therapi
resist
hypothes
ependymoma
recurr
driven
subpopul
tumor
cell
enhanc
tumorigen
scid
mice
object
studi
tumorigen
recurr
pediatr
ependymoma
differ
clinic
stage
whether
diagnosi
first
recurr
second
recurr
beyond
designmethod
last
year
collect
total
pediatr
ependymoma
patient
tumor
sampl
across
countri
identifi
patient
recurr
ependymoma
collect
tumor
sampl
recurr
n
set
median
age
patient
year
old
rang
year
median
time
first
recurr
month
rang
month
set
recurr
studi
tumorigen
brain
tumor
differ
clinic
stage
directli
implant
tumor
cell
cellsmous
patient
match
locat
brain
scid
mice
eg
human
cerebr
tumor
mous
cerebrum
human
cerebellar
tumor
mous
cerebellum
monitor
tumor
format
result
set
tumor
format
confirm
mous
brain
latest
recurr
patient
tumor
sampl
patient
earlier
stage
either
form
tumor
mous
brain
current
pend
tumor
format
remain
model
still
pend
conclus
preliminari
find
demonstr
progress
enhanc
tumorigen
ependymoma
recurr
becom
uniqu
extrem
valuabl
platform
studi
brain
tumor
recurr
ana
luiza
fabro
edilson
forlin
lucian
valdez
flora
watanab
edna
carboni
ana
paula
pedro
bom
gabriela
fernand
luiz
camil
vicentini
samantha
nichel
cilmara
kuwahara
euripid
ferreira
hospit
pequeno
princip
curitiba
parana
brazil
background
bone
reconstruct
resect
malign
tumor
block
subject
constant
debat
nearli
year
develop
biolog
reconstruct
method
vivo
tumor
destruct
cryoablat
liquid
nitrogen
option
treatment
pediatr
patient
bone
tumor
object
present
preliminari
result
bone
reconstruct
redeploy
bone
tumor
treatment
liquid
nitrogen
pediatr
patient
bone
tumor
hospit
pequeno
princip
designmethod
retrospect
studi
includ
patient
diagnos
ewe
sarcoma
osteosarcoma
treat
depart
pediatr
oncolog
pediatr
orthopaed
pequeno
hospit
septemb
decemb
perform
bone
reconstruct
redeploy
bone
tumor
treatment
liquid
nitrogen
result
seven
patient
analyz
mean
age
year
rang
year
local
recurr
rate
consolid
time
vari
month
occur
averag
month
surgeri
limb
function
consolid
classifi
good
excel
record
three
death
unrel
appli
techniqu
conclus
techniqu
offer
altern
biolog
reconstruct
ad
benefit
allow
perfect
bone
fit
easi
adjust
ligament
tendon
depend
bone
bank
foreign
materi
provid
rapid
consolid
lower
cost
greater
graft
longev
ryuma
tanaka
soumen
khatua
wafik
zaki
marta
weather
vivek
subbiah
md
anderson
cancer
center
houston
texa
unit
state
background
vemurafenib
us
fda
approv
treatment
relaps
refractori
braf
mutat
posit
malign
melanoma
demonstr
activ
multipl
braf
mutat
cancer
well
resist
alway
develop
monotherapi
studi
demonstr
concurr
mtor
inhibit
overcom
innat
acquir
resist
braf
inhibit
object
hypothes
combin
vemurafenib
plu
everolimu
mtor
inhibitor
well
toler
secondari
object
includ
efficaci
combin
therapi
posit
pediatr
aya
brain
tumor
designmethod
conduct
phase
studi
vemurafenib
everolimu
braf
mutat
tumor
includ
pediatr
aya
brain
tumor
appli
standard
design
step
wise
dose
modif
dose
vemurafenib
start
mgday
everolimu
start
mgday
result
five
patient
brain
tumor
age
rang
treat
two
glioblastoma
one
optic
pathway
glioma
one
pleomorph
xanthoastrocytoma
one
anaplast
astrocytoma
patient
previous
treat
includ
braf
inhibitor
monotherapi
three
patient
mgday
vemurafenib
mgday
everolimu
given
month
toxic
includ
grade
rash
two
heavili
patient
show
progress
diseas
cycl
treatment
one
discontinu
treatment
due
although
radiograph
partial
respons
seen
two
patient
activ
studi
partial
respons
stabl
diseas
month
conclus
combin
therapi
well
toler
one
except
grade
rash
patient
abl
continu
treatment
dose
modif
treatment
effect
observ
combin
therapi
even
patient
previous
treat
braf
inhibitor
monotherapi
studi
emphas
import
genom
profil
pediatr
aya
brain
tumor
hyman
puzanov
subbiah
et
al
n
engl
j
med
ana
luiza
fabro
edilson
forlin
lucian
valdez
flora
watanab
edna
carboni
ana
paula
pedro
bom
gabriela
fernand
luiz
camil
vicentini
cilmara
kuwahara
samantha
nichel
euripid
ferreira
hospit
pequeno
princip
curitiba
parana
brazil
background
primari
malign
bone
tumor
sixth
common
malign
children
third
adolesc
leukemia
lymphoma
recommend
treatment
chemotherapi
follow
clear
margin
resect
andor
radiotherapi
object
evalu
aspect
diagnosi
treatment
outcom
possibl
prognost
factor
patient
ewe
sarcoma
osteosarcoma
designmethod
retrospect
studi
includ
patient
diagnos
ewe
sarcoma
patient
osteosarcoma
patient
treat
depart
pediatr
oncolog
pediatr
orthopaed
pequeno
hospit
januari
decemb
accord
brazilian
protocol
result
mean
age
year
male
femal
analyz
mean
tumor
size
cm
period
earli
symptom
onset
diagnosi
week
metastas
rate
time
diagnosi
frequent
surgeri
resect
reconstruct
follow
amput
resect
without
reconstruct
twenti
patient
recurr
mainli
pulmonari
primari
site
surviv
rate
five
year
statist
signific
presenc
metastas
diagnosi
relaps
shorter
surviv
statist
signific
time
diagnosi
surviv
conclus
despit
optimist
expect
advanc
diagnost
tool
therapi
tumor
osteosarcoma
ewe
children
local
advanc
diseas
metastasi
diagnosi
still
poor
prognosi
tabitha
cooney
sonia
partap
tina
clark
dur
stanford
univers
palo
alto
california
unit
state
background
dispar
within
pediatr
oncolog
outcom
well
studi
studi
evalu
racialethn
differ
children
central
nervou
system
cn
tumor
yield
inconsist
result
furthermor
pediatr
cn
tumor
studi
examin
racialethn
differ
context
socioeconom
factor
object
examin
racialethn
differ
surviv
outcom
pediatr
medulloblastoma
glioma
whether
neighborhood
socioeconom
characterist
mitig
racialethn
differ
designmethod
collect
data
california
children
age
year
first
diagnosi
glioma
medulloblastoma
primari
outcom
measur
overal
surviv
os
cox
regress
covari
includ
gender
age
raceethn
neighborhood
socioeconom
statu
se
insur
statu
result
total
medulloblastoma
patient
glioma
patient
identifi
use
cox
regress
analysi
medulloblastoma
patient
public
health
insur
wors
outcom
publicmedicaid
vs
privat
hazard
ratio
hr
confid
interv
ci
surviv
differ
raceethn
found
medulloblastoma
patient
adjust
se
insur
statu
howev
racial
differ
found
glioma
patient
even
adjust
se
black
glioma
patient
wors
outcom
white
counterpart
black
vs
white
hr
ci
conclus
studi
examin
racialethn
differ
surviv
pediatr
medulloblastoma
glioma
adjust
socioeconom
neighborhood
characterist
alarmingli
medulloblastoma
patient
public
health
insur
fare
wors
privat
insur
regardless
statu
comparison
racial
dispar
found
pediatr
glioma
even
adjust
se
futur
research
need
uncov
remedi
reason
dispar
christoph
kuo
richard
jacobson
antonio
logan
paul
kent
rush
medic
colleg
chicago
illinoi
unit
state
background
adolesc
young
adult
aya
patient
recurrentmetastat
sarcoma
poor
prognosi
live
year
current
standard
treatment
patient
docetaxol
taxoter
bevacizumab
avastin
gemcitabin
gemzar
g
activ
sarcoma
one
studi
children
use
tag
yield
partial
respons
patient
stabl
diseas
one
jpho
object
report
preliminari
experi
novel
combin
sarcoma
aya
patient
designmethod
three
week
cycl
tag
day
day
g
day
given
aya
relaps
sarcoma
ewe
sarcoma
osteosarcoma
cycl
median
age
male
multipl
relaps
nineteen
fail
multipl
chemotherapi
regimen
multipl
surgeri
radiat
result
median
overal
progress
free
surviv
month
respect
seven
patient
achiev
clinic
remiss
cr
sustain
remiss
partial
respons
pr
reduct
recist
stabl
diseas
progress
diseas
side
effect
includ
mucos
nasolacrim
duct
obliter
septal
perfor
infect
thrombosi
cycl
tag
given
toxic
death
organ
failur
need
stop
prescrib
therapi
conclus
uncontrol
studi
combin
taxoter
avastin
gemcitabin
tag
show
respons
cr
pr
relaps
pretreat
young
sarcoma
patient
tag
toxic
manag
tag
may
offer
choic
prolong
life
highli
treat
relaps
aya
sarcoma
patient
jacob
henderson
jake
wagner
monika
davar
doernbech
children
hospit
oregon
health
scienc
univers
portland
oregon
unit
state
background
medulloblastoma
mb
common
malign
pediatr
brain
tumor
molecular
profil
recent
enabl
classif
mb
four
distinct
subgroup
group
patient
worst
prognosi
object
aim
discov
valid
target
lesion
mb
use
function
screen
designmethod
perform
kinas
inhibitor
screen
group
mb
cell
line
compar
sensit
individu
cell
line
primari
leukemia
sampl
establish
human
cancer
cell
line
identifi
recur
hit
within
pathway
specif
particular
line
use
target
western
blot
evalu
biochem
correl
pathway
vivo
efficaci
assess
use
murin
model
clinic
avail
inhibitor
lastli
primari
patient
cell
expand
intracrani
murin
model
plate
function
screen
result
interpret
cell
line
data
result
kinas
screen
reveal
cluster
sensit
mtor
inhibitor
igfr
inhibitor
aurora
kinas
inhibitor
cell
respect
western
blot
corrobor
pathway
hyperactiv
cell
line
interest
uniqu
exom
sequenc
reveal
novel
somat
variant
unknown
function
signific
tumor
suppressor
gene
molecular
analysi
mutat
demonstr
diminish
protein
destabil
heterolog
express
system
vivo
studi
show
target
tumor
suppress
use
mtor
inhibitor
cell
minim
suppress
cell
confirm
screen
reveal
specif
target
pathway
perhap
importantli
success
obtain
inhibitor
data
primari
patient
tumor
import
tool
provid
reliabl
inform
primari
sampl
less
hour
conclus
taken
togeth
find
indic
subset
mb
patient
may
function
relev
hyperactiv
target
pathway
may
found
tradit
exom
sequenc
function
screen
may
offer
addit
tool
inform
adjunct
treatment
decis
complex
heterogen
diseas
hatel
moonat
gangxiong
huang
nanci
gordon
eugeni
kleinerman
univers
texa
md
anderson
cancer
center
houston
texa
unit
state
background
osteosarcoma
os
common
primari
malign
bone
tumor
children
adolesc
surviv
remain
stagnant
past
year
new
therapeut
combin
desper
need
previou
studi
use
car
shown
benefit
treatment
os
howev
car
therapi
alon
complet
erad
tumor
immun
checkpoint
pathway
program
ligand
tumor
cell
shown
limit
immunotherapeut
efficaci
blockad
shown
surviv
prognost
benefit
variou
tumor
object
investig
combin
approach
use
car
antibodi
treat
os
cell
designmethod
car
gener
peripher
blood
mononuclear
cell
pbmc
baselin
express
determin
flow
cytometri
cell
expans
car
human
os
cell
without
antibodi
cytotox
measur
compar
group
use
calcein
releas
assay
chang
express
also
analyz
flow
cytometri
untreat
treat
car
differ
time
point
purifi
serv
control
result
express
increas
car
purifi
expans
compar
baselin
express
exposur
tumor
cell
surfac
express
decreas
car
purifi
success
blockad
surfac
express
achiev
via
antibodi
blockad
pathway
use
antibodi
combin
car
therapi
provid
addit
benefit
cell
compar
car
alon
respons
note
control
combin
antibodi
compar
control
alon
conclus
combin
therapi
car
antibodi
os
cell
provid
addit
benefit
car
therapi
alon
studi
need
test
better
combin
therapi
understand
downstream
effect
block
pathway
os
block
pathway
may
impact
immunosuppress
pathway
aditi
bagchi
jefferi
mackeigan
albert
corneliu
van
andel
research
institut
graduat
school
grand
rapid
michigan
unit
state
background
medulloblastoma
harbor
multipl
copi
number
myc
oncogen
associ
therapeut
resist
relaps
current
literatur
implic
role
autophagi
oncogen
driven
malign
transform
tumor
growth
surviv
notabl
recent
public
guo
et
al
note
kra
driven
tumor
reli
autophagi
sustain
cellular
metabol
evad
cell
death
similarli
note
myc
induc
lymphoma
model
shrna
direct
essenti
autophagi
gene
augment
cell
death
follow
activ
amravadi
et
al
base
current
literatur
preliminari
data
hypothes
myc
driven
medulloblastoma
high
autophagi
key
mechan
therapeut
resist
cell
surviv
object
primari
object
establish
increas
myc
express
induc
higher
level
autophagi
medulloblastoma
cell
chemic
inhibitor
autophagi
augment
effect
cytotox
drug
use
treatment
medulloblastoma
designmethod
experiment
model
use
test
hypothesi
daoy
cell
medulloblastoma
cell
deriv
pediatr
patient
tumor
known
myc
amplif
oncogen
myc
introduc
use
lentivir
construct
empti
express
vector
control
order
gener
isogen
cell
line
primari
assay
util
assess
autophagi
autophag
flux
use
detect
protein
level
immunoblot
without
lysomotroph
agent
result
cell
consist
demonstr
higher
basal
autophagi
compar
demonstr
detect
higher
protein
treat
lysomotroph
agent
treatment
hcq
demonstr
similar
flux
cell
line
indic
presenc
function
autophagi
furthermor
phenotyp
lost
myc
inhibit
use
rnai
cell
moreov
protein
express
diminish
cell
conclus
introduc
myc
medulloblastoma
cell
increas
autophagi
basal
growth
condit
phenotyp
autophagi
increas
note
lab
cell
line
driven
kra
oncogen
highlight
share
resist
mechan
two
distinct
oncogen
patrick
leavey
harish
babu
arunachalam
bogdan
armaselu
ovidiu
daescu
anita
sengupta
dinesh
rakheja
stephen
skapek
bach
samuel
glick
kevin
cederberg
ut
southwestern
medic
center
dalla
dalla
texa
unit
state
background
tumor
necrosi
tn
remain
signific
predictor
surviv
patient
osteosarcoma
interpret
tn
provid
data
first
week
chemotherapi
provid
inform
late
make
clinic
meaning
adjust
therapi
propos
modern
technolog
digit
whole
slide
imag
wsi
imag
pattern
recognit
provid
basi
enhanc
interpret
import
biomark
object
accur
identifi
featur
tumor
necrosi
imag
pattern
recognit
ipr
histolog
whole
slide
imag
wsi
resect
osteosarcoma
designmethod
develop
investig
team
clinic
scientist
univers
texa
southwestern
dalla
comput
scientist
univers
texa
dalla
archiv
sampl
patient
treat
children
medic
center
dalla
identifi
case
repres
singl
tumor
slide
time
biopsi
avail
use
imag
segment
slide
case
time
resect
necrosi
determin
slide
scan
use
aperio
store
portabl
terabyt
sv
format
compress
tiff
file
format
use
tumor
map
creat
time
origin
histolog
evalu
slide
digit
knit
singl
whole
slide
imag
imag
segment
requir
featur
identif
base
region
color
cellular
shape
region
cellular
densiti
ongo
result
retriev
tumor
map
tumor
biopsi
tumor
resect
specimen
archiv
store
case
osteosarcoma
respect
complet
digit
case
develop
comput
tool
digit
knit
singl
slide
case
singl
whole
slide
imag
wsi
initi
process
imag
segment
prospect
tumor
necrosi
test
case
two
pathologist
blind
interpret
develop
analysi
softwar
conclus
begun
develop
necessari
technolog
autom
interpret
tn
osteosarcoma
prospect
studi
comparison
routin
evalu
tn
newli
diagnos
patient
scott
coven
ethan
hollingsworth
joseph
stanek
jonathan
finlay
nationwid
children
hospit
columbu
ohio
unit
state
background
central
nervou
system
cn
tumor
common
solid
tumor
childhood
adolesc
lead
caus
death
one
nineteen
year
age
unit
state
unit
kingdom
uk
recognit
delay
diagnosi
led
develop
program
call
headsmart
design
enhanc
awar
sign
symptom
brain
cancer
children
among
healthcar
provid
gener
public
goal
reduc
delay
diagnosi
apart
singl
report
diagnost
delay
children
glioma
addit
report
evalu
delay
unit
state
sinc
late
object
establish
accur
ohio
baselin
symptom
onset
definit
diagnosi
children
cn
tumor
designmethod
medic
record
retrospect
review
children
cn
tumor
januari
august
nationwid
children
hospit
sinc
electron
medic
record
system
began
late
usabl
data
patient
record
review
age
gender
tumor
type
present
symptom
number
healthcar
visit
prior
diagnosi
time
interv
month
onset
symptom
definit
diagnosi
associ
genet
syndrom
result
patient
cn
tumor
children
known
syndrom
neurofibromatosi
type
tuber
sclerosi
among
remain
children
median
time
interv
symptom
onset
definit
diagnosi
day
mean
symptom
interv
day
rang
day
addit
common
present
symptom
among
institut
cohort
headach
nausea
vomit
unsteadi
gait
visual
disturb
seizur
conclus
document
quantifi
contemporari
delay
diagnosi
childhood
brain
tumor
central
ohio
serv
benchmark
futur
plan
intervent
reduc
time
interv
symptom
onset
diagnosi
adapt
uk
headsmart
program
throughout
state
ohio
ultim
throughout
usa
wen
luo
changxin
xu
janet
ayello
filemon
dela
cruz
jeremi
rosenblum
stephen
lessnick
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
ewe
sarcoma
es
highli
invas
metastat
pediatr
solid
tumor
patient
metastat
diseas
dismal
outcom
ewsfli
master
regul
es
act
aberr
transcript
factor
dysregul
downstream
target
involv
cancer
phenotyp
previous
review
ewsfli
analys
use
public
dataset
multipl
model
system
identifi
core
target
ewsfli
studi
focu
protein
phosphatas
inhibitor
potenti
regul
cell
migrat
object
defin
role
es
pathogenesi
evalu
potenti
specif
therapeut
target
es
especi
metastat
tumor
designmethod
examin
express
es
cell
tumor
western
blot
public
data
mine
character
ewsfli
regul
use
data
analys
quantit
luciferas
assay
combin
shrna
knockdown
soft
agar
well
boyden
chamber
assay
assess
effect
oncogen
transform
cell
migrat
test
associ
tumor
growth
metastasi
orthotop
xenograft
mous
model
next
character
molecular
mechan
underli
role
knockdownrescu
function
assay
result
found
highli
express
es
put
cell
origin
mesenchym
stem
cell
directli
ewsfli
via
ggaa
microsatellit
enhanc
element
deplet
decreas
oncogen
transform
limit
xenograft
tumor
growth
p
furthermor
reduct
decreas
cell
migrat
metastasi
anim
p
demonstr
phosphoryl
activ
protein
kinas
pka
subsequ
bind
inhibit
requir
function
evidenc
rescu
induc
phenotyp
constitut
activ
bind
defici
consist
found
es
cell
line
sensit
treatment
pka
inhibitor
pki
conclus
collect
data
suggest
relat
pathway
play
posit
role
tumorigenesi
metastasi
es
target
pathway
potenti
therapeut
valu
treatment
primari
metastat
es
brianna
conforti
sharon
ghazarian
ernest
amankwah
staci
stapleton
children
hospit
john
hopkin
medicin
st
petersburg
florida
unit
state
background
brain
tumor
second
common
caus
cancer
children
common
solid
tumor
neuron
mix
tumor
central
nervou
system
cn
rel
rare
world
health
organ
classif
revis
includ
four
addit
tumor
type
total
subtyp
although
two
publish
studi
includ
mix
popul
mani
adult
patient
knowledg
avail
tumor
case
seri
includ
larg
number
pediatr
patient
one
center
object
describ
demograph
clinic
characterist
treatment
outcom
neurogli
tumor
pediatr
patient
tertiari
care
center
designmethod
studi
retrospect
review
patient
age
less
year
diagnos
surgic
patholog
neuron
mix
tumor
subtyp
base
classif
tertiari
care
children
hospit
case
met
elig
review
data
includ
demograph
clinic
imag
patholog
treatment
morbid
mortal
extract
hospit
cn
databas
neuropathologist
neuroradiologist
particip
patient
select
adjust
patholog
patient
classif
diagnos
prior
guidelin
result
patient
met
elig
criteria
averag
follow
time
three
year
predomin
tumor
subtyp
ganglioglioma
dysembryoplast
neuroepitheli
tumor
patient
treat
surgeri
alon
three
patient
receiv
chemotherapi
two
patient
receiv
radiat
nine
patient
progress
tumor
first
resect
averag
time
progress
month
patient
progress
like
present
seizur
v
like
undergo
subtot
resect
overal
surviv
conclus
neuron
mix
tumor
cn
extrem
rare
understand
differ
neurogli
tumor
subtyp
remain
difficult
studi
contribut
pediatr
literatur
describ
first
time
diagnosi
treatment
prognos
rare
tumor
type
children
pamela
camacho
dougla
harrison
michael
kupferman
joseph
ludwig
mari
franc
mcaleer
winston
huh
md
anderson
cancer
center
houston
texa
unit
state
background
ewe
sarcoma
es
second
common
malign
bone
tumor
found
children
adolesc
ewe
sarcoma
head
neck
uncommon
literatur
note
certain
primari
site
consid
littl
data
regard
headneck
region
object
character
clinic
present
clinic
outcom
institut
cohort
patient
treat
es
relat
tumor
designmethod
retrospect
review
patient
treat
ewe
sarcoma
headneck
januari
decemb
twelv
patient
elig
analysi
clinic
characterist
treatment
detail
clinic
outcom
evalu
genet
transloc
note
avail
result
nine
patient
male
femal
median
age
diagnosi
year
rang
year
age
median
month
rang
month
eight
patient
paramening
tumor
primari
site
patient
extraoss
tumor
includ
patient
orbit
tumor
patient
present
metastat
diseas
seven
tumor
transloc
initi
chemotherapi
regimen
includ
vdcie
vai
vac
local
control
consist
surgeri
radiat
therapi
surgeri
radiat
therapi
median
dose
radiat
therapi
receiv
rang
gy
last
patient
aliv
evid
diseas
ned
patient
aliv
diseas
four
patient
die
diseas
includ
patient
initi
present
metastasi
patient
paramening
tumor
aliv
ned
aliv
diseas
patient
orbit
tumor
aliv
ned
month
conclus
patient
ewe
sarcoma
head
neck
es
locat
presenc
metastasi
diagnosi
singl
import
factor
overal
surviv
small
cohort
size
prevent
subset
analysi
prognost
factor
treatment
h
n
es
patient
requir
multimod
specialti
care
perform
treatment
center
well
vers
treat
rare
bone
tumor
katrina
ohalloran
kassi
eno
gari
mason
children
hospit
pittsburgh
pittsburgh
pennsylvania
unit
state
background
choroid
plexu
carcinoma
aggress
grade
iii
tumor
commonli
found
children
despit
multimod
treatment
overal
surviv
close
object
describ
case
patient
recurr
choroid
plexu
carcinoma
evid
diseas
undergo
treatment
abscess
resect
caviti
designmethod
case
report
result
girl
diagnos
right
pariet
choroid
plexu
carcinoma
present
progress
unsteadi
gait
famili
histori
notabl
breast
cancer
mother
subsequ
genet
workup
posit
mutat
li
fraumeni
syndrom
diagnos
underw
near
total
resect
tumor
follow
cycl
chemotherapi
etoposid
carboplatin
cyclophosphamid
three
month
complet
treatment
note
larg
recurr
surgic
caviti
repeat
resect
underw
radiat
therapi
first
brain
mri
radiat
therapi
show
enhanc
nodul
upon
resect
found
recurrentresidu
tumor
start
chemotherapi
temozolomid
irinotecan
bevacizumab
ten
day
initi
chemotherapi
patient
develop
subgal
epidur
intraparenchym
abscess
along
surgic
tract
oper
wound
cultur
posit
staphylococcu
aureu
treatment
antibiot
initi
cours
complic
recurr
wound
dehisc
unsuccess
primari
closur
despit
multipl
attempt
due
deterior
qualiti
life
face
tumor
recurr
parent
chose
pursu
palli
care
continu
oral
antibiot
prophylaxi
month
repeat
mri
brain
show
persist
right
pariet
lobe
abscess
peripher
enhanc
around
surgic
caviti
suggest
inflammatori
reaction
rather
tumor
restart
iv
antibiot
palli
purpos
repeat
mri
brain
month
antibiot
therapi
show
resolut
abscess
evid
tumor
conclus
case
rais
interest
question
regard
role
immunomodul
cancer
therapi
given
follow
develop
inflammatori
respons
bacteri
intracrani
abscess
tumor
previous
resist
numer
resect
chemotherapeut
agent
cranial
irradi
appar
resolv
ayman
lauri
davi
jordan
wright
mukund
dole
dayton
children
hospit
dayton
ohio
unit
state
background
primari
histiocyt
sarcoma
hs
rare
neoplasm
common
adult
children
origin
liver
splenic
gastrointestin
lymphoid
cutan
tissu
central
nervou
system
cn
primari
locat
less
common
usual
aggress
poor
prognosi
case
report
children
medic
literatur
among
case
even
fewer
primari
cn
tumor
current
underli
etiolog
hs
unknown
standard
therapi
object
report
case
primari
cn
histocyt
sarcoma
year
old
male
order
increas
knowledg
avail
medic
literatur
regard
rare
tumor
designmethod
review
perform
patient
medic
record
avail
medic
literatur
pertain
pediatr
hs
focu
cn
tumor
result
review
english
medic
literatur
sinc
identifi
pediatr
patient
cn
hs
among
patient
age
patient
year
old
male
pmh
autism
speech
delay
perinat
hiv
exposur
asthma
sleep
apnea
present
visual
hallucin
new
onset
seizur
disord
mri
brain
identifi
left
pariet
dural
base
mass
surgic
resect
mass
perform
patholog
show
prolifer
histiocyt
nuclear
atypia
consist
hs
patient
receiv
proton
beam
radiat
therapi
start
ice
ifosfamid
carboplatin
etoposid
base
therapi
ongo
evalu
third
cycl
conclus
current
standard
therapi
hs
treatment
strategi
includ
surgic
resect
chemotherapi
radiat
complet
surgic
resect
feasibl
consid
sinc
may
provid
better
prognosi
sever
chemotherapi
regimen
use
includ
type
therapi
high
dose
cytarabin
chop
ice
report
poor
outcom
report
patient
treatment
regimen
highlight
need
collabor
effort
intern
registri
clinic
trial
develop
novel
therapeut
approach
jessica
zimmerman
mariko
sato
john
buatti
arnold
menez
brian
dlouhi
jeremi
greenle
saul
wilson
univers
iowa
children
hospit
iowa
citi
iowa
unit
state
background
pilomyxoid
astrocytoma
pma
similar
featur
pilocyt
astrocytoma
pa
howev
poorer
prognosi
sinc
origin
descript
pma
sever
case
seri
pma
publish
treatment
chosen
pma
similar
treatment
pilocyt
astrocytoma
object
review
clinic
characterist
outcom
pma
case
univers
iowa
children
hospit
compar
clinic
outcom
pa
pma
report
literatur
designmethod
retrospect
chart
review
six
patient
diagnos
pma
perform
demograph
locat
tumor
present
symptom
extent
initi
resect
type
durat
adjuv
therapi
progress
free
surviv
current
clinic
statu
collect
result
age
diagnosi
rang
month
year
locat
tumor
includ
hypothalam
chiasmat
region
ventricl
cerebellar
hemispher
two
case
achiev
gross
total
resect
present
cerebellar
hemispher
three
case
partial
resect
surgeri
progress
observ
period
patient
gross
total
resect
progress
diseas
progress
eventu
receiv
radiat
therapi
age
year
progress
patient
live
diseas
stabl
imag
find
time
review
endocrinopathi
present
tumor
neurolog
deficit
rare
typic
involv
visual
defect
conclus
gross
total
resect
cerebellar
pma
prevent
tumor
recurr
cohort
similar
find
pa
hypothalam
chiasmat
lesion
tumor
less
apt
complet
resect
henc
requir
differ
manag
hypothalam
chiasmat
tumor
also
experi
differ
late
effect
base
locat
treatment
patient
aliv
henc
reveal
poorer
prognosi
compar
pa
although
import
observ
patient
longer
period
time
definit
establish
surviv
late
effect
pma
patient
compar
matur
pa
patient
seri
schlosser
shannon
buck
david
grynspan
brigitt
lemyr
elain
leung
donna
johnston
children
hospit
eastern
ontario
ottawa
ontario
canada
background
outcom
children
infant
diagnos
acut
myeloid
leukemia
aml
improv
howev
literatur
treatment
infant
aml
diagnos
utero
object
report
first
case
fetu
diagnos
aml
utero
designmethod
parent
consent
background
clinic
inform
histori
present
ill
result
relev
laboratori
investig
intend
cours
manag
review
result
cordocentesi
done
woman
week
gestat
age
ga
investig
fetal
hepatomegali
show
hemoglobin
gl
leukocytosi
thrombocytopenia
investig
includ
morpholog
examin
flow
cytometri
confirm
diagnosi
aml
monocyt
type
fetu
subsequ
cytogenet
analysi
show
mix
lineag
leukemia
mll
aneuploidi
mll
gene
disrupt
exchang
transfus
via
cordocentesi
plan
extend
gestat
optim
neonat
outcom
mother
develop
mirror
syndrom
week
ga
underw
urgent
caesarean
section
live
femal
infant
born
edema
distend
abdomen
petechia
ecchymos
spontan
respiratori
effort
labwork
show
hemoglobin
gl
white
blood
cell
count
platelet
abnorm
coagul
profil
resuscit
unsuccess
two
hour
life
parent
chose
palliat
child
autopsi
demonstr
dissemin
leukemia
involv
central
nervou
system
liver
bone
marrow
placenta
conclus
possibl
diagnos
hematolog
malign
fetu
even
neonat
littl
inform
direct
manag
intend
begin
exchang
transfus
via
cordocentesi
reduc
leukocytosi
therebi
prolong
gestat
stabl
deliveri
use
low
dose
chemotherapi
infant
term
thought
abl
toler
full
treatment
unfortun
mother
infant
well
enough
pursu
cours
fetal
leukemia
consid
differenti
diagnosi
fetu
present
hepatomegali
similar
case
identifi
clinician
share
experi
provid
futur
guidanc
manag
theodor
johnson
cole
giller
ian
heger
eugen
kennedi
ravindra
kolh
wale
mourad
amyn
rojiani
rams
sadek
nichola
vahanian
tobey
macdonald
david
munn
augusta
universitygru
cancer
center
augusta
georgia
unit
state
background
indoleamin
ido
natur
mechan
suppress
immun
although
clinic
trial
current
combin
immunotherapi
drug
chemotherapi
preclin
data
suggest
indoximod
synerg
chemotherapi
radiat
therefor
develop
trial
studi
indoximod
companion
adult
glioblastoma
studi
combin
indoximod
temozolomid
well
toler
toxic
surviv
pf
adult
patient
compar
relaps
glioblastoma
histor
two
patient
previous
progress
temozolomid
one
patient
one
patient
demonstr
partial
respons
month
therapi
respect
patient
surviv
month
date
continu
therapi
object
present
interim
result
ongo
pediatr
studi
designmethod
trial
assess
feasibl
safeti
preliminari
evid
efficaci
combin
indoximod
either
temozolomid
radiat
therapi
follow
temozolomid
treat
children
age
progress
malign
brain
tumor
exclud
dipg
indoximod
dose
level
start
adult
recommend
dose
result
one
year
old
patient
recurr
metastat
ependymoma
treat
indoximod
stereotact
radiosurgeri
toler
without
toxic
went
receiv
indoximod
combin
temozolomid
time
enrol
previous
receiv
separ
surgeri
proton
therapi
posterior
fossa
fraction
proton
therapi
fraction
proton
therapi
lower
spine
fraction
experiment
cabozantinib
experiment
vaccin
residu
paraventricular
tumor
contour
extrem
complex
locat
field
previous
receiv
aggress
radiat
start
indoximod
day
prior
receiv
gamma
plan
target
residu
intracrani
tumor
conclus
indoximod
may
synerg
standard
radiat
chemotherapi
children
brain
tumor
goal
incorpor
combin
indoximod
radiat
chemotherapi
treatment
pediatr
brain
tumor
aggress
local
control
option
partial
respond
relaps
diseas
settingsponsor
alex
lemonad
stand
foundat
cannonbal
kid
cancer
foundat
newlink
genet
corpor
dipti
digh
oyinad
akinyed
nidhi
bhatt
asneha
iqbal
lisa
giordano
john
h
stroger
jr
hospit
cook
counti
chicago
illinoi
unit
state
background
intrathec
methotrex
mtx
high
dose
intraven
methotrex
hd
mtx
import
compon
central
nervou
system
cn
prophylaxi
acut
leukemia
acut
neurotox
present
within
day
mtx
hd
mtx
headach
confus
disorient
seizur
focal
deficit
establish
guidelin
manag
acut
event
subsequ
cn
prophylaxi
patient
object
describ
manag
seri
adolesc
acut
leukemia
neurotox
designmethod
case
seri
result
patient
hispan
femal
high
risk
present
paralysi
left
hand
intermitt
dysarthria
delay
intensif
two
dose
weekli
mtx
symptom
resolv
spontan
within
one
day
patient
hispan
male
present
slur
speech
express
aphasia
left
side
facial
upper
extrem
weak
confus
consolid
chemotherapi
three
weekli
dose
mtx
symptom
resolv
spontan
within
five
dayspati
hispan
femal
mix
phenotyp
acut
leukemia
present
facial
palsi
quadriparesi
aphasia
consolid
chemotherapi
three
weekli
dose
mtx
patient
treat
dextromethorphan
day
symptom
resolv
within
hour
patient
twenti
hispan
male
philadelphia
chromosom
posit
present
confus
slur
speech
numb
tingl
leg
tongu
consolid
chemotherapi
one
week
hd
mtx
delay
clearanc
symptom
resolv
spontan
within
day
standard
protocol
util
subsequ
cn
prophylaxi
next
dose
mtx
omit
follow
dose
substitut
cytarabin
subsequ
mtx
dose
cap
mg
leucovorin
rescu
po
dose
hour
mtx
patient
experienc
recurr
episod
neurotox
cn
relaps
conclus
continu
intrathec
cn
prophylaxi
patient
neurotox
use
protocol
safe
effect
prevent
subsequ
neurotox
cn
relaps
larg
seri
patient
acut
leukemia
analyz
see
hispan
patient
higher
risk
neurotoxicti
lauren
tannenbaum
scott
moerdler
daniel
weiser
jonathan
gill
michael
roth
albert
einstein
colleg
medicin
bronx
new
york
unit
state
background
fine
needl
aspir
fna
frequent
util
diagnos
head
neck
mass
adult
due
fewer
surgic
risk
lack
requir
sedat
seemingli
high
diagnost
accuraci
otolaryngologist
begun
perform
fna
pediatr
patient
similar
reason
oncolog
literatur
gold
standard
diagnos
head
neck
mass
excision
biopsi
object
assess
differ
pediatr
oncologist
otolaryngologist
view
surgic
approach
diagnos
head
neck
mass
children
designmethod
design
survey
consist
patient
case
sent
via
electron
mail
practic
pediatr
oncologist
otolaryngologist
result
one
hundr
six
pediatr
oncologist
forti
one
otolaryngologist
respond
survey
year
old
girl
firm
mobil
anterior
chain
mass
resolv
antibiot
otolaryngologist
like
perform
fna
oncologist
vs
respect
p
otolaryngologist
also
like
perform
fna
old
girl
recurr
fever
weight
loss
hard
fix
supraclavicular
lymph
node
vs
respect
p
oncologist
otolaryngologist
would
complet
stage
begin
treatment
patient
refer
fna
demonstr
lymphoma
patholog
vs
respect
p
howev
patient
refer
fna
demonstr
inflamm
oncologist
otolaryngologist
would
proceed
biopsi
mass
vs
respect
p
conclus
otolaryngologist
pediatr
oncologist
differ
initi
approach
diagnos
head
neck
mass
children
research
need
understand
reason
behind
differ
determin
potenti
implic
provid
initi
diagnost
approach
rachel
rau
julienn
brackett
baylor
colleg
medicin
texa
children
cancer
center
houston
texa
unit
state
background
hypoglycemia
uncommon
side
effect
mercaptopurin
attribut
high
level
prior
report
mercaptopurin
metabol
respons
effect
appear
hepatotox
patient
preferenti
metabol
ad
allopurinol
oral
shown
reduc
level
maintain
therapeut
level
patient
inflammatori
bowel
diseas
acut
lymphoblast
leukemia
therefor
reason
reduct
level
addit
allopurinol
could
prevent
associ
hypoglycemia
strategi
previous
report
object
describ
use
allopurinol
success
prevent
induc
hypoglycemia
reduc
level
patient
hypoglycemia
designmethod
case
report
result
old
hispan
male
cell
receiv
mainten
chemotherapi
present
frequent
episod
nauseavomit
dehydr
blood
glucos
mgdl
rang
endocrin
includ
acth
stimul
test
neg
metabolit
notabl
dramat
elev
level
erythrocyt
refer
rang
attempt
intervent
includ
high
complex
carbohydr
diet
morn
dose
split
dose
led
modest
improv
symptom
nadir
level
erythrocyt
allopurinol
mg
daili
introduc
along
dose
reduct
led
dramat
improv
symptom
stabil
blood
glucos
resumpt
normal
diet
level
fell
erythrocyt
level
rose
erythrocyt
refer
rang
split
erythrocyt
despit
dose
reduct
conclus
ad
allopurinol
optim
balanc
metabolit
reduc
hypoglycem
episod
find
also
offer
support
elev
level
etiolog
induc
hypoglycemia
joseph
bernard
solon
notr
dame
dhaiti
haiti
background
wilm
tumor
nephroblastoma
repres
pediatr
cancer
accord
one
studi
common
cancer
among
haitian
children
object
main
object
studi
determin
predictor
poor
outcom
relaps
death
children
wilm
tumor
manag
haitian
pediatr
hospit
designmethod
studi
children
diagnos
manag
wilm
tumor
st
damien
hospit
februari
april
chart
review
focus
key
variabl
age
gender
geograph
origin
number
kidney
affect
siop
stage
type
treatment
metastat
diseas
occurr
complic
odd
ratio
report
associ
poor
outcom
variabl
chi
squar
test
use
determin
statist
signific
predictor
poor
outcom
set
result
case
wilm
tumor
identifi
studi
period
children
femal
age
rang
year
old
affect
proport
mass
abdomin
distens
respect
note
case
children
one
kidney
affect
associ
malform
found
metastas
found
case
term
treatment
patient
receiv
standard
combin
neoadjuv
chemotherapysurgeryadjuv
chemotherapi
children
achiev
complet
remiss
mortal
rate
predictor
poor
outcom
relaps
death
stage
iii
v
siop
classif
odd
ratio
p
bilater
wilm
diseas
p
presenc
metastas
p
occurr
complic
p
conclus
diagnosi
wilm
tumor
haiti
perform
late
stage
result
delay
manag
poor
outcom
earli
diagnosi
thu
key
better
manag
childhood
cancer
haiti
r
therrien
et
al
le
cancer
chez
lenfant
jg
lucien
j
bernard
jr
predictor
mortal
among
haitian
children
treat
cancer
pediatr
hospit
unpublish
studi
mohamad
sinno
grace
nehm
ralph
martello
univers
kansa
school
medicin
wichita
kansa
unit
state
background
invas
fungal
infect
major
caus
morbid
mortal
pediatr
oncolog
patient
receiv
chemotherapi
current
guidelin
recommend
antifung
prophylaxi
patient
mainli
acut
myelogen
leukemia
aml
allogen
transplant
patient
secondari
prophylaxi
indic
prolong
immunosuppress
expect
posaconazol
noxafil
merck
co
inc
whitehous
station
nj
oral
extend
spectrum
triazol
lesser
interact
profil
shown
safe
adult
howev
data
avail
regard
posaconazol
safeti
children
object
report
case
vincristin
toxic
boy
acut
lymphoblast
leukemia
histoplasmosi
receiv
concomit
posaconazol
designmethod
case
report
review
medic
literatur
result
caucasian
boy
mainten
therapi
daili
weekli
methotrex
monthli
vincristin
present
tertiari
care
hospit
febril
neutropenia
cough
patient
diagnos
pulmonari
histoplasmosi
base
find
diffus
reticulonodular
opac
ct
scan
posit
urin
histoplasma
antigen
liposom
amphotericin
b
voriconazol
normal
recommend
dose
use
discontinu
two
three
day
respect
due
acut
kidney
hepat
injuri
respect
patient
shift
iv
posaconazol
mgkgday
day
chang
po
form
respond
well
therapi
avoid
possibl
interact
posaconazol
vincristin
dose
reduc
origin
dose
howev
day
later
patient
present
grade
ctcae
peripher
neuropathi
posaconazol
discontinu
due
high
suspicion
posaconazol
potenti
vincristin
neuropathi
peripher
neuropathi
resolv
within
day
vincristin
restart
reduc
dose
patient
continu
neurolog
intact
conclus
unlik
triazol
antifung
posaconazol
interact
fewer
hepat
isoenzym
name
affect
vincristin
metabol
addit
posaconazol
may
inhibit
vincristin
efflux
may
potenti
vincristin
toxic
specul
happen
case
best
knowledg
three
report
case
posaconazol
induc
vincristin
toxic
report
case
increas
awar
signific
yet
prevent
interact
especi
posaconazol
increasingli
use
pediatr
oncologist
daniel
bell
junyan
tao
sucha
singh
maria
chikina
sarangarajan
ranganathan
satdarshan
monga
univers
pittsburgh
pittsburgh
pennsylvania
unit
state
background
hepatoblastoma
common
type
pediatr
liver
malign
signal
abnorm
pathway
associ
tumor
fact
protein
observ
hepatoblastoma
patient
overexpress
yap
mice
led
hepatoblastoma
develop
gene
array
analysi
mrna
isol
tumor
bear
liver
reveal
gene
show
signific
upregul
tumor
also
bind
site
promot
transcript
factor
bind
tead
bind
yap
one
gene
lipocalin
small
molecul
protein
known
antibacteri
properti
found
express
varieti
adult
cancer
object
determin
lipocalin
express
human
hepatoblastoma
designmethod
use
tissu
microarray
patient
hepatoblastoma
sampl
tertiari
care
pediatr
hospit
evalu
presenc
lipocalin
immunohistochemistri
tumor
classifi
histolog
type
degre
lipocalin
stain
grade
scale
stain
stratifi
either
nuclear
cytoplasm
next
cell
lysat
cell
cultur
human
heptoblastoma
cell
line
test
presenc
lipocalin
use
western
blot
analysi
result
lipocalin
normal
express
hepatocyt
found
present
either
nucleu
cytoplasm
pediatr
hepatoblastoma
sampl
degre
stain
lipocalin
vari
within
sampl
base
tumor
histolog
embryon
compon
strongli
posit
lipocalin
stain
score
percent
crowd
fetal
histolog
compon
posit
lipocalin
stain
although
stain
rang
intens
minim
express
lipocalin
blastema
small
cell
undifferenti
compon
lipocalin
also
confirm
present
hepatoblastoma
cell
cultur
western
blot
analysi
conclus
identifi
increas
express
lipocalin
downstream
yap
activ
hepatoblastoma
cell
patient
tissu
lipocalin
may
play
import
role
driven
hepatoblastoma
develop
jessica
meznarich
anupam
verma
primari
children
hospit
univers
utah
salt
lake
citi
utah
unit
state
background
cytomegaloviru
cmv
retin
complic
immunosuppress
host
typic
seen
acquir
immunodefici
syndrom
hematopoiet
stem
cell
transplant
patient
howev
cmv
retin
occur
therapi
acut
lymphoblast
leukemia
without
transplant
rare
describ
object
describ
case
adolesc
acut
lymphoblast
leukemia
mainten
present
acut
vision
loss
due
cmv
retin
designmethod
case
report
review
literatur
result
old
male
mainten
present
acut
vision
loss
right
eye
ophthalmolog
examin
show
affer
pupillari
defect
poor
visual
acuiti
larg
visual
field
deficit
left
eye
vision
unaffect
fundoscop
examin
reveal
bilater
optic
disc
edema
peripapillari
hemorrhag
scatter
retin
hemorrhag
central
larg
area
retin
whiten
cotton
wool
spot
differenti
diagnosi
base
ophthalmolog
examin
includ
leukem
versu
infecti
retinopathi
mri
brainorbit
neg
intracrani
patholog
orbit
mass
optic
nerv
edema
total
white
blood
cell
count
absolut
neutrophil
count
anc
absolut
lymphocyt
count
alc
vitreou
aspir
perform
intravitr
inject
amphotericin
vancomycin
ceftazidim
clindamycin
ganciclovir
vitreou
fluid
posit
cmv
polymeras
chain
reaction
pcr
cmv
dna
also
detect
serum
quantit
pcr
vitreou
cell
neg
malign
flow
cytometri
bone
marrow
cerebrospin
fluid
also
neg
malign
therefor
diagnosi
cmv
retin
made
treat
cours
valganciclovir
follow
prophylact
dose
visual
acuiti
stabl
improv
retin
fundoscop
exam
remain
visual
field
deficit
conclus
cmv
retin
rare
report
complic
therapi
without
transplant
occurr
recogn
especi
patient
immunodefici
patient
alc
time
present
cmv
retin
ophthalmolog
exam
find
alon
may
differenti
leukem
infiltr
cmv
retin
case
vitreou
aspir
consid
confirm
diagnosi
adriana
fonseca
sheridan
furqan
shaikh
abha
gupta
ted
gerstl
hospit
sick
children
toronto
ontario
canada
background
treatment
hepatoblastoma
hb
includ
surgic
resect
chemotherapi
twenti
percent
patient
requir
orthotop
liver
transplant
olt
current
guidelin
recommend
patient
proceed
olt
complet
tumour
resect
neg
margin
achiev
object
object
report
seri
children
hb
jan
treat
hospit
sick
children
undergo
complex
hepatectomi
neg
plan
microscop
posit
margin
avoid
olt
designmethod
demograph
data
clinic
characterist
surgic
patholog
detail
complic
surviv
inform
collect
chart
review
result
six
children
hb
median
age
year
diagnosi
rang
month
year
pretext
classif
follow
ii
n
patient
vascular
involv
inferior
vena
cava
ivc
hepat
vein
iii
n
iv
n
synchron
pulmonari
metastas
present
patient
tumour
histolog
n
mix
epitheli
mesenchym
n
pure
epitheli
n
median
afp
diagnosi
uglt
rang
million
patient
receiv
chemotherapi
platinum
agent
median
cycl
rang
cycl
extend
right
hepatectomi
perform
patient
patient
two
addit
wedg
resect
segment
left
lobe
extend
left
hepatectomi
patient
margin
posit
patient
patient
margin
neg
closest
margin
rang
mm
two
patient
requir
vascular
reconstruct
ivc
month
median
rang
year
none
patient
local
recurr
patient
recurr
pulmonari
diseas
month
surgeri
case
afp
fall
expect
start
rise
soon
surgeri
conclus
patient
advanc
hb
receiv
complex
surgic
resect
posit
microscop
margin
close
neg
margin
margin
mm
good
outcom
hypothes
plan
posit
microscop
margin
highli
select
hb
patient
may
spare
morbid
olt
aime
foord
van
huynh
lilibeth
torno
choc
children
hospit
orang
counti
orang
california
unit
state
background
dramat
increas
obes
rate
among
children
unit
state
us
associ
obes
cancer
wide
studi
show
obes
patient
risk
multipl
side
effect
poor
outcom
nonalcohol
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
pediatr
patient
us
known
effect
treatment
nafld
except
diet
exercis
use
prior
studi
treat
liver
toxic
use
pediatr
oncolog
patient
fatti
liver
identifi
group
pediatr
oncolog
patient
risk
develop
fatti
liver
complic
object
describ
pediatr
patient
relaps
acut
lymphoblast
leukemia
fatti
liver
diseas
treat
designmethod
review
medic
record
result
obes
thirteen
boy
relaps
found
persist
elev
liver
enzym
ast
alt
peak
normal
respect
despit
break
chemotherapeut
regimen
imag
perform
show
chang
consist
fatti
liver
due
risk
sinusoid
obstruct
syndrom
so
bone
marrow
transplant
bmt
held
maintain
remiss
given
chemotherapi
addit
start
gram
oral
twice
day
attempt
lower
liver
enzym
three
month
treatment
ast
alt
gradual
improv
near
normal
level
bmt
donor
pursu
transplant
regimen
overal
well
toler
without
evid
so
patient
continu
remiss
continu
side
effect
observ
conclus
patient
thought
improv
transamin
enabl
undergo
bmt
transamin
due
fatti
liver
signific
factor
lead
alter
interrupt
chemotherapi
regimen
increas
transplant
morbid
thu
affect
overal
surviv
increas
risk
relaps
supplement
along
diet
exercis
regimen
may
abl
improv
transamin
revers
fatti
liver
overal
without
signific
toxic
prospect
studi
need
mari
nelson
holli
meani
children
nation
medic
center
washington
district
columbia
unit
state
background
hepatocellular
carcinoma
hcc
second
common
pediatr
liver
malign
annual
incid
per
million
children
unit
state
hcc
associ
underli
hepat
cellular
injuri
lead
liver
cell
dysplasia
describ
hemochromatosi
defici
hereditari
tyrosinemia
glycogen
storag
disord
diseas
type
c
npc
autosom
recess
liposom
storag
diseas
character
dysfunct
cholesterol
transport
accumul
sphingomyelin
cholesterol
lysosom
result
hepatosplenomegali
hepat
dysfunct
rare
case
hcc
npc
exist
literatur
clear
link
two
establish
object
present
male
npc
present
acut
abdomin
distens
hemodynam
instabl
mri
reveal
larg
solid
mass
medial
segment
left
hepat
lobe
smaller
lesion
anterior
right
hepat
lobe
concern
intrahepat
metastasi
head
chest
ct
scan
neg
distant
metastas
biopsi
confirm
hcc
stage
iii
diseas
alpha
fetoprotein
afp
diagnosi
elev
iuml
patient
underw
upfront
resect
left
side
mass
biopsi
right
hepat
lesion
designmethod
upfront
resect
improv
likelihood
success
treatment
due
residu
right
hepat
diseas
patient
receiv
cycl
cisplatin
doxorubicin
administ
everi
week
modifi
plado
regimen
twice
daili
sorafenib
tyrosin
kinas
inhibitor
due
vomit
diarrhea
complianc
issu
approxim
plan
sorafenib
dose
administ
result
patient
respond
treatment
evid
diseas
mri
imag
afp
normal
iuml
follow
surgic
resect
cycl
chemotherapi
three
month
therapi
evid
diseas
recurr
mri
imag
monthli
afp
remain
normal
rang
iuml
conclus
hcc
rare
challeng
entiti
pediatr
oncolog
classic
associ
npc
patient
suffer
hepat
damag
time
risk
malign
transform
rais
question
regard
routin
screen
either
radiograph
laboratori
test
monitor
afp
level
craig
erker
anna
huppler
thoma
walsh
neel
bhatt
paul
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
invas
fungal
infect
children
cancer
disproportion
affect
leukemia
patient
conidiobolu
entomopthoromycota
found
tropic
region
associ
rhinofaci
infect
although
rare
pediatr
oncolog
high
mortal
spread
rapidli
report
treatment
adolesc
acut
lymphoblast
leukemia
multidrug
resist
mdr
invas
sinopulmonari
conidiobolu
infect
object
describ
manag
strategi
support
neutrophil
function
treat
invas
conidiobolu
infect
patient
receiv
chemotherapi
designmethod
case
report
result
male
present
intermitt
fever
fatigu
cough
petechia
sever
neutropen
circul
blast
diagnos
began
induct
chemotherapi
concomit
antifung
prophylaxi
day
induct
develop
congest
facial
pain
nasal
endoscopi
reveal
pale
insens
mucosa
imag
show
diffus
nodular
ground
glass
opac
throughout
lung
nasal
biopsi
reveal
branch
hyph
septat
suggest
aspergillu
voriconazol
micafungin
start
empir
day
cultur
fungu
show
zygospor
promin
beak
sporangiola
characterist
conidiobolu
speci
organ
resist
antifung
agent
except
terbinafin
amphotericin
b
anidulafungin
intermedi
treatment
chang
liposom
amphotericin
b
lamb
anidulafungin
terbinafin
bone
marrow
aspir
neg
leukemia
day
induct
due
progress
pulmonari
sinu
diseas
extend
skull
base
chemotherapi
temporarili
halt
neutrophil
support
augment
daili
granulocyt
infus
hyperbar
oxygen
therapi
hbot
granulocyt
infus
discontinu
follow
endogen
neutrophil
recoveri
day
diagnosi
lamb
hbot
continu
sever
week
imag
dramat
improv
sinu
fungal
cultur
becam
neg
week
without
neutropenia
chemotherapi
resum
continu
aggress
neutrophil
support
sever
neutropen
leukemia
remain
remiss
without
evid
progress
fungal
diseas
conclus
multidisciplinari
care
crucial
simultan
treatment
life
threaten
fungal
infect
use
aggress
support
neutrophil
function
effect
control
dissemin
mdr
conidiobolu
infect
allow
deliveri
myelosuppress
chemotherapi
jina
kim
zhifei
sun
moham
adam
obinna
adib
henri
rice
april
salama
paul
mosca
elisabeth
traci
duke
univers
medic
center
durham
north
carolina
unit
state
background
current
treatment
pediatr
melanoma
adapt
adult
studi
although
children
melanoma
demonstr
differ
pathophysiolog
clinic
outcom
adult
exampl
adjuv
immunotherapi
melanoma
studi
prospect
adult
similar
studi
lack
children
object
review
nation
cancer
data
base
ncdb
understand
impact
adjuv
immunotherapi
surviv
children
melanoma
designmethod
ncdb
queri
patient
less
year
age
diagnos
stage
iib
iic
iii
cutan
melanoma
patient
receiv
adjuv
chemotherapi
radiat
exclud
patient
group
whether
receiv
adjuv
immunotherapi
multivari
proport
hazard
method
use
compar
overal
surviv
result
total
patient
met
studi
criteria
patient
receiv
adjuv
immunotherapi
among
children
receiv
adjuv
immunotherapi
stage
iii
diseas
baselin
children
receiv
adjuv
immunotherapi
experienc
wors
surviv
vs
year
p
adjust
patient
tumor
treatment
characterist
children
receiv
adjuv
immunotherapi
signific
improv
overal
surviv
adjust
hazard
ratio
confid
interv
p
conclus
benefit
adjuv
immunotherapi
children
melanoma
remain
unclear
studi
examin
specif
immunotherapi
regimen
would
use
answer
import
question
ultim
creation
pediatr
melanoma
registri
would
valuabl
develop
guidelin
melanoma
therapi
children
robert
hartemay
teresa
kuhta
stelio
manti
paul
kent
rush
univers
medic
center
chicago
illinoi
unit
state
background
long
act
use
treatment
acut
lyphoblast
leukemia
work
inhibit
protein
synthesi
increas
apoptosi
common
side
effect
hyperglycemia
due
either
inhibit
insulin
synthesi
acut
pancreat
rare
case
induc
hyperinsulinemia
symptomat
hypoglycemia
set
weekli
intens
object
describ
case
symptomat
hypoglycemiahyperinsulininemia
patient
treat
weekli
relaps
designmethod
review
pubm
ovid
googl
scholar
similar
case
identifi
previous
report
case
associ
hypoglycemia
unknown
caus
result
year
old
femal
trisomi
relaps
treat
induct
chemotherapi
weekli
vincristin
weekli
tid
prednison
weekli
daunomycin
exhibit
persist
hypoglycemia
serum
glucos
despit
continu
iv
dextros
day
induct
patient
syncop
blood
glucos
ioniz
calcium
electrolyt
normal
fibrinogen
level
consist
predict
inhibit
protein
synthesi
concurr
glucos
insulin
betahydroxybutyr
free
fatti
acid
confirm
hyperinsulinemia
without
exogen
insulin
patient
receiv
prednison
tid
normal
amylaselipas
rule
associ
pancreat
steroid
defici
clinic
sign
sepsi
patient
treat
iv
dextros
hypoglycemia
resolv
week
complet
induct
remain
clinic
remiss
conclus
hyperinsulinemia
lead
symptomat
hypoglycemia
induct
chemotherapi
rare
similar
report
case
unexpect
hypoglycemia
danger
find
identifi
rel
simpl
manag
mechan
find
entir
clear
time
propos
mechan
lead
preferenti
inhibit
insulin
degrad
enzym
ide
synthesi
lead
delay
clearanc
oppos
inappropri
insulin
synthesi
patient
interestingli
ide
polymoph
describ
trisomi
individula
possibl
explan
well
known
risk
earli
onset
alzheim
diseas
hope
report
increas
awar
inquiri
rare
side
effect
lucarelli
neurosci
let
david
steffin
taylor
olmst
richard
hurwitz
alex
georg
texa
children
hospit
houston
texa
unit
state
background
associ
iron
defici
anemia
ida
cerebr
vascular
accid
previous
establish
varieti
case
report
although
exact
pathogenesi
unknown
sever
iron
defici
anemia
associ
near
risk
develop
symptom
compar
patient
without
ida
littl
current
literatur
describ
arteri
dissect
associ
iron
defici
anemia
though
recent
studi
older
children
adult
demonstr
associ
anemia
stroke
cervic
arteri
dissect
well
wors
outcom
stroke
concurr
anemia
object
present
case
child
evid
weak
found
arteri
dissect
presenc
iron
defici
anemia
highlight
atyp
present
sever
ida
need
aggress
treatment
prevent
care
patient
designmethod
retrospect
chart
review
perform
two
year
old
femal
texa
children
hospit
houston
texa
compar
data
previous
publish
case
complic
sever
iron
defici
anemia
result
patient
present
approxim
day
fatigu
pallor
progress
weak
right
extrem
admiss
hemoglobin
level
mcv
ferritin
transferrin
ct
angiographi
brain
identifi
dissect
left
intern
carotid
arteri
neck
evid
trauma
comprehens
connect
tissu
diseas
genet
workup
neg
underw
transfus
pack
red
blood
cell
aspirin
follow
unfraction
heparin
transit
lovenox
steadili
improv
transfer
outsid
hospit
near
home
rehabilit
therapi
conclus
link
iron
defici
anemia
thrombot
ischem
stroke
link
arteri
dissect
previous
describ
patient
unusu
present
suggest
arteri
dissect
consequ
ida
judici
manag
anemia
transfus
therapi
along
anticoagul
lead
signific
clinic
improv
case
highlight
novel
complic
ida
provid
guidanc
manag
complex
case
kami
wolf
schneider
qi
wei
susan
kuldanek
kathrin
bernt
children
hospit
colorado
univers
colorado
anschutz
medic
campu
aurora
colorado
unit
state
background
previous
healthi
year
old
femal
present
abdomin
pain
fever
headach
lymphadenopathi
fatigu
matern
famili
histori
remark
first
cousin
clinic
diagnosi
famili
mediterranean
fever
molecular
mefv
test
grandfath
chronic
lymphocyt
leukemia
serial
peripher
blood
cell
count
show
fall
hemoglobin
fall
platelet
rise
monocyt
blast
count
bone
marrow
analysi
show
mild
dysplasia
hemophagocytosi
bone
marrow
blast
increas
object
clarifi
diagnosi
treatment
option
genet
test
pursu
designmethod
chromosom
analysi
reveal
mosaic
xxx
bone
marrow
cell
analyz
mosaic
xxx
also
detect
cultur
stimul
peripher
blood
lymphocyt
skin
fibroblast
xx
next
gener
sequenc
panel
bone
marrow
detect
variant
mutat
previous
report
juvenil
myelomonocyt
leukemia
variant
report
hematopoiet
malign
also
rare
singl
nucleotid
polymorph
healthi
popul
consid
variant
uncertain
signific
result
genet
counselor
involv
multipl
decis
point
discuss
potenti
constitut
mosaic
xxx
famili
leukemia
due
germlin
mutat
noonan
syndrom
due
germlin
mutat
differenti
diagnos
base
person
famili
histori
genet
counsel
also
util
discuss
collect
appropri
specimen
genet
test
eg
buccal
swabsaliva
versu
skin
fibroblast
implic
genet
test
result
diagnosi
treatment
option
ie
marker
respons
therapi
select
bone
marrow
donor
hereditari
cancer
genet
counsel
topic
includ
psychosocialeth
consider
medic
famili
reproduct
implic
possibl
interpret
chromosom
find
includ
contamin
constitut
mosaic
vari
differ
tissu
multilineag
myeloidlymphoid
clonal
hematopoiet
malign
ultim
base
buccal
cell
analys
mutat
appear
somat
variant
appear
germlin
conclus
case
illustr
complex
germlin
genet
counsel
result
somat
genet
test
import
genet
profession
avail
consult
type
test
order
kelli
lastrap
gita
massey
debra
shockey
devon
wojcikewych
egidio
del
fabbro
virginia
commonwealth
univers
richmond
virginia
unit
state
background
approxim
adolesc
young
adult
aya
age
diagnos
cancer
unit
state
yearli
despit
inferior
outcom
compar
pediatr
adult
counterpart
integr
palli
medicin
routin
care
aya
popul
remain
infrequ
object
highlight
challeng
commun
occur
transit
legal
adulthood
designmethod
two
young
peopl
lost
live
cancer
year
turn
eighteen
thespian
yo
theatr
lover
burden
osteosarcoma
bladder
sarcoma
tumor
infiltr
spine
leav
parapleg
complet
depend
famili
time
independ
paramount
lay
hospit
bed
twin
brother
search
colleg
dream
mom
fire
palli
care
frank
code
statu
discuss
slap
face
mortal
guardian
yo
metastat
ewe
sarcoma
gang
aya
male
carri
diagnosi
prognosi
mother
insist
never
told
bad
delirium
plagu
final
day
despit
desper
attempt
keep
truth
throughout
treatment
cours
parent
devast
could
nt
particip
decis
make
due
patient
famili
refus
palli
care
involv
two
week
prior
guis
call
support
care
team
result
young
men
die
hospit
minim
palli
care
support
conclus
uniqu
development
social
emot
ethic
existenti
struggl
aya
popul
benefit
highli
special
interdisciplinari
approach
howev
case
highlight
conflict
autonomi
parent
protect
possibl
deviat
norm
develop
barrier
effect
care
aya
popul
earlier
engag
educ
aya
patient
famili
regard
palli
care
may
facilit
improv
commun
weiner
clin
oncol
adolesc
young
adult
anant
vatsayan
ashish
gupta
rose
beck
rachel
egler
sanjay
ahuja
yousif
matloub
uh
rainbow
babi
children
hospit
cleveland
ohio
unit
state
background
viru
associ
mucocutan
ulcer
ebvmcu
recent
character
entiti
ebv
lymphoprolif
disord
ebvlpd
polyclon
prolifer
occur
mucocutan
tissu
elderli
patient
immunosenesc
patient
immunosuppress
therapi
limit
true
incid
ebvmcu
unknown
due
natur
limit
awar
amongst
clinician
object
gener
awar
ebvmcu
amongst
clinician
designmethod
case
report
result
year
old
male
intermedi
risk
mainten
phase
chemotherapi
cog
protocol
present
left
side
throat
pain
exud
left
tonsillar
ulcer
concern
abscess
versu
leukem
infiltr
tonsillar
biopsi
show
dens
polymorph
infiltr
lymphocyt
neutrophil
plasma
cell
histiocyt
small
sheet
larg
atyp
consist
cell
promin
rais
concern
larg
cell
lymphoma
lymphoprolif
disord
cellsdemonstr
follow
immunophenotyp
eber
rna
consist
immunoblast
tdt
immunostain
neg
ebv
pcr
peripher
blood
iuml
peripher
blood
smear
reveal
blast
peripher
blood
immunophenotyp
show
reduct
absenc
cell
whole
bodi
pet
ct
show
local
hypermetabol
foci
left
tonsil
base
clinicopatholog
find
diagnosi
ebvmcu
made
sinc
ulcer
regress
despit
stop
oral
chemotherapi
week
dose
rituximab
tri
tonsillar
ulcer
complet
resolv
week
rituximab
present
month
follow
dose
rituximab
remain
remiss
conclus
despit
strike
histopatholog
immunophenotyp
resembl
b
cell
lymphoma
ebvlpd
ebvmcu
repres
indol
local
variant
ebvlpd
excel
prognosi
extens
workup
includ
imag
bone
marrow
biopsi
serolog
may
need
rule
system
lpd
mandat
aggress
treatment
appropri
diagnosi
help
clinician
make
critic
decis
like
withhold
immunosuppress
drug
necessari
immun
reconstitut
repertoir
control
ebv
infect
case
resolv
spontan
stop
immunosuppress
therapi
refractori
relaps
case
may
requir
aggress
approach
like
rituximab
radiotherapi
seethal
jacob
mark
vander
lugt
peter
shaw
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
background
william
syndrom
ws
genet
syndrom
associ
characterist
faci
hypercalcemia
cardiovascular
anomali
hematolog
abnorm
rare
describ
object
object
present
infant
ws
bone
marrow
bm
failur
found
autosom
recess
ar
infantil
malign
osteopetrosi
op
designmethod
designmethod
case
reporta
full
term
infant
found
murmur
earli
life
echocardiogram
show
supravalvular
aortic
pulmon
stenosi
rais
concern
ws
genet
test
confirm
month
age
find
characterist
delet
soon
evalu
dehdyr
found
anem
thrombocytopen
bm
biopsi
demonstr
fibrosi
requir
period
transfus
bm
failur
syndrom
includ
fanconi
anemia
dyskeratosi
congenita
neg
imag
show
boni
chang
concern
op
repeat
bm
biopsi
show
increas
osteoclast
genet
test
demonstr
mutat
consist
infantil
malign
op
ar
type
patient
underw
hematopoiet
stem
cell
transplant
hsct
result
result
ws
constel
sign
symptom
caus
delet
chromosom
american
academi
pediatr
establish
clinic
guidelin
care
patient
ws
includ
necessari
surveil
hematolog
issu
rare
associ
syndrom
part
guidelinesop
manifest
variou
age
depend
mode
inherit
ar
form
infantil
malign
op
present
earli
life
caus
mutat
rank
rankl
manifest
hypocalcemia
sclerot
bone
frequent
fractur
sometim
visual
loss
hear
loss
bm
failur
due
expans
bone
hsct
halt
slow
diseas
progress
replac
defect
osteoclast
ws
op
previous
describ
togeth
although
ws
mous
model
shown
featur
without
osteoclast
dysfunct
defici
seen
op
conclus
conclus
ws
op
well
character
first
document
case
diagnos
patient
research
potenti
genet
associ
two
diseas
may
elucid
pathophysiolog
anant
vatsayan
rachel
egler
agn
petrosiut
uh
rainbow
babi
children
hospit
cleveland
ohio
unit
state
background
primari
pleural
synovi
sarcoma
ppss
extrem
rare
tumor
first
describ
case
seri
patient
children
year
report
first
case
ppss
associ
paraspin
ganglioneuroma
serou
cystadenoma
ovari
mutat
met
oncogen
unknown
signific
occurr
multipl
differ
tumor
young
patient
genet
mutat
suggest
possibl
hitherto
unknown
cancer
predisposit
syndrom
object
report
rare
present
ppss
associ
paraspin
ganglioneuroma
serou
cystadenoma
ovari
designmethod
case
report
result
caucasian
femal
present
week
right
chest
pain
august
famili
histori
signific
multipl
solid
tumor
laryng
thyroid
colon
renal
mri
chest
show
right
pleural
mass
biopsi
resect
mass
suggest
monophas
synovi
sarcoma
posit
margin
immunohistochemistri
posit
vimentin
ema
cytogenet
reveal
x
metastat
workup
reveal
left
lumbar
paraspin
lesion
right
adnex
mass
biopsi
left
paraspin
lesion
reveal
matur
ganglioneuroma
biopsi
resect
adnex
mass
consist
diagnosi
serou
cystadenoma
ovari
genet
work
reveal
constitut
heterozyg
mutat
met
g
patient
stage
ir
gradeiii
stageiii
pog
grade
iii
receiv
cycl
ifosfamid
doxorubicin
cog
protocol
gy
radiat
current
patient
remain
remiss
conclus
ppss
never
report
associ
tumor
cell
origin
ppss
still
remain
enigma
base
recent
demonstr
immunophenotyp
overlap
ss
malign
peripher
nerv
sheath
tumor
folp
et
al
besid
constitut
express
ss
associ
fusion
gene
neuroepitheli
tissu
brujin
et
al
genet
mutat
unknown
signific
patient
hypothes
constel
tumor
patient
may
mere
coincident
tumor
may
aris
common
pleuripot
mesenchym
stem
cell
verifi
hypothesi
immunophenotyp
cytogenet
analysi
ganglioneuroma
cystadenoma
hemant
menghani
rene
gardner
loli
yu
louisiana
state
univers
health
scienc
center
new
orlean
louisiana
unit
state
background
diseas
scd
one
common
sever
genet
disord
worldwid
scd
individu
demonstr
increas
adhes
blood
cell
includ
red
blood
cell
neutrophil
eosinophil
platelet
play
fundament
role
process
aplast
anemia
aa
character
peripher
blood
pancytopenia
hypocellular
bone
marrow
paroxysm
nocturn
hemoglobinuria
pnh
acquir
hemolyt
diseas
associ
intravascular
hemolysi
thrombosi
object
present
rare
occurr
sever
aplast
anemia
saa
pnh
clone
teenag
scd
clinic
challeng
combin
present
designmethod
case
report
result
old
african
american
femal
scd
follow
comprehens
care
clinic
initi
found
isol
thrombocytopenia
later
progress
pancytopenia
bone
marrow
done
consist
diagnosi
saa
start
cyclosporin
immun
suppress
therapi
ist
respond
transient
eventu
becam
transfus
depend
month
later
pnh
clone
increas
declar
pnh
point
underw
transplant
unrel
donor
molecularli
match
without
complic
current
month
post
transplant
evid
pnh
clone
stabl
count
hemoglobin
electrophoresi
consist
sickl
cell
trait
conclus
aa
rare
disord
thought
due
mediat
destruct
hematopoiet
cell
bone
marrow
ist
bone
marrow
transplant
first
line
treatment
option
aa
children
respond
primari
ist
requir
therapi
respond
relaps
clonal
evolut
hematopoiesi
pnh
thought
occur
aa
patient
clonal
abnorm
frequent
detect
diagnosi
clonal
hematopoiesi
pnh
may
also
develop
year
ist
treatment
patient
requir
follow
special
care
center
knowledg
late
manifest
diseas
shashi
ranjani
intezar
mehdi
chaithra
sreenath
rasmi
palasseri
pooja
mallya
hcg
hospit
bengaluru
karnataka
india
background
extraneur
metastasi
enm
medulloblastoma
rare
enm
usual
occur
bone
enm
subcutan
tissu
rare
literatur
review
came
across
three
case
object
describ
case
medulloblastoma
subcutan
metastasi
designmethod
case
report
result
year
old
indian
male
present
symptom
obstruct
hydrocephalu
found
larg
posterior
fossa
mass
drop
lesion
thorac
spine
level
near
total
resect
patholog
show
grade
iv
medulloblastoma
receiv
radiat
chemotherapi
lomustin
vincristin
cisplatin
treatment
patient
develop
extern
mass
surgic
scar
associ
posterior
cervic
lymphadenopathi
imag
show
new
lesion
subcutan
plane
infiltr
erector
spina
muscl
lymph
node
metastasi
simultan
recurr
primari
tumour
bed
metastasi
biopsi
lesion
confirm
subcutan
recurr
medulloblastoma
aggress
surgic
resect
combin
high
dose
chemotherapi
stem
cell
rescu
suggest
cur
option
treat
team
famili
opt
palli
approach
metronom
chemotherapi
use
cyclophosphamid
etoposid
rapid
diseas
progress
worsen
lymphadenopathi
result
intern
jugular
vein
compress
facial
edema
well
right
facial
nerv
palsi
metronom
chemotherapi
withdrawn
patient
ultim
succumb
diseas
five
month
recurr
note
conclus
report
discuss
unusu
subcutan
metastasi
medulloblastoma
subcutan
metastasi
may
indic
aggress
tumour
poor
prognosi
howev
avail
literatur
subcutan
metastasi
shown
almost
alway
metastasi
vicin
surgic
incis
could
impli
implant
surgic
procedur
brandon
mcnew
christoph
roke
daniel
dimeo
blank
children
hospit
unitypoint
health
de
moin
iowa
unit
state
background
although
tradit
practic
avoid
concurr
use
allopurinol
administr
mercaptopurin
world
oncolog
recent
literatur
describ
intent
use
allopurinol
optim
metabol
treatment
inflammatori
bowel
diseas
process
even
malign
process
acut
lymphoblast
leukemia
reportedli
shown
safe
shunt
metabol
away
hepatoxicmyelotox
metabolit
toward
favorableefficaci
metabolit
metabolit
synergist
potenti
allopurinol
employ
cancer
center
despit
recent
evid
support
potenti
efficaci
natur
drug
combin
user
must
remain
cautiou
possibl
myelotox
even
effect
report
case
attempt
optim
metabolit
profil
may
result
aplast
anemia
object
describ
aplast
anemia
complic
concurr
allopurinol
mercaptopurin
therapi
pediatr
patient
designmethod
case
report
result
yo
tpmt
wild
type
male
histori
crohn
diseas
diagnos
present
progress
pancytopenia
receiv
combin
mercaptopurin
daili
allopurinol
therapi
daili
combin
therapi
initi
previous
due
unfavor
metabolit
profil
mercaptopurin
monotherapi
daili
risk
toxic
therapeut
metabolit
profil
associ
mild
pancytopenia
addit
allopurinol
even
concurr
dose
reduct
mercaptopurin
result
signific
elev
metabolit
bone
marrow
evalu
reveal
markedli
hypocellular
marrow
panhypoplasia
consist
aplast
anemia
evid
infecti
etiolog
malign
lymphoprolif
disord
one
month
therapi
patient
return
peripher
blood
count
pancytopen
patient
requir
one
prbc
transfus
symptomat
anemia
requir
intervent
cytopenia
conclus
optim
mercaptopurin
metabolit
profil
concurr
allopurinol
therapi
difficult
balanc
act
potenti
signific
myelotox
effect
includ
aplast
anemia
samara
potter
rajkumar
venkatramani
scott
wenderf
brett
graham
yape
yang
christin
eng
richard
gibb
angshumoy
roy
sharon
plon
donald
parson
baylor
colleg
medicin
texa
children
hospit
houston
texa
unit
state
background
renal
cell
carcinoma
rare
malign
pediatr
renal
tumor
associ
variou
inherit
diseas
includ
von
tuber
sclerosi
complex
tsc
patient
tsc
risk
number
renal
tumor
includ
angiomyolipoma
renal
cell
carcinoma
due
germlin
mutat
one
two
tsc
associ
gene
patient
without
tsc
also
rare
develop
renal
cell
carcinoma
due
somat
mutat
gene
present
child
methylmalon
acidemia
mma
develop
renal
cell
carcinoma
two
somat
inactiv
mutat
gene
object
report
case
renal
cell
carcinoma
sporad
mutat
patient
mma
designmethod
molecular
case
report
result
year
old
femal
mma
renal
tubular
acidosi
chronic
kidney
diseas
refer
oncolog
servic
due
persist
elev
pth
relat
peptid
hypercalcemia
whole
bodi
petct
scan
reveal
solitari
focu
hypermetabol
uptak
within
cm
left
kidney
lesion
partial
nephrectomi
perform
histolog
examin
demonstr
encapsul
neoplasm
consist
polygon
cell
eosinophil
vacuol
cytoplasm
despit
nuclear
express
fish
test
gene
rearrang
neg
tumor
diagnos
renal
cell
carcinoma
no
whole
exom
sequenc
perform
tumor
peripher
blood
part
clinic
studi
germlin
analysi
reveal
two
heterozyg
pathogen
variant
mut
gene
known
caus
mma
tumor
sequenc
identifi
two
somat
inactiv
mutat
gene
encod
tuberin
princip
cellular
inhibitor
mtor
signal
complex
hamartin
encod
conclus
patient
mma
prone
chronic
kidney
diseas
eventu
renal
failur
known
associ
pediatr
renal
cell
carcinoma
first
report
case
renal
cell
carcinoma
somat
mutat
patient
mma
inhibitor
mtor
signal
approv
treatment
relaps
metastat
renal
cell
carcinoma
might
consid
event
tumor
recurr
patient
known
mutat
activ
pathway
andrea
whitfield
david
white
j
antonio
quiro
shayla
bergmann
medic
univers
south
carolina
charleston
south
carolina
unit
state
background
hereditari
hemorrhag
telangiectasia
hht
vascular
dysplasia
character
telangiectasia
arterioven
malform
avm
nose
gastrointestin
tract
lung
brain
liver
hht
affect
one
five
thousand
peopl
nineti
percent
affect
person
thought
undiagnos
diseas
process
often
initi
present
epistaxi
adolesc
object
discuss
present
diagnosi
treatment
option
rare
case
aggress
hht
four
male
designmethod
case
report
result
four
male
present
local
emerg
depart
acut
onset
emesi
fatigu
laboratori
evalu
reveal
sever
anemia
hemoglobin
gmdl
otherwis
normal
blood
count
stool
hemoccult
urinalysi
neg
suggest
concomit
iron
defici
although
initi
work
diagnosi
transient
erythroblastopenia
childhood
tec
laboratori
evid
hemolysi
note
bone
marrow
evalu
show
normal
cellular
compensatori
erythroid
hyperplasia
transfus
appropri
rise
hemoglobin
person
famili
histori
intermitt
epistaxi
mention
thought
contributori
time
two
month
later
return
emerg
depart
epistaxi
rectal
bleed
meckel
scan
upperlow
endoscopi
tag
red
blood
cell
scan
unremark
test
hemophilia
von
willebrand
diseas
neg
due
persist
anemia
despit
frequent
transfus
worsen
epistaxi
refer
ent
nasal
endoscopi
reveal
telangiectasia
throughout
consist
hht
confirm
genet
test
demonstr
heterozyg
frameshift
mutat
eng
gene
sinc
diagnosi
endoscopi
small
larg
intestin
show
scatter
avm
throughouthht
rare
present
aggress
child
attempt
local
control
includ
laser
nasal
bevacizumab
inject
argon
beam
coagul
current
propranolol
beta
blockad
signific
improv
aggress
treatment
option
rapamycin
infliximab
may
need
consid
conclus
hht
often
goe
unrecogn
undiagnos
consid
confront
suspici
famili
histori
andor
refractori
epistaxi
anemia
improv
treatment
option
aggress
pediatr
diseas
need
continu
investig
amanda
saraf
mari
franc
wedekind
nilay
shah
mark
ranal
nationwid
children
hospit
columbu
ohio
unit
state
background
renal
cell
carcinoma
rcc
pediatr
patient
carri
dismal
prognosi
cur
therapeut
option
patient
receiv
surgic
gross
total
resect
cabozantinib
small
molecul
receptor
tyrosin
kinas
inhibitor
protein
known
express
rcc
adult
children
current
medullari
thyroid
carcinoma
data
use
pediatr
rcc
object
describ
clinic
cours
two
patient
metastat
rcc
treat
cabozantinib
nationwid
children
hospit
designmethod
two
patient
stage
iv
rcc
rearrang
receiv
sunitinib
follow
resect
suffer
diseas
recurr
within
month
diagnosi
pulmonari
skelet
nodal
site
cabozantinib
daili
given
monitor
clinic
symptomat
respons
radiograph
respons
advers
effect
qualiti
life
dose
adjust
made
base
clinic
criteria
result
initi
cabozantinib
patient
clinic
benefit
despit
prior
use
tki
therapi
one
patient
resolut
malign
pleural
effus
measur
reduct
infiltr
lymph
node
revers
cachexia
normal
weight
gain
patient
improv
pain
control
return
normal
daili
activ
qualit
improv
mri
patient
remain
drug
month
month
respect
though
second
patient
dose
reduct
due
advers
effect
ae
common
ae
relat
cabozantinib
includ
erythrodysesthesia
loss
appetit
weight
loss
diarrhea
nausea
adult
patient
popul
often
dose
limit
howev
patient
toler
well
overal
one
mild
nausea
requir
dose
adjust
exhibit
erythrodysesthesia
requir
dose
reduct
resolut
ae
also
manifest
hypothyroid
manag
levothyroxin
conclus
cabozantinib
demonstr
clinic
radiograph
benefit
two
pediatr
patient
metastat
rcc
present
addit
therapeut
option
diseas
studi
examin
use
broadli
rcc
pediatr
cancer
ravi
vamse
nibal
zaghloul
harumi
jyonouchi
saint
peter
univers
hospit
new
brunswick
new
jersey
unit
state
background
autosom
domin
mutat
encod
catalyt
subunit
phosphatidyl
recent
identifi
genet
caus
common
variabl
immunodefici
cvid
play
key
role
activ
prolifer
cell
multipl
lineag
mutat
predispos
affect
subject
autoimmun
malign
complic
howev
clinic
spectrum
mutat
earli
life
known
object
address
clinic
laboratori
find
male
probabl
mutat
whose
initi
present
earli
onset
hemolyt
anemia
associ
acut
febril
ill
designmethod
retrospect
review
clinic
laboratori
find
present
case
whose
clinic
featur
domin
hematolog
abnorm
result
patient
initi
present
coomb
neg
hemolyt
anemia
age
week
subsequ
develop
pancytopenia
hepatosplenomegali
within
month
frequent
episod
febril
ill
worsen
pancytopenia
respond
oral
steroid
gradual
rise
igm
posit
famili
histori
hyper
igm
syndrom
mother
led
immun
workup
although
maintain
immunoglobulin
level
lack
clinic
evid
deep
seat
sinopulmonari
infect
eventu
mother
diagnos
mutat
lead
us
test
result
pend
although
never
exhibit
low
igg
iga
prior
start
supplement
ivig
enumer
tb
cell
subset
reveal
decreas
number
regulatori
cell
isotyp
switch
memori
b
cell
absent
along
invert
ratio
vs
memori
cell
persist
lymphopenia
compensatori
increas
nk
cell
number
unclear
matern
mutat
affect
clinic
featur
patient
clinic
stabl
sirolimu
supplement
ivig
conclus
mutat
manifest
predomin
hematolog
abnorm
without
hypogammaglobulinemia
enumer
tb
cell
subset
may
inform
proceed
gene
mutat
analysi
high
index
suspicion
requir
given
fact
diseas
specif
treatment
ie
sirolimu
avail
brian
friend
robert
venick
doug
farmer
eileen
tsai
patricia
weng
noah
federman
mattel
children
hospit
univers
california
lo
angel
lo
angel
california
unit
state
background
autosom
recess
polycyst
kidney
diseas
arpkd
hereditari
diseas
result
renal
diseas
congenit
hepat
fibrosi
children
common
hepat
complic
includ
portal
hypertens
bile
duct
dilat
cholang
hepatocellular
carcinoma
hcc
previous
report
popul
object
describ
first
pediatr
patient
report
literatur
arpkd
hcc
designmethod
extens
medlin
search
perform
hcc
arpkd
congenit
hepat
fibrosi
also
examin
literatur
malign
associ
arpkd
clinic
exom
sequenc
patient
germlin
current
pend
result
report
old
male
histori
kidney
transplant
secondari
arpkd
known
hepat
fibrosi
found
biopsi
proven
hcc
pulmonari
metastas
current
undergo
neoadjuv
chemotherapi
cisplatin
doxorubicin
partial
respons
therapi
base
respons
evalu
criteria
solid
tumor
recist
criteria
primari
lesion
metastas
decreas
size
afp
decreas
cycl
cisplatindoxorubicin
chemotherapi
germlin
patient
exom
sequenc
result
pend
report
time
public
conclus
first
report
case
hcc
pediatr
patient
arpkd
histori
concurr
hepat
fibrosi
like
contribut
progress
hcc
extrem
young
age
present
uncommon
exom
sequenc
may
help
determin
whether
patient
novel
pathogen
variant
polycyst
kidney
hepat
diseas
arpkd
gene
nicol
baca
aime
foord
arash
mahajerin
choc
children
hospit
orang
counti
orang
california
unit
state
background
lupu
lahp
rare
condit
result
hypercoagul
often
seen
patient
underli
autoimmun
disord
thrombocytopenia
found
patient
lahp
associ
bleed
risk
object
describ
case
patient
lupu
anticoagul
hypoprothrombinemia
associ
thrombocytopenia
present
protract
oral
bleed
follow
dental
extract
designmethod
medic
record
literatur
review
result
previous
healthi
boy
present
ecchymos
petechia
oral
bleed
ten
day
follow
dental
extract
initi
lab
signific
platelet
count
kul
prothrombin
time
pt
second
intern
normal
ratio
activ
partial
thromboplastin
time
aptt
second
aptt
mix
studi
demonstr
inhibitor
pt
mix
studi
reveal
factor
defici
later
found
lupu
anticoagul
low
factor
ii
activ
respect
autoimmun
workup
reveal
tripl
antiphospholipid
antibodi
posit
apa
posit
antinuclear
antibodi
ana
doubl
strand
dna
dsdna
antibodi
well
low
complement
compon
posit
direct
antiglobulin
test
given
presenc
lupu
anticoagul
well
low
factor
ii
activ
diagnos
lahp
initi
therapi
includ
intraven
immunoglobulin
ivig
gmkg
hydroxychloroquin
mg
oral
daili
peak
platelet
respons
ivig
bone
marrow
aspir
biopsi
reveal
trilineag
hematopoiesi
megakaryocyt
hyperplasia
normal
cytogenet
neg
myelodysplast
syndrom
panel
fish
third
dose
ivig
platelet
count
remain
clinic
sign
bleed
resolv
conclus
lahp
rare
phenomenon
children
predomin
hematolog
concern
thrombosi
small
percentag
patient
bleed
complic
typic
due
thrombocytopenia
due
contrast
seriou
risk
patient
need
monitor
close
hematologist
futur
assess
includ
serial
monitor
blood
count
renal
function
apa
ana
dsdna
antibodi
futur
therapi
consid
lahp
typic
chosen
base
clinic
symptom
includ
corticosteroid
monoclon
antibodi
therapi
well
thrombopoietin
mimet
worsen
thrombocytopenia
patient
current
stabl
singl
regimen
hydroxychloroquin
lauren
draper
mark
fluchel
univers
utah
salt
lake
citi
utah
unit
state
background
undifferenti
embryon
sarcoma
liver
uesl
rare
aggress
pediatr
liver
malign
character
frequent
recurr
standard
cur
therapi
involv
complet
resect
system
chemotherapi
transcathet
arteri
chemoembol
tace
commonli
util
treat
liver
tumor
particularli
hepatocellular
carcinoma
hcc
emerg
therapi
liver
tumor
current
report
either
modal
use
local
control
pediatr
uesl
object
report
case
femal
extens
uesl
diaphragmat
invas
poor
respons
two
cycl
neoadjuv
ifosfamid
doxorubicin
two
cycl
gemcitabin
taxoter
administ
tumor
show
moder
volumetr
respons
patient
experienc
neurotox
tumor
remain
unresect
sever
pain
persist
therefor
perform
largest
portion
tumor
follow
tace
bead
diaphragmat
portion
tumor
via
phrenic
arteri
designmethod
case
report
due
uniqu
approach
local
control
uesl
bead
chosen
tace
larg
inferior
portion
tumor
studi
hcc
show
equival
outcom
less
pain
tace
chosen
smaller
superior
portion
attempt
spare
healthi
liver
tissu
share
blood
suppli
phrenic
arteri
result
procedur
well
toler
within
three
week
embol
long
act
narcot
discontinu
time
tace
procedur
decreas
tumor
size
measur
avail
tace
also
well
toler
requir
one
overnight
stay
pain
control
tumor
deem
resect
within
week
follow
procedur
conclus
case
highlight
possibl
role
embol
uesl
therapi
case
tace
util
part
neoadjuv
regimen
facilit
surgic
resect
modal
consid
viabl
option
unresect
uesl
unrespons
upfront
chemotherapi
jessica
garcia
richard
tower
ii
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
multicentr
reticulohistiocytosi
mrh
rare
multisystem
cell
histiocyt
disord
mrh
rarer
children
onset
diseas
typic
occur
fourth
decad
life
clinic
present
includ
papulonodular
skin
erupt
inflammatori
polyarthr
debilit
etiolog
disord
unknown
associ
solid
tumor
hematolog
malign
present
report
case
treatment
mrh
without
associ
malign
includ
nonsteroid
drug
corticosteroid
antirheumat
drug
object
report
pediatr
patient
multicentr
reticulohistiocytosi
designmethod
singl
case
report
result
year
old
caucasian
femal
present
year
histori
periung
papul
hand
feet
month
histori
bilater
knee
swell
stiff
multipl
joint
periung
papul
initi
treat
wart
fail
improv
subsequ
refer
dermatolog
shave
biopsi
one
lesion
result
mrh
due
associ
mrh
malign
refer
oncolog
evalu
sign
symptom
malign
screen
lab
normal
ct
neck
chest
abdomen
pelvi
obtain
evalu
malign
normal
rheumatolog
diagnos
arthriti
neck
elbow
knee
receiv
methotrex
naproxen
three
month
therapi
improv
skin
lesion
arthriti
futur
evalu
malign
depend
sign
symptom
clinic
exam
plan
routin
surveil
imag
conclus
pediatr
case
mrh
report
literatur
due
rariti
current
standard
approach
surveil
malign
pediatr
oncologist
need
awar
associ
mrh
malign
patient
mrh
need
evalu
malign
prior
treatment
mrh
sinc
involv
drug
activ
nayf
edre
lee
hilliard
univers
alabama
birmingham
birmingahm
alabama
unit
state
background
hepatoblastoma
common
liver
tumor
children
hepatoblastoma
affect
mostli
children
year
age
surviv
patient
hepatoblastoma
howev
patient
refractori
metastat
diseas
prognosi
dismalbevacizumab
sorafenib
cyclophosphamid
use
report
hepatoblastoma
object
report
patient
recurr
resist
metastat
hepatoblastoma
treat
combin
lead
stabl
diseas
fall
afp
excel
qualiti
life
designmethod
male
abdomin
mass
initi
afp
proven
pure
fetal
hepatoblastoma
initi
stage
show
evid
metastat
diseas
howev
surgic
resect
possibl
due
compress
standard
adjuv
chemotherapi
cisplatin
vincristin
given
four
cycl
follow
complet
surgic
resect
neg
margin
surgeri
follow
two
cycl
afp
level
fell
gradual
nadir
end
treatment
month
therapi
rise
afp
comput
tomographi
lung
reveal
two
pulmonari
nodul
proven
hepatoblastoma
biopsi
cours
ensu
month
three
distinct
chemotherapeut
combin
util
regimen
includ
ifosfamidecarboplatinetoposid
ii
doxorubicin
ifosfamid
iii
irinotecantemodar
temsirolimu
addit
resect
pulmonari
metastas
patient
develop
transthorac
mass
invad
rib
caus
patholog
fractur
despit
extens
exposur
chemotherapi
afp
level
continu
rise
serial
ct
scan
demonstr
progress
diseas
result
sorafenib
po
daili
combin
iv
bevacizumab
mgkg
week
po
cyclophosphamid
daili
initi
reassess
afp
ct
scan
lungsabdomen
done
everi
month
respect
cycl
regimen
patient
continu
stabl
diseas
possibl
slight
decreas
size
afp
fell
patient
side
effect
normal
qualiti
life
conclus
combin
sorafenib
bevacizumab
cyclophosphamid
may
repres
combin
excel
qualiti
life
refractori
hepatoblastoma
stabil
diseas
process
lauren
amo
maxin
hetherington
linda
cooley
elena
repnikova
weiji
li
children
merci
hospit
clinic
kansa
citi
missouri
unit
state
background
anaplast
larg
cell
lymphoma
alcl
form
lymphoma
repres
childhood
lymphoma
alcl
rare
report
associ
hemophagocyt
lymphohistiocytosi
hlh
hlh
disord
involv
macrophag
activ
cytokin
releas
caus
dysfunct
leukem
peripher
blood
cn
involv
alcl
occur
infrequ
case
alcl
children
alk
posit
alk
express
result
transloc
chromosom
transloc
chromosom
extrem
rare
report
year
old
male
patient
alcl
rearrang
alk
partner
gene
object
report
present
hlh
metabol
acidosi
hyperleukocytosi
secondari
alk
posit
alcl
chromosom
rearrang
designmethod
case
report
patient
year
old
male
admit
pediatr
intens
care
unit
persist
fever
respiratori
distress
massiv
hepatosplenomegali
laboratori
evalu
show
lactic
acidosi
leukocytosi
anemia
thrombocytopenia
develop
respiratori
failur
requir
intub
renal
failur
requir
dialysi
met
criteria
hlh
due
absent
nk
function
elev
solubl
receptor
white
blood
cell
count
increas
mcl
bone
marrow
aspir
perform
initi
patholog
evalu
bone
marrow
neg
malign
chromosom
analysi
bone
marrow
reveal
main
clonal
rearrang
fish
analysi
confirm
alk
gene
rearrang
chromosom
short
arm
long
arm
bone
marrow
nuclei
fish
perform
peripher
blood
show
alk
gene
rearrang
nuclei
subsequ
bone
marrow
morpholog
identifi
scatter
atyp
cell
alk
kidney
shape
fold
nuclei
abund
cytoplasm
one
dose
etoposid
white
blood
cell
count
decreas
significantli
brain
mri
show
enhanc
lesion
consist
metastasi
treatment
start
per
result
patient
complet
two
cycl
chemotherapi
due
brain
mri
bone
marrow
evalu
prior
third
cycl
conclus
case
repres
uniqu
present
hlh
associ
alk
posit
alcl
rare
chromosom
transloc
cn
leukem
peripher
blood
involv
rohini
singh
mariko
sato
yutaka
sato
graem
pitcher
simon
kao
univers
iowa
hospit
clinic
iowa
citi
iowa
unit
state
background
children
bilater
renal
mass
carri
diagnosi
bilater
wilm
tumor
case
wilm
tumor
burkitt
lymphoma
occur
similar
age
group
children
howev
initi
diagnost
approach
treatment
differ
burkitt
lymphoma
requir
biopsi
nephrectomi
gener
contraind
contrast
bilater
wilm
tumor
requir
initi
diagnost
biopsi
radiograph
imag
show
typic
find
case
report
bilater
kidney
tumor
wilm
tumor
also
limit
object
present
case
report
year
old
male
burkitt
lymphoma
case
pose
diagnost
treatment
challeng
due
bilater
kidney
involv
resembl
bilater
wilm
tumor
also
review
relev
literatur
designmethod
case
report
review
literatur
result
old
male
present
gross
hematuria
follow
acut
renal
failur
imag
initi
interpret
bilater
nephroblastomatosi
wilm
tumor
left
kidney
later
diagnosi
chang
bilater
wilm
tumor
due
tumor
thrombu
right
side
patient
receiv
treatment
wilm
tumor
without
patholog
diagnosi
tumor
respons
kidney
remark
howev
exhibit
cn
symptom
csf
studi
reveal
burkitt
lymphoma
current
receiv
burkitt
lymphoma
treatment
accord
conclus
bilater
renal
burkitt
lymphoma
could
caus
diagnost
therapeut
challeng
younger
age
group
case
report
provid
rare
case
burkitt
lymphoma
initi
treat
accord
bilater
wilm
tumor
therapi
initi
present
gross
hematuria
renal
failur
tumor
lysi
syndrom
may
prompt
patholog
confirm
prior
treatment
earlier
point
arpan
sinha
shubhi
kaushik
lisa
figueiredo
children
hospit
montefior
bronx
new
york
unit
state
background
hemophagocyt
lymphohistiocytosi
hlh
rare
hyperinflammatori
syndrom
caus
excess
ineffect
immun
system
activ
pulmonari
alveolar
proteinosi
pap
abnorm
accumul
surfact
lung
alveoli
caus
respiratori
diseas
describ
two
case
critic
ill
toddler
present
sign
along
progress
respiratori
compromis
subsequ
diagnos
acquir
hlh
pap
object
increas
index
suspicion
pap
patient
hlh
support
earli
thorough
evalu
similar
case
describ
avail
treatment
option
designmethod
first
patient
week
year
old
girl
chronic
lung
diseas
second
patient
month
old
boy
histori
failur
thrive
recurr
pneumonia
present
persist
fever
respiratori
failur
alongwith
signific
lymphadenopathi
hepatosplenomegali
workup
hlh
show
elev
ferritin
bicytopenia
hypertriglyceridemia
hypofibrinogenemia
hemophagocytosi
bone
marrow
patient
plu
elev
solubl
receptor
patient
one
nk
function
normal
met
criteria
hlh
respect
result
genet
test
hlh
normal
patient
one
show
compound
heterozyg
mutat
associ
lysinur
protein
intoler
lpi
patient
two
lung
biopsi
evalu
progress
respiratori
diseas
show
pap
case
patient
treat
induct
chemotherapi
per
protocol
pap
treat
whole
lung
lavag
ecmo
resolut
symptom
patient
one
howev
treatment
option
pap
limit
patient
two
due
underli
lpi
hlh
pap
describ
independ
patient
lpi
second
patient
unifi
pictur
inborn
aminoaciduria
lead
macrophag
dysfunct
immun
dysregul
caus
hlh
pap
whole
lung
lavag
limit
util
situat
bone
marrow
transplant
describ
conclus
diagnosi
similar
complex
case
challeng
given
progress
natur
diseas
broad
rang
differenti
time
requir
diagnost
evalu
howev
high
index
suspicion
earli
thorough
evalu
benefici
sever
case
paul
kent
jonathan
petrean
kyle
petersen
rush
univers
medic
center
chicago
illinoi
unit
state
background
soto
syndrom
ss
rare
genet
condit
character
excess
growth
frontal
boss
downslant
palpebr
fissur
dolichocephal
head
shape
hypertelor
promin
jaw
caus
mutat
gene
increas
risk
pediatr
cancer
associ
ss
especi
hematopoiet
malign
present
case
year
old
boy
ss
diagnos
classic
hodgkin
lymphoma
hl
object
describ
case
adolesc
hl
ss
designmethod
conduct
search
pubm
ovid
googl
scholar
search
use
term
soto
syndrom
hodgkin
lymphoma
previous
report
case
hematolog
malign
associ
soto
syndrom
none
hl
note
studi
indic
male
affect
much
often
femal
case
increas
number
report
result
year
old
young
man
ss
present
firm
fix
anterior
neck
mass
proven
excision
biopsi
hl
workup
confirm
stage
ia
diseas
search
yield
manuscript
patient
success
treat
cycl
doxorubicin
vincristin
prednison
cyclophosphamid
remain
remiss
month
conclus
soto
syndrom
rare
genet
diseas
appear
increas
risk
leukemia
lymphoma
case
case
first
hl
hope
increas
awar
possibl
associ
ss
hl
research
condit
kurotaki
natur
genet
cohen
j
med
genet
tamara
hagoel
shipra
kaicker
ludovico
guarini
christina
gagliardo
vidya
moni
maimonid
infant
children
hospit
brooklyn
new
york
unit
state
background
pneumocysti
jirovecii
pneumonia
pjp
common
caus
pneumonia
oncolog
patient
immunosuppress
high
index
suspicion
pjp
maintain
oncolog
patient
undergo
activ
chemotherapi
present
fever
dyspnea
cough
hypoxia
bronchoalveolar
lavag
bal
recommend
method
specimen
collect
diagnos
pjp
howev
risk
associ
perform
bal
immunosuppress
oncolog
patient
must
care
weigh
benefit
less
invas
diagnost
approach
induc
sputum
routin
use
pjp
diagnosi
oncolog
patient
low
burden
organ
sampl
lead
low
test
sensit
scant
data
support
use
induc
sputum
diagnosi
pjp
pediatr
oncolog
patient
three
pediatr
patient
acut
lymphoblast
leukemia
undergo
activ
chemotherapi
present
fever
cough
respiratori
distress
hypoxia
induc
sputum
sent
three
patient
pjp
polymeras
chain
reaction
one
patient
underw
bal
clinic
stabl
object
demonstr
util
pjp
induc
sputum
immunosuppress
pediatr
patient
designmethod
retrospect
chart
review
three
pediatr
patient
diagnos
pjp
via
induc
sputum
perform
pjp
perform
focu
diagnost
result
induc
sputum
three
patient
bal
specimen
one
patient
underw
bronchoscopi
posit
pjp
via
patient
treat
demonstr
clinic
improv
conclus
send
induc
sputum
pjp
less
invas
potenti
use
approach
diagnos
pjp
immunosuppress
pediatr
oncolog
patient
unabl
undergo
bronchoscopi
bal
neel
bhatt
gabriela
gheorgh
michael
kelli
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
incid
lymphoprolif
disord
ptld
increas
rise
solid
organ
transplant
children
higher
level
immun
suppress
neg
ebv
serostatu
transplant
subsequ
seroconvers
earli
age
transplant
major
risk
factor
world
health
organ
classifi
ptld
four
type
earli
lesion
polymorph
monomorph
hodgkin
lymphoma
major
monomorph
ptld
origin
describ
rare
histolog
variant
diffus
larg
lymphoma
dlbcl
child
ptld
show
sinusoid
invas
lineag
malign
cell
object
describ
uniqu
histolog
treatment
outcom
child
diagnos
sinusoid
dlbcl
post
heart
transplant
designmethod
singl
case
report
result
year
old
femal
receiv
heart
transplant
ebv
donor
posit
recipi
neg
week
age
due
pulmonari
atresia
intact
ventricular
septum
tacrolimu
mycophenol
use
immun
suppress
present
week
histori
left
neck
mass
fever
imag
show
extens
lymphadenopathi
diaphragm
interv
increas
blood
ebv
dna
iuml
note
excision
biopsi
perform
histolog
show
larg
pleomorph
lymphoid
cell
sinusoid
pattern
invas
differenti
diagnosi
includ
hodgkin
lymphoma
hl
anaplast
larg
cell
lymphoma
alcl
sinusoid
variant
dlbcl
immunohistochemistri
verifi
lineag
sinusoid
cell
posit
neg
situ
hybrid
ebv
eber
posit
numer
malign
nuclei
focal
bone
marrow
invas
also
note
base
find
final
diagnosi
stage
iv
sinusoid
dlbcl
made
complet
treatment
rituximab
chemotherapi
group
b
arm
current
remain
remiss
conclus
sinusoid
dlbcl
report
pediatr
ptld
set
mimic
hl
alcl
base
similar
morpholog
immunohistochemistri
high
degre
suspicion
extens
immunohistochem
panel
necessari
reach
diagnosi
rare
entiti
accur
histolog
diagnosi
import
patient
ptld
order
make
appropri
treatment
decis
meghan
drayton
jackson
sarita
joshi
melissa
rose
nationwid
children
hospit
columbu
ohio
unit
state
background
two
form
hereditari
neutropenia
cyclic
neutropenia
cyn
sever
congenit
neutropenia
scn
attribut
mutat
elan
gene
distinct
clinic
relev
patient
scn
increas
infecti
complic
heighten
risk
develop
myelodysplasia
myeloid
leukemia
autoimmun
neutropenia
acquir
neutropenia
secondari
antibodi
direct
granulocyt
precursor
infect
less
frequent
inherit
caus
neutropenia
object
describ
genotyp
phenotyp
mutationsvari
identifi
within
elan
gene
associ
scn
cyn
designmethod
review
clinic
cours
laboratori
find
two
uniqu
patient
elan
mutationsvari
result
case
year
old
caucasian
femal
histori
recurr
fever
associ
oral
ulcer
abdomin
pain
genet
panel
show
mutat
elan
gene
associ
scn
serial
lab
show
neutropenia
mother
clinic
histori
neutropenia
infect
yet
carri
mutat
patient
respond
colchicin
famili
mediterranean
fever
addit
note
heterozyg
mutat
mefv
gene
case
year
old
caucasian
male
present
fatigu
poor
oral
intak
diarrhea
bruis
infect
histori
signific
singl
staph
infect
wound
respond
outpati
antibiot
sever
persist
neutropenia
note
serial
test
novel
elan
variant
identifi
child
mother
mother
report
episod
cellul
abscess
site
cesarean
section
inguin
lymphaden
although
report
healthi
prior
mother
without
neutropenia
serial
test
patient
also
demonstr
posit
test
antibodi
conclus
mutat
variant
within
elan
gene
associ
scn
cyn
major
case
yet
modifi
gene
autoimmun
neutropenia
confound
diagnosi
caution
use
attribut
neutropenia
clinic
symptomatolog
sole
genet
etiolog
given
phenotyp
variabl
elan
mutat
genet
counsel
sought
genet
test
request
aml
kelada
andrew
zeft
jame
cook
gregori
plautz
aron
flagg
cleveland
clinic
cleveland
ohio
unit
state
background
extranod
margin
zone
b
cell
lymphoma
lymphoid
tissu
emzl
predominantli
seen
adult
median
age
year
compris
lymphoma
diagnos
emzl
rare
children
often
secondari
underli
immunodefici
adult
mzl
associ
chronic
infect
autoimmun
diseas
syndrom
ss
emzl
due
ss
previous
describ
childhood
object
describ
clinic
patholog
featur
teen
emzl
subsequ
diagnos
ss
designmethod
case
report
relat
literatur
review
perform
result
boy
present
right
mass
long
histori
intermitt
cervic
lymphadenopathi
bilater
parotid
swell
year
fine
needl
aspir
show
benign
lymphoid
tissu
evid
malign
serolog
test
cmv
ebv
hiv
toxoplasmosi
tuberculosi
cat
scratch
diseas
syphili
streptococcu
show
remot
infect
cmv
ebv
posit
igg
neg
igm
erythrocyt
sediment
rate
esr
mmh
parotidectomi
perform
diagnost
emzl
unclear
surgic
margin
gy
radiotherapi
deliv
evid
recurr
month
test
chlamydia
psittaci
hepat
b
viru
hepat
c
viru
infect
neg
howev
signific
elev
antinuclear
antibodi
dilut
speckl
pattern
rheumatoid
factor
iuml
ssa
antibodi
antibodi
index
ssb
antibodi
antibodi
index
total
igg
mgdl
test
system
lupu
erythemat
neg
despit
vagu
sicca
symptom
ophthalmolog
exam
reveal
corneal
conjunctiv
eros
patient
given
diagnosi
ss
hydroxychloroquin
rituximab
prescrib
reduct
esr
mmh
subsequ
parotid
swell
similar
publish
case
emzl
occur
pediatr
ss
patient
report
date
conclus
emzl
occur
pediatr
ss
patient
previous
describ
potenti
pauciti
clinic
symptom
evalu
ss
autoimmun
diseas
undertaken
children
emzl
andrew
doan
mark
bittman
alex
williamson
morri
edelman
derek
hanson
gregori
rieli
carolyn
fein
levi
cohen
children
medic
center
new
hyde
park
new
york
unit
state
background
thymic
carcinoma
tc
rare
adult
less
common
children
account
less
childhood
mediastin
tumor
adult
first
treatment
usual
surgic
resect
approxim
tc
metastat
diagnosi
unresect
medial
surviv
current
chemotherapi
regimen
approxim
year
ongo
studi
tyrosin
kinas
inhibitor
tki
advanc
thymic
tumor
report
use
mainten
therapi
metastat
tc
children
object
report
use
cisplatin
docetaxel
follow
sunitinib
mainten
chemotherapi
pediatr
patient
metastat
tc
designmethod
year
old
male
autism
present
mediastin
mass
diagnos
stage
iv
tc
tumor
unresect
multipl
metastat
lung
lesion
patient
treat
cisplatin
docetaxel
everi
week
prevent
regrowth
initi
mainten
therapi
sunitinib
drug
report
stabil
diseas
adult
advanc
thymic
malign
result
cycl
chemotherapi
imag
reveal
reduct
anterior
mediastin
mass
reduct
decreas
pulmonari
metastas
follow
cycl
chemotherapi
repeat
imag
show
decreas
size
reduct
number
pulmonari
metastas
due
aggress
natur
diseas
start
sunitinib
oral
daili
side
effect
includ
discolor
skin
surround
use
administr
faint
erythemat
rash
chest
sinc
start
sunitinib
patient
continu
reduct
primari
tumor
size
recent
chest
ct
perform
month
initi
sunitinib
show
reduct
origin
mass
resolut
lung
metastas
conclus
thymic
malign
rare
tumor
aggress
difficult
treat
advanc
stage
demonstr
diseas
respons
use
sunitinib
mainten
therapi
prevent
regrowth
sunitinib
patient
continu
diseas
reduct
minim
side
effect
given
rariti
tumor
promis
therapeut
approach
tumor
pediatr
patient
mari
nelson
reuven
schore
shana
jacob
children
nation
heath
system
washington
district
columbia
district
columbia
unit
state
background
repair
diseas
caus
predisposit
malign
patient
develop
cancer
mostli
lymphoid
origin
patient
pose
uniqu
challeng
due
sensit
radiat
increas
risk
chemotherapi
complic
hemorrhag
cystiti
sever
infect
object
discuss
femal
present
two
week
neck
swell
excision
biopsi
reveal
matur
lymphoma
stage
petct
scan
show
local
diseas
designmethod
patient
treatment
base
success
treatment
elderli
patient
lymphoma
cycl
chop
cyclophosphamid
doxorubicin
vincristin
prednison
combin
rituximab
result
complet
respons
cr
rate
modifi
therapi
limit
toxic
receiv
one
cycl
cop
cyclophosphamid
vincristin
prednison
near
cr
mri
first
cycl
cyclophosphamid
dose
reduc
remain
hospit
count
nadir
recoveri
due
risk
infect
signific
nadir
cyclophosphamid
escal
full
dose
subsequ
cycl
complic
includ
prolong
febril
neutropenia
c
difficil
coliti
right
thrombu
requir
anticoagul
result
follow
four
cycl
mri
show
cr
follow
fifth
cycl
admit
fever
neutropenia
hypotens
requir
vasopressor
support
echocardiogram
reveal
eject
fraction
follow
cumul
anthracyclin
dose
intub
develop
worsen
hypotens
desatur
progress
cardiac
arrest
despit
cardiopulmonari
resuscit
spontan
cardiac
function
return
patient
die
sign
heart
failur
evid
limit
autopsi
chest
howev
underli
etiolog
remain
unclear
conclus
despit
superior
treatment
mani
lymphoma
patient
continu
present
obstacl
due
exquisit
sensit
commonli
employ
therapi
may
accept
regimen
patient
may
still
toxic
increas
risk
cardiac
toxic
report
may
anoth
sensit
patient
addit
studi
warrant
understand
special
patient
popul
lead
adapt
treatment
improv
protect
toxic
andrew
doan
richard
glick
nelson
rosen
morri
edelman
lee
collin
lindsay
frazier
carolyn
fein
levi
cohen
children
medic
center
new
hyde
park
new
york
unit
state
background
pediatr
germ
cell
tumor
gct
rare
account
pediatr
malign
somat
malign
transform
smt
gct
therefor
extrem
unusu
event
henc
standard
treatment
guidelin
consensu
treatment
direct
malign
compon
undergon
somat
transform
prior
report
prognosi
guard
report
success
treatment
extracrani
central
pnet
aros
gct
object
report
treatment
two
gct
underw
smt
pnet
modifi
head
start
ii
regimen
follow
high
dose
chemotherapi
stem
cell
rescu
designmethod
month
old
femal
month
old
male
b
present
abdomin
distens
urinari
retent
constip
found
sacrococcyg
teratoma
sct
somat
transform
central
pnet
case
upfront
resect
possibl
due
tumor
encas
rectum
case
b
upfront
surgic
resect
complic
tumor
ruptur
treat
modifi
head
start
regimen
consist
vincristin
vcr
mgkg
cisplatin
mgkg
etoposid
mgkg
cyclophosphamid
ctx
methotrex
exclud
regimen
avoid
addit
toxic
sinc
tumor
extracrani
case
chemotherapi
follow
gross
total
resect
posit
margin
patient
underw
consolid
chemotherapi
hdct
carboplatin
mgkg
thiotepa
mgkg
etoposid
mgkg
follow
autolog
peripher
stem
cell
rescu
neither
patient
receiv
radiat
therapi
result
chemotherapi
regimen
toler
well
patient
develop
wound
dehisc
patient
b
current
without
evid
diseas
period
month
month
respect
conclus
present
two
case
sct
underw
smt
central
pnet
treat
modifi
head
start
regimen
follow
hdct
methotrex
exclud
regimen
sinc
need
penetr
barrier
gct
smt
treatabl
aggress
therapi
target
somat
malign
compon
melani
chihak
shakila
khan
carola
arndt
domind
kaur
svetomir
markov
mayo
clinic
rochest
minnesota
unit
state
background
ulcer
primari
melanoma
associ
poor
prognosi
studi
show
ulcer
melanoma
treat
adjuv
pegyl
interferon
improv
surviv
adult
cutan
melanoma
object
report
experi
use
pegyl
interferon
pediatr
patient
ulcer
stage
iiib
melanoma
designmethod
case
report
result
girl
present
right
lower
extrem
lesion
patholog
reveal
malign
melanoma
spitzoid
featur
invas
least
clark
level
iv
breslow
depth
least
mm
microscop
focu
ulcer
mitot
rate
pet
scan
show
increas
uptak
right
inguin
lymph
node
distant
metastasi
underw
wide
local
excis
skin
graft
sentinel
lymph
node
biopsi
patholog
neg
residu
diseas
cm
margin
one
lymph
node
focal
involv
metastat
melanoma
mm
radic
inguin
lymph
node
dissect
perform
neg
diseasegiven
presenc
diseas
ulcer
start
induct
therapi
week
limit
pediatr
data
start
mainten
adult
dose
mcgkgdose
weekli
subcutan
inject
dose
increas
mcgkg
week
full
induct
dose
mcgkg
follow
induct
continu
mainten
therapi
mcgkgweek
week
side
effect
organ
toxic
monitor
monthli
throughout
cours
despit
premed
acetaminophen
patient
experienc
fever
chill
myalgia
follow
first
dose
subsequ
inject
follow
schedul
acetaminophen
hour
prevent
symptom
report
mild
fatigu
one
two
day
follow
inject
deni
symptom
depress
headach
nausea
vomit
monthli
laboratori
monitor
myelosuppress
hepat
renal
dysfunct
perform
along
tsh
triglycerid
level
everi
three
month
persist
abnorm
seen
conclus
patient
toler
pegyl
interferon
signific
advers
side
effect
organ
toxic
first
report
pediatr
patient
melanoma
treat
therapi
rajkumar
venkatramani
nahir
santiago
lizmeri
suarez
ferguson
pulivarthi
rao
dolor
eumenia
castro
baylor
colleg
medicin
houston
texa
unit
state
background
tumor
fusion
recent
describ
entiti
usual
aris
soft
tissu
two
prior
publish
articl
report
six
case
two
children
aris
tongu
object
report
unusu
gastric
tumor
aris
pylor
wall
stomach
old
child
harbor
except
rare
transloc
result
gene
fusion
designmethod
case
report
result
previous
healthi
femal
present
one
episod
abdomin
pain
vomit
epigastr
mass
palpat
comput
tomographi
scan
abdomen
show
local
x
x
solid
cystic
mass
aris
distal
stomach
preoper
differenti
includ
gastrointestin
stromal
tumor
inflammatori
myofibroblast
tumor
child
underw
exploratori
laparotomi
reveal
mobil
mass
attach
anterior
portion
pyloru
mass
complet
resect
pyloroplasti
perform
microscop
examin
mass
reveal
spindl
cell
prolifer
diffus
posit
vimentin
focal
ema
initi
patholog
report
angiomatoid
fibrou
histiocytoma
cytogenet
studi
show
balanc
transloc
involv
short
arm
chromosom
long
arm
chromosom
xx
diagnosi
chang
pericytoma
presenc
fusion
transcript
confirm
genom
dna
amplif
child
remiss
month
conclus
case
first
report
gastric
tumor
transloc
confirm
fusion
gene
pediatr
patient
unusu
locat
morpholog
made
differenti
diagnosi
quit
difficult
make
genet
molecular
analys
imper
correct
diagnosi
evid
recurr
metastasi
document
prior
report
case
resect
seem
treatment
choic
angela
steineck
clare
twist
john
mackenzi
stanford
univers
palo
alto
california
unit
state
background
despit
advanc
multimod
therapi
high
risk
hr
neuroblastoma
surviv
remain
suboptim
retinoid
therapi
acid
contribut
improv
outcom
synthet
retinoid
fenretinid
demonstr
vitro
toxic
neuroblastoma
cell
develop
resist
retinoid
favor
toxic
profil
phase
trial
skelet
effect
includ
prematur
physeal
closur
describ
retinoid
describ
children
treat
fenretinid
date
object
report
two
patient
neuroblastoma
develop
prematur
physeal
closur
follow
protract
fenretinid
therapi
designmethod
retrospect
chart
review
result
patient
caucasian
girl
patient
african
american
boy
diagnos
age
year
respect
hr
stage
singl
copi
mycn
neuroblastoma
fail
induct
therapi
receiv
investig
follow
consolid
chemotherapi
stem
cell
rescu
local
radiat
therapi
due
persist
metastat
diseas
receiv
oral
fenretinid
capsular
format
mg
po
tid
total
cycl
respect
ultim
achiev
complet
remiss
treatment
fenretinid
develop
asymmetr
prematur
physeal
closur
multipl
long
bone
result
limb
length
discrep
angular
deform
nearli
decad
therapi
aliv
remiss
neuroblastoma
conclus
phase
ii
studi
fenretinid
children
report
skelet
toxic
late
effect
therapi
unusu
strikingli
similar
radiograph
clinic
find
strongli
suggest
skelet
abnorm
may
consequ
protract
fenretinid
exposur
studi
potenti
skelet
toxic
neuroblastoma
patient
receiv
retinoid
therapi
indic
better
understand
mechan
risk
factor
retinoid
bone
toxic
fadi
nossair
virginia
kimoni
lilibeth
torno
children
hospit
orang
counti
orang
california
unit
state
background
pediatr
colorect
cancer
crc
account
cancer
patient
age
year
lynch
syndrom
ls
cancer
predisposit
syndrom
caus
mutat
one
mismatch
repair
mmr
gene
occur
adult
crc
rare
seen
pediatr
mutat
gene
result
defect
surveillancerepair
dna
replic
result
microsatellit
instabl
second
hit
occur
due
acquir
local
stress
malign
transform
may
result
mutat
repres
biallel
germlin
mutat
mmr
though
account
ls
mutat
object
report
novel
gene
mutat
young
adult
cin
examin
ethic
therapeut
dilemma
highlight
case
discuss
potenti
mechan
malign
evolut
designmethod
male
conceiv
via
sperm
donat
male
descent
present
persist
rectal
bleed
matern
famili
histori
signific
crc
grandmoth
bladder
cancer
uncl
rel
skin
cancer
histori
refractori
epilepsi
sever
intellectu
disabl
diagnos
use
whole
exom
sequenc
rare
potassium
channelopathi
due
heterozyg
mutat
gene
also
histori
recurr
volvulu
signific
colon
resect
syndrom
colon
neuropathi
intestin
malabsorpt
result
colonoscopi
reveal
tubular
villou
adenoma
dysplasia
consist
cin
stage
workup
includ
cea
evalu
neg
reanalysi
exom
data
known
gene
reveal
heterozyg
g
mutat
result
stop
codon
gene
present
mother
exom
sequenc
conclus
case
report
present
novel
mutat
uniqu
observ
patient
known
channelopathi
emerg
role
mutat
pediatr
cancer
possibl
mechan
second
hit
therapeut
dilemma
cin
patient
ls
import
consider
illustr
uniqu
case
also
highlight
ethic
dilemma
surround
report
incident
find
whole
exom
sequenc
context
detect
clinic
oncogenet
potenti
eden
stori
donna
johnston
children
hospit
eastern
ontario
ottawa
ontario
canada
background
neuroblast
tumor
classif
depend
differenti
neuroblast
presenc
absenc
schwannian
stromal
develop
fall
along
spectrum
tumor
matur
dictat
tumor
aggress
cours
ganglioneuroma
intermix
ganglioneuroblastoma
matur
subtyp
tend
present
unifoc
diseas
benign
cours
object
present
uniqu
case
boy
multipl
tumor
identifi
initi
present
histolog
consist
multipl
soft
tissu
ganglioneuroma
abdomin
intermix
ganglioneuroblastoma
designmethod
patient
previous
healthi
boy
present
mass
posterior
aspect
right
thigh
increas
size
period
mri
thigh
reveal
lesion
within
muscl
biopsi
lesion
keep
ganglioneuroma
abdomin
mri
perform
part
stage
reveal
mass
right
adren
fossa
biopsi
mass
consist
intermix
ganglioneuroblastoma
amplifi
either
lesion
remaind
stage
includ
urin
vanillylmandel
acid
vma
homovanil
acid
hva
bone
scan
bilater
bone
marrow
aspir
biopsi
mibg
scan
unremark
although
metastat
diseas
present
upon
present
base
histolog
subtyp
tumor
likelihood
progress
diseas
low
therefor
observ
without
activ
treatment
result
remain
well
without
diseas
progress
almost
follow
diagnosi
conclus
report
metastat
ganglioneuroma
intermix
ganglioneuroblastoma
literatur
limit
knowledg
first
pediatr
case
concurr
adren
ganglioneuroblastoma
multipl
soft
tissu
ganglioneuroma
metastas
present
initi
diagnosi
rare
present
multifoc
soft
tissu
ganglioneuroma
abdomin
intermix
ganglioneuroblastoma
rais
possibl
lesion
less
matur
neuroblast
tumor
underw
matur
given
distribut
diseas
patient
possibl
patient
stage
neuroblastoma
subsequ
matur
primari
tumor
metastas
oluwaseun
olaiya
beth
speckhart
reuben
antoni
karen
fernandez
uicomp
peoria
illinoi
unit
state
background
adren
cortic
carcinoma
acc
rare
aggress
malign
neoplasm
report
incid
case
per
million
popul
account
malign
major
tumor
function
approxim
patient
experienc
endocrin
symptomatolog
typic
character
cush
syndrom
mix
hormon
pictur
cush
syndrom
seen
associ
viril
rare
patient
present
pure
hormon
syndrom
femin
hyperaldosteron
respect
object
report
rare
case
primari
hyperaldosteron
associ
acc
designmethod
case
report
result
year
old
girl
present
neuromuscular
symptom
inabl
rise
arm
head
sever
hypokalemia
hypernatremia
borderlin
hypertens
mmhg
sign
viril
note
laboratori
evalu
show
hyperaldosteron
plasma
aldosteron
ngdl
plasma
renin
activ
ngmlh
ct
abdomen
show
cm
noncalcifi
vascular
mass
aris
right
adren
gland
imping
posterior
inferior
vena
cava
patient
underw
open
adrenalectomi
diagnosi
stage
acc
made
due
presenc
tumor
thrombu
adren
vein
patholog
report
reveal
poorli
differenti
grade
iii
adren
cortic
carcinoma
strong
famili
histori
cancer
note
mother
die
age
breast
cancer
matern
grandfath
testicular
cancer
die
lung
cancer
age
matern
die
skin
cancer
year
old
matern
grandmoth
die
breast
cancer
age
matern
die
abdomin
organ
cancer
prompt
genet
test
reveal
heterozyg
mutat
gene
known
associ
syndrom
patient
biochem
laboratori
data
normal
postop
enrol
cog
clinic
trial
acc
complet
therapi
mitotan
etoposid
cisplatin
doxorubicin
decemb
current
aliv
without
evid
diseas
side
effect
adren
insuffici
conclus
rare
adren
cortic
carcinoma
may
occur
consid
differenti
diagnosi
adren
tumor
children
patienc
obasaju
jennif
brondon
juli
blatt
lynn
fordham
sabina
mir
univers
north
carolina
chapel
hill
north
carolina
unit
state
background
neuroblastoma
common
extracrani
solid
tumor
children
common
cancer
infanc
tumor
may
present
spectrum
paraneoplast
syndrom
protein
lose
enteropathi
ple
describ
small
number
children
neuroblastoma
unrel
gastrointestin
involv
cancer
thought
either
rare
paraneoplast
syndrom
due
catecholamin
effect
gut
lymphat
obstruct
mass
effect
noonan
syndrom
associ
independ
neuroblastoma
ple
object
describ
clinic
cours
phenotyp
normal
babi
concurr
neuroblastoma
ple
whose
tumor
dna
found
mutat
gene
designmethod
month
old
caucasian
femal
ple
refer
evalu
retroperiton
mass
laparoscop
biopsi
confirm
diagnosi
favor
histolog
neuroblastoma
unusu
constel
clinic
abnorm
rais
concern
abil
predict
either
tumor
ple
would
respond
treatment
led
us
tumor
evalu
action
mutat
might
provid
treatment
option
need
result
next
gener
sequenc
tumor
identifi
mutat
gene
normal
dna
peripher
blood
thu
noonan
syndrom
common
form
result
autosom
dominantli
inherit
constitut
mutat
possibl
mosaic
explan
comorbid
remain
evalu
conclus
conclud
find
ple
children
rais
consider
mutat
identif
mutat
tumor
patient
neuroblastoma
prompt
consider
studi
constitut
tissu
evid
full
blown
mosaic
noonan
syndrom
rare
pediatr
cancer
increas
capabl
genet
analysi
provid
opportun
deciph
miss
link
explain
unusu
case
present
includ
paraneoplast
howland
seer
cancer
statist
review
citak
pediatr
blood
cancer
ekval
clinic
genet
jami
aye
stuart
cramer
univers
alabama
birmingham
birmingham
alabama
unit
state
background
inflammatori
myofibroblast
tumor
imt
rare
benign
neoplasm
unknown
origin
associ
malign
featur
local
invas
recurr
complet
surgic
resect
treatment
choic
howev
alway
feasibl
due
anatom
challeng
case
report
demonstr
tumor
reduct
inoper
imt
use
agent
varieti
chemotherapi
drug
combin
target
therapi
crizotinib
imt
gene
rearrang
current
standard
approach
inoper
imt
establish
object
describ
case
inoper
pelvic
imt
treat
vincristin
dactinomycin
cyclophosphamid
vac
combin
celecoxib
designmethod
singl
case
report
result
caucasian
femal
present
histori
poor
oral
intak
constip
abdomin
distent
imag
demonstr
larg
presacr
mass
measur
cm
biopsi
perform
due
tumor
unresect
note
myofibroblast
prolifer
mark
inflamm
consist
imt
sequenc
reveal
alter
gene
previous
report
poor
prognost
marker
rectal
cancer
normal
gene
initi
treat
celecoxib
methylprednisolon
howev
tumor
ruptur
result
abdomin
compart
syndrom
hypertens
obstip
bladder
outlet
obstruct
bilater
hydronephrosi
transit
vac
chemotherapi
consist
cycl
vincristin
mgkgdose
weekli
dactinomycin
mgkgdose
day
cyclophosphamid
mgkgdose
day
addit
daili
celecoxib
therapi
toler
cycl
therapi
minim
side
effect
occasion
growth
factor
support
recent
imag
reveal
tumor
measur
cm
complet
resolut
hypertens
obstip
bladder
outlet
obstruct
mark
improv
bilater
hydronephrosi
continu
regimen
complet
resect
feasibl
conclus
vac
use
combin
celecoxib
may
therapeut
option
inoper
imt
jennif
michlitsch
lui
braga
rodrigo
romao
abha
gupta
armando
lorenzo
hospit
sick
children
toronto
ontario
canada
background
vagin
rm
associ
favor
prognosi
although
optim
local
control
approach
controversi
due
long
term
reproduct
musculoskelet
psycholog
sequela
rt
local
control
approach
attempt
patient
group
iii
vagin
rm
elimin
need
rt
object
describ
new
surgic
approach
local
vagin
rm
use
minim
invas
surgic
resect
follow
autolog
buccal
graft
vaginoplasti
reconstruct
designmethod
case
seri
patient
local
vagin
botryoid
rm
institut
treat
chemotherapi
per
subset
b
result
patient
year
age
rang
month
botryoid
rm
patient
receiv
maximum
cyclophosphamid
follow
vincristinedactinomycin
therapi
surgeri
perform
differ
time
week
patient
underw
subtot
total
vaginectomi
autolog
buccal
graft
vaginoplasti
reconstruct
one
patient
surgic
margin
posit
two
closest
margin
mm
patient
receiv
rt
median
length
month
patient
remain
conclus
herein
report
case
vagin
rm
success
treat
without
rt
preliminari
data
suggest
surgic
local
control
immedi
reconstruct
feasibl
spare
young
patient
complic
associ
rt
longer
critic
secur
diseas
free
surviv
function
malika
kapadia
michael
beck
melani
comito
smita
dandekar
penn
state
hershey
medic
center
hershey
pennsylvania
unit
state
background
scurvi
thought
histor
signific
commonli
misdiagnos
develop
countri
children
unit
state
consum
less
vitamin
c
per
day
present
anemia
petechi
rash
bone
pain
gingiv
bleed
lead
extens
hematolog
workup
object
three
case
scurvi
present
hematolog
complic
designmethod
retrospect
review
three
case
scurvi
present
pediatr
hematologyoncolog
center
result
seventeen
gingiv
hyperplasia
present
subungu
hemorrhag
lower
extrem
ecchymosi
swell
bloodwork
reveal
hemolyt
anemia
hemoglobin
gdl
total
bilirubin
mgdl
ptinr
physic
exam
reveal
perifollicular
hyperkeratosi
corkscrew
hair
dietari
histori
reveal
liter
diet
pepsi
per
day
bread
peanut
butter
jelli
devoid
vitamin
c
contain
food
rule
coagul
defici
vitamin
k
cholecalciferol
ascorb
acid
start
empir
respond
remark
five
tuber
sclerosi
ts
ketogen
diet
epilepsi
present
difficulti
ambul
secondari
bone
pain
anemia
petechi
rash
ct
scan
normal
knee
wrist
ankl
demonstr
metaphys
lucenc
soft
tissu
swell
seen
salter
fractur
inflammatori
condit
bloodwork
reveal
hemoglobin
gmdl
thrombocytopenia
coagulopathi
ptinr
inappropri
reticulocyt
respons
prompt
bone
marrow
biopsi
rule
malign
physic
exam
dietari
histori
neg
marrow
rais
concern
scurvi
vitamin
c
initi
demonstr
immedi
clinic
improv
twelv
present
year
long
histori
left
knee
pain
recent
leg
limp
mri
bone
scan
reveal
chronic
relaps
multifoc
osteomyel
crmo
versu
bone
malign
bone
biopsi
show
osteonecrosi
new
bone
format
marrow
fibrosi
consist
crmo
metabol
bone
disord
dietari
histori
reveal
restrict
diet
devoid
fruit
vegetablesal
three
patient
vitamin
c
level
conclus
restrict
diet
lead
multipl
nutrit
defici
avoidantrestrict
food
intak
disord
arfid
publish
dsm
v
disord
highlight
associ
restrict
diet
pediatr
nutrit
defici
scurvi
often
present
bleed
manifest
bone
pain
result
referr
pediatr
hematologistoncologist
moham
elsaid
ley
charl
kara
gill
thoma
warner
john
heiner
dian
puccetti
univers
wisconsin
school
medicin
public
health
madison
wisconsin
unit
state
background
rhabdomyosarcoma
rm
singl
common
type
soft
tissu
sarcoma
children
adolesc
case
diagnos
children
younger
six
year
age
rare
neonat
extrem
tumor
present
commonli
adolesc
frequent
alveolar
type
presenc
congenit
extrem
rm
extrem
rare
consid
present
object
increas
clinic
suspicion
congenit
embryon
rm
neonat
present
extrem
soft
tissu
mass
designmethod
report
uniqu
case
congenit
embryon
rm
hand
immedi
birth
term
neonat
notic
approxim
x
soft
mass
left
thenar
emin
overli
skin
discolor
note
mass
size
progress
increas
period
two
week
dorsal
extens
concomit
chang
mass
consist
soft
hard
day
life
mri
scan
left
hand
show
hyperintens
mass
interdigit
extens
second
third
fourth
metacarp
surgic
biopsi
obtain
day
life
patholog
report
consist
embryon
rhabdomyosarcoma
spindl
cell
varieti
tumor
cytogenet
normal
clinic
left
axillari
lymph
node
notic
enlarg
stage
imag
ct
scan
subsequ
biopsi
left
axillari
lymph
node
neg
metastat
diseas
whole
bodi
pet
scan
show
evid
metastat
diseas
accord
soft
tissu
sarcoma
committe
children
oncolog
group
cog
pretreat
stage
system
patient
diseas
stratifi
group
iii
intermedi
risk
rm
result
rm
treat
per
cog
protocol
regimen
vac
chemotherapi
consist
cyclophosphamid
vincristin
dactinomycin
local
control
obtain
radiocarp
disarticul
patient
month
complet
treatment
without
evid
diseas
relaps
conclus
third
case
medic
literatur
describ
congenit
rm
hand
clinician
awar
rare
present
establish
diagnosi
start
earli
treatment
lindi
zhang
daniel
weiser
albert
einstein
colleg
medicin
bronx
new
york
unit
state
background
pure
choriocarcinoma
testi
highli
malign
tumor
deriv
trophoblast
cell
potenti
earli
metastasi
account
primari
testicular
germ
cell
tumor
given
rariti
propens
older
patient
pure
choriocarcinoma
often
differenti
patient
present
pediatr
oncolog
servic
object
describ
case
pure
choriocarcinoma
male
patient
review
pediatricadolesc
case
discuss
use
pubert
statu
testicular
tumor
work
designmethod
report
case
previous
healthi
normal
develop
tanner
iv
male
patient
present
asymmetr
enlarg
right
testicl
follow
blunt
trauma
subsequ
chest
pain
fever
emesi
right
radic
orchiectomi
perform
patholog
show
pure
choriocarcinoma
imag
reveal
extens
metastat
diseas
includ
lung
brain
literatur
search
pubm
identifi
previous
report
case
testicular
pure
choriocarcinoma
adolesc
result
due
rariti
pure
choriocarcinoma
testi
mostli
appear
case
report
within
current
literatur
patient
report
case
n
rang
age
year
mean
age
patient
youngest
known
report
case
pure
choriocarcinoma
often
initi
misdiagnos
given
tendenc
present
symptom
secondari
lung
skin
andor
brain
metastasi
oppos
testicular
swell
like
testicular
tumor
misdiagnosi
may
relat
gap
knowledg
regard
testicular
tumor
differenti
workup
puberti
play
import
role
frequenc
testicular
tumor
type
teenag
adolesc
patient
like
present
patient
often
fall
studi
literatur
research
studi
often
use
age
studi
versu
testicular
tumor
yet
variabl
age
puberti
onset
varieti
puberti
stage
suggest
suboptim
conclus
boy
risk
testicular
cancer
typic
identifi
cohort
report
testicular
pure
choriocarcinoma
highlight
uniqu
characterist
tumor
import
puberti
statu
pediatr
oncolog
workup
algorithm
chaithra
sreenath
intezar
mehdi
rasmi
palasseri
shashi
ranjani
kumar
swami
hcg
hospit
bangalor
karnataka
india
background
rhabdomyosarcoma
rm
common
sarcoma
children
perian
site
unusu
occurr
associ
lower
cure
rate
case
treat
gross
total
surgic
resect
convent
radiotherapi
report
associ
sphincter
dysfunct
anal
ulcer
object
describ
case
localis
perian
embryon
rm
manag
use
neoadjuv
chemotherapi
stereotact
radiosurgeri
designmethod
singl
case
report
result
three
year
old
boy
present
pain
swell
right
perian
region
sinc
two
month
examin
reveal
cm
soft
tender
diffus
swell
right
perian
region
open
wedg
biopsi
lesion
suggest
embryon
rhabdomyosarcoma
immunohistochemistri
posit
desmin
focal
cd
neg
pan
ck
fdg
pet
ct
scan
show
cm
metabol
activ
enhanc
soft
tissu
mass
right
perian
region
extend
perineum
right
half
gluteal
cleft
evid
distal
metastas
receiv
four
cours
neoadjuv
chemotherapi
iva
ifosphamid
vincristin
actinomycin
child
treat
stereotact
radiosurgeri
dose
ctv
gtv
perian
area
subsequ
receiv
five
cours
iva
base
chemotherapi
thirti
nine
month
post
complet
treatment
child
complet
remiss
normal
sphincter
function
conclus
perian
rm
rare
tumor
associ
poor
outcom
delay
diagnosi
worsen
chanc
cure
lack
definit
guidelin
make
manag
case
challeng
surgic
manag
tumor
involv
risk
life
long
rectal
incontin
sphincter
dysfunct
multimod
treatment
includ
stereotact
radiosurgeri
offer
better
result
minim
complic
therebi
better
qualiti
life
franc
austin
gita
massey
seth
corey
massey
cancer
center
children
hospit
richmond
virginia
commonwealth
univers
richmond
virginia
unit
state
background
yo
fratern
twin
male
product
ivf
present
hematuria
diagnos
pleomorph
sarcoma
pelvi
invad
bladder
favor
leiomyosarcoma
found
left
humer
mass
biopsi
diagnos
telangiectat
osteosarcoma
complet
five
cycl
ifosfamidedoxorubicin
local
radiat
follow
surgic
resect
pelvic
tumor
diseas
continu
progress
die
month
diagnosi
signific
famili
histori
cancer
sequenc
peripher
blood
lymphocyt
reveal
de
novo
germ
line
synonym
mutat
g
posit
within
dna
bind
domain
sequenc
mother
father
reveal
object
relev
mutat
designmethod
review
literatur
structur
dna
bind
site
review
databas
http
result
mutat
result
amino
acid
substitut
dna
bind
domain
mutat
result
full
length
protein
produc
gain
function
present
case
novel
mutat
g
mutat
hotspot
associ
dna
bind
site
result
gain
function
associ
alter
cancer
spectrum
deregul
metabol
pathway
increas
metastas
enhanc
chemotherapi
resist
bind
et
moz
involv
histon
methyl
acetyl
found
report
mutat
found
missens
mutat
result
splice
variant
well
number
indel
occur
synonym
mutat
may
play
part
cancer
biolog
affect
cryptic
altern
splice
site
includ
supek
et
al
cell
found
mutat
extrem
recurr
affect
nucleotid
directli
adjac
splice
site
conclus
document
mutat
literatur
work
must
done
determin
relev
one
experi
would
creat
mini
gene
construct
evalu
splice
analyz
cell
activ
hypothes
synonym
mutat
may
affect
splice
rna
fold
codon
usag
serv
driver
two
concurr
aggress
primari
tumor
rida
abid
akash
nahar
jinglan
liu
ayman
samkari
marta
rozan
gregori
halligan
st
christoph
hospit
children
philadelphia
pennsylvania
unit
state
background
syndrom
fss
rare
distal
arthrogryposi
character
contractur
face
distal
extrem
main
caus
mutat
embryon
skelet
myosin
gene
lead
alter
muscl
physiolog
patient
one
three
mutat
although
incid
soft
tissu
sarcoma
especi
embryon
rm
erm
higher
children
abnorm
muscl
develop
report
fss
object
report
case
orbit
embryon
rhabdomyosaroma
child
fss
discuss
possibl
associ
popul
designmethod
caucasian
male
known
diagnosi
fss
diagnos
right
orbit
erm
present
five
day
progress
right
eye
swell
famili
histori
posit
fss
mother
fss
cours
involv
g
tube
placement
bilater
hear
aid
multipl
surgic
procedur
mark
contractur
result
metastat
work
neg
microarray
cma
orbit
mass
reveal
cytogenet
heterogen
near
triploid
chromosom
gain
loss
uniparent
disomi
cma
blood
show
normal
male
karyotyp
test
peripher
blood
confirm
mutat
g
result
amino
acid
substitut
arginin
histamin
treat
per
cog
protocol
arst
chemotherapi
radiat
therapi
remain
remiss
month
complet
conclus
import
normal
develop
express
mainli
utero
may
persist
adult
stage
especi
muscl
mutat
lead
aberr
muscl
develop
possibl
block
differenti
predispos
tumerogenesi
develop
erm
patient
could
suggest
mutat
embryon
myosin
continu
influenc
contractil
function
postnat
lead
permiss
environment
chang
spontan
develop
erm
fernandez
et
al
demonstr
similar
concept
spontan
develop
muscl
deriv
erm
one
year
age
mous
model
duchenn
muscular
dystrophi
limb
girdl
muscular
dystrophi
report
similar
case
histolog
studi
may
enhanc
understand
underli
mechan
daniel
johnston
rajkumar
venkatramani
arnold
paulino
texa
children
cancer
hematolog
center
houston
texa
unit
state
background
background
radiat
recal
character
inflamm
skin
superfici
tissu
radiat
field
follow
administr
chemotherapi
agent
doxorubicin
taxan
involv
skelet
muscl
radiat
recal
rare
object
report
patient
relaps
nasopharyng
carcinoma
develop
radiat
recal
myositi
follow
administr
gemcitabin
contain
regimen
designmethod
case
report
result
femal
stage
iii
nasopharyng
carcinoma
treat
per
children
oncolog
group
protocol
receiv
gy
radiat
nasopharynx
bilater
neck
end
therapi
develop
new
right
hip
pain
positron
emiss
tomographi
scan
show
multipl
bone
metastas
along
axial
skeleton
left
posterior
rib
bone
soft
tissu
lesion
start
gemcitabin
oxaliplatin
everi
week
cycl
complet
resolut
lesion
end
cycl
develop
bilater
neck
swell
pain
magnet
reson
imag
neck
show
diffus
muscl
swell
consist
myositi
neck
swell
resolv
spontan
final
cycl
chemotherapi
neck
swell
recur
area
myositi
correspond
radiat
field
start
steroid
immedi
improv
sinc
requir
multipl
cours
steroid
current
mainten
steroid
regimen
good
control
symptom
month
conclus
unlik
radiat
sensit
agent
gemcitabin
may
induc
radiat
recal
injuri
deeper
tissu
increas
use
gemcitabin
pediatr
salvag
regimen
pediatr
oncologist
awar
rare
side
effect
patient
receiv
prior
radiat
therapi
steroid
provid
symptomat
relief
gemcitabin
induc
radiat
recal
myositi
destini
haus
kaci
steinbrech
amanda
ross
bulent
arslan
paul
kent
rush
univers
medic
center
chicago
illinoi
unit
state
background
relaps
osteosarcoma
relaps
ewe
sarcoma
poor
prognosi
surviv
remiss
aggress
system
local
control
provid
best
chanc
surviv
surgeri
radiat
possibl
minim
invas
abl
therapi
irrevers
electropor
ire
radiofrequ
ablat
rfa
microwav
ablat
mwa
may
offer
promis
altern
local
control
ire
describ
solid
tumor
unreport
primari
boni
sarcoma
rfa
describ
rare
pediatr
ewso
object
report
outcom
case
treat
minim
abl
therapi
local
tumor
control
designmethod
collect
retrospect
data
patient
treat
ire
rfa
andor
mwa
last
year
institut
result
seven
patient
median
age
age
rang
treat
total
time
first
intervent
patient
remiss
cr
stabl
diseas
sd
progress
death
pd
patient
includ
femal
sacrum
treat
ire
cr
month
male
vertebra
lung
treat
rfa
lesion
cr
month
femal
femur
lung
treat
lung
lesion
pd
month
male
pelvic
bone
spine
lung
treat
lung
paraspin
lesion
pd
month
male
femur
lung
heart
treat
rfa
lung
lesion
pd
month
male
fibula
femur
lung
treat
lungparamediastin
lesion
sd
month
male
femur
humeru
lung
treat
lung
lesion
sd
monthcompl
includ
spinal
cord
infarct
patient
recurr
pneumothorax
patient
conclus
ire
rfa
mwa
may
promis
altern
achiev
local
control
select
tumor
children
young
adult
metastat
addit
research
warrant
priscilla
hor
w
bowman
anish
ray
cook
children
medic
center
fort
worth
texa
unit
state
background
pleuropulmonari
blastoma
ppb
rare
pediatr
lung
tumor
typic
compos
primit
lung
mesenchym
studi
report
famili
case
ppb
associ
gene
mutat
object
although
congenit
lung
cyst
benign
requir
intervent
import
consid
rare
entiti
ppb
patient
ppb
prognosi
impact
prompt
evalu
intervent
histolog
classif
also
aim
stress
import
gene
mutat
analysi
patient
diagnos
ppb
famili
designmethod
report
previous
healthi
girl
present
sever
week
histori
fever
intermitt
cough
review
famili
histori
reveal
patient
father
diagnos
right
lower
lobe
lung
cyst
underw
surgic
resect
adolesc
addit
father
current
undergo
evalu
new
thyroid
nodul
comput
tomographi
patient
chest
demonstr
larg
cystic
mass
solid
mural
nodul
anterior
segment
right
upper
lobe
patient
underw
resect
cyst
correspond
lobectomi
histolog
diagnosi
consist
type
ii
ppb
neg
margin
evid
metastat
diseas
identifi
result
genet
investig
patient
found
posit
gene
mutat
current
receiv
adjuv
chemotherapi
ifosfamid
dactinomycin
doxorubicin
vincristin
remain
free
tumor
plan
includ
surveil
malign
associ
gene
mutat
conclus
associ
autosom
domin
mutat
ppb
prompt
genet
counsel
patient
other
order
identifi
rel
age
mutat
may
benefit
surveil
recommend
includ
increas
awar
rare
tumor
among
pediatr
oncologist
pathologist
surgeon
encourag
appropri
clinic
evalu
pediatr
lung
cyst
surgic
resect
aim
toward
secur
neg
margin
given
recurr
metastat
ppb
associ
poor
outcom
stress
need
collabor
research
improv
understand
gene
mutat
famili
manifest
ppb
jame
wendi
chang
patrick
malafront
kimberli
fagen
jave
kahn
kip
hartman
walter
reed
nation
militari
medic
center
bethesda
maryland
unit
state
background
differenti
diagnosi
soft
tissu
mass
extrem
infant
span
spectrum
benign
eg
vascular
malform
fibroblast
tumor
malign
eg
rhabdomyosarcoma
mrt
rare
extrem
aggress
cancer
overal
surviv
seer
databas
occur
central
nervou
system
kidney
less
frequent
soft
tissu
object
present
case
old
previous
healthi
male
develop
rapidli
grow
mass
within
left
axilla
initi
biopsi
result
diagnosi
primit
sarcoma
tumor
exhibit
interv
growth
despit
standard
chemotherapi
patholog
review
primari
biopsi
suspici
mrt
tumor
continu
progress
patient
taken
surgeri
requir
extrem
amput
due
extent
neurovascular
involv
chest
ct
reveal
pulmonari
metastasi
diseas
progress
rapidli
patient
succumb
diseas
five
month
diagnosi
designmethod
case
report
result
subsequ
evalu
patient
tumor
whole
exom
sequenc
mutat
analysi
reveal
mutat
gene
mutat
predict
result
insert
novel
stop
result
loss
express
protein
mrt
typic
loss
heterozygos
member
swisnf
complex
drive
tumorigenesi
epigenet
dysregul
mutat
frequent
detect
germlin
patient
first
somat
mutat
kind
epigenet
target
therapi
mutat
hold
promis
treatment
mrt
potenti
therapeut
agent
includ
inhibitor
histon
deacetyl
dna
methyl
histon
methyl
kinas
aurora
kinas
anim
model
show
promis
result
mrt
respons
pediatr
phase
iii
clinic
trial
current
underway
sever
agent
conclus
case
illustr
occurr
rare
malign
infant
dismal
prognosi
mrt
need
pursu
improv
target
treatment
earlier
identif
action
mutat
particularli
lead
directli
target
therapi
allison
foertsch
liz
hunt
alan
homan
univers
vermont
children
hospit
burlington
vermont
unit
state
background
giant
cell
tumor
bone
gctb
rare
diagnosi
pediatr
account
gctb
diagnos
histolog
benign
tumor
metastas
recent
studi
shown
respons
denosumab
howev
littl
data
avail
describ
sever
recurr
hypercalcemia
respons
denosumab
discontinu
denosumab
metastat
gctb
child
object
discuss
complic
associ
discontinu
denosumab
gctb
child
util
treat
recurr
episod
hypercalcemia
designmethod
twelv
male
present
episod
hip
pain
difficulti
mri
reveal
cystic
lesion
left
ischium
treatment
monthli
denosumab
initi
dramat
improv
note
clinic
radiograph
forti
month
asymptomat
stabl
denosumab
discontinu
one
month
later
present
nausea
vomit
hypercalcem
mgdl
acut
kidney
injuri
serum
creatinin
mgdl
calcitonin
hyperhydr
lasix
unsuccess
treat
denosumab
rapid
resolut
hypercalcemia
follow
five
month
hypercalcemia
recur
twice
resolut
within
hour
treatment
denosumab
respect
result
gctb
benign
histolog
diagnosi
local
aggress
natur
complic
treatment
definit
manag
often
surgic
preclud
patient
metastat
diseas
tumor
cell
express
receptor
activ
nuclear
ligand
rankl
interact
rank
monocyt
activ
osteoclast
precursor
giant
cell
promot
bone
resorpt
denosumab
human
monoclon
antibodi
bind
inhibit
rankl
suppress
bone
turnov
upon
discontinu
denosumab
inhibitori
effect
osteoclast
hyperact
may
caus
rebound
hypercalcemia
phenomenon
may
pronounc
skelet
immatur
child
increas
rate
bone
metabol
treatment
denosumab
resolv
episod
hypercalcemia
conclus
patient
highlight
util
low
dose
denosumab
manag
sever
hypercalcem
episod
follow
treatment
denosumab
research
need
determin
ideal
dose
effect
recurr
treatment
recommend
monitor
potenti
need
gradual
discontinu
therapi
sarah
rumler
andrew
cluster
jeffrey
bednarski
jaim
libe
univers
illinoi
colleg
medicin
peoria
peoria
illinoi
unit
state
background
interdigit
reticulum
cell
sarcoma
rare
spindl
cell
sarcoma
lymph
node
stromal
cell
known
interdigit
reticulum
cell
tumor
cell
posit
protein
cd
treatment
regimen
vari
poor
overal
prognosi
abl
identifi
case
report
literatur
adult
popul
none
pediatr
popul
object
introduc
pediatr
case
interdigit
reticulum
cell
sarcoma
designmethod
clinic
case
report
result
patient
year
old
male
adopte
brought
us
industri
region
china
month
old
still
live
china
diagnos
fibrosarcoma
lower
back
underw
complet
resect
wide
margin
treat
vincristin
dactinomycin
adjuv
chemotherapi
prior
move
us
reportedli
remiss
visit
year
age
us
right
axillari
mass
note
ct
scan
underw
complet
resect
mass
well
wedg
resect
left
lower
lobe
pulmonari
nodul
stabl
sinc
age
final
patholog
site
reveal
atyp
spindl
cell
sarcoma
mostli
suggest
interdigit
reticulum
cell
sarcoma
treat
ifosfamid
doxorubicin
per
children
oncolog
group
protocol
six
week
complet
therapi
scan
remain
stabl
prior
therapi
continu
right
upper
lobe
pulmonari
nodul
uncertain
etiolog
stabl
sinc
year
age
sinc
diseas
slow
grow
parent
opt
observ
scan
month
prior
proceed
resect
remain
nodul
next
month
conclus
exceedingli
rare
case
interdigit
reticulum
cell
sarcoma
pediatr
patient
industri
region
china
optim
treatment
regimen
yet
determin
impact
exposur
industri
region
cancer
incid
unknown
allison
foertsch
paul
zimaka
alan
homan
univers
vermont
children
hospit
burlington
vermont
unit
state
background
type
diabet
associ
autoimmun
diseas
name
thyroid
celiac
diseas
autoimmun
gastric
diseas
two
condit
initi
present
howev
exceedingli
rare
describ
child
novel
simultan
present
thrombocytopenia
hyperglycemia
lead
concurr
diagnos
immun
thrombocytopenia
itp
object
describ
child
sever
thrombocytopenia
hyperglycemia
lead
new
diagnos
itp
explor
known
autoimmun
diagnos
signific
behind
less
commonli
report
pair
designmethod
five
male
present
bruis
viral
uri
one
week
prior
cbc
cmp
reveal
thrombocytopenia
kcmm
hyperglycemia
mgdl
urinalysi
posit
glucos
neg
keton
bleed
histori
neg
physic
exam
reveal
wet
purpura
scatter
bruis
present
consist
itp
hyperglycemia
attribut
acut
ill
stress
respons
receiv
ivig
platelet
improv
kcmm
elev
serum
glucos
persist
overnight
hemoglobin
elev
indic
chronic
hyperglycemia
autoantibodi
test
obtain
prior
ivig
demonstr
elev
acid
decarboxylas
antibodi
diagnost
start
insulin
therapi
stabil
serum
glucos
result
pleomorph
natur
symptomatolog
autoimmun
diseas
challeng
confound
associ
condit
genet
immun
dysregul
disord
consid
present
associ
condit
thrombocytopenia
unusu
pair
knowledg
five
pediatr
case
describ
associ
none
simultan
present
result
cell
destruct
pancreat
itp
mediat
circul
autoantibodi
platelet
condit
share
basi
autoimmun
dysregul
independ
mechan
associ
may
signific
implic
treatment
recent
studi
suggest
tradit
treatment
fail
rituximab
therapi
target
b
lymphocyt
may
prove
benefici
mani
autoimmun
disord
includ
itp
conclus
complex
autoimmun
disord
consid
patient
develop
multipl
autoimmun
condit
less
commonli
recogn
associ
like
itp
earli
recognit
manag
critic
patient
success
respons
convent
treatment
util
antibodi
therapi
resist
case
consid
pham
navin
pinto
univers
chicago
chicago
illinoi
unit
state
background
synovi
sarcoma
malign
mesenchym
malign
commonli
origin
deep
soft
tissu
extrem
report
head
neck
region
object
present
male
histori
progress
left
upper
extrem
pain
weak
exacerb
slip
fall
left
elbow
designmethod
mri
demonstr
intraspin
extradur
tumor
involv
left
aspect
spinal
canal
neural
foramina
paraspin
soft
tissu
level
biopsi
reveal
malign
mesenchym
neoplasm
neg
immunohistochem
marker
rhabdomyosarcoma
ewe
sarcoma
molecular
studi
posit
fusion
transcript
confer
diagnosi
synovi
sarcoma
positron
emiss
tomographi
scan
neg
metastat
diseasewhil
await
diagnost
biopsi
result
patient
develop
worsen
left
arm
pain
swell
accompani
increas
facial
edema
venou
doppler
ultrasound
reveal
extens
deep
vein
thrombos
span
intern
jugular
vein
proxim
brachial
vein
transthorac
echocardiogram
reveal
echogen
mass
right
atrium
extend
tricuspid
valv
right
ventricl
comput
tomographi
cardiac
angiogram
demonstr
contigu
mass
superior
vena
cava
left
brachiocephal
intern
jugular
vein
underw
urgent
surgeri
due
impend
hemodynam
deterior
patholog
resect
specimen
left
brachiocephal
vein
right
atriumtricuspid
annulu
consist
synovi
sarcoma
result
subsequ
receiv
neoadjuv
treatment
chemotherapi
convent
radiat
follow
surgic
resect
postop
proton
radiat
boost
adjuv
chemotherapi
evid
diseas
upon
complet
therapi
monitor
regular
surveil
conclus
primari
synovi
sarcoma
involv
spine
rare
tumor
thrombi
describ
synovi
sarcoma
first
known
report
extens
right
side
heart
multidisciplinari
care
neurosurgeri
cardiothorac
surgeri
otolaryngolog
oncolog
radiat
oncolog
key
render
patient
free
diseas
nathan
hall
ashish
risal
children
merci
hospit
kansa
citi
missouri
unit
state
background
chuvash
polycythemia
rare
form
congenit
polycythemia
caus
alter
pathway
recogn
chuvash
republ
russian
feder
clinic
distinct
entiti
polycythemia
vera
autosom
recess
inherit
pattern
specif
mutat
von
vhl
gene
result
amino
acid
substitut
lead
upregul
hypoxia
induc
factor
despit
normal
oxygen
level
lead
chronic
increas
red
blood
cell
product
mutat
vhl
gene
chromosom
mutat
subsequ
found
peopl
european
pakistanibangladeshi
ethnic
patient
year
old
femal
pakistani
descent
present
neurologist
longstand
histori
headach
lab
evalu
reveal
hemoglobin
level
hematocrit
famili
histori
posit
father
undiagnos
polycythemia
regular
phlebotomi
perform
parent
cousin
object
describ
rare
case
chuvash
polycythemia
diagnosi
treatment
outcom
pediatr
patient
designmethod
case
report
result
extens
workup
polycythemia
conduct
confirm
hgb
hct
level
primari
secondari
polycythemia
work
polycythemia
vera
exon
neg
erythopoetin
level
normal
addit
oxygen
affinifi
studi
found
normal
gene
test
perform
reveal
homozyg
mutat
vhl
gene
confirm
diagnosi
chuvash
polycythemia
date
treatment
chuvash
polycythemia
howev
symptom
manag
phlebotomi
thought
accept
phlebotomi
help
headach
ruddi
complexion
morbid
may
lead
iron
defici
anemia
also
signific
increas
stroke
thrombot
event
patient
paradox
increas
bleed
event
well
stroke
hemorrhag
complic
includ
pulmonari
hypertens
hemangioma
conclus
chuvash
polycythemia
rare
caus
polycythemia
promptli
diagnos
treat
base
upon
clinic
symptom
prevent
long
term
morbid
mortal
suraj
pratap
hanumantha
pokala
william
meyer
maria
palacio
bradley
gehr
jimmi
everest
center
pediatr
hematolog
oncolog
univers
oklahoma
colleg
medicin
oklahoma
citi
oklahoma
unit
state
background
osteosarcoma
common
primari
bone
tumor
children
metastat
diseas
seen
patient
lung
common
site
metastasi
follow
boney
site
bone
marrow
metastasi
affect
hematopoiesi
extrem
rare
case
report
literatur
object
describ
case
metastat
osteosarcoma
diffus
infiltr
bone
marrow
contigu
distant
locat
physiolog
function
bone
marrow
compromis
patient
show
suppress
hematopoiet
cell
lineag
designmethod
discuss
includ
clinic
present
diagnost
featur
note
initi
diseas
evalu
magnet
reson
imag
computer
tomographi
scan
bone
scintigraphi
serial
blood
count
provid
histolog
find
biopsi
primari
tumor
bone
marrow
also
compar
contrast
symptom
cours
diseas
typic
metastat
osteosarcoma
result
caucasian
femal
present
intermitt
pain
right
leg
week
imag
show
destruct
mass
right
distal
femur
local
bone
marrow
soft
tissu
involv
biopsi
reveal
osteoblast
osteosarcoma
metastat
evalu
demonstr
sub
centimet
nodul
addit
extens
skelet
diseas
involv
bilater
femur
bilater
humeri
skull
rib
pelvi
complet
blood
count
done
prior
biopsi
remark
white
blood
count
hemoglobin
platelet
bone
marrow
evalu
perform
sampl
bilater
iliac
crest
demonstr
pleomorph
tumor
cell
marrow
involv
osteoid
format
along
normal
hematopoiet
cell
avail
clinic
trial
patient
receiv
standard
therapi
consist
methotrex
adriamycin
cisplatin
platelet
count
recov
initi
cours
chemotherapi
suggest
marrow
diseas
respond
extent
unfortun
respons
site
poor
result
death
progress
diseas
month
treatment
conclus
bone
marrow
involv
impair
hematopoiesi
quit
uncommon
metastat
osteosarcoma
patient
osteosarcoma
present
abnorm
complet
blood
count
evalu
bone
marrow
metastas
patient
typic
dismal
prognosi
lauren
raney
maria
velez
children
hospit
new
orlean
louisiana
new
orlean
louisiana
unit
state
background
zr
year
old
previous
healthi
male
present
extens
indur
cellul
right
forearm
thigh
associ
right
axillari
inguin
lymphadenopathi
fever
fail
oral
antibiot
hospit
start
appropri
parenter
antibiot
clinic
improv
develop
palpabl
hepatosplenomegali
neutropenia
mild
anemia
object
report
rare
case
subcutan
lymphoma
designmethod
bone
marrow
biopsi
obtain
signific
hemophagocytosi
blast
popul
observ
due
concern
hemophagocyt
lymphohystiocytosi
work
obtain
ultim
skin
lymph
node
biopsi
reveal
rare
diagnosi
subcutan
lymphoma
sptcl
matur
lymphoma
extranod
cutan
origin
result
process
typic
present
singl
multipl
focal
nodul
plaqu
extrem
trunk
face
associ
fever
lymphadenopathi
hepatosplenomegali
cytopenia
rare
hemophagocytosi
extrem
rare
diagnosi
defin
epidemiolog
incid
organ
treatment
approach
current
treatment
approach
includ
steroid
alon
immunosuppress
agent
chemotherapi
even
autolog
stem
cell
transplant
current
median
surviv
roughli
depend
greatli
upon
phenotyp
cell
receptor
tcr
phenotyp
significantli
better
prognosi
aggress
phenotyp
often
associ
hemophagocytosi
found
tcr
concern
aggress
phenotyp
thu
begun
treatment
chemotherapi
regimen
receiv
two
cycl
doxorubicin
vincristin
prednison
cyclophosphamid
per
ahod
receiv
methotrex
cytarabin
per
mri
extrem
ct
abdomen
therapi
show
near
resolut
size
induat
plaqu
plan
treat
least
month
pend
respons
conclus
case
stress
import
broaden
differenti
diagnosi
patient
respond
appropri
treatment
provid
much
need
insight
success
treat
pediatr
patient
rare
diagnosi
sptcl
associ
hemophagocytosi
mark
bouchard
sarah
rivkah
vaiselbuh
children
cancer
center
staten
island
univers
hospit
staten
island
new
york
unit
state
background
technolog
chang
practic
medicin
practition
access
electron
medic
record
use
desktop
laptop
comput
face
challeng
thousand
healthcar
mobil
applic
app
avail
smart
phone
app
program
piec
softwar
design
run
handheld
devic
perform
specif
purpos
object
identifi
need
app
pediatr
pho
commun
tool
improv
workflow
enhanc
traine
patient
educ
designmethod
hematolog
oncolog
mesh
term
list
search
appl
itun
store
simpl
keyword
english
languag
master
list
uniqu
app
creat
app
divid
four
categori
medic
teach
provid
tool
resourc
consum
sever
subcategori
result
search
mesh
term
itun
store
result
app
iphon
app
ipad
total
iphon
app
consid
potenti
use
pho
field
categori
medic
teach
provid
tool
yield
highest
number
interest
app
howev
resourc
found
pediatr
stage
journal
confer
use
handbook
app
potenti
use
four
app
spanish
app
found
conclus
mobil
technolog
app
conveni
may
lead
superior
faster
clinic
improv
accuraci
enhanc
product
pho
howev
clearli
need
design
pediatr
app
aspho
take
lead
coordin
respons
field
design
organ
app
encourag
pho
use
new
app
optim
patient
care
educ
farag
obstretr
gynecolog
beel
armijo
ghada
abusin
univers
iowa
children
hospit
iowa
citi
iowa
unit
state
background
neutropen
enterocol
occur
commonli
individu
hematolog
malign
neutropen
develop
breakdown
gut
mucos
integr
result
cytotox
chemotherapi
clinic
manifest
includ
fever
abdomin
symptom
pain
distent
cramp
tender
nausea
vomit
wateri
bloodi
diarrhea
diagnosi
confirm
imag
treatment
broad
spectrum
antibiot
tubercul
enter
rare
unit
state
us
sign
symptom
often
result
diagnost
delay
object
report
aml
complic
typhliti
tubercul
enter
designmethod
case
report
result
hispan
femal
aml
receiv
treatment
children
oncolog
b
follow
neutropen
statu
comput
tomographi
ct
reveal
abnorm
mucos
enhanc
ascend
colon
ct
scan
remaind
treatment
demonstr
necrot
abdomin
lymph
node
ln
persist
ileocec
inflamm
remain
primarili
unchang
despit
antibiot
therapi
bowel
rest
end
therapi
persist
fever
set
protract
cours
typhliti
imag
show
mildli
promin
left
supraclavicular
ln
partial
improv
colon
wall
thicken
confin
cecum
proxim
ascend
colon
ct
also
reveal
nonspecif
pulmonari
nodul
lung
parenchym
diseas
hilar
adenopathi
excision
biopsi
left
ln
show
necrot
granuloma
rare
bacilli
afb
afb
stain
tuberculosi
tb
polymeras
chain
reaction
test
stool
cultur
also
posit
born
us
famili
el
salvador
report
visit
two
year
prior
diagnosi
known
tb
exposur
start
therapi
defervesc
neutrophil
count
improv
nine
month
post
complet
therapi
remain
first
remiss
hypocellular
bone
marrow
bone
marrow
afb
stain
cultur
neg
date
conclus
tubercul
enter
rare
suspect
even
harder
identifi
pediatr
oncolog
popul
due
overlap
symptom
cancer
treatment
publish
report
gastrointestin
tb
children
commonli
report
abdomin
pain
fever
weight
loss
present
symptom
highlight
decept
clinic
present
diseas
set
cancer
diagnosi
jessi
l
barnum
brandon
triplett
st
jude
children
research
hospit
memphi
tennesse
unit
state
background
leukemia
shown
mix
chimer
mc
preced
relaps
strategi
treat
patient
mc
vari
object
aim
studi
efficaci
safeti
donor
lymphocyt
infus
dli
patient
leukemia
mc
hematopoiet
cell
transplant
hct
designmethod
evalu
consecut
patient
leukemia
underw
allogen
hct
st
jude
children
research
hospit
juli
februari
receiv
dli
follow
hct
mc
mc
defin
less
donor
chimer
day
year
hct
variabl
number
tandem
repeat
dose
dli
base
donor
type
gradual
escal
toler
patient
consid
respond
donor
chimer
increas
evid
leukemia
result
diagnos
includ
acut
myelogen
leukemia
acut
lymphoblast
leukemia
chronic
myelogen
leukemia
biphenotyp
leukemia
juvenil
myelomonocyt
leukemia
donor
type
haploident
match
unrel
donor
match
sibl
donor
patient
mc
alon
respond
dli
three
respond
develop
grade
acut
graft
versu
host
diseas
gvhd
develop
limit
chronic
gvhd
patient
mc
also
mrd
posit
respond
dli
one
respond
develop
extens
chronic
gvhd
respond
mrd
time
dli
nonrespond
mc
mrd
posit
diseas
develop
gvhd
neither
patient
mc
morpholog
relaps
respons
dli
develop
gvhd
mc
predat
morpholog
relaps
day
two
patient
dli
delay
conclus
administ
promptli
evid
mc
alon
dli
donor
type
increas
donor
chimer
low
risk
gvhd
may
prevent
relaps
advoc
close
monitor
donor
chimer
hct
earli
administr
dli
use
dose
escal
regimen
nurah
lawal
clair
anderson
lydia
pecker
evelio
allistair
abraham
children
nation
medic
center
washington
dc
unit
state
background
donor
patient
african
descent
requir
hematopoiet
stem
cell
transplant
hsct
limit
nation
registri
donor
pool
limit
match
donor
disqualifi
total
nucleat
cell
tnc
count
marrow
graft
requir
donat
threshold
probabl
like
peopl
african
descent
often
lower
white
blood
cell
count
european
counterpart
addit
patient
sickl
cell
diseas
scd
tnc
threshold
higher
diseas
tnckg
recipi
bodi
weight
versu
tnckg
threshold
establish
anecdot
base
hypothesi
higher
tnc
dose
would
decreas
reject
risk
graft
dose
tradit
done
use
tnc
graft
content
may
better
predictor
transplant
outcom
object
divers
popul
hsct
donor
determin
whether
tnc
concentr
percentag
differ
ethnic
determin
whether
tnc
dose
affect
morbid
mortal
designmethod
retrospect
chart
review
allogen
hsct
donor
recipi
mann
whitney
u
test
use
compar
tnc
concentr
percentag
group
univari
logist
regress
analysi
use
evalu
transplant
outcom
result
includ
allogen
hsct
patient
donor
diagnos
scd
n
leukemialymphomamyeloma
n
myelodysplast
syndrom
n
n
donor
caucasian
black
asian
hispan
otherunknown
tnc
concentr
bone
marrow
graft
lower
black
vs
donor
n
vs
median
vs
p
median
fraction
higher
black
vs
donor
vs
p
time
engraft
incid
acut
chronic
gvhd
incid
reject
mortal
vari
significantli
base
tnc
dose
conclus
data
show
significantli
lower
tnc
concentr
higher
fraction
graft
collect
black
vs
donor
differ
outcom
suggest
tnc
threshold
bone
marrow
harvest
lower
black
donor
regina
myer
monica
bhatia
jennif
levin
daniel
dietzen
elana
smilow
chalitha
robinson
jean
sosna
prakash
satwani
columbia
univers
medic
center
new
york
new
york
unit
state
background
limit
data
exist
regard
burden
late
morbid
follow
allohct
children
nonmalign
diseas
object
assess
incid
sever
late
effect
survivor
allohct
nonmalign
condit
designmethod
conduct
prospect
assess
patient
columbia
univers
medic
center
surviv
year
allohct
childhood
age
transplant
begin
march
patient
particip
comprehens
clinic
visit
includ
object
lab
imag
test
screen
late
effect
qualiti
life
evalu
pediatr
qualiti
life
inventori
pedsql
assess
educ
attain
late
effect
grade
common
terminolog
criteria
advers
event
version
result
januari
patient
age
year
enrol
studi
mean
year
allohct
diagnos
includ
hemoglobinopathi
n
bone
marrow
failur
n
hlhimmunodefici
n
among
particip
match
sibl
donor
unrel
donor
receiv
bone
marrow
cord
blood
pbsc
underw
myeloabl
condit
fifti
percent
particip
develop
least
one
chronic
health
condit
develop
grade
condit
grade
condit
frequent
late
effect
ovarian
failur
femal
growth
impair
low
bone
miner
densiti
thyroid
dysfunct
chronic
kidney
diseas
malign
addit
histori
chronic
gvhd
histori
late
acut
viral
infect
requir
hospit
urin
microalbuminuria
hyperferritinemia
mild
pulmonari
function
test
abnorm
without
clinic
signific
mean
pedsql
score
within
standard
deviat
popul
norm
domain
overal
score
impair
rang
standard
deviat
popul
norm
thirti
eight
percent
particip
delay
educ
attain
conclus
heterogen
cohort
survivor
allohct
nonmalign
diseas
late
effect
common
sever
late
effect
infrequ
ongo
studi
abl
identifi
risk
factor
advers
outcom
rachel
phelan
paul
orchard
margaret
nichola
smiley
weston
miller
univers
minnesota
minneapoli
minnesota
unit
state
background
allogen
hematopoiet
cell
transplant
hct
remain
standard
therapi
variou
rare
inherit
metabol
diseas
imd
surviv
improv
assess
outcom
often
hamper
patient
attrit
distanc
treat
center
object
pilot
methodolog
remot
studi
parent
patient
perspect
behavior
emot
function
follow
hct
imd
designmethod
univers
minnesota
bmt
databas
queri
surviv
imd
patient
diseas
characterist
parentspati
invit
studi
particip
research
electron
data
captur
redcap
system
use
electron
administ
retriev
standard
behavior
assess
system
children
second
edit
survey
tool
analysi
respons
parentpati
pair
analyz
pair
sampl
subscal
area
anxieti
depress
atyp
attent
problem
result
identifi
patient
transplant
imd
survivor
parent
andor
patient
enrol
parentpati
pair
success
complet
survey
imd
diagnos
includ
hurler
syndrom
pair
adrenoleukodystrophi
pair
mannosidosi
pair
syndrom
pair
median
time
transplant
assess
year
iqr
rang
signific
differ
percept
anxieti
p
depress
p
atyp
p
attent
problem
p
compar
parent
patient
respons
major
patient
perform
averag
level
comparison
age
gender
base
norm
parent
score
patient
score
perspect
subscal
analyz
conclus
effect
remot
assess
behavior
emot
function
via
electron
method
feasibl
larg
cohort
imd
patient
surviv
hct
importantli
score
anxieti
depress
atyp
attent
disord
significantli
differ
parent
patient
report
suggest
patient
unabl
provid
function
parent
perspect
may
serv
adequ
represent
continu
popul
critic
provid
appropri
counsel
regard
outcom
patient
famili
consid
hct
treatment
option
imd
heather
allewelt
jill
adam
mendizab
mahsa
taskindoust
paul
l
martin
vinod
prasad
kristin
page
jean
sander
joann
kurtzberg
duke
univers
pediatr
blood
marrow
transplant
program
durham
north
carolina
unit
state
background
infant
young
children
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
late
effect
due
exposur
develop
organ
chemotherapi
radiat
therapi
typic
util
part
condit
regimen
busulfan
bu
myeloabl
condit
regimen
develop
elimin
radiat
exposur
young
children
hope
late
effect
would
minim
report
late
effect
date
focus
outcom
older
children
adult
remain
pauciti
data
regard
late
effect
young
children
undergo
hsct
follow
regimen
object
aim
retrospect
studi
describ
late
effect
observ
cohort
young
patient
underw
cord
blood
transplant
cbt
use
condit
regimen
designmethod
medic
record
patient
underw
cbt
cytoreduct
year
age
septemb
surviv
year
review
overal
surviv
descript
statist
mean
height
standard
deviat
score
cumul
incid
key
late
effect
calcul
cox
regress
model
explor
associ
predictor
late
effect
result
median
age
transplant
year
rang
median
age
year
rang
overal
surviv
year
rang
nearli
patient
experienc
least
one
signific
late
effect
two
late
effect
document
patient
dental
problem
document
patient
commonli
observ
late
effect
includ
short
statur
cognit
pulmonari
pubert
delaygonad
failur
short
statur
cognit
deficit
frequent
patient
inherit
metabol
diseas
conclus
avoid
irradi
young
undergo
cbt
may
decreas
elimin
late
effect
result
inform
clinic
care
guidelin
well
add
grow
inform
regard
late
effect
hsct
gener
survivor
cbt
infanc
earli
childhood
requir
regular
identifi
late
effect
amelior
associ
consequ
alicia
gesenhu
ashley
stella
davi
sharat
chandra
adam
lane
parinda
mehta
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
pediatr
patient
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
invas
fungal
diseas
ifd
gold
standard
fungal
prophylaxi
regimen
hsct
cincinnati
children
hospit
medic
center
cchmc
util
three
altern
dose
strategi
antifung
prophylaxi
popul
voriconazol
micafungin
limit
data
regard
efficaci
regimen
compar
superior
object
aim
studi
assess
efficaci
regimen
prevent
ifd
pediatr
allogen
hsct
patient
secondari
aim
includ
safeti
comparison
pharmacoeconom
assess
designmethod
retrospect
chart
review
conduct
patient
year
receiv
allogen
hsct
januari
juli
proven
probabl
possibl
ifd
defin
use
updat
european
organ
research
treatment
cancer
mycos
studi
group
definit
examin
first
day
result
allogen
transplant
perform
patient
patient
met
inclus
criteria
patient
receiv
receiv
micafungin
receiv
voriconazol
start
day
zero
proven
probabl
ifd
occur
patient
three
micafungin
group
candida
parapsilosi
voriconazol
group
saccharomyc
cerevisia
candida
glabrata
group
candida
glabrata
p
eighteen
patient
antifung
prophylaxi
chang
due
possibl
ifd
occur
micafungin
group
overal
micafungin
group
advers
event
ae
total
ae
compar
voriconazol
group
p
conclus
result
show
rate
proven
probabl
ifd
similar
three
regimen
although
possibl
infect
increas
altern
day
micafungin
overal
safeti
toler
significantli
better
micafungin
group
compar
voriconazol
group
sub
analys
ongo
delin
patient
activ
gvhd
increas
immun
suppress
data
along
pharmacoeconom
result
add
insight
risk
benefit
balanc
regimen
anant
vatsayan
david
askew
saada
eid
alex
tong
frederick
allen
kenneth
r
cook
john
letterio
alex
huang
univers
hospit
case
medic
center
rainbow
babi
children
hospit
cleveland
ohio
unit
state
background
cyclin
depend
kinas
ubiquit
express
prolin
direct
serinethreonin
kinas
preclin
clinic
data
suggest
activ
lie
neurosci
inflamm
cancer
immun
surveil
lab
identifi
novel
role
acut
diseas
agvhd
hypothes
inhibit
donor
lead
reduc
migrat
secondari
lymphoid
organ
slo
reduc
sever
agvhd
murin
model
allogen
hematopoiet
stem
cell
transplant
object
investig
role
traffick
syngen
allogen
hsct
model
translat
goal
use
inhibit
novel
strategi
prevent
agvhd
designmethod
small
molecul
inhibitor
roscovitin
use
vitro
vivo
experi
pharmacolog
inhibit
respect
donor
knockout
hematopoiet
chimer
mice
adopt
transfer
haploident
mice
studi
role
function
agvhd
lineag
specif
cell
knockout
mice
use
futur
experi
fluoresc
activ
cell
sort
use
studi
quantit
differ
migrat
roscovitin
treat
donor
versu
appropri
control
cellular
interact
pattern
differenti
label
subset
use
real
time
imag
laser
scan
microscopi
result
baselin
syngen
experi
compar
allogen
model
result
loss
express
donor
associ
reduc
migrat
prolifer
differenti
donor
express
import
develop
agvhd
loss
donor
reduc
mortal
morbid
due
agvhd
discuss
addit
result
confer
conclus
preliminari
data
identifi
inhibit
novel
approach
prevent
agvhd
nonspecif
inhibitor
earli
clinic
phase
trial
specif
small
molecul
inhibitor
develop
project
major
translat
implic
treatment
numer
diseas
play
crucial
role
incit
inflamm
organ
damag
nanci
kernan
paul
g
richardson
brandon
triplett
stephan
grupp
joseph
h
antin
yoav
messing
wei
liang
robin
hume
alison
l
hannah
robert
j
soiffer
pediatr
bone
marrow
transplant
servic
memori
sloan
ketter
cancer
center
new
york
new
york
unit
state
background
vodso
typic
consid
unpredict
potenti
hematopoiet
stem
cell
transplant
hsct
complic
howev
known
risk
without
hsct
sever
hepat
vodso
dysfunct
mod
may
associ
mortal
defibrotid
approv
sever
hepat
vodso
treatment
adult
pediatr
patient
eu
us
new
drug
applic
file
approv
treatment
object
describ
updat
efficaci
safeti
result
defibrotid
patient
vodso
designmethod
defibrotid
avail
us
ongo
protocol
patient
hepat
vodso
baltimoremodifi
seattl
criteria
biopsi
withwithout
mod
renal
andor
pulmonari
dysfunct
dose
mgkgd
divid
dose
recommend
day
result
patient
develop
vodso
defibrotid
dose
april
receiv
chemotherapi
without
hsct
mod
median
age
year
rang
year
patient
year
age
male
common
primari
diseas
acut
lymphocyt
leukemia
acut
myelogen
leukemia
chemotherapeut
agent
receiv
patient
vincristin
cyclophosphamid
cytarabin
doxorubicin
methotrex
gemtuzumab
inotuzumab
receiv
patient
respect
estim
surviv
overal
ci
patient
mod
patient
without
mod
patient
report
advers
event
ae
assess
least
possibl
commonli
hypotens
nausea
vomit
epistaxi
hematochezia
gastrointestin
pulmonari
hemorrhag
hemorrhag
ae
sever
occur
patient
pulmonari
epistaxi
hematochezia
gastric
gastrointestin
seriou
ae
report
patient
ae
led
discontinu
patient
two
death
least
possibl
conclus
surviv
patient
pediatr
develop
vodso
chemotherapi
without
hsct
clinic
encourag
studi
defibrotid
gener
possibl
fatal
patient
discontinu
due
ae
stephan
grupp
paul
g
richardson
nanci
kernan
joel
brochstein
shin
mineishi
amanda
termuhlen
eva
c
guinan
paul
l
martin
gideon
steinbach
amrita
krishnan
eneida
r
nemecek
reggi
duerst
john
j
doyl
joseph
h
antin
rajind
bajwa
ralph
b
dagostino
kathleen
f
villa
maja
miloslavski
robin
l
hume
massimo
iacobelli
bijan
nejadnik
alison
l
hannah
robert
j
soiffer
children
hospit
philadelphia
philadelphia
pennsylvania
unit
state
background
treatment
hepat
vodso
potenti
complic
condit
regimen
stem
cell
transplant
sct
sever
case
defin
dysfunct
mod
may
result
mortal
object
present
updat
surviv
complet
respons
cr
analys
pivot
phase
trial
defibrotid
vodso
mod
includ
data
obtain
respons
us
health
author
designmethod
multicent
phase
histor
control
hc
studi
elig
patient
baltimor
criteria
plu
mod
renal
andor
pulmonari
dysfunct
exclus
criteria
sever
liver
gut
diseas
clinic
signific
bleed
need
pressor
blind
medic
review
committe
determin
unequivoc
vodso
mod
hc
patient
medic
chart
df
dose
mgkgd
iv
infus
recommend
treatment
durat
day
primari
endpoint
surviv
key
secondari
endpoint
cr
surviv
cr
rate
differ
confid
interv
calcul
use
propens
estim
number
need
treat
nnt
absolut
risk
reduct
reciproc
arr
equal
control
minu
experiment
event
rate
result
patient
hc
baselin
characterist
similar
surviv
defibrotid
hc
group
respect
differ
surviv
ci
p
nnt
observ
cr
rate
differ
cr
ci
p
respect
nnt
group
advers
event
ae
seriou
ae
least
possibl
relat
defibrotid
patient
ae
lead
death
similar
defibrotid
hc
patient
hemorrhag
ae
hypotens
conclus
patient
improv
surviv
improv
cr
rate
base
number
expect
nnt
prevent
one
death
achiev
one
cr
respect
overal
hemorrhag
fatal
ae
incid
similar
group
ae
consist
expect
critic
ill
popul
stephan
grupp
paul
g
richardson
brandon
triplett
nanci
kernan
joseph
h
antin
wei
liang
robin
hume
alison
l
hannah
robert
j
soiffer
children
hospit
philadelphia
philadelphia
pennsylvania
unit
state
background
vodso
unpredict
potenti
complic
condit
hsct
sever
vodso
mod
associ
mortal
defibrotid
approv
treatment
sever
vodso
eu
us
new
drug
applic
defibrotid
propos
treatment
hepat
vodso
mod
file
us
defibrotid
avail
ongo
studi
object
investig
impact
treatment
initi
ti
patient
vodso
withwithout
mod
designmethod
studi
patient
vodso
baltimoremodifi
seattl
criteria
biopsi
withwithout
renalpulmonari
mod
receiv
defibrotid
mgkgd
divid
dose
recommend
day
surviv
hsct
patient
examin
post
hoc
base
time
vodso
diagnosi
defibrotid
ti
two
analys
conduct
surviv
rate
ti
patient
day
fisher
exact
test
surviv
rate
patient
ti
particular
day
test
trend
across
day
result
among
hsct
patient
enrol
april
receiv
defibrotid
dose
ti
date
avail
patient
mod
defibrotid
start
day
diagnosi
patient
patient
start
defibrotid
day
analysi
initi
beforeaft
day
earlier
defibrotid
ti
associ
higher
surviv
rate
statist
signific
except
day
pt
ti
analysi
relationship
surviv
ti
day
statist
signific
trend
time
higher
surviv
earlier
initi
p
conclus
data
indic
decreas
surviv
associ
longer
treatment
delay
confirm
test
p
thu
consid
defibrotid
initi
soon
possibl
vodso
diagnosi
withwithout
mod
day
provid
viabl
better
outcom
sarah
taylor
christen
eben
melisa
k
stricherz
cathryn
jennissen
kristina
nelson
univers
minnesota
mason
children
hospit
fairview
minnesota
unit
state
background
invas
fungal
infect
set
profound
immun
suppress
often
lethal
femal
sever
aplast
anemia
follow
month
neutropenia
unrespons
stimul
factor
present
rhizopu
sinus
obliter
nasal
septum
invad
cribriform
plate
despit
prophylact
therapi
voriconazol
month
month
micafungin
object
demonstr
effect
approach
rhizopu
infect
includ
surgic
debrid
system
topic
medic
granulocyt
infus
allogen
hematopoiet
cell
transplant
allohct
import
tailor
pharmacotherapi
base
fungal
suscept
pharmacokinet
monitor
safeti
intraven
posaconazol
isavuconazol
profoundli
immunocompromis
pediatr
patient
designmethod
patient
treat
twice
daili
intranas
amphotericin
b
irrig
period
surgic
sinu
debrid
topic
amphotericin
b
wash
tissu
sampl
initi
cultur
grow
rhizopu
reveal
suscept
posaconazol
amphotericin
b
treatment
oral
posaconazol
liposom
amphotericin
b
preced
allohct
condit
cyclophosphamid
fludarabin
globulin
radiat
one
month
posaconazol
held
cyclophosphamid
administr
restart
intraven
therapi
condit
regimen
neutrophil
engraft
patient
receiv
donor
granulocyt
infus
week
therapi
patient
rhizopu
demonstr
resist
posaconazol
increas
amphotericin
b
mic
posaconazol
discontinu
amphotericin
b
dose
increas
isavuconazol
confirm
suscept
treatment
initi
achiev
minimum
goal
trough
level
ugml
studi
thu
far
found
correl
trough
level
efficacysafeti
report
date
use
pediatr
patient
patient
engraft
neutrophil
day
follow
allohct
result
endoscop
sinu
radiolog
evalu
show
resolut
infect
side
effect
isavuconazol
posaconazol
observ
surgic
debrid
topic
therapi
discontinu
week
patient
remain
liposom
amphotericin
b
isavuconazol
conclus
approach
includ
surgic
debrid
evolv
topic
system
therapi
adjust
base
serial
suscept
test
pharmacokinet
monitor
adopt
immunotherapi
granulocyt
allohct
success
rescu
sever
immunocompromis
patient
invas
rhizopu
infect
talano
cori
abikoff
theodor
b
moor
rona
singer
weinberg
carolyn
brenda
j
grossman
lee
ann
susan
parson
suzann
braniecki
erin
morri
sandra
fabricator
janet
ayello
mildr
carmella
van
de
ven
shalini
shenoy
yaya
chu
jame
verbski
mitchel
cairo
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
background
hla
msd
allosct
remain
cur
therapi
patient
scd
howev
less
elig
scd
patient
unaffect
msd
fhi
allosct
altern
allogen
donor
sourc
limit
graft
failur
gf
delay
immun
reconstitut
andor
sever
gvhd
overcom
barrier
previous
investig
approach
enrich
cell
addback
pediatr
recipi
util
mud
demonstr
engraft
incid
grade
agvhd
designmethod
scd
patient
age
one
high
risk
featur
talanocairo
et
al
ejh
receiv
fhi
allosct
parent
donor
follow
enrich
target
final
product
cell
addback
final
product
tacrolimu
agvhd
prophylaxi
wbc
donor
rbc
chimer
perform
str
immun
reconstitut
studi
perform
local
central
core
laboratori
result
fifteen
patient
enrol
median
engraft
myeloid
cell
platelet
day
respect
probabl
agvhd
cgvhd
donor
chimer
peripher
blood
day
donor
chimer
erythroid
lineag
day
nk
cell
reconstitut
follow
fhi
allosct
enrichmentt
cell
add
back
rapid
peak
cellsul
nk
cell
express
high
level
activ
receptor
inhibitori
receptor
median
day
cellsul
cellsul
cellul
cellsul
graft
failur
probabl
os
conclus
preliminari
result
demonstr
safeti
feasibl
efficaci
fhi
allosct
util
enrich
cell
addback
parent
scd
trait
donor
patient
engraft
low
incid
grade
agvhd
high
sustain
donor
chimer
robust
immun
reconstitut
absenc
scd
symptom
organ
complic
scd
popul
research
support
fda
grant
kanwaldeep
k
mallhi
angela
r
smith
todd
e
defor
paul
j
orchard
weston
p
miller
univers
minnesota
minneapoli
minnesota
unit
state
background
umbil
cord
blood
transplant
ucbt
demonstr
efficaci
numer
inherit
metabol
disord
imd
sever
imd
donor
chimer
may
correl
treatment
effect
object
sought
evalu
impact
ucbrecipi
hla
allel
dispar
compar
convent
match
algorithm
engraft
surviv
donor
myeloid
chimer
outcom
follow
ucbt
imd
designmethod
consecut
first
singl
ucbt
imd
univers
minnesota
evalu
ucbrecipi
hla
allel
match
characterist
well
major
outcom
assess
result
median
age
ucbt
year
patient
receiv
myeloabl
condit
primari
diagnos
hurler
syndrom
cald
mldgld
median
tnc
year
estim
overal
surviv
entir
cohort
ci
median
time
neutrophil
platelet
recoveri
day
respect
rate
sever
acut
chronic
gvhd
low
convent
match
ucbt
allel
convent
ucbt
allel
dispar
allel
engraft
surviv
year
observ
convent
ucb
recipi
respect
p
use
allel
criteria
engraft
surviv
observ
recipi
recipi
p
overal
graft
failur
rate
convent
ucbt
analysi
patient
use
allel
criteria
reveal
graft
failur
rate
recipi
recipi
p
conclus
larg
cohort
patient
undergo
ucbt
imd
hla
allel
match
consider
may
better
predict
fulli
engraft
surviv
multivari
analysi
confirm
find
ongo
evalu
signific
particular
allel
mismatch
includ
class
ii
mch
loci
continu
well
karina
shannon
golden
jennif
schneiderman
morri
kletzel
yasmin
gosiengfao
ann
robert
h
luri
children
hospit
chicago
chicago
illinoi
unit
state
background
outcom
neuroblastoma
remain
modern
treatment
protocol
util
intens
induct
follow
myeloabl
consolid
chemotherapi
autolog
stem
cell
rescu
ascr
improv
surviv
rate
sequela
emerg
time
object
evalu
late
effect
high
dose
chemotherapi
induct
follow
myeloabl
consolid
chemotherapi
tripl
ascr
pediatr
follow
organ
system
endocrin
renal
cardiac
second
malign
neoplasm
cohort
report
designmethod
retrospect
review
data
patient
treat
follow
chicago
pilot
protocol
patient
receiv
contemporari
standard
intens
nbl
chemotherapi
follow
tripl
ascr
evalu
tripl
ascr
condit
chemotherapi
includ
two
cycl
carboplatinetoposid
one
cyclophosphamidethiotepa
receiv
focal
radiat
primari
site
diseas
none
receiv
total
bodi
irradi
data
includ
age
diagnosi
gender
prior
post
ascr
height
weight
blood
pressur
buncr
eject
shorten
fraction
gonad
statu
result
patient
aliv
complet
data
focal
radiat
site
includ
whole
abdomen
left
flank
right
flank
mediastinum
chest
pelvi
focal
brain
spine
short
statur
defin
either
failur
reach
height
growth
occur
seven
patient
hypothyroid
includ
surgic
hypothyroid
due
papillari
carcinoma
gonad
failur
occur
femal
male
cardiac
morbid
normal
renal
function
calcul
creatinin
equat
median
time
initi
diagnosi
year
conclus
signific
hormon
growth
thyroid
gonad
late
effect
note
intens
induct
follow
myeloabl
consolid
chemotherapi
tripl
ascr
patient
cohort
minim
renal
cardiac
long
term
effect
survivor
treat
requir
ensur
appropri
surveil
treatment
sequela
johanna
sheu
elena
hawryluk
wendi
london
dongj
guo
madhumitha
sridharan
corinna
rea
md
lesli
lehmann
md
christin
duncan
jennif
huang
boston
children
cancer
institut
boston
massachusett
unit
state
background
data
suggest
childhood
cancer
survivor
risk
melanoma
nonmelanoma
skin
cancer
howev
late
effect
skin
pediatr
hematopoiet
stem
cell
transplant
hsct
well
describ
object
primari
object
studi
character
nevi
associ
risk
factor
pediatr
hsct
recipi
also
examin
incid
cancer
precancer
skin
lesion
cohort
designmethod
studi
cohort
studi
pediatr
hsct
recipi
control
match
age
gender
fitzpatrick
skin
type
studi
particip
underw
full
skin
hair
nail
examin
pediatr
dermatologist
medic
record
review
obtain
demograph
clinic
data
result
hsct
patient
match
control
enrol
year
period
median
age
studi
visit
year
hsct
patient
median
time
hsct
year
hsct
patient
significantli
nevi
control
patient
median
rang
vs
p
hsct
patient
significantli
nevi
mm
diamet
atyp
nevi
control
factor
associ
increas
nevi
count
hsct
patient
includ
malign
indic
hsct
pretranspl
chemotherapi
exposur
total
bodi
irradi
tbi
myeloabl
condit
fair
skin
histori
sunburn
factor
associ
atyp
nevi
includ
malign
indic
exposur
tbi
myeloabl
condit
chronic
graft
versu
host
diseas
cgvhd
hsct
patient
histori
cancer
precancer
skin
lesion
includ
solar
lentigo
scc
actin
keratosi
porokeratosi
bcc
sum
hsct
cohort
develop
one
cancer
precancer
skin
lesion
lesion
associ
increas
melanoma
risk
conclus
found
increas
number
benign
nevi
atyp
nevi
cancer
precancer
skin
lesion
cohort
pediatr
hsct
recipi
identifi
malign
diseas
total
bodi
irradi
chronic
gvhd
signific
risk
factor
find
larger
prospect
studi
long
term
follow
cohort
need
confirm
expand
find
divya
devadasan
sun
tim
town
frederick
goldman
univers
alabama
birmingham
alabama
unit
state
background
hematopoiet
stem
cell
transplant
hsct
patient
sickl
cell
diseas
scd
cur
though
signific
toxic
myeloabl
condit
limit
util
previous
develop
knockin
mice
produc
normal
aa
sickl
ss
human
hemoglobin
recapitul
sever
anemia
hyposthanuria
limit
lifespan
found
scd
patient
reduc
intens
prepar
regimen
decreas
transplant
toxic
prefer
disord
newer
agent
develop
includ
treosulfan
alkyl
antibodi
creat
bone
marrow
bm
nich
block
function
object
optim
condit
murin
model
scd
allow
suffici
donor
rbc
chimer
diseas
amelior
designmethod
mice
receiv
vari
condit
regimen
rescu
control
aa
marrow
includ
irradi
gy
tbi
treosulfan
ip
ip
hematolog
effect
respect
treatment
determin
assess
marrow
cellular
peripher
cbc
erythroid
donor
chimer
focus
urin
concentr
abil
surrog
renal
tubular
function
also
assess
result
erythroid
hyperplasia
note
bm
scd
mice
treosulfan
independ
manner
decreas
bm
cellular
induc
cytopenia
control
scd
mice
overal
scd
mice
abl
toler
dose
treosulfan
tbi
rel
control
scd
mice
evid
donor
erythroid
engraft
week
sustain
donor
erythroid
chimer
normal
reticulocyt
urin
osmol
found
scd
mice
sustain
donor
erythroid
chimer
mice
remain
hyposthanur
anim
follow
fertil
surviv
conclus
scd
mice
close
mimic
human
diseas
phenotyp
abl
condit
intoler
treosulfan
alon
unabl
sustain
erythroid
chimer
major
anim
suggest
current
dose
nonetheless
anim
least
donor
erythroid
chimer
normal
urin
osmol
cbc
consist
clinic
experi
scd
transplant
incomplet
donor
erythroid
engraft
suffici
amelior
diseas
phenotyp
current
studi
assess
combinatori
effect
treosulfan
hemalatha
g
rangarajan
ghada
abusin
rajind
bajwa
jefferi
j
auletta
edwin
horwitz
rolla
nationwid
children
hospit
columbu
ohio
unit
state
background
thrombot
microangiopathi
occur
around
hematopoiet
cell
transplant
hct
recipi
howev
pediatr
patient
receiv
hct
hemoglobinopathi
larg
undescrib
herein
report
three
patient
hemoglobinopathi
develop
sequela
sever
progress
despit
treatment
eculizumab
patient
year
old
male
sickl
cell
diseas
scd
present
relat
massiv
pericardi
effus
tamponad
uncontrol
hypertens
day
post
myeloabl
match
relat
umbil
cord
blood
transplant
despit
discontinu
tacrolimu
effus
worsen
requir
polypharmaci
therapi
treatment
eculizumab
effus
resolv
hypertens
improv
tma
lab
normal
month
transplant
continu
chronic
kidney
diseas
estim
gfr
patient
year
old
male
scd
develop
posterior
revers
encephalopathi
syndrom
pre
seizur
day
follow
match
sibl
bone
marrow
transplant
despit
discontinu
tacrolimu
one
month
later
present
refractori
statu
epilepticu
requir
six
hypertens
imag
confirm
recurr
pre
left
tempor
hemorrhag
laboratori
test
consist
post
treatment
eculizumab
seizur
abat
tma
lab
normal
current
month
residu
neurocognit
defect
patient
year
old
asian
femal
major
receiv
myeloabl
match
unrel
bone
marrow
transplant
six
month
present
tma
relat
intract
hypertens
acut
kidney
injuri
requir
dialysi
seizur
renal
biopsi
mri
brain
show
chang
consist
tma
minim
respons
discontinu
tacrolimu
therapeut
plasma
exchang
follow
eculizumab
therapi
hematolog
paramet
normal
taken
dialysi
howev
develop
sever
chronic
kidney
diseas
estim
gfr
hypertens
die
sixteen
month
due
respiratori
failur
caus
rsv
conclus
patient
hemoglobinopathi
ongo
endotheli
dysfunct
may
place
greater
risk
latter
devast
clinic
consequ
investig
need
order
determin
eculizumab
may
warrant
treatment
seemingli
popul
michael
j
eckrich
carri
barnhart
kim
zahn
staci
epstein
darci
grochowski
mark
cannon
traci
fuch
michel
hyland
javier
oesterheld
andrew
l
gilman
levin
children
hospit
carolina
medic
center
charlott
north
carolina
unit
state
background
patient
could
cure
sickl
cell
diseas
scd
stem
cell
transplant
match
sibl
donor
mani
match
unrel
donor
success
use
altern
donor
includ
mismatch
famili
member
could
provid
donor
almost
patient
scd
object
use
condit
regimen
select
peripher
blood
stem
cell
pbsc
graft
allow
engraft
low
incid
diseas
gvhd
designmethod
ten
pediatr
scd
patient
underw
transplant
altern
donor
indic
transplant
includ
pain
crisi
n
concurr
kostmann
n
stroke
n
condit
transcrani
doppler
development
delay
nocturn
hypoxia
n
patient
receiv
median
prbc
transfus
rang
within
three
year
prior
transplant
condit
regimen
consist
melphalan
thiotepa
x
fludarabin
x
without
immunosuppress
six
patient
receiv
rituximab
condit
seven
patient
receiv
plan
donor
lymphocyt
infus
dli
day
methotrex
iv
gvhd
prophylaxi
companion
studi
two
patient
receiv
therapeut
dli
infus
result
median
age
transplant
year
rang
eight
patient
two
match
unrel
donor
median
pbsc
dose
rang
patient
receiv
patient
engraft
anc
median
day
rang
nine
ten
patient
aliv
median
month
rang
three
patient
lymphoprolif
disord
ptld
one
die
consequ
treatment
ptld
seriou
viral
diseas
observ
acut
grade
gvhd
develop
transplant
dli
one
case
occur
dli
patient
chronic
gvhd
conclus
condit
regimen
follow
altern
donor
transplant
provid
reliabl
engraft
low
incid
gvhd
approach
may
increas
avail
transplant
pediatr
patient
scd
match
sibl
donor
matthew
r
kudek
ryan
shanley
nicol
zantek
angela
r
smith
weston
p
miller
iv
univers
minnesota
divis
blood
marrow
transplant
minneapoli
minnesota
unit
state
background
exist
literatur
show
mix
conclus
regard
impact
abo
incompat
outcom
follow
hematopoiet
cell
transplant
futur
umbil
cord
blood
ucb
expans
technolog
bright
assess
whether
graft
characterist
impact
variou
outcom
follow
ucb
transplant
ucbt
disord
nmd
object
determin
impact
abo
match
statu
outcom
interest
patient
undergo
first
ucbt
nmd
designmethod
prospect
maintain
institut
bmt
program
databas
queri
patient
undergo
first
ucbt
nmd
demograph
diseas
characterist
ucb
recipi
abo
compat
consid
match
major
mismatch
recipi
isoagglutinin
ucb
antigen
minor
mismatch
ucb
isoagglutinin
recipi
antigen
mismatch
doubl
ucbt
compat
statu
domin
unit
consid
impact
abo
incompat
assess
follow
overal
surviv
graft
failur
agvhd
grade
cgvhd
time
neutrophil
platelet
recoveri
prbc
transfus
requir
donor
hematopoiet
chimer
result
decemb
patient
undergon
first
ucbt
variou
nmd
percent
underli
storag
disord
marrow
failur
anoth
indic
among
four
abo
compat
group
signific
differ
seen
age
gender
nmd
diagnosi
categori
condit
intens
cell
dose
number
ucb
unit
transplant
era
perform
score
gvhd
prophylaxi
cmv
serostatu
abo
compat
statu
appear
impact
outcom
assess
though
trend
toward
increas
grade
iii
iv
agvhd
seen
recipi
major
mismatch
unit
multivari
initi
subgroup
analys
abo
compat
significantli
impact
studi
includ
prbc
transfus
burden
conclus
abo
compat
statu
appear
impact
select
outcom
follow
ucbt
larg
nmd
cohort
yaya
chu
ashlin
yahr
bokun
cheng
brian
huang
janet
ayello
matthew
barth
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
bl
patient
relaps
prognosi
dismal
due
resist
group
success
modifi
expand
peripher
blood
natur
killer
cell
expbnk
car
target
bl
cell
vitro
nsg
mice
romidepsin
histon
deacetylas
hdac
inhibitor
increas
express
ligand
bl
object
investig
effect
romidepsin
alon
combin
car
modifi
expbnk
cell
bl
cell
vitro
human
bl
nsg
mice
designmethod
car
modifi
expbnk
cell
produc
describ
daudi
raji
cell
treat
romidepsin
gener
provid
celgen
engraft
mice
inject
romidepsin
pb
follow
car
expbnk
cell
mock
expbnk
cell
inject
later
tumor
regress
andor
progress
monitor
weekli
result
hdac
level
significantli
increas
bl
cell
compar
white
blood
cell
total
acetyl
enhanc
raji
follow
romidepsin
importantli
romidepsin
significantli
inhibit
bl
cell
prolifer
p
induc
apoptosi
rituximab
sensit
bl
cell
cell
cycl
arrest
resist
bl
cell
p
romidepsin
significantli
inhibit
vivo
daudi
raji
cell
growth
xenograft
nsg
mice
reduc
tumor
burden
p
bioluminesc
p
vitro
cytotox
car
expbnk
cell
significantli
enhanc
romidepsin
treat
bl
cell
compar
untreat
e
p
n
compar
mock
expbnk
p
n
human
raji
xenograft
nsg
mice
surviv
time
romidepsincar
expbnk
treat
mice
significantli
extend
compar
untreat
mice
median
day
p
car
expbnk
treat
mice
median
day
p
romidepsin
treat
mice
median
day
p
addit
observ
enhanc
micab
express
daudi
xenograft
mice
romidepsin
treatment
conclus
result
suggest
therapeut
potenti
combin
car
modifi
expbnk
cell
romidepsin
resist
bl
continu
investig
whether
enhanc
micab
express
mice
associ
extend
surviv
refer
cairo
et
al
jco
goldmancairo
et
al
leukemia
chucairo
et
al
imm
re
chucairo
et
al
cytotherapi
abikoff
ca
nash
nickerson
b
harrison
l
pulsiph
giller
r
boyer
shi
q
abram
morri
e
ayello
j
horowitz
la
keat
zhang
x
gurney
j
cairo
ms
new
york
medic
colleg
valhalla
new
york
unit
state
background
rapid
avail
allow
greater
hla
mismatch
low
rate
gvhd
make
ucb
attract
stem
cell
sourc
howev
low
cell
dose
lead
delay
engraft
increas
transplant
relat
mortal
celgen
cellular
therapeut
cct
develop
proprietari
process
collect
hpdsc
higher
concentr
cell
lower
hla
class
ii
express
ucb
hpdsc
shown
enhanc
rate
probabl
engraft
potenti
suppress
inflamm
combin
ucb
transplant
mice
object
determin
safeti
feasibl
ucb
transplant
follow
hpdsc
use
myeloabl
reduc
intens
ri
condit
malign
diseas
designmethod
multicent
consortium
enrol
patient
elig
malign
nonmalign
condit
patient
singl
doubl
cord
blood
unit
least
hla
match
cumul
tnc
x
ri
condit
singl
doubl
ucb
infus
follow
infus
hpdsc
donor
chimer
perform
previous
describ
result
patient
enrol
date
receiv
singl
receiv
doubl
ucb
transplant
patient
transplant
malign
condit
patient
aliv
day
except
patient
earli
relaps
patient
neutrophil
engraft
median
day
rang
hpdsc
persist
beyond
day
patient
although
mix
chimer
persist
least
day
doubl
ucbt
probabl
grade
agvhd
cgvhd
immun
reconstitut
rapid
day
absolut
count
igg
level
surviv
patient
respect
conclus
ucb
transplant
follow
hpdsc
infus
children
young
adult
malign
diseas
appear
safe
lower
expect
incid
jorg
galvez
silva
ossama
maher
minjeong
park
dian
liu
chloe
tillman
demetrio
petropoulo
nidal
tarek
ej
shpall
priti
tewari
univers
texa
md
anderson
cancer
center
houston
texa
unit
state
background
allogen
hematopoiet
stem
cell
transplant
hsct
reli
avail
suitabl
donor
patient
match
sibl
donor
altern
donor
hsct
umbil
cord
blood
ucbt
haploident
donor
continu
increas
viabl
donor
sourc
object
evalu
lead
caus
readmiss
follow
ucbt
pediatr
young
adult
patient
designmethod
conduct
retrospect
review
patient
age
year
readmit
within
month
follow
either
ucbt
inform
patient
characterist
includ
diagnosi
condit
regimen
complic
reason
readmiss
analyz
result
patient
median
age
rang
receiv
either
ucbt
patient
requir
hospit
receiv
ucbt
underw
patient
event
among
readmit
group
patient
receiv
mainli
myeloabl
regimen
major
hematolog
malign
five
patient
complet
remiss
three
patient
condit
patient
receiv
similar
agvhd
prophylaxi
howev
also
receiv
addit
cyclophosphamid
signific
differ
univari
analysi
index
admiss
among
document
infect
agvhd
engraft
syndrom
vod
fourteen
patient
ucbt
patient
one
admiss
nineteen
patient
admiss
within
month
ucbt
group
document
infect
lead
caus
admiss
group
ucbt
acut
gvhd
complic
caus
admiss
relaps
etiolog
admiss
patient
group
first
readmiss
number
subsequ
readmiss
influenc
outcom
conclus
trend
toward
readmiss
ucbt
group
howev
signific
differ
reach
number
readmiss
caus
sourc
cohort
lead
caus
admiss
document
infect
group
larger
collabor
studi
warrant
brinda
mehta
olga
militano
mehmet
f
ozkaynak
carmella
van
deven
berkley
nickerson
debra
abram
harrison
l
carl
hambi
mitchel
cairo
new
york
medic
colleg
valhalla
new
york
unit
state
background
acut
gvhd
remain
major
challeng
allohpt
previous
demonstr
safeti
tacrolimusmmf
combin
pharmacokinet
studi
suggest
mmf
dose
ideal
dose
mmf
pediatr
allohpt
recipi
remain
defin
object
investig
efficaci
tacrolimu
plu
mmf
administ
agvhd
prophylaxi
caya
recipi
allohpt
designmethod
caya
recipi
allohpt
recruit
month
period
agvhd
prophylaxi
consist
tacrolimu
mgkgday
iv
continu
infus
mgkgday
po
divid
target
concentr
ngml
mmf
max
gdose
mgkg
patient
year
age
weight
kg
max
gdose
ivpo
start
day
mmf
discontinu
day
absenc
agvhd
result
caya
recipi
sex
median
age
year
year
either
malign
nonmalign
condit
analyz
donor
sourc
includ
match
sibl
donor
msd
peripher
blood
stem
cell
pbsc
match
unrel
donor
mud
pbsc
unrel
cord
blood
cb
msd
cb
match
sibl
cb
plu
bone
marrow
bm
mud
bm
match
sibl
bm
mud
bm
condit
regimen
includ
myeloabl
regimen
median
time
myeloid
platelet
engraft
day
respect
probabl
grade
grade
acut
gvhd
respect
probabl
extens
limit
chronic
gvhd
respect
probabl
os
mac
predict
significantli
higher
risk
agvhd
univari
analysi
p
hr
conclus
studi
demonstr
low
incid
agvhd
cgvhd
divers
cohort
caya
allohpt
recipi
follow
tacrolimu
mmf
prophylaxi
compar
prior
studi
util
dose
refer
bhatia
cairo
et
al
biol
blood
marrow
transplant
orli
r
klein
jessica
buddenbaum
noah
tucker
allen
r
chen
kenneth
r
cook
christoph
gamper
david
loeb
elia
zambidi
nicola
j
llosa
jeffrey
huo
nanci
robey
mari
jo
holuba
yvett
kasamon
shannon
r
mccurdi
richard
ambind
javier
leo
luznik
ephraim
j
fuch
richard
j
jone
heather
j
symon
john
hopkin
univers
school
medicin
baltimor
maryland
unit
state
background
lower
intens
condit
regimen
haploident
bone
marrow
transplant
bmt
safe
efficaci
adult
patient
hematolog
malign
object
report
first
data
pediatricyoung
adult
patient
hematolog
malign
treat
nonmyeloabl
haploident
bmt
cyclophosphamid
ptci
designmethod
major
patient
receiv
prepar
regimen
iv
fludarabin
day
iv
cyclophosphamid
mgkgday
day
total
bodi
irradi
cgi
day
two
patient
receiv
along
alemtuzumab
two
patient
receiv
iv
busulfan
iv
everi
hour
day
instead
cy
patient
receiv
haploident
replet
bone
marrow
peripher
blood
stem
cell
day
immunosuppress
consist
iv
cyclophosphamid
mgkgday
day
mycophenol
mofetil
day
tacrolimu
day
result
median
age
year
rang
diagnos
includ
aml
leukemia
md
cml
hodgkin
lymphoma
nhl
seventeen
patient
undergon
prior
myeloabl
bmt
donor
engraft
occur
patient
evalu
day
median
time
neutrophil
day
rang
platelet
without
transfus
day
rang
cumul
incid
acut
gvhd
grade
grade
day
respect
cumul
incid
chronic
gvhd
includ
chronic
gvhd
transplant
relat
mortal
trm
year
caus
includ
infect
diffus
alveolar
hemorrhag
cumul
incid
relaps
year
median
month
rang
actuari
overal
surviv
surviv
year
conclus
demonstr
excel
rate
engraft
gvhd
trm
pediatricyoung
adult
patient
treat
regimen
compar
publish
adult
data
approach
safe
feasibl
young
patient
high
risk
hematolog
malign
includ
preclud
elig
myeloabl
clinic
trial
warrant
directli
assess
benefit
prepar
regimen
intens
heather
b
allewelt
kristin
page
mahsa
taskindoust
jess
troy
susan
wood
suhag
parikh
vinod
prasad
joann
kurtzberg
duke
univers
pediatr
blood
marrow
transplant
program
durham
north
carolina
unit
state
background
hematopoiet
stem
cell
transplant
hsct
halt
progress
krabb
diseas
kd
via
engraft
cell
bone
marrow
brain
organ
hsct
prior
develop
symptom
associ
improv
surviv
remain
pauciti
inform
regard
function
qualiti
life
surviv
patient
object
aim
studi
report
function
outcom
follow
hsct
seri
presymptomat
infant
infantil
kd
order
inform
guidelin
earli
intervent
hsct
care
follow
hsct
infantil
kd
designmethod
record
patient
follow
duke
pediatr
blood
marrow
transplant
program
hsct
kd
month
age
review
inform
regard
function
outcom
overal
surviv
descript
statist
calcul
function
outcom
compar
transplant
day
n
day
life
n
result
patient
diagnos
due
famili
histori
n
via
newborn
screen
nb
n
median
age
transplant
day
rang
five
year
overal
surviv
os
ci
ci
median
time
transplant
year
rang
one
death
due
diseas
progress
occur
year
sixteen
patient
surviv
year
nine
patient
abl
commun
normal
eleven
patient
attend
school
appropri
grade
level
twelv
patient
abl
feed
independ
ten
patient
remain
ambulatori
poorer
outcom
occur
frequent
transplant
day
transplant
day
domain
commun
feed
mobil
conclus
improv
function
outcom
observ
patient
presymptomat
infantil
kd
hsct
perform
first
month
life
defin
critic
period
earli
intervent
emphas
need
acceler
evalu
influenc
public
polici
regard
nb
jessica
e
roger
h
giller
deborah
r
liptzin
gwendolyn
kerbi
urvi
sanghvi
abdul
alsultan
ralph
r
quinon
ami
keat
elain
hild
nadia
benkhalil
dawn
law
shaun
cosgrov
angela
peltz
brandon
nuechterlein
kelli
drake
john
craddock
children
hospit
colorado
univers
colorado
school
medicin
aurora
colorado
unit
state
background
unrel
cord
blood
transplant
ucbt
offer
readili
avail
stem
cell
sourc
individu
lack
suitabl
relat
donor
acut
chronic
graft
versu
host
diseas
gvhd
import
contributor
morbid
mortal
current
literatur
support
lower
incid
gvhd
ucbt
compar
altern
donor
sourc
shown
gvhd
follow
ucbt
impact
overal
surviv
object
aim
defin
cours
outcom
gvhd
follow
ucbt
designmethod
patient
enrol
ucbt
trial
januari
juli
thirteen
patient
exclud
analysi
due
death
prior
engraft
graft
reject
gvhd
activ
use
immunosuppress
therapi
overal
surviv
collect
year
perform
score
determin
year
pulmonari
function
test
pft
analyz
two
eight
year
result
median
age
transplant
evalu
patient
year
rang
forti
patient
develop
gvhd
grade
acut
gvhd
de
novo
chronic
gvhd
occur
day
seventeen
patient
acut
gvhd
activ
gvhd
extend
past
day
patient
prior
gvhd
presenc
activ
gvhd
year
patient
remain
immunosuppress
therapi
respect
surviv
diagnos
gvhd
year
year
year
twenti
patient
prior
gvhd
interpret
pft
demonstr
normal
stabl
lung
function
perform
score
patient
year
show
score
score
conclus
gvhd
follow
ucbt
associ
increas
mortal
resolv
nearli
patient
year
limit
impact
pulmonari
function
overal
qualiti
life
jeffrey
r
andolina
ritika
walia
andrea
baran
myra
coppag
univers
rochest
medic
center
rochest
new
york
unit
state
background
increas
number
human
leukocyt
antigen
hla
allogen
hematopoiet
stem
cell
transplant
hsct
perform
antibodi
recipi
routin
test
prior
stem
cell
transplant
may
specif
data
regard
gener
antibodi
role
stem
cell
transplant
outcom
object
determin
incid
risk
factor
develop
antibodi
stem
cell
transplant
recipi
associ
outcom
designmethod
review
allogen
transplant
patient
institut
data
collect
includ
antibodi
presenc
strength
specif
transplant
recipi
screen
panel
reactiv
antibodi
class
class
ii
hla
mean
fluoresc
intens
mfi
calcul
addit
data
collect
includ
demograph
inform
prior
transfus
pregnanc
transplant
type
condit
regimen
use
overal
surviv
os
surviv
ef
mortal
trm
result
cohort
includ
patient
mean
age
transplant
year
rang
year
patient
male
receiv
myeloabl
condit
patient
unrel
donor
patient
donor
recipi
patient
detect
antibodi
prior
transplant
includ
patient
class
class
ii
one
patient
cohort
antibodi
signific
risk
factor
develop
antibodi
includ
prior
pregnanc
odd
ratio
blood
transfus
os
entir
cohort
year
os
ef
trm
similar
recipi
without
antibodi
outcom
remain
similar
broken
antibodi
type
titer
graft
failur
rate
ident
among
without
detect
antibodi
one
patient
antibodi
die
due
trm
conclus
antibodi
detect
signific
portion
stem
cell
transplant
recipi
prior
pregnanc
prior
transfus
signific
risk
factor
develop
antibodi
presenc
gener
antibodi
recipi
correl
patient
outcom
stem
cell
transplant
jani
benoit
jonathan
c
howel
stella
davi
michael
grimley
sonata
jodel
pooja
khandelw
javier
rebecca
marsh
adam
nelson
greg
wallac
chri
dandoy
paulin
daniel
abigail
pate
lesley
breech
holli
hoefgen
susan
r
rose
kasiani
myer
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
reduc
intens
condit
ric
increasingli
use
hematopoiet
stem
cell
transplant
hsct
goal
maintain
therapeut
efficaci
limit
toxic
current
understand
late
endocrin
effect
use
ric
hsct
extrem
limit
risk
infertil
myeloabl
hsct
known
high
current
data
regard
infertil
risk
ric
hsct
object
longitudin
evalu
gonad
function
fertil
potenti
young
men
ric
hsct
designmethod
children
young
adult
year
singl
ric
hsct
regimen
follow
prospect
cohort
studi
evalu
late
endocrin
effect
fertil
potenti
subject
evalu
pubert
develop
hormon
statu
subject
semen
analysi
perform
result
preliminari
result
obtain
subject
subject
receiv
fludarabin
melphalan
campath
without
total
bodi
irradi
five
subject
receiv
prior
chemotherapi
malign
median
age
time
hsct
year
rang
averag
age
time
evalu
year
rang
median
time
hsct
year
rang
eleven
subject
pubert
pubert
subject
avail
laboratori
test
one
abnorm
elev
gonadotropin
lh
fsh
similarli
one
abnorm
low
testosteron
level
remaind
normal
test
tanner
stage
four
abnorm
low
inhibin
b
level
suggest
reduc
fertil
sertoli
cell
dysfunct
semen
analysi
abnorm
subject
test
azoospermia
oligoteratospermia
conclus
result
suggest
ric
hsct
may
associ
high
risk
infertil
howev
gonadotropin
testosteron
level
appear
normal
young
male
ric
hsct
therefor
normal
pubert
develop
ensur
normal
fertil
potenti
data
suggest
inhibin
b
level
could
use
screen
test
howev
semen
analysi
remain
gold
standard
test
fertil
potenti
risk
infertil
includ
counsel
ric
hsct
fertil
preserv
discuss
offer
prior
hsct
parul
rai
md
children
hospit
research
center
oakland
oakland
california
unit
state
background
radiat
therapi
induc
chronic
oxid
stress
hematopoiet
stem
cell
hsc
lead
impair
hsc
self
renew
abil
induct
senesc
increas
oxid
dna
damag
result
prematur
exhaust
hsc
reserv
subsequ
develop
late
bone
marrow
injuri
sirtuin
mitochondri
protein
deacetylas
reduc
cellular
reactiv
oxygen
speci
ro
level
activ
mitochondri
antioxid
enzym
like
superoxid
dismutas
isocitr
dehydrogenas
though
mitochondria
seat
cellular
respir
main
sourc
cellular
ro
yet
proven
whether
mitig
mitochondri
ro
play
essenti
role
hsc
mainten
stress
condit
like
radiat
object
determin
whether
radiat
induc
chronic
oxid
stress
amelior
sirtuin
overexpress
designmethod
sirtuin
overexpress
transgen
cre
mice
strain
use
strain
mice
divid
group
one
group
expos
gy
total
bodi
radiat
group
radiat
mice
sacrif
week
later
hsc
popul
isol
ro
level
detect
incub
hsc
dichlorohydrofluorescein
diacet
min
data
collect
lsrii
flow
cytomet
analyz
use
flowjo
treestar
result
compar
hsc
popul
irradi
unirradi
cre
mice
note
fold
increas
ro
level
radiat
similarli
overexpress
mice
hsc
popul
exhibit
fold
increas
ro
level
radiat
hsc
mice
strain
demonstr
persist
oxid
stress
month
radiat
howev
ro
level
mice
significantli
lower
cre
mice
conclus
studi
limit
small
sampl
size
failur
optim
radiat
dose
accord
bodi
surfac
area
mice
though
unabl
demonstr
protect
effect
sirtuin
overexpress
significantli
decreas
radiat
induc
chronic
oxid
stress
yet
result
show
interest
trend
aim
explor
futur
experi
correct
aforement
factor
kristen
e
barbieri
marijean
miller
alaa
bou
ghannam
mohamad
jaafar
kirsten
william
children
nation
health
system
washington
dc
unit
state
background
cidofovir
treatment
dissemin
adenoviru
infect
complic
hematopoiet
stem
cell
transplant
hsct
patient
institut
monitor
toxic
cidofovir
often
cite
literatur
includ
renal
insuffici
marrow
suppress
object
present
year
old
femal
histori
acut
myelogen
leukemia
second
complet
remiss
statu
post
umbil
cord
hsct
complic
acut
graft
versu
host
diseas
skin
lower
gi
tract
gvhd
develop
protract
dissemin
adenoviru
nasopharynx
gastrointestin
tract
blood
month
hsct
due
persist
posit
infect
continu
concern
gvhd
flare
gi
tract
patient
continu
weekli
cidofovir
month
total
time
present
week
histori
inject
irrit
eye
without
symptom
infect
gvhd
patient
refer
ophthalmolog
designmethod
differenti
diagnosi
includ
infecti
etiolog
rule
chart
review
ongo
surveil
part
standard
bmt
care
adenoviru
pcr
cmv
pcr
result
diagnosi
chronic
bilater
uveiti
though
complet
exam
hinder
poor
dilat
result
iri
synechai
vitreou
clear
ultrasound
eye
within
normal
limit
treat
cessat
cidofovir
steroid
drop
feasibl
time
due
recent
neg
blood
adenoviru
pcr
absenc
diarrhea
despit
posit
stool
test
conclus
review
ophthalmolog
literatur
show
dose
cidofovir
month
patient
signific
risk
develop
uveiti
could
result
vision
loss
underappreci
fact
hsct
literatur
practic
discuss
ophthalmolog
expert
recommend
made
involv
ophthalmolog
patient
requir
chronic
cidofovir
therapi
greater
dose
hsct
patient
present
inject
irrit
eye
seth
j
rotz
thoma
ryan
adam
lane
javier
sonata
jodel
anna
maria
holdcroft
kelli
lake
alyss
anderson
avni
patel
stella
davi
christoph
e
dandoy
cincinnati
children
hospit
medic
center
cincinnati
ohio
unit
state
background
cardiac
dysfunct
increasingli
recogn
complic
survivor
pediatr
stem
cell
transplant
sct
recent
report
incid
left
ventricular
systol
dysfunct
lvsd
day
object
hypothes
chemotherapi
prepar
regimen
sourc
cardiac
injuri
subsequ
lvsd
seen
first
day
sct
pediatr
patient
designmethod
retrospect
assay
cardiac
biomark
cardiac
prohormon
brain
natriuret
peptid
store
specimen
patient
new
lvsd
control
six
time
point
lvsd
defin
eject
fraction
less
shorten
fraction
less
two
standard
deviat
age
adjust
mean
newli
occur
first
day
result
among
sampl
test
elev
ngml
occur
sampl
patient
least
one
sampl
elev
among
sampl
test
elev
pgml
occur
sampl
patient
least
one
sampl
elev
among
patient
lvsd
day
day
wherea
control
elev
cohort
cyclophosphamid
prepar
chemotherapi
cpc
associ
new
lvsd
lvsd
v
control
associ
seen
previou
anthracyclin
use
cell
sourc
bacteremia
total
bodi
irradi
thrombot
microangiopathi
acut
graft
versu
host
diseas
conclus
cardiac
injuri
occur
frequent
patient
undergo
sct
evidenc
elev
patient
develop
lvsd
first
day
associ
cpc
day
evid
prospect
monitor
patient
receiv
cpc
measur
infus
ossama
maher
jorg
galvez
silva
anna
rk
franklin
partow
kebriaei
minjeong
park
dian
liu
chloe
tillman
demetrio
petropoulo
nidal
tarek
priti
tewari
md
anderson
cancer
center
houston
texa
unit
state
background
hematopoiet
stem
cell
transplant
hsct
provid
potenti
cur
treatment
variou
condit
howev
high
rate
patient
requir
readmiss
hospit
transplant
designmethod
retrospect
analysi
patient
year
younger
treat
hsct
univers
texa
md
anderson
cancer
center
conduct
result
chart
review
children
adolesc
young
adult
patient
underw
hsct
reveal
patient
least
hospit
readmiss
median
age
transplant
year
rang
year
primari
diagnos
follow
hematolog
malign
solid
tumor
condit
n
receiv
allogen
hsct
receiv
autolog
hsct
total
readmiss
event
report
document
infect
graft
versu
host
diseas
complic
fever
without
sourc
gastrointestin
relat
symptom
relaps
median
time
transplant
month
confid
interv
ci
among
patient
underw
allogen
hsct
readmit
hospit
least
within
day
hsct
lower
overal
surviv
os
p
surviv
df
p
higher
readmiss
rate
associ
lower
rate
os
p
df
p
allogen
recipi
multivari
analysi
male
sex
hazard
ratio
hr
ci
p
document
infect
index
admiss
subsequ
readmiss
hr
ci
p
prior
treatment
chemotherapi
regimen
hr
ci
p
associ
lower
rate
os
age
year
younger
associ
lower
rate
df
hr
ci
p
allogen
group
conclus
earli
hospit
readmiss
within
day
affect
surviv
outcom
patient
underw
allogen
hsct
underw
autolog
hsct
frequent
monitor
patient
morbid
improv
educ
health
care
provid
might
help
prevent
earli
hospit
readmiss
larisa
brogli
alfr
rademak
john
galvin
william
tse
reggi
duerst
jennif
schneiderman
ayita
ray
morri
kletzel
sonali
chaudhuri
ann
robert
h
luri
children
hospit
chicago
chicago
illinoi
unit
state
background
calprotectin
protein
found
neutrophil
quantifi
fecal
sampl
gastrointestin
inflamm
diagnost
screen
test
inflammatori
bowel
diseas
ibd
differenti
ibd
enter
studi
evalu
fecal
calprotectin
marker
gastrointestin
gi
acut
graft
versu
host
diseas
agvhd
hematopoiet
cell
transplant
hct
object
studi
sought
determin
fecal
calprotectin
level
would
predict
develop
gastrointestin
agvhd
prior
onset
symptom
predict
steroid
respons
agvhd
designmethod
stool
sampl
obtain
condit
patient
diagnos
agvhd
addit
sampl
obtain
onset
symptom
week
treatment
serum
albumin
obtain
time
point
elisa
calprotectin
perform
stool
sampl
agvhd
grade
per
standard
criteria
median
valu
determin
compar
use
result
sixti
patient
enrol
data
current
avail
patient
agvhd
occur
patient
skin
gi
agvhd
fecal
calprotectin
level
significantli
differ
precondit
develop
agvhd
gi
agvhd
sever
grade
agvhd
albumin
level
significantli
differ
without
agvhd
gi
agvhd
median
albumin
grade
agvhd
median
albumin
compar
median
agvhd
less
sever
agvhd
grade
p
respect
higher
fecal
calprotectin
onset
agvhd
predict
steroid
refractori
versu
ugg
conclus
although
fecal
calprotectin
unabl
predict
occurr
agvhd
differenti
gi
agvhd
abl
predict
steroid
refractori
gi
agvhd
onset
symptom
low
albumin
better
predictor
gi
grade
agvhd
marker
may
help
identifi
patient
aggress
diseas
guid
manag
agvhd
carter
biewen
angela
smith
jakub
tolar
weston
miller
univers
minnesota
minneapoli
minnesota
unit
state
background
donor
lymphocyt
infus
dli
one
strategi
potenti
stabil
revers
wane
donor
chimer
littl
report
util
donor
dli
follow
hematopoiet
stem
cell
transplant
hct
disord
nmd
object
describ
outcom
dli
insuffici
donor
chimer
hct
larg
pediatr
nmd
cohort
designmethod
queri
institut
bmt
databas
patient
nmd
receiv
dli
insuffici
donor
chimer
human
leukocyt
antigen
hla
type
graft
select
origin
condit
per
institut
guidelin
use
time
dose
dli
discret
treat
physician
donor
chimer
valu
myeloid
fraction
peripher
blood
review
patient
consid
best
respond
donor
chimer
improv
recent
chimer
result
patient
femal
identifi
underw
total
dli
median
dli
cycl
per
patient
iqr
maximum
median
cumul
dose
x
median
zenith
chimer
iqr
observ
median
day
median
chimer
prior
first
dli
median
time
first
dli
day
five
patient
best
dli
respond
mean
year
retain
mean
chimer
mean
increas
best
respons
dli
depend
hct
total
nucleat
cell
dose
donor
related
serotherapi
agent
hct
regimen
chimer
total
dli
dose
best
respond
tend
undergon
myeloabl
condit
donor
receiv
first
dli
later
median
day
versu
day
respond
median
chimer
last
iqr
post
dli
two
patient
develop
agvhd
two
patient
develop
cgvhd
conclus
larg
nmd
cohort
undergo
dli
hct
sustain
high
donor
chimer
respons
observ
patient
stabl
nmd
recent
observ
patient
weston
miller
troy
lund
md
paul
orchard
gerald
raymond
david
nascen
univers
minnesota
minneapoli
minnesota
unit
state
background
neurolog
function
outcom
unpredict
vari
follow
allogen
hematopoiet
stem
cell
transplant
hsct
advanc
cerebr
adrenoleukodystrophi
cald
resolut
contrast
enhanc
mri
lesion
consid
extinguish
activ
cald
pathophysiolog
patient
popul
observ
variabl
brain
mri
contrast
enhanc
follow
hsct
object
retrospect
analyz
patient
transplant
advanc
cald
signific
contrast
resolut
day
designmethod
patient
undergo
hsct
advanc
cald
loe
radiograph
sever
score
assess
mri
gadolinium
contrast
hsct
correl
day
enhanc
statu
resolv
versu
made
outcom
characterist
result
evalu
patient
demonstr
resolut
day
patient
rapid
resolut
enhanc
resolv
show
less
clinic
neurolog
progress
neurolog
function
scale
score
mean
chang
versu
p
day
resolut
statu
correl
surviv
versu
p
chang
loe
score
versu
p
patient
demonstr
resolut
day
averag
experienc
faster
neutrophil
recoveri
day
versu
p
greater
donor
myeloid
chimer
versu
p
set
loe
score
neurolog
disabl
rate
patient
age
allograft
type
correl
day
mri
enhanc
statu
trend
toward
greater
likelihood
day
resolut
contrast
enhanc
follow
myeloabl
condit
observ
conclus
resolut
gadolinium
enhanc
brain
mri
day
follow
hsct
advanc
cald
predict
favor
clinic
neurolog
outcom
faster
neutrophil
recoveri
greater
donor
chimer
correl
significantli
extinguish
day
radiograph
marker
may
use
immedi
surrog
clinic
outcom
assess
establish
novel
therapi
enhanc
cald
daniel
larson
david
nascen
troy
lund
gerald
raymond
paul
orchard
weston
miller
univers
minnesota
minneapoli
minnesota
unit
state
background
clinic
outcom
follow
hsct
boy
advanc
cerebr
adrenoleukodystrophi
cald
variabl
mri
sever
score
loe
score
risk
factor
unfavor
neurolog
function
boy
go
sever
diseas
progress
transplant
addit
prognost
factor
sought
object
assess
impact
diseas
veloc
rate
chang
loe
score
time
outcom
boy
advanc
cald
loe
score
designmethod
consecut
patient
cald
underw
mri
evalu
hsct
univers
minnesota
februari
march
instanc
previou
scan
avail
review
thu
allow
determin
rate
chang
radiograph
loe
score
dloesdt
hsct
perform
patient
suffici
imag
meet
inclus
criteria
clinic
diseas
progress
evalu
ald
neurolog
function
scale
nf
correl
assess
dloesdt
chang
loe
nf
score
differ
recent
valu
result
patient
includ
two
group
defin
patient
loe
score
patient
loe
score
patient
median
iqr
hsct
correl
dloesdt
patient
highli
variabl
score
follow
transplant
patient
slow
mri
progress
dloesdt
day
median
iqr
median
month
iqr
contrast
patient
rapid
mri
progress
dloesdt
day
median
iqr
p
median
month
iqr
contrast
chang
mri
sever
score
follow
transplant
depend
upon
dloesdt
median
iqr
median
month
conclus
evalu
boy
undergo
hsct
advanc
cald
dloesdt
may
use
predictor
clinic
outcom
kanwaldeep
k
mallhi
christen
l
eben
jakub
tolar
weston
p
miller
paul
j
orchard
troy
c
lund
univers
minnesota
minneapoli
minnesota
unit
state
background
allogen
hematopoiet
cell
transplant
hct
offer
cur
therapi
sever
condit
howev
rate
graft
failur
popul
exceed
patient
malign
indic
hct
salvag
condit
regimen
outcom
second
allogen
hct
graft
failur
vari
immens
literatur
object
sought
evalu
feasibl
outcom
reduc
intens
condit
regimen
patient
diseas
requir
second
allogen
hct
graft
failur
designmethod
report
consecut
patient
diseas
underw
second
allogen
hct
graft
failur
univers
minnesota
children
hospit
januari
juli
use
singl
reduc
intens
regimen
median
time
second
hct
day
iqr
day
second
hct
patient
receiv
intraven
busulfan
mgkgday
divid
mgkgday
year
age
total
mgkg
mgkg
respect
intraven
fludarabin
day
day
total
singl
fraction
cgi
total
bodi
irradi
cyclosporin
mycophenyl
mofetil
began
gvhd
prophylaxi
graft
sourc
includ
umbil
cord
blood
unrel
bone
marrow
unrel
peripher
blood
stem
cell
patient
result
percent
patient
achiev
stabl
donor
hematopoiesi
year
overal
surviv
ci
transplant
relat
mortal
includ
death
attribut
sepsi
pneumon
failur
cumul
incid
neutrophil
recoveri
day
second
hct
ci
neutropen
graft
failur
rate
third
allogen
hct
perform
individu
fail
donor
engraft
infecti
complic
follow
second
hct
includ
viral
reactiv
invas
fungal
infect
incid
grade
acut
diseas
grade
conclus
summari
demonstr
excel
overal
surviv
accept
toxic
novel
reduc
intens
condit
regimen
second
hct
salvag
initi
hct
graft
failur
patient
condit
sandeepkumar
kuril
jennif
jaroscak
cindi
kramer
stacey
warnek
lori
donahoo
michel
hudspeth
medic
univers
south
carolina
charleston
south
carolina
unit
state
background
syndrom
ch
rare
autosom
recess
diseas
due
mutat
lysosom
traffick
regul
gene
lyst
character
oculocutan
albin
immunodefici
platelet
aggreg
disord
microscop
find
larg
granul
hematopoiet
cell
patient
ch
experi
hemophagocyt
lymphohistiocytosi
hlh
disord
term
acceler
phase
ap
allogen
hematopoiet
stem
cell
transplant
sole
cur
therapi
prevent
ap
object
describ
clinic
cours
ch
patient
underw
unrel
donor
bone
marrow
transplant
mud
bmt
success
outcom
despit
low
donor
cell
chimer
designmethod
case
report
result
patient
underw
myeloabl
age
sixteen
month
prepar
regimen
includ
iv
busulfan
mgkgday
x
day
target
pharmacokinet
cyclophosphamid
mgkgday
x
day
receiv
unmanipul
bone
marrow
bm
graft
x
tnckg
gvhd
prophylaxi
consist
cyclosporin
methotrex
initi
cours
complic
engraft
syndrom
coronaviru
requir
intub
steroid
engraft
neutrophil
day
platelet
day
bm
donor
chimer
day
fell
day
subsequ
peripher
blood
pb
monitor
show
sort
chimer
stabl
bm
donor
chimer
day
despit
earli
cyclosporin
taper
pb
sort
chimer
continu
fall
day
began
donor
lymphocyt
infus
dli
receiv
total
dli
dose
rang
x
x
complet
dli
pb
sort
chimer
whole
blood
chimer
level
remain
stabl
one
year
occasion
fluctuat
mild
neutropenia
sever
viral
infect
without
evid
ap
conclus
despit
recurr
underli
diseas
patient
current
aliv
well
episod
ap
viral
infect
year
similar
hlh
low
level
donor
chimer
may
suffici
prevent
ap
weston
miller
troy
lund
paul
orchard
univers
minnesota
minneapoli
minnesota
unit
state
background
allogen
hematopoiet
stem
cell
transplant
hsct
remain
standard
treatment
hurler
syndrom
inherit
metabol
disord
imd
though
complic
common
patient
hurler
syndrom
observ
infrequ
hemorrhag
cystiti
hc
patient
popul
furthermor
medic
report
suggest
therapeut
effect
sever
hc
administ
glycosaminoglycan
gag
interestingli
gag
accumul
high
level
untreat
hurler
patient
due
impair
catabol
object
aim
determin
incid
hemorrhag
cystiti
follow
hsct
hurler
syndrom
compar
follow
hsct
imd
designmethod
identifi
patient
imd
transplant
center
follow
myeloabl
regimen
contain
cyclophosphamid
andor
tbi
allograft
sourc
vari
incid
hc
determin
patient
hurler
syndrom
compar
patient
imd
result
patient
includ
analysi
hurler
syndrom
cerebr
adrenoleukodystrophi
cald
globoid
cell
leukodystrophi
gld
metachromat
leukodystrophi
mld
imd
observ
frequenc
hc
diseas
follow
hurler
syndrom
cald
gldmld
imd
p
signific
differ
patient
hurler
syndrom
imd
respect
follow
characterist
allograft
sourc
use
serotherapi
exposur
tbi
median
age
transplant
hurler
year
imd
year
significantli
differ
imd
identifi
larger
group
n
patient
median
age
hsct
year
p
differ
median
age
hsct
compar
patient
hurler
syndrom
imd
continu
demonstr
higher
incid
hc
compar
patient
hurler
syndrom
versu
p
differ
observ
frequenc
conclus
hurler
patient
appear
less
suscept
hc
follow
hsct
compar
patient
imd
diagnos
protect
benefit
excess
urinari
gag
hurler
syndrom
plausibl
reason
margaret
oat
devona
william
children
nation
medic
center
washington
dc
unit
state
background
increas
risk
factor
invas
mold
infect
led
chang
primari
fungal
prophylaxi
fluconazol
voriconazol
allogen
stem
cell
transplant
patient
institut
due
wide
variabl
polymorph
variabl
bioavail
within
pediatr
popul
therapeut
drug
monitor
voriconazol
essenti
assess
safeti
efficaci
previous
patient
receiv
standard
dose
everi
hour
current
voriconazol
dose
everi
hour
patient
year
everi
hour
patient
year
addit
dual
therapi
caspofungin
trough
therapeut
result
studi
evalu
alter
voriconazol
dose
practic
determin
effect
attain
therapeut
trough
incid
breakthrough
fungal
infect
report
object
primari
object
time
first
therapeut
voriconazol
trough
secondari
object
includ
correspond
dose
therapeut
trough
concomit
dose
factor
incid
breakthrough
fungal
infect
adher
protocol
chang
designmethod
retrospect
chart
review
pediatr
patient
admit
bmt
servic
receiv
voriconazol
primari
antifung
prophylaxi
juli
august
perform
patient
divid
base
dose
weight
base
versu
base
result
patient
includ
analysi
baselin
characterist
significantli
differ
group
adjust
dose
increas
probabl
reach
therapeut
trough
level
day
vs
day
p
higher
dosag
hr
interact
hr
oral
formul
voriconazol
hr
associ
lower
probabl
achiev
therapeut
level
incid
fungal
infect
statist
signific
group
overal
protocol
adher
also
decreas
institut
chang
conclus
base
dose
superior
weight
base
dose
achiev
therapeut
voriconazol
trough
level
due
limit
studi
unabl
conclud
definit
associ
dose
time
therapeut
trough
larger
prospect
studi
perform
determin
optim
dose
pediatr
specif
children
year
age
patrick
j
hanley
michael
keller
maria
gema
martin
manso
caridad
martinez
kathryn
leung
conrad
r
cruz
cecilia
bares
sarah
mccormack
min
luo
bob
r
kranc
david
jacobsohn
cliona
rooney
helen
e
heslop
ej
shpall
catherin
bollard
children
nation
health
system
washington
dc
unit
state
background
defici
convent
antivir
therapeut
stem
cell
sct
cord
blood
transplant
cbt
increas
interest
immunotherapeut
approach
viral
disord
object
develop
strategi
grow
mctl
target
cytomegaloviru
cmv
viru
ebv
adenoviru
one
peripher
blood
pb
adult
donor
anoth
naiv
cord
blood
cb
treat
prevent
viral
infect
designmethod
use
express
overlap
viral
peptid
cmv
ebv
adenoviru
hexon
penton
present
dendrit
cell
monocyt
gener
singl
cultur
mctl
mean
sfc
spot
form
cell
cell
mean
elispot
assay
contain
cell
specif
least
viru
mctl
deriv
cb
pb
contain
mixtur
effector
central
memori
phenotyp
base
deep
receptor
sequenc
polyclon
mctl
result
thirteen
patient
infus
patient
patient
receiv
mctl
infus
day
rang
toxic
gvhd
grade
ii
observ
increas
week
measur
elispot
patient
enrol
two
studi
patient
experienc
cmv
ebv
adenoviru
viral
infectionsreactiv
immedi
mctl
infus
nine
patient
remain
eight
patient
complet
respons
partial
respons
coincid
increas
three
patient
respond
therapi
overal
respons
rate
group
patient
viral
diseas
studi
demonstr
mctl
deriv
pb
seroposit
donor
well
cb
viru
naiv
donor
expand
vivo
activ
multipl
virus
conclus
restor
immun
multipl
virus
simultan
prophylaxi
pharmacotherapi
elimin
thu
improv
effici
protect
recipi
virus
dolor
corral
jaim
david
bueno
pilar
carrasco
raquel
de
paz
rebeca
rodriguez
lucia
fernandez
antonio
bala
lui
vicario
dario
campana
joaquin
martinez
miguel
antonio
infantil
hospit
universitario
la
paz
madrid
spain
background
current
therapi
fail
children
refractori
relaps
leukaemia
novel
therapi
need
leukaemia
cell
suscept
kill
activ
natur
killer
nk
cell
object
gener
highli
activatedexpand
nk
cell
stimul
human
leukocyt
cell
line
genet
modifi
express
develop
sjcrh
memphi
tn
method
test
safeti
feasibl
haploident
activ
expand
nk
cell
therapi
heavili
paediatr
popul
two
phase
iii
trial
eudract
eudract
designmethod
twenti
one
children
median
age
year
refractori
allogen
stem
cell
transplant
acut
leukaemia
b
cell
lymphoblast
leukaemia
cell
lymphoblast
leukaemia
acut
myeloid
leukaemia
treat
rescu
chemotherapi
follow
infus
fresh
activ
expand
nk
cell
obtain
haploident
donor
peripher
blood
follow
three
time
hjek
subcutan
administr
low
dose
rescu
chemotherapi
consist
patient
clofarabinebas
patient
patient
patient
result
date
infus
nk
cell
product
contain
median
kg
infus
well
toler
thirteen
patient
complet
treatment
ongo
addit
patient
treatment
could
complet
leukaemia
progress
n
toxic
n
among
patient
complet
treatment
achiev
neg
minim
residu
diseas
cytolog
remiss
diseas
progress
patient
achiev
neg
minim
residu
diseas
receiv
allogen
stem
cell
transplant
four
median
day
conclus
infus
fresh
activ
expand
nk
cell
therapi
feasibl
safe
heavili
paediatr
popul
investig
patient
leukaemia
miguel
angel
diaz
antonio
blanca
herrero
natalia
deltoro
isabel
martinez
manuel
ramirez
lorea
abad
julian
sevilla
md
eva
merino
julia
ruiz
jose
l
vicario
marta
infantil
hospit
universitario
la
paz
madrid
spain
background
haploident
hematopoiet
stem
cell
transplant
use
deplet
graft
valid
option
pediatr
patient
hematolog
malign
need
allogen
transplant
lack
donor
use
deplet
graft
manipul
method
help
retain
larg
number
import
immun
cell
graft
well
unalt
cell
object
aim
prospect
studi
analyz
outcom
risk
factor
surviv
pediatr
patient
receiv
allogen
transplant
mismatch
andor
full
haploident
rel
donor
use
graft
designmethod
patient
enrol
studi
januari
decemb
includ
pediatr
patient
diagnos
hematolog
malign
need
allogen
transplant
good
clinic
condit
lack
either
match
relat
donor
mrd
match
unrel
donor
mud
result
transplant
perform
seventi
patient
patient
aml
advanc
md
jmmcl
cr
cr
cr
consid
refractori
diseas
time
transplant
four
patient
develop
graft
failur
among
engraft
patient
median
time
neutrophil
platelet
recoveri
rang
day
rang
respect
case
infect
diagnos
transplant
probabl
nrm
day
transplant
median
month
probabl
relaps
df
conclus
haploident
transplant
use
deplet
associ
encourag
result
especi
patient
earli
phase
diseas
kir
b
haplotyp
donor
confer
rapid
nk
cell
expans
earli
transplant
result
lower
probabl
relaps
suggest
gvl
effect
apart
gvh
reaction
donor
infus
high
amount
cell
recommend
order
improv
reconstitut
david
bueno
berta
gonzalez
diego
plaza
pedro
rubio
yasmina
mozo
sonsol
san
roman
blanca
rosich
ana
sastr
estefania
garcia
raquel
de
paz
juan
torr
monts
torrent
isabel
badel
luisi
sisini
antonio
infantil
hospit
universitario
la
paz
madrid
spain
background
allogen
hematopoiet
cell
transplant
hct
potenti
cur
option
hematolog
chilhood
cancer
mani
children
donor
object
haploident
stem
cell
transplant
becom
interest
strategi
avoid
problem
requir
deplet
produc
profund
inmunosupress
well
graft
failur
reject
identifi
express
believ
caus
graft
versu
host
diseas
gvhd
memori
provid
inmedi
effect
allogen
hct
use
deplet
aris
novel
approach
designmethod
six
children
malign
immunodefici
transplant
follow
nonmyeloabl
condit
regimen
patient
receiv
two
cell
product
one
creat
select
deplet
fraction
clinimac
devic
result
graft
consist
mean
cellskg
cellskg
cell
cell
depletionresult
mean
log
log
six
patient
engraft
mean
day
rapidli
achiev
donor
chimer
graft
failur
observ
one
patient
develop
gvhd
ii
sensibl
steroid
led
immun
recoveri
achiev
valu
higher
cellsmcl
cellsmcl
day
respectivelli
cell
cell
median
respect
number
cell
remain
low
median
respect
recapitul
deplet
graft
composit
total
patient
present
cmv
reactiv
none
progress
diseas
mean
day
follow
two
patient
relaps
minim
residu
diseas
posit
two
patient
die
one
debt
leukemia
progress
one
cardiogen
shock
conclus
deplet
well
toler
rapid
engraft
minim
risk
gvhd
acceler
inmunolog
reconstitut
intan
juliana
abd
hamid
mari
slatter
mark
pearc
andrew
genneri
institut
cellular
medicin
newcastl
univers
newcastl
upon
tyne
unit
kingdom
background
hematopoiet
stem
cell
transplant
hsct
proven
cur
sever
combin
immunodefici
scid
object
discuss
outcom
donor
chimer
thymic
output
scid
centr
designmethod
studi
scid
patient
underw
hsct
condit
regimen
use
reduc
intens
condit
ric
fludarabinemelphalan
low
toxic
condit
treosulphanfludarabin
treosulphancyclophosphamid
condit
mac
busulphancyclophosphamid
cell
measur
use
indic
thymic
output
result
patient
scid
surviv
surviv
median
age
last
follow
year
old
rang
full
donor
cell
chimer
donor
cell
observ
patient
irrespect
donor
condit
regimen
receiv
howev
b
cell
myeloid
donor
chimer
last
follow
best
follow
low
toxic
condit
regimen
match
relat
mrd
match
unrel
donor
murd
compar
uncondit
match
sibl
donor
msd
recipi
donor
recipi
poor
myeloid
chimer
donor
cell
despit
receiv
mac
condit
sixteen
patient
ivig
b
myeloid
chimer
donor
b
myeloid
chimer
donor
thirteen
patient
b
myeloid
chimer
donor
continu
ivig
mean
count
last
follow
highest
receiv
msd
uncondit
transplant
recipi
low
toxic
condit
higher
count
compar
ric
mac
condit
across
type
donor
msd
uncondit
transplant
best
thymic
output
last
follow
follow
mrd
murd
low
toxic
condit
conclus
cell
donor
chimer
influenc
condit
donor
type
howev
condit
mrd
murd
demonstr
better
myeloid
cell
chimer
compar
uncondit
msd
donor
recipi
mac
sustain
output
seen
year
scid
even
though
uncondit
msd
recipi
poor
myeloid
chimer
highest
thymic
output
last
follow
intan
juliana
abd
hamid
mari
slatter
fiona
mckendrick
mark
pearc
andrew
genneri
institut
cellular
medicin
newcastl
univers
newcastl
upon
tyne
unit
kingdom
background
mani
studi
demonstr
evolut
scarc
data
consid
qualiti
life
qol
one
studi
suggest
poor
function
compar
healthi
control
object
object
assess
qol
scid
survivor
centr
accord
genet
diagnosi
designmethod
scid
patient
year
attend
clinic
follow
invit
answer
pediatr
qualiti
life
inventori
pedsql
gener
score
scale
questionnair
part
routin
psycholog
assess
pedsql
questionnair
consist
parent
patient
report
domain
physic
emot
social
school
psychosoci
total
result
patient
respond
compris
patient
age
year
famili
fourteen
children
age
year
old
exclud
child
questionnair
patient
contact
three
refus
median
interv
year
rang
proport
respond
accord
scid
genotyp
scid
defici
adenosin
deaminas
ada
artemi
qol
patient
defici
artemi
scid
significantli
differ
publish
uk
norm
patient
report
domain
contrast
previou
studi
howev
ada
scid
survivor
significantli
lower
qol
across
except
emot
compon
parent
scid
report
significantli
lower
qol
domain
compar
uk
normal
whilst
parent
ada
scid
report
significantli
lower
qol
across
except
emot
domain
qol
score
significantli
differ
artemi
defici
scid
domain
parent
children
scid
report
significantli
lower
qol
school
domain
parent
scid
intraven
immunoglobulin
therapi
report
lower
qol
compar
without
therapi
conclus
contrast
previous
number
scid
genotyp
associ
normal
qol
particular
risk
factor
includ
ada
scid
need
ongo
medic
larger
qualit
studi
need
clarifi
qol
differ
scid
survivor
refer
titman
p
et
al
blood
kristen
beeb
kyri
hospodar
niketa
shah
dana
sazberg
holli
miller
roberta
adam
alexand
ngwube
phoenix
children
hospit
phoenix
arizona
unit
state
background
report
indic
pediatr
patient
undergo
hematopoiet
stem
cell
transplant
hsct
frequenc
afflict
vitamin
defici
whether
vitamin
defici
affect
hsct
outcom
pediatr
patient
yet
proven
object
report
preval
vitamin
defici
pediatr
patient
underw
hsct
determin
short
term
impact
surviv
designmethod
review
serum
level
perform
prospect
start
hsct
baselin
day
transplant
children
present
hsct
januari
decemb
also
abstract
demograph
laboratori
treatment
data
result
two
children
male
femal
median
age
rang
year
assess
stage
median
serum
level
rang
patient
supplement
therapi
patient
suboptim
vitamin
level
ngml
hsct
half
sever
vitamin
defici
ngml
preval
chang
hematopoiet
stem
cell
transplant
patient
suboptim
vitamin
level
sever
vitamin
defici
day
transplant
despit
supplement
therapi
subject
statist
signific
associ
low
vitamin
level
prior
hsct
develop
acut
chronic
gvhd
infecti
rate
immun
recoveri
howev
sever
vitamin
defici
ngml
associ
decreas
overal
surviv
transplant
p
rate
overal
surviv
versu
conclus
major
pediatr
patient
come
transplant
vitamin
defici
vitamin
may
play
role
outcom
pediatr
hsct
studi
investig
impact
need
laberko
slatter
lankest
r
brediu
schulz
hoenig
b
neven
n
mahlaoui
b
gaspar
worth
burn
f
porta
v
courteil
fischer
genneri
institut
cellular
medicin
newcastl
univers
newcastl
upon
tyne
unit
kingdom
background
scid
maturationfunct
disord
present
infect
infanc
hsct
cur
data
immun
function
physic
statu
qualiti
life
qol
outcom
object
gather
miss
data
designmethod
european
scid
patient
use
pidtc
includ
reticular
dysgenesi
transplant
year
ago
identifi
scetid
registri
result
median
age
diagnosi
month
rang
transplant
month
rang
cgc
ada
artemi
rag
known
unknown
defect
receiv
condit
infect
uncondit
hsct
haploident
mrd
mmrd
urd
median
last
fu
year
os
ci
ef
death
consid
event
ci
signific
differ
os
ef
condit
uncondit
transplant
patient
requir
second
uncondit
condit
third
transplant
die
year
infect
die
late
first
earli
second
third
hsct
trm
ci
differ
condit
uncondit
transplant
patient
agvhd
grade
aliv
year
follow
impair
immun
function
condit
uncondit
transplant
low
lymphocyt
level
trec
requir
ivigantimicrobi
persist
wart
previous
also
ada
artemi
phenotyp
develop
malign
meningeoma
autoimmun
sle
hemolyt
anemia
vitiligo
autoimmun
hepat
qol
consid
normal
patient
universitycolleg
educ
unknown
conclus
signific
differ
os
ef
trm
condit
uncondit
hsct
despit
miss
data
preliminari
analysi
demonstr
requir
estim
risk
factor
impair
immun
function
physic
statu
qol
scid
patient
refer
j
allergi
clin
immunol
lancet
